prednisone has been researched along with Diffuse Large B-Cell Lymphoma in 2346 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell-like (ABC) subtype." | 9.41 | Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. ( Amengual, JE; Casulo, C; Cohen, JB; Friedberg, JW; Habermann, TM; Hong, F; Kahl, BS; Khan, N; King, RL; Kostakoglu, L; Leonard, JP; Little, RF; Macon, WR; Nagargoje, GG; Nowakowski, GS; Reynolds, CM; Richards, KL; Scott, DW; Wade, JL; Wagner-Johnston, N; Witzig, TE, 2021) |
| "Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 9.41 | ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. ( Belada, D; Bergua, JM; Cavallo, F; Chiappella, A; Czuczman, M; Gascoyne, RD; Hersey, S; Hong, X; Hudak, K; Izutsu, K; Jin, J; Jurczak, W; Kato, K; Kilcoyne, A; Mócikova, H; Molinari, AL; Nowakowski, GS; Özcan, M; Piazza, F; Russo, J; Scott, DW; Tani, M; Vitolo, U; Wade, S; Witzig, TE; Yamamoto, K; Yoon, DH; Zhang, J; Zhang, Q; Zhu, J, 2021) |
| "Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study." | 9.34 | Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. ( Abraham, J; Bouabdallah, R; Bron, D; Caballero, D; Casadebaig, ML; Casasnovas, RO; Catalano, J; Cohen, AM; Coiffier, B; Costello, R; da Silva, MG; Daguindau, N; Deeren, D; Eisenmann, JC; Fitoussi, O; Fruchart, C; Gaulard, P; Gonzalez, H; Greil, R; Grosicki, S; Howlett, S; Le Du, K; Lionne-Huyghe, P; Morschhauser, F; Mounier, N; Nicolas-Virezelier, E; Obéric, L; Perrot, A; Pica, GM; Roulin, L; Snauwaert, S; Takeshita, K; Thieblemont, C; Tilly, H; Tricot, S; Trotman, J; van Eygen, K, 2020) |
| "While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival." | 9.34 | ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. ( Brody, J; Cao, J; Han, I; Heineman, T; Jing, H; Jivani, M; Lansigan, F; Li, L; Liu, Y; Lue, JK; Luo, W; Maly, J; Nowakowski, GS; Rizvi, S; Smith, SD; Song, Y; Sun, J; Sun, X; Zhang, L; Zhang, Q; Zhu, J, 2020) |
| "Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 9.24 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. ( Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A, 2017) |
| "Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL)." | 9.24 | Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. ( Abrisqueta, P; Belada, D; Burke, JM; Carella, AM; Catalani, O; Chua, N; Demeter, J; Fingerle-Rowson, G; Flinn, I; Hong, X; Kim, WS; Martelli, M; Nielsen, T; Oestergaard, MZ; Pinto, A; Sehn, LH; Shi, YK; Tatsumi, Y; Trněný, M; Vitolo, U; Wenger, M, 2017) |
| "During the Rituximab era, high dose intravenous methotrexate (HD) and intrathecal methotrexate (IT) are recommended prophylaxis in preventing central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) patients." | 9.22 | Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. ( Liu, B; Shi, X; Wang, Z; Xie, X; Xu, D; Zhang, N, 2022) |
| "To compare disease-free survival (DFS) after maintenance therapy with the selective protein kinase C β (PKCβ) inhibitor, enzastaurin, versus placebo in patients with diffuse large B-cell lymphoma (DLBCL) in complete remission and with a high risk of relapse after first-line therapy." | 9.22 | Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. ( Crump, M; Di Rocco, A; Fayad, L; Habermann, T; Hagberg, H; Hahka-Kemppinen, M; Hsi, ED; Kahl, B; Lee, JJ; Leppä, S; Lin, B; Mackensen, A; Nguyen, T; Offner, F; Ogura, M; Pinter-Brown, L; Rifkin, R; Savage, KJ; Schmitz, N; Schnell, F; Shi, P; Smith, S; Thornton, D; Tobinai, K; Yeh, SP, 2016) |
| "The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus." | 9.22 | Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. ( Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; McPhail, E; Micallef, IN; Nowakowski, GS; Witzig, TE, 2016) |
| "Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL)." | 9.20 | Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. ( Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE, 2015) |
| "To compare the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients seropositive for the hepatitis B surface antigen with untreated diffuse large B-cell lymphoma receiving chemotherapy treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 9.19 | Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. ( Cao, Y; Huang, H; Li, H; Li, X; Lin, S; Lin, T; Lin, Y; Liu, Q; Peng, J; Wang, W; Wu, X; Xu, B; Ye, S; Zhang, H; Zhu, J, 2014) |
| "Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse." | 9.17 | Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. ( Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M, 2013) |
| "We compared the efficacy and toxic effect of CPOP-R (substituting pixantrone for doxorubicin) against CHOP-R in untreated, diffuse large B-cell lymphoma (DLBCL) patients." | 9.17 | Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. ( Cernohous, P; Engert, A; Herbrecht, R; Le Gouill, S; Macdonald, D; Machida, C; Myint, H; Saleh, A; Singer, J; van der Jagt, R; Wilhelm, M, 2013) |
| "We conducted a prospective randomized phase II study to evaluate two chemotherapy regimens: (i) rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (R-HCVAD) alternating with rituximab, high-dose methotrexate, and cytarabine (R-MA) and (ii) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in diffuse large B-cell lymphoma (DLBCL)." | 9.17 | Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. ( Chuang, H; Fanale, M; Fayad, L; Fowler, N; Hagemeister, FB; Kwak, LW; McLaughlin, P; Neelapu, S; Oki, Y; Orlowski, RZ; Ouzounian, ST; Rodriguez, MA; Romaguera, JE; Samaniego, F; Vega, F; Wang, M; Westin, JR; Younes, A, 2013) |
| "We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 9.16 | Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT ( Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A, 2012) |
| " We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)." | 9.15 | Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. ( Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM, 2011) |
| "This Phase II study assessed feasibility and efficacy of a biweekly R-COMP-14 regimen (rituximab, cyclophosphamide, non-pegylated liposome-encapsulated doxorubicin, vincristine and prednisone) in untreated elderly patients with poor-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high 'life threat' impact NIA/NCI cardiac comorbidity." | 9.15 | Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. ( Amore, A; Arcamone, M; Becchimanzi, C; Capobianco, G; Caronna, A; Corazzelli, G; De Filippi, R; Frigeri, F; Lucania, A; Marcacci, G; Mastrullo, L; Morelli, E; Pinto, A; Rosariavilla, M; Russo, F; Volzone, F, 2011) |
| "Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma." | 9.13 | Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. ( Abella, E; García, M; Gardella, S; González-Barca, E; López, A; López-Guillermo, A; Miralles, P; Morgades, M; Oriol, A; Ribera, JM, 2008) |
| "In this pilot study, the authors assessed the feasibility of combination epratuzumab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)." | 9.12 | A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. ( Ansell, SM; Colgan, JP; Dogan, A; Geyer, S; Habermann, TM; Inwards, DJ; Kahl, BS; Maurer, MJ; Micallef, IN; White, WL, 2006) |
| "Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied." | 9.10 | Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 9.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "This prospective study aimed to investigate the efficacy and safety of preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF) for HBsAg-positive patients with newly diagnosed diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy." | 8.31 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. ( Chang, MH; Eom, HS; Hyun, SY; Jo, JC; Kang, HJ; Kim, DY; Kim, HJ; Kim, IH; Kim, JS; Kim, MK; Kim, WS; Kim, YR; Kwak, JY; Lee, JO; Lee, WS; Lim, SN; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yang, DH; Yoo, KH; Yoon, DH, 2023) |
| "Approximately 40% patients of diffuse large B-cell lymphoma (DLBCL) would develop disease recurrence/progression after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis." | 8.31 | Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. ( Ding, K; Jiang, X; Wang, X; Yu, L, 2023) |
| " Over the past 10 years, the association between clozapine, which is the criterion standard treatment for refractory schizophrenia, and hematological malignancies has been described." | 8.31 | Diffuse Large B-Cell Lymphoma with Cutaneous Manifestations in a Young Patient Using Clozapine for Schizophrenia: A Case Report. ( Alves Junior, MP; Gouveia, PADC; Guedes, MMV; Lira, AC; Moraes de Brito, MC; Nascimento, JDS; Pimentel Jatobá, V, 2023) |
| "Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear." | 8.02 | Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. ( Batlevi, CL; Bobillo, S; Caron, PC; Dogan, A; Ghione, P; Hamilton, A; Hamlin, PA; Horwitz, SM; Joffe, E; Kumar, A; Matasar, MJ; Mondello, P; Moskowitz, A; Noy, A; Owens, CN; Palomba, ML; Sermer, D; Seshan, VE; Straus, D; von Keudell, G; Younes, A; Zelenetz, AD, 2021) |
| "Other iatrogenic immunodeficiency-associated lymphoproliferative disorders induced by immunosuppressive drugs, such as methotrexate (MTX-LPD), exhibit numerous pathological findings." | 7.96 | Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer. ( Carreras, J; Kikuti, YY; Kondo, Y; Moriya, K; Nakamura, N; Shiraiwa, S, 2020) |
| "In diffuse large B-cell lymphoma (DLBCL), there is an unmet medical need to select patients who would benefit from intensified frontline treatments such as adding etoposide to an R-CHOP regimen." | 7.96 | Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment. ( Bloigu, R; Haapasaari, KM; Hakalahti, A; Honkavaara, P; Kari, EJM; Karihtala, P; Kuittinen, O; Kuusisto, MEL; Pirinen, R; Teppo, HR; Turpeenniemi-Hujanen, T, 2020) |
| "A 52-year-old woman was treated for colorectal diffuse large B-cell lymphoma (DLBCL) after a prolonged treatment period of azathioprine (AZA) and infliximab (IFX) for Crohn's disease (CD)." | 7.96 | Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. ( Daikuhara, S; Hirayama, A; Sato, K; Suga, T; Tanaka, E; Uehara, T, 2020) |
| "Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL)." | 7.88 | Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. ( Ansell, SM; Castellino, A; Cavallo, F; Chiappella, A; Ciccone, G; Congiu, A; Foran, JM; Gaidano, G; Habermann, TM; Inghirami, G; King, RL; LaPlant, BR; Macon, WR; Molinari, AL; Nowakowski, GS; Pavone, V; Pederson, LD; Reeder, CB; Rivera, CE; Spina, M; Tucci, A; Vitolo, U; Witzig, TE, 2018) |
| "No randomised study in the rituximab era has been performed specifically to evaluate addition of etoposide to treatment of diffuse large B-cell lymphoma (DLBCL)." | 7.85 | Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. ( Hartman, L; Jerkeman, M; Székely, E; Wästerlid, T, 2017) |
| " The principal objective of this study was to determine whether the tumors' microenvironment expressions of CD11c and FOXP3 are predictive of clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients receiving treatment with rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy." | 7.85 | Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. ( Jeong, JS; Ju, MH; Kim, DH; Kim, HJ; Kim, SH; Kim, SY; Koh, MS; Kwak, JY; Lee, JH; Lee, S; Oh, SY; Pak, MG, 2017) |
| "This study evaluated the efficacy of central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell lymphoma (DLBCL)." | 7.81 | Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. ( Fujimaki, K; Hagihara, M; Hashimoto, C; Ishibashi, D; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Kishimoto, K; Koyama, S; Motomura, S; Numata, A; Ohshima, R; Sakai, R; Tachibana, T; Taguchi, J; Takahashi, H; Takasaki, H; Takemura, S; Tomita, N; Watanabe, R, 2015) |
| "We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions." | 7.81 | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lympho ( Ahn, JS; Bae, SH; Do, YR; Go, SI; Hong, J; Kang, HJ; Kim, HJ; Kim, JS; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, WS; Kim, YR; Lee, B; Lee, GW; Lee, H; Lee, SI; Lee, WS; Oh, S; Oh, SY; Song, MK; Suh, C; Yhim, HY, 2015) |
| "Addition of etoposide to the R-CHOP chemotherapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOEP) has resulted in improved survival in young patients with high-risk diffuse large B-cell lymphoma (DLBCL)." | 7.81 | Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. ( Brown, P; Gang, AO; Høgdall, E; Klausen, TW; Knudsen, H; Lauritzen, AF; Nielsen, SL; Nørgaard, P; Pedersen, M; Pedersen, MØ, 2015) |
| "The purpose of this study was to analyze the pre- and post-treatment neutrophil to lymphocyte ratio (pre- and post-NLR) in combination with immunologic profiles in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 7.81 | Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. ( Ha, H; Heo, DS; Jeon, YK; Keam, B; Kim, CW; Kim, DW; Kim, TM; Lee, SH, 2015) |
| "This study evaluated the effect of age and cell of origin on the prognostic significance of Ki-67 labeling index (Ki-67 LI) on overall survival (OS) of diffuse large B-cell lymphoma (DLBCL) in a cohort of 697 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 7.81 | Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. ( Huh, J; Hwang, HS; Koh, YW; Park, CS; Suh, C; Yoon, DH, 2015) |
| "To study expression of CD68, cyclin D1 protein and rearrangement of bcl-6 gene impact on the prognosis of diffuse large B-cell lymphoma (DLBCL)." | 7.81 | [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma]. ( Bai, W; Liang, X; Sun, R; Wang, J, 2015) |
| "Summary We report a case of a 56-year-old woman with a high-grade diffuse large B-cell lymphoma who unexpectedly developed toxic plasma levels of methotrexate (MTX) following the first cycle of rituximab-cyclophosphamide, hydroxydanorubicin, oncovin, prednisolone (R-CHOP) with a high-dose MTX chemotherapy protocol." | 7.80 | The utility of online haemodiafiltration in methotrexate poisoning. ( Abdelsalam, MS; Alfurayh, O; Althaf, MM; Maghfoor, I, 2014) |
| "Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is regarded as the first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), but it is often necessary to reduce the dose or prolong the intervals between doses." | 7.79 | Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. ( Aoki, K; Ishikawa, T; Kurata, M; Matsushita, A; Nagai, K; Tabata, S; Takahashi, T, 2013) |
| "We assessed the prognostic impact of occult bone marrow involvement, determined by flow cytometry and/or polymerase chain reaction, in a population of 117 consecutive patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 7.79 | Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. ( Arima, H; Imai, Y; Ishikawa, T; Kurata, M; Maruoka, H; Matsushita, A; Nasu, K; Tabata, S; Takahashi, T, 2013) |
| "As lymphocytes play an active role in tumor control and as targets for immunochemotherapy, the prognostic significance of the absolute lymphocyte count (ALC) and its changes after rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) were investigated in patients with early-stage diffuse large B-cell lymphoma (DLBCL)." | 7.78 | Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. ( Chae, YS; Kang, BW; Kim, JG; Lee, JJ; Lee, SJ; Moon, JH; Park, TI; Shin, H; Sohn, SK; Yang, DH, 2012) |
| "When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor." | 7.78 | [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012) |
| "Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 7.78 | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. ( Ben-Neriah, S; Braziel, RM; Brunhoeber, P; Campo, E; Chan, WC; Connors, JM; Cook, JR; Delabie, J; Gascoyne, RD; Grogan, TM; Holcroft, C; Iqbal, J; Jaffe, ES; Johnson, NA; Lenz, G; Meyer, PN; Ott, G; Rimsza, LM; Rogic, S; Rosenwald, A; Savage, KJ; Scott, DW; Sehn, LH; Slack, GW; Staudt, LM; Steidl, C; Tan, KL; Tubbs, RR; Valentino, C; Weisenburger, DD; Wright, G, 2012) |
| " This study investigated the effects of statins in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-based chemoimmunotherapy, and the impact of commonly used drugs, metformin and aspirin, on the clinical outcomes of patients receiving chemoimmunotherapy." | 7.77 | Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. ( Ha, T; Koo, YX; Lim, ST; Ong, WS; Quek, R; Tai, DW; Tan, DS; Tan, IB; Tao, M, 2011) |
| " We therefore evaluated the impact of the ABCG2 V12M and Q141K polymorphisms on the therapeutic outcomes and toxicities of primary rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in 145 Korean patients with diffuse large B-cell lymphoma (DLBCL)." | 7.74 | ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. ( Eom, HS; Hwang, SH; Kim, DC; Kim, HG; Kim, IS; Kong, SY; Lee, EY; Lee, GW; Shin, HJ, 2008) |
| "The combination of cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) alternating with total body irradiation (TBI) has been shown earlier to be effective therapy in patients with malignant lymphoma who have received prior chemotherapy and/or radiation therapy." | 7.66 | The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation. ( Antunez, A; Dixon, D; Fabian, CJ; Kraus, TA; Weick, JK, 1983) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 7.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "Management of acquired immunodeficiency syndrome (AIDS)-related diffuse large B-cell (DLBCL) and plasmablastic lymphomas (PBL) poses significant challenges." | 7.30 | Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. ( Agarwal, A; Alahari, A; Bagal, B; Gota, V; Gujral, S; Gupta, H; Jain, H; Kannan, S; Kumar, S; Laskar, SS; Menon, H; Nayak, L; Rangarajan, V; Sengar, M; Sharma, N; Shet, T; Sridhar, E; Thorat, J, 2023) |
| "Lenalidomide has response rates of 45% in relapsed transformed DLBCL." | 7.01 | Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. ( Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE, 2021) |
| " No organ-oriented toxicity increased with tazemetostat dosage escalation (severity and incidence)." | 6.94 | A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. ( Cullières-Dartigues, P; Dubois, R; Dubois, S; Herbaux, C; Jardin, F; Karlin, L; Le Gouill, S; Michot, JM; Molina, T; Morschhauser, F; Picquenot, JM; Ribrag, V; Salles, G; Sarkozy, C; Suttle, B; Tilly, H, 2020) |
| " We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)- EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) combined with high-dose methotrexate (HD-MTX) in newly diagnosed patients with CD5+ DLBCL." | 6.94 | DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. ( Asano, N; Igarashi, T; Izutsu, K; Katayama, N; Kato, K; Kinoshita, T; Miyawaki, K; Miyazaki, K; Nishikawa, M; Nishikori, M; Nishimura, Y; Ohata, K; Ohshima, K; Okamoto, M; Sakai, R; Sunami, K; Suzumiya, J; Takahashi, N; Tamaru, S; Yamada, T; Yamaguchi, M; Yamamoto, G; Yano, H; Yoshida, I, 2020) |
| "Everolimus has single-agent activity in lymphoma." | 6.87 | Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. ( Belada, D; Bermudez Silva, CD; Bouabdallah, K; Cavalli, F; Costa, LJ; Fan, J; Fayad, L; Hino, M; Ikeda, T; Kattan, JG; Kim, WS; Kuruvilla, J; Larouche, JF; Louveau, AL; Mayer, J; Ogura, M; Ozcan, M; Rigacci, L; Shi, Y; Tobinai, K; Vanazzi, A; Voi, M; Witzig, TE; Wu, C; Zhu, J, 2018) |
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 6.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "Lenalidomide 10 mg/d was identified as the MTD because, in the 15 mg cohort, one patient experienced dose-limiting toxicity (grade 3 angioedema) and two patients had mobilization failure." | 6.82 | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. ( Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A, 2016) |
| "Lenalidomide has high activity in relapsed or refractory aggressive B-cell lymphomas." | 6.79 | Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. ( Baldi, I; Botto, B; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; Congiu, A; Dreyling, M; Fattori, PP; Franceschetti, S; Gaidano, G; Gaudiano, M; Inghirami, G; Ladetto, M; Liberati, AM; Molinari, AL; Pavone, V; Rossi, G; Salvi, F; Spina, M; Vitolo, U; Zaccaria, A; Zanni, M; Zinzani, P, 2014) |
| " Two toxic deaths were observed." | 6.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| "Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients." | 5.69 | Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. ( Burke, JM; Cheson, BD; Diefenbach, CS; Ferrari, S; Hahn, UH; Hawkes, EA; Khan, C; Lossos, IS; Musuraca, G; Nielsen, TG; Raval, A; Sellam, G; Sharman, JP; Shivhare, M; Tani, M; Vitolo, U; Younes, A; Yuen, S, 2023) |
| "Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease." | 5.69 | A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. ( Alig, SK; Alizadeh, AA; Cherng, HJ; Craig, AFM; Davis, RE; Fayad, L; Feng, L; Flowers, CR; Green, MR; Hagemeister, F; Kurtz, DM; Lee, HJ; Macaulay, CW; McDonnell, TJ; Nastoupil, LJ; Neelapu, SS; Oki, Y; Rodriguez, MA; Turturro, F; Vega, F; Westin, JR, 2023) |
| "In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma, polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with similar safety." | 5.69 | Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. ( Ando, K; Bu, L; Cao, J; Eom, HS; Feng, J; Gau, JP; Goto, H; Hirata, J; Huang, H; Izutsu, K; Jiang, Y; Jin, J; Kim, TM; Kim, WS; Koh, H; Lee, C; Li, W; Rai, S; Sehn, LH; Sharman, JP; Shin, HJ; Song, Y; Terui, Y; Tilly, H; Tsai, XC; Wang, X; Yang, Y; Zhang, H; Zhang, L; Zhu, J, 2023) |
| "Most patients with diffuse large B-cell lymphoma (DLBCL) can be cured with immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)." | 5.69 | Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis. ( Altmann, B; Casasnovas, O; Chartier, L; Fitoussi, O; Frontzek, F; Glass, B; Haioun, C; Held, G; Ketterer, N; Lenz, G; Molina, T; Morschhauser, F; Mounier, N; Ott, G; Poeschel, V; Récher, C; Renaud, L; Rosenwald, A; Schmitz, N; Thieblemont, C; Tilly, H; Ziepert, M, 2023) |
| "Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant." | 5.69 | Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. ( André, M; Belada, D; Bergua Burgues, JM; Burke, JM; Dirnberger-Hertweck, M; Duell, J; Kopeckova, K; Mukhopadhyay, A; Nowakowski, GS; Persona, EP; Pichler, P; Staber, PB; Stevens, D; Trneny, M; Wagner, S; Waldron-Lynch, M, 2023) |
| "The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) but whether the same efficacy can be achieved with reduced chemotherapy regimen of four cycles for non-bulky DLBCL patients with an IPI of 1 remains unclear." | 5.69 | Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial. ( Chen, SJ; Cheng, S; Dong, L; Fu, D; He, Y; Jiang, XF; Mu, RJ; Qin, W; Shi, Q; Song, Q; Wang, L; Xu, PP; Yi, HM; Zhao, WL, 2023) |
| "Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.51 | Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. ( Abrisqueta, P; Bergua-Burgués, JM; Burke, JM; Chauchet, A; Cheung, MC; Flowers, CR; Friedberg, JW; Gau, JP; Greil, R; Hapgood, G; Herbaux, C; Hirata, J; Izutsu, K; Jiang, Y; Jurczak, W; Lee, C; Matasar, M; Mehta-Shah, N; Morschhauser, F; Munhoz, E; Mykhalska, L; Oberic, L; Pinto, A; Rai, S; Salles, G; Sehn, LH; Sharman, JP; Shin, HJ; Song, Y; Tilly, H; Trněný, M; Yan, M, 2022) |
| " We retrospectively analyzed a cohort of 130 newly diagnosed diffuse large B-cell lymphomas with unfavorable clinical features treated with first-line rituximab, dose-adjusted etoposide, prednisone, vincristine [Oncovin], cyclophosphamide, hydroxydaunorubicin (R-DA-EPOCH) immunochemotherapy in period 2005-2019." | 5.51 | No Evident Prognostic Benefit of Statin Use in Diffuse Large B-Cell Lymphoma Patients with Unfavorable Disease Features Treated with R-DA-EPOCH. ( Kusec, R; Lucijanic, M; Pejsa, V; Sabljic, A; Sedinic Lacko, M, 2022) |
| "Sarcopenia is known to be related to an increased risk of chemotherapy toxicity and to a poor prognosis in patients with malignancy." | 5.43 | Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. ( Go, SI; Kang, MH; Kim, HG; Kim, RB; Kim, Y; Lee, GW; Lee, HR; Lee, SI; Park, MJ; Song, HN, 2016) |
| "The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma (DLBCL), including patients demonstrating Bcl-2 protein overexpression by immunohistochemistry (Bcl-2 IHC+)." | 5.41 | A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. ( Bazeos, A; Clark, E; de Vos, S; Feugier, P; Flinn, IW; Gasiorowski, R; Greil, R; Humphrey, K; Illés, Á; Jiang, Y; Johnson, NA; Kim, SY; Larouche, JF; Lugtenburg, PJ; Mir, F; Morschhauser, F; Patti, C; Punnoose, E; Salles, GA; Samineni, D; Sinha, A; Spielewoy, N; Trněný, M; Zelenetz, AD, 2021) |
| "Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, particularly in the activated B-cell-like (ABC) subtype." | 5.41 | Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. ( Amengual, JE; Casulo, C; Cohen, JB; Friedberg, JW; Habermann, TM; Hong, F; Kahl, BS; Khan, N; King, RL; Kostakoglu, L; Leonard, JP; Little, RF; Macon, WR; Nagargoje, GG; Nowakowski, GS; Reynolds, CM; Richards, KL; Scott, DW; Wade, JL; Wagner-Johnston, N; Witzig, TE, 2021) |
| "Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL)." | 5.41 | A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. ( Ando, K; Dobashi, N; Fukuhara, N; Hotta, T; Iida, S; Imaizumi, Y; Ishizawa, K; Kinoshita, T; Kuroda, J; Maruyama, D; Masaki, Y; Miyazaki, K; Mizutani, T; Murayama, T; Nagai, H; Nosaka, K; Ogawa, G; Ogura, M; Ohmachi, K; Suehiro, Y; Takamatsu, Y; Tobinai, K; Tokunaga, T; Tsukamoto, N; Tsukasaki, K; Uchida, T; Utsumi, T; Yakushijin, Y; Yamamoto, K; Yamauchi, N; Yoshida, I; Yoshida, S; Yoshino, T, 2021) |
| "Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.41 | ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. ( Belada, D; Bergua, JM; Cavallo, F; Chiappella, A; Czuczman, M; Gascoyne, RD; Hersey, S; Hong, X; Hudak, K; Izutsu, K; Jin, J; Jurczak, W; Kato, K; Kilcoyne, A; Mócikova, H; Molinari, AL; Nowakowski, GS; Özcan, M; Piazza, F; Russo, J; Scott, DW; Tani, M; Vitolo, U; Wade, S; Witzig, TE; Yamamoto, K; Yoon, DH; Zhang, J; Zhang, Q; Zhu, J, 2021) |
| "We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without ibrutinib." | 5.41 | Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib. ( Balasubramanian, S; Carey, J; Gerecitano, J; Hodkinson, B; Johnson, P; Major, C; Schaffer, M; Sehn, LH; Shreeve, SM; Staudt, LM; Sun, S; Vermeulen, J; Wang, S; Wilson, W; Zinzani, PL, 2021) |
| "Cyclin D1 expression has been reported in a subset of patients with diffuse large B-cell leukemia (DLBCL), but studies have been few and generally small, and they have demonstrated no obvious clinical implications attributable to cyclin D1 expression." | 5.40 | Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. ( Bhagat, G; Dybkaer, K; Farnen, JP; Han van Krieken, J; Hsi, ED; Medeiros, LJ; Montes-Moreno, S; Møller, MB; O'Malley, DP; Ok, CY; Orazi, A; Piris, MA; Ponzoni, M; Richards, KL; Tzankov, A; Visco, C; Winter, JN; Xu-Monette, ZY; Young, KH; Zu, Y, 2014) |
| " No guidelines exist for chemotherapy dosing in the elderly population, and a clear assessment of treatment toxicity and benefits has not been previously reported." | 5.38 | Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. ( Greer, JP; Huntington, SF; Morgan, DS; Reddy, N; Talbott, MS, 2012) |
| "He had no previous history of convulsion." | 5.38 | Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma. ( Baniasadi, S; Fahimi, F; Foroughinia, F; Seifi, S, 2012) |
| "Although prophylaxis against CNS recurrence with either intrathecal or intravenous methotrexate is commonly used for such patients, to the authors' knowledge, there is no standard of care." | 5.36 | Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. ( Abramson, JS; Barnes, JA; Hammerman, P; Hellmann, M; Hochberg, EP; Muzikansky, A; Takvorian, T; Toomey, C, 2010) |
| "Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study." | 5.34 | Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. ( Abraham, J; Bouabdallah, R; Bron, D; Caballero, D; Casadebaig, ML; Casasnovas, RO; Catalano, J; Cohen, AM; Coiffier, B; Costello, R; da Silva, MG; Daguindau, N; Deeren, D; Eisenmann, JC; Fitoussi, O; Fruchart, C; Gaulard, P; Gonzalez, H; Greil, R; Grosicki, S; Howlett, S; Le Du, K; Lionne-Huyghe, P; Morschhauser, F; Mounier, N; Nicolas-Virezelier, E; Obéric, L; Perrot, A; Pica, GM; Roulin, L; Snauwaert, S; Takeshita, K; Thieblemont, C; Tilly, H; Tricot, S; Trotman, J; van Eygen, K, 2020) |
| "While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival." | 5.34 | ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. ( Brody, J; Cao, J; Han, I; Heineman, T; Jing, H; Jivani, M; Lansigan, F; Li, L; Liu, Y; Lue, JK; Luo, W; Maly, J; Nowakowski, GS; Rizvi, S; Smith, SD; Song, Y; Sun, J; Sun, X; Zhang, L; Zhang, Q; Zhu, J, 2020) |
| "Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL)." | 5.34 | Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). ( Arens, AI; Beeker, A; Bilgin, MY; Böhmer, LH; Brouwer, RE; Burggraaff, CN; D'Amore, FA; de Jong, D; de Jongh, E; de Keizer, B; de Nully Brown, P; Doorduijn, JK; Fijnheer, R; Hoekstra, OS; Hoogendoorn, M; Jie, KG; Kersten, MJ; Koene, HR; Lam, KH; Larsen, TS; Leijs, MB; Lugtenburg, PJ; Nijland, M; Oosterveld, M; Pruijt, JF; Silbermann, MH; Tick, LW; van der Burg-de Graauw, NC; van der Holt, B; van der Poel, MW; van Esser, JW; van Marwijk Kooy, M; Verhoef, GE; Zijlstra-Baalbergen, JM, 2020) |
| "This unplanned post-hoc analysis was based on data from the phase Ib DBL1002 study (NCT01569750) and evaluated the association between molecular biomarkers and clinical response to combined treatment with ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma (DLBCL) subtypes." | 5.34 | Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. ( Aquino, R; Balasubramanian, S; Chaturvedi, S; Davis, C; de Jong, J; Fourneau, N; Oki, Y; Schaffer, M; Younes, A, 2020) |
| "Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL." | 5.33 | Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Best, JH; Hornberger, JC, 2005) |
| "This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes." | 5.30 | Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. ( Bessudo, A; Costa, LJ; Evens, AM; Fayad, LE; Fingerle-Rowson, G; Flinn, IW; Flowers, CR; Forero-Torres, A; Inhorn, L; Kaminski, MS; Kelly, K; Mobasher, M; Mundt, KE; Sahin, D; Sandmann, T; Sharman, JP; Vignal, C; Zelenetz, AD, 2019) |
| "Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL)." | 5.30 | Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. ( Cao, Y; Fang, X; Guo, C; Guo, H; Hong, H; Huang, H; Li, W; Li, X; Lin, S; Lin, T; Lin, Y; Liu, Q; Peng, J; Pu, X; Wang, W; Wang, Z; Wu, X; Xie, D; Xu, B; Ye, S; Yi, J; Zhan, H; Zhou, Y, 2019) |
| "Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma." | 5.30 | Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. ( Abramson, JS; Bartlett, NL; Blum, KA; Chadburn, A; Chang, JE; Cheson, BD; Fisher, RI; Friedberg, JW; Gopal, AK; Hsi, ED; Jung, SH; Kahl, BS; Leonard, JP; Mathew, S; Maurer, MJ; Pederson, LD; Pitcher, BN; Polley, MC; Reddy, NM; Richards, KL; Schöder, H; Staudt, LM; Wagner-Johnston, ND; Wilson, WH; Winter, JN; Zelenetz, AD, 2019) |
| "This phase II trial evaluated the efficacy of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were not candidates for rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.30 | Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. ( Berdeja, JG; Daniel, DB; Erter, J; Flinn, IW; Mace, JR, 2019) |
| "R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL)." | 5.30 | Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms. ( Abenhardt, W; Harde, J; Jänicke, M; Kaiser-Osterhues, A; Knauf, W; Marschner, N; Mohm, J; Rauh, J, 2019) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 5.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.24 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. ( Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A, 2017) |
| "Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL)." | 5.24 | Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. ( Abrisqueta, P; Belada, D; Burke, JM; Carella, AM; Catalani, O; Chua, N; Demeter, J; Fingerle-Rowson, G; Flinn, I; Hong, X; Kim, WS; Martelli, M; Nielsen, T; Oestergaard, MZ; Pinto, A; Sehn, LH; Shi, YK; Tatsumi, Y; Trněný, M; Vitolo, U; Wenger, M, 2017) |
| "This study aimed to evaluate the efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treating patients with diffuse large B-cell lymphoma (DLBCL)." | 5.24 | Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. ( Ding, SS; Guo, L; Hu, X; Li, S; Liang, X; Wen, SJ; Yang, SE; Zeng, M, 2017) |
| "Patterns of myeloid growth factor (GF) usage and febrile neutropenia (FN) were examined in patients >60 years of age with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) enrolled on CALGB 9793/ECOG-SWOG 4494, receiving initial therapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or rituximab + CHOP (R-CHOP)." | 5.24 | Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). ( Cheson, BD; Fisher, RI; Habermann, TM; Li, S; Morrison, VA; Peterson, BA; Weller, EA, 2017) |
| "The standard of care for diffuse large B-cell lymphoma (DLBCL) is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.22 | Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma. ( Hamada, T; Hatta, Y; Iizuka, K; Iriyama, N; Miura, K; Nakagawa, M; Nakamura, H; Ohtake, S; Takahashi, H; Uchino, Y, 2022) |
| "R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been used as the standard treatment regimen for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), since the introduction of rituximab in the early 2000s." | 5.22 | [Current status and future prospects of diffuse large B-cell lymphoma treatment]. ( Yamaguchi, M, 2022) |
| "During the Rituximab era, high dose intravenous methotrexate (HD) and intrathecal methotrexate (IT) are recommended prophylaxis in preventing central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) patients." | 5.22 | Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. ( Liu, B; Shi, X; Wang, Z; Xie, X; Xu, D; Zhang, N, 2022) |
| "Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients." | 5.22 | Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. ( Asensio, A; Bargay, J; Bello, JL; Briones, J; Caballero, D; Canales, MA; Domingo-Domenech, E; Ferrer, S; García-Frade, J; Gardella, S; González-Barca, E; Grande, C; López, A; Oriol, A; Peñalver, FJ; Salar, A; Sánchez-Blanco, JJ; Tomás, JF; Vidal, MJ, 2016) |
| "To compare disease-free survival (DFS) after maintenance therapy with the selective protein kinase C β (PKCβ) inhibitor, enzastaurin, versus placebo in patients with diffuse large B-cell lymphoma (DLBCL) in complete remission and with a high risk of relapse after first-line therapy." | 5.22 | Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. ( Crump, M; Di Rocco, A; Fayad, L; Habermann, T; Hagberg, H; Hahka-Kemppinen, M; Hsi, ED; Kahl, B; Lee, JJ; Leppä, S; Lin, B; Mackensen, A; Nguyen, T; Offner, F; Ogura, M; Pinter-Brown, L; Rifkin, R; Savage, KJ; Schmitz, N; Schnell, F; Shi, P; Smith, S; Thornton, D; Tobinai, K; Yeh, SP, 2016) |
| "The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus." | 5.22 | Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. ( Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; McPhail, E; Micallef, IN; Nowakowski, GS; Witzig, TE, 2016) |
| "Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8)." | 5.22 | Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. ( Friedberg, JW; LeBlanc, ML; Li, H; Persky, D; Puvvada, SD; Smith, SM; Stephens, DM, 2016) |
| "Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL)." | 5.20 | Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. ( Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE, 2015) |
| "The present multicenter phase II trial evaluated the safety and efficacy of pegylated liposomal doxorubicin (PLD) instead of conventional doxorubicin in standard R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisone) therapy for elderly patients with diffuse large B-cell lymphoma." | 5.20 | Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. ( Astrow, AB; Durand, JB; Ewer, MS; Fanale, M; Fayad, LE; Fisch, MJ; Fowler, N; Hagemeister, FB; Huang, X; Kwak, LW; Lenihan, DJ; McLaughlin, P; Neelapu, SS; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Wang, M; Younes, A, 2015) |
| "The primary objective of this prospective, randomized study was to compare the efficacy of a reduced regimen of only four doses of unpegylated filgrastim from day +8 to +11 per cycle with a standard once per cycle administration of pegylated filgrastim to maintain dose-intensity of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone given every 14 d) in previously untreated elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 5.20 | Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma. ( Alma, E; Bellesi, S; Bozzoli, V; D'Alo', F; Hohaus, S; Leone, G; Maiolo, E; Tisi, MC; Voso, MT, 2015) |
| "Patients with early stage diffuse large B-cell lymphoma (DLBCL) receive RCHOP (rituximab cyclophosphamide, doxorubicin, vincristine, prednisone) alone or with involved field radiotherapy (IFRT)." | 5.20 | A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. ( Advani, RH; Dogan, A; Gascoyne, RD; Hong, F; Horning, SJ; Kahl, BS; Micallef, IN; Wagner, H; Witzig, TE, 2015) |
| "This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally confirmed by immunohistochemistry (Hans method)." | 5.20 | Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. ( Chaturvedi, S; Enny, C; Eom, HS; Ferhanoglu, B; Offner, F; Osmanov, E; Pavlov, V; Raposo, J; Ricci, D; Rizo, A; Samoilova, O; Topp, MS; van de Velde, H; Zhu, E, 2015) |
| " In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP)." | 5.19 | R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. ( Catalano, J; Coiffier, B; Csinady, E; Moore, N; Pfreundschuh, M; Sehn, LH; Seymour, JF; Trnĕný, M, 2014) |
| "The objective was to investigate the expression and prognostic value of CD59 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent rituximab-cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP)." | 5.19 | Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. ( Cho, WC; Gu, L; He, B; Pan, Y; Song, G; Wang, S, 2014) |
| "Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.19 | Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. ( Amorim, S; Balasubramanian, S; Bandyopadhyay, N; de Vries, R; Flinn, I; Fourneau, N; Friedberg, JW; Hellemans, P; Hivert, B; Morschhauser, F; Oki, Y; Smit, JW; Thieblemont, C; Vermeulen, J; Westin, J; Younes, A, 2014) |
| "To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP)." | 5.19 | Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho ( Berger, F; Brière, J; Canioni, D; Casasnovas, O; Coiffier, B; Copie-Bergman, C; Copin, MC; Fabiani, B; Fermé, C; Gaulard, P; Haioun, C; Jais, JP; Jardin, F; Leroy, K; Molina, TJ; Morschauser, F; Mounier, N; Petrella, T; Recher, C; Salles, G; Thieblemont, C; Tilly, H, 2014) |
| "To compare the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients seropositive for the hepatitis B surface antigen with untreated diffuse large B-cell lymphoma receiving chemotherapy treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.19 | Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. ( Cao, Y; Huang, H; Li, H; Li, X; Lin, S; Lin, T; Lin, Y; Liu, Q; Peng, J; Wang, W; Wu, X; Xu, B; Ye, S; Zhang, H; Zhu, J, 2014) |
| "Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma." | 5.17 | Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. ( Bologna, S; Bosly, A; Casasnovas, O; Delarue, R; Delmer, A; Fermé, C; Fitoussi, O; Fruchart, C; Ghesquières, H; Hacini, M; Haioun, C; Molina, TJ; Mounier, N; Petrella, T; Salles, G; Thieblemont, C; Thyss, A; Tilly, H; Van Hoof, A; Ysebaert, L, 2013) |
| "Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse." | 5.17 | Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. ( Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M, 2013) |
| "We compared the efficacy and toxic effect of CPOP-R (substituting pixantrone for doxorubicin) against CHOP-R in untreated, diffuse large B-cell lymphoma (DLBCL) patients." | 5.17 | Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. ( Cernohous, P; Engert, A; Herbrecht, R; Le Gouill, S; Macdonald, D; Machida, C; Myint, H; Saleh, A; Singer, J; van der Jagt, R; Wilhelm, M, 2013) |
| "We conducted a prospective randomized phase II study to evaluate two chemotherapy regimens: (i) rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (R-HCVAD) alternating with rituximab, high-dose methotrexate, and cytarabine (R-MA) and (ii) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in diffuse large B-cell lymphoma (DLBCL)." | 5.17 | Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. ( Chuang, H; Fanale, M; Fayad, L; Fowler, N; Hagemeister, FB; Kwak, LW; McLaughlin, P; Neelapu, S; Oki, Y; Orlowski, RZ; Ouzounian, ST; Rodriguez, MA; Romaguera, JE; Samaniego, F; Vega, F; Wang, M; Westin, JR; Younes, A, 2013) |
| "The activity and safety of two-weekly dose-adjusted (DA)-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) was explored in 20 patients with previously untreated poor prognosis diffuse large B-cell lymphoma (DLBCL)." | 5.17 | Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. ( Arribas, I; Burgaleta, C; Callejas, M; Casco, CR; Curto, N; Flores, E; García-Suárez, J; Gil-Fernández, JJ; Guillén, H; Martín, Y; Olmedilla, G, 2013) |
| "The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated." | 5.17 | Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). ( Anglaret, B; Bologna, S; Bonnet, C; Bordessoule, D; Brière, J; Casasnovas, O; Christian, B; Coiffier, B; Connerotte, T; Delarue, R; Fabiani, B; Fermé, C; Fruchart, C; Haioun, C; Ketterer, N; Morschhauser, F; Récher, C; Soussain, C; Thieblemont, C; Tilly, H, 2013) |
| "We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 5.16 | Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT ( Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A, 2012) |
| "In international prognostic index (IPI) risk-tailored adult patients with diffuse large B-cell lymphoma (DLBCL), it is still unclear whether the addition of maintenance rituximab (MR) improves progression-free (PFS) and overall survival (OS), after RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy." | 5.16 | How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. ( Huang, BT; Ji, HB; Li, BS; Xiao, Z; Yu, J; Zeng, QC; Zhang, CL, 2012) |
| "A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma." | 5.16 | A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. ( Canellos, G; Chadburn, A; Cheson, BD; Czuczman, M; Dunleavy, K; Hsi, ED; Hurd, D; Johnson, J; Jones, D; Jung, SH; Lai, R; Martin, SE; Porcu, P; Said, J; Wilson, WH; Zelenetz, AD, 2012) |
| "Pharmacokinetics of 8 doses of rituximab (375 mg/m(2)) given in combination with 2-week cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone (CHOP-14) was determined by ELISA in 20 elderly patients with diffuse large B-cell lymphoma (DLBCL) 10 minutes before and after each infusion and 1 week and 1, 2, 3, 6, and 9 months after the last infusion." | 5.16 | The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ( Held, G; Lengfelder, E; Metzner, B; Müller, C; Murawski, N; Nickenig, C; Peter, N; Pfreundschuh, M; Poeschel, V; Reiser, M; Rixecker, T; Wenger, M; Wiesen, MH; Zeynalova, S; Zwick, C, 2012) |
| "S0515 was a phase 2 trial to determine whether the addition of bevacizumab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab (R-CHOP) would improve progression-free survival (PFS) without adding significant toxicity in patients with newly diagnosed advanced diffuse large B-cell lymphoma." | 5.16 | A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. ( Farnsworth, B; Fisher, RI; Glenn, MJ; Iannone, M; LeBlanc, M; Miller, TP; Rimsza, LM; Stopeck, AT; Unger, JM, 2012) |
| " One thousand one hundred thirteen patients with diffuse large B-cell lymphoma (DLBCL) received rituximab (R)-CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisone) in an observational study." | 5.16 | Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. ( Bendall, K; Jaeger, U; Krall, W; Lugtenburg, P; Noens, L; Rossi, FG; Silvestre, AS; Szabo, Z, 2012) |
| " In this study, we performed immunohistochemical analysis for IDO expression using mouse anti-human IDO monoclonal antibody in 119 tissue samples of diffuse large B-cell lymphoma (DLBCL) obtained before treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.15 | Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. ( Goto, N; Hara, T; Hirose, Y; Hoshi, M; Ito, H; Kanemura, N; Kasahara, S; Moriwaki, H; Ninomiya, S; Saito, K; Seishima, M; Shimizu, M; Takahashi, T; Takami, T; Tsurumi, H; Yamada, T, 2011) |
| " We evaluated dose-escalated bortezomib plus standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (R) in patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)." | 5.15 | Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. ( Cesarman, E; Chadburn, A; Cheung, K; Coleman, M; Elstrom, R; Ely, S; Furman, RR; Lacasce, A; Lee, SM; Leonard, JP; Martin, P; Morrison, J; Ruan, J; Vose, JM, 2011) |
| "This Phase II study assessed feasibility and efficacy of a biweekly R-COMP-14 regimen (rituximab, cyclophosphamide, non-pegylated liposome-encapsulated doxorubicin, vincristine and prednisone) in untreated elderly patients with poor-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high 'life threat' impact NIA/NCI cardiac comorbidity." | 5.15 | Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. ( Amore, A; Arcamone, M; Becchimanzi, C; Capobianco, G; Caronna, A; Corazzelli, G; De Filippi, R; Frigeri, F; Lucania, A; Marcacci, G; Mastrullo, L; Morelli, E; Pinto, A; Rosariavilla, M; Russo, F; Volzone, F, 2011) |
| "This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL)." | 5.14 | Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. ( Coiffier, B; Emile, JF; Fermé, C; Gabarre, J; Gisselbrecht, C; Haioun, C; Herbrecht, R; Morchhauser, F; Mounier, N; Ranta, D; Récher, C; Tilly, H, 2009) |
| "To evaluate the prognostic value of cell of origin immunohistochemical markers and BCL2, BCL6, and c-MYC translocations in a homogeneous cohort of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.14 | Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. ( Baia, M; Banham, AH; Berger, F; Briere, J; Coiffier, B; Copie-Bergman, C; Emile, JF; Feugier, P; Gaulard, P; Gisselbrecht, C; Haioun, C; Jais, JP; Leroy, K; Molina, TJ; Mounier, N; Salles, GA; Tilly, H, 2009) |
| "This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20(+) diffuse large B-cell lymphoma." | 5.14 | The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. ( Carrasquillo, JA; Dunleavy, K; Grant, N; Jaffe, ES; Little, RF; Pittaluga, S; Steinberg, SM; Wayne, AS; Wilson, WH; Yarchoan, R, 2010) |
| "This study aimed to evaluate the efficacy and safety of the treatment with (90)Y-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients with previously untreated diffuse large B-cell lymphoma (DLBCL)." | 5.14 | Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. ( Argnani, L; Baccarani, M; Bottelli, C; Botto, B; Broccoli, A; Cabras, MG; Derenzini, E; Di Rocco, A; Fanti, S; Fina, M; Franceschetti, S; Gandolfi, L; Montini, GC; Pellegrini, C; Petti, MC; Pileri, S; Rossi, G; Stefoni, V; Tucci, A; Zinzani, PL, 2010) |
| "5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years." | 5.14 | Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. ( Belhadj, K; Bordessoule, D; Castaigne, S; Coiffier, B; Fermé, C; Lefort, S; Lepeu, G; Macro, M; Marit, G; Plantier, I; Sebban, C; Thieblemont, C; Tilly, H; Van Den Neste, E, 2010) |
| " A phase 1 evaluation was conducted of bortezomib with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL)." | 5.14 | Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. ( Cheung, YK; Coleman, M; Elstrom, R; Furman, RR; LaCasce, AS; Leonard, JP; Martin, P; Ruan, J; Vose, JM, 2010) |
| "To assess if immunochemotherapy influenced the prognostic value of IPI in elderly diffuse large B-cell lymphoma (DLBCL) patients, we evaluated the performance of the standard International Prognostic Index (IPI) and following modifications: age adjusted (AA)-IPI, revised (R)-IPI, and an elderly IPI with age cut-off 70 years (E-IPI) in patients > 60 years treated with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)." | 5.14 | Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in ( Advani, RH; Chen, H; Fisher, RI; Gascoyne, RD; Habermann, TM; Horning, SJ; Morrison, VA; Peterson, BA; Weller, EA, 2010) |
| " GM-CSF was combined with standard rituximab + CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy (R-CHOP) in the treatment of elderly patients with de novo diffuse large B-cell lymphoma (DLBCL)." | 5.14 | Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. ( Bottner, WA; Chang, JE; Kahl, BS; Kim, KM; Longo, WL; Rodrigues, GA; Sanchez, FA; Saphner, TJ; Seo, S; Werndli, JE, 2010) |
| "Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma." | 5.13 | Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. ( Abella, E; García, M; Gardella, S; González-Barca, E; López, A; López-Guillermo, A; Miralles, P; Morgades, M; Oriol, A; Ribera, JM, 2008) |
| "A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients." | 5.13 | A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. ( Alinari, L; Baccarani, M; Bacci, F; Castellucci, P; de Vivo, A; Derenzini, E; Fanti, S; Farsad, M; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL, 2008) |
| "To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (R) infusional therapy in diffuse large B-cell lymphoma (DLBCL) with analysis of germinal center B-cell (GCB) and post-GCB subtypes by immunohistochemistry." | 5.13 | Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. ( Chabner, BA; Dunleavy, K; Grant, N; Gutierrez, M; Hegde, U; Jaffe, ES; Janik, JE; Pittaluga, S; Raffeld, M; Staudt, L; Steinberg, SM; Wilson, WH, 2008) |
| "The emerging molecular and prognostic characterization of diffuse large B-cell lymphoma (DLBCL) has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in recent years, with the identification of several DLBCL subtypes associated with significantly inferior survival after standard R-CHOP therapy." | 5.12 | DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? ( Major, A; Smith, SM, 2021) |
| "A major evolution in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) occurred almost two decades ago, with clinical trials demonstrating that the addition of rituximab (R) to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), which had been the "gold standard" of therapy since 1976, significantly improved outcome, including response rate and disease-free survival, of these patients." | 5.12 | Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective. ( Morrison, VA, 2021) |
| "Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard of care first line treatment for diffuse large B-cell lymphoma (DLBCL), though outcomes remain suboptimal." | 5.12 | R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. ( Gafter-Gvili, A; Gurion, R; Pasvolsky, O; Raanani, P; Rozental, A, 2021) |
| "Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more treatment-resistant." | 5.12 | Lenalidomide in DLBCL: are we past the cell of origin? ( Cooper, DL; Goldfinger, M, 2021) |
| "The precise mechanism of rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is not fully elucidated." | 5.12 | FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. ( Do, YR; Hyun, MS; Jung, HD; Kim, DH; Kim, JG; Kim, MK; Lee, JJ; Park, YH; Shin, HJ; Sohn, SK; Yang, DH, 2006) |
| "To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a two-stage randomized trial of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP (R-CHOP), with a second random assignment to maintenance rituximab (MR) or observation in responding patients." | 5.12 | Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. ( Cassileth, PA; Cohn, JB; Dakhil, SR; Fisher, RI; Gascoyne, RD; Habermann, TM; Horning, SJ; Morrison, VA; Peterson, BA; Weller, EA; Woda, B, 2006) |
| "In this pilot study, the authors assessed the feasibility of combination epratuzumab and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (ER-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)." | 5.12 | A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. ( Ansell, SM; Colgan, JP; Dogan, A; Geyer, S; Habermann, TM; Inwards, DJ; Kahl, BS; Maurer, MJ; Micallef, IN; White, WL, 2006) |
| "To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma." | 5.11 | Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. ( Bosly, A; Bouabdallah, R; Christian, B; Coiffier, B; Fermé, C; Feugier, P; Gaulard, P; Gisselbrecht, C; Lepage, E; Morschhauser, F; Reyes, F; Salles, G; Sebban, C; Solal-Celigny, P; Tilly, H; Van Hoof, A, 2005) |
| "Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied." | 5.10 | Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002) |
| "The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)." | 5.10 | CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. ( Bouabdallah, R; Briere, J; Coiffier, B; Gaulard, P; Gisselbrecht, C; Herbrecht, R; Lederlin, P; Lepage, E; Morel, P; Reyes, F; Salles, G; Tilly, H; Van Den Neste, E, 2002) |
| "We hypothesized that incremental improvements in the cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy regimen through optimization of drug selection, schedule, and pharmacokinetics would improve outcome in patients with large B-cell lymphomas." | 5.10 | Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. ( Balis, F; Chabner, BA; Cheson, BD; Cole, D; Drbohlav, N; Grossbard, ML; Gutierrez, M; Harris, N; Jaffe, ES; Janik, J; Little, RF; Longo, DL; Pearson, D; Pittaluga, S; Raffeld, M; Staudt, L; Steinberg, SM; Wilson, WH; Wittes, R, 2002) |
| "Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes." | 5.05 | R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. ( Li, LR; Wang, L, 2020) |
| "Two triple-drug combinations (cyclophosphamide, vincristine, and prednisone [CVP] and adriamycin, bleomycin, and prednisone [ABP]) were randomly tested in 57 consecutive patients with pathologic stage IV non-Hodgkin's lymphoma." | 5.04 | Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas. ( Bonadonna, G; Monfardini, S; Villa, E, 1977) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 5.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| " R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard treatment for diffuse large B-cell lymphoma (DLBCL) in line with the prior 2013 guidelines." | 5.01 | [Diffuse large B-cell lymphoma: standard treatment and research questions]. ( Ohmachi, K, 2019) |
| " Herpes zoster was suspected and valacyclovir was administered." | 4.93 | Diffuse large B-cell lymphoma recurring with zosteriform cutaneous lesions. ( Mori, K; Noda, T; Ozaki, S; Sekimoto, E; Shibata, H; Shigekiyo, T; Shikiji, T; Sumitani, R; Yamashita, K, 2016) |
| "A 72-year-old man with recently diagnosed diffuse large B-cell lymphoma became unresponsive 4 days after initiation of R-CHOP and intrathecal methotrexate." | 4.93 | Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature. ( Blattner, M; Fowler, S; How, J; Schindler, SE; Wang-Gillam, A, 2016) |
| "Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL), ∼30% to 50% of patients are not cured by this treatment, depending on disease stage or prognostic index." | 4.93 | Diffuse large B-cell lymphoma: R-CHOP failure-what to do? ( Coiffier, B; Sarkozy, C, 2016) |
| "Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail R-CHOP have a dismal outcome." | 4.91 | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. ( Gascoyne, RD; Sehn, LH, 2015) |
| "Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma." | 4.91 | A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. ( Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE, 2015) |
| "This study systematically reviewed and meta-analysed the prognostic value of complete remission status at end-of-treatment (18) F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 4.91 | Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. ( Adams, HJ; Kwee, TC; Nievelstein, RA, 2015) |
| "The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP)." | 4.91 | The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis. ( Deng, C; Hu, C; Wang, J; Zhang, G; Zou, W, 2015) |
| "The influence of Fc gamma receptor IIIA (FCGR3A) 158V/F polymorphisms on the response to rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP) therapy in diffuse large B-cell lymphoma (DLBCL) is uncertain." | 4.90 | FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. ( Deng, L; Ding, H; Ding, N; He, Y; Jin, X; Liu, F; Song, Y; Zhu, J, 2014) |
| "Central nervous system (CNS) prophylaxis for diffuse large B-cell lymphoma (DLBCL) is controversial with even less evidence in the era of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy." | 4.88 | Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. ( Berinstein, N; Buckstein, R; Cheung, MC; Guirguis, HR; Imrie, KR; Mahrous, M; Piliotis, E; Zhang, L, 2012) |
| "For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs)." | 4.86 | Unresolved issues in diffuse large B-cell lymphomas. ( Murawski, N; Pfreundschuh, M; Zwick, C, 2010) |
| "More than 60% of patients with diffuse large B-cell lymphoma (DLBCL) will be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 4.85 | Early detection of patients with poor risk diffuse large B-cell lymphoma. ( Sehn, LH, 2009) |
| "The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy was a milestone in the development of front-line therapy for diffuse large B-cell lymphoma (DLBCL)." | 4.84 | Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. ( Gisselbrecht, C, 2008) |
| "The CHOP (cyclophosphamide/doxorucibin/vincristine/prednisone) regimen has been established as the standard treatment for diffuse large B-cell lymphoma (DLBCL)." | 4.84 | Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma. ( Gleissner, B; Pfreundschuh, M; Zwick, C, 2007) |
| "Among the strategies developed to improve results in patients with diffuse large B-cell lymphoma, increasing the dose of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) regimen (dose-intense regimen) and decreasing the duration of cycles (dose-dense regimen) or doing both had been proposed before the rituximab era." | 4.84 | Strategies for improving outcomes with 14-day anthracycline-based regimens in patients with aggressive lymphomas. ( Broussais-Guillaumot, F; Coiffier, B, 2007) |
| "A review of the use of rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) in diffuse large B-cell lymphomas is presented, focusing on the recent presentation of the combination of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) plus rituximab in elderly patients." | 4.81 | Rituximab in the treatment of diffuse large B-cell lymphomas. ( Coiffier, B, 2002) |
| "A Markov model was constructed to compare four strategies for patients with newly diagnosed intermediate- to high-risk diffuse large B-cell lymphoma: strategy 1: polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) plus second-line CAR-T for early relapse (< 12 months); strategy 2: polatuzumab-R-CHP plus second-line salvage therapy ± autologous stem-cell transplant; strategy 3: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus second-line CAR-T for early relapse; strategy 4: SOC (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus second-line salvage therapy ± autologous stem-cell transplant)." | 4.31 | Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Dif ( Crump, M; Jain, M; Kuruvilla, J; Prica, A; Vijenthira, A, 2023) |
| "Diffuse large B-cell lymphoma (DLBCL) is frequently treated with chemotherapy incorporating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), which induces remission in 80% to 95% of cases." | 4.31 | Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy-treated diffuse large B-cell lymphoma. ( Childress, MO; Dhawan, D; Mukhopadhyay, A; Ramos-Vara, JA; Ruple, A; Zaidi, B, 2023) |
| "This prospective study aimed to investigate the efficacy and safety of preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF) for HBsAg-positive patients with newly diagnosed diffuse large B-cell lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy." | 4.31 | A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. ( Chang, MH; Eom, HS; Hyun, SY; Jo, JC; Kang, HJ; Kim, DY; Kim, HJ; Kim, IH; Kim, JS; Kim, MK; Kim, WS; Kim, YR; Kwak, JY; Lee, JO; Lee, WS; Lim, SN; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yang, DH; Yoo, KH; Yoon, DH, 2023) |
| "To compare the efficacy and safety of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Waldeyer's ring diffuse large B-cell lymphoma (WR-DLBCL) at a single institution." | 4.31 | Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution. ( Liang, Y; Liu, X; Piao, Y; Wang, H; Wang, L; Wei, L; Yang, J, 2023) |
| "The International prognostic Index (IPI) is the most widely used clinical prediction model for diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but may be suboptimal in older patients." | 4.31 | The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy. ( Barzenje, D; Brodtkorb, M; Fluge, O; Galleberg, R; Holte, H; Isaksen, KT; Liestol, K; Lingjarde, OC; Mastroianni, MA; Meyer, P; Ramslien, F; Rinde, M; Rusten, LS; Slaaen, M; Smeland, EB, 2023) |
| "Approximately 40% patients of diffuse large B-cell lymphoma (DLBCL) would develop disease recurrence/progression after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis." | 4.31 | Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. ( Ding, K; Jiang, X; Wang, X; Yu, L, 2023) |
| "Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL)." | 4.31 | A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma. ( Arcari, A; Balzarotti, M; Bernuzzi, P; Botto, B; Cavallo, F; Cencini, E; Dessì, D; Di Rocco, A; Fabbri, A; Ferrero, S; Flenghi, L; Gini, G; Hohaus, S; Luminari, S; Mahmoud, AM; Mammi, C; Marcheselli, L; Marino, D; Merli, F; Merli, M; Musuraca, G; Nassi, L; Pagani, C; Pelliccia, S; Pennese, E; Puccini, B; Rigacci, L; Sartori, R; Spina, M; Tabanelli, V; Tani, M; Tarantini, G; Tucci, A; Usai, SV; Vallisa, D; Zanni, M; Zilioli, VR, 2023) |
| " Over the past 10 years, the association between clozapine, which is the criterion standard treatment for refractory schizophrenia, and hematological malignancies has been described." | 4.31 | Diffuse Large B-Cell Lymphoma with Cutaneous Manifestations in a Young Patient Using Clozapine for Schizophrenia: A Case Report. ( Alves Junior, MP; Gouveia, PADC; Guedes, MMV; Lira, AC; Moraes de Brito, MC; Nascimento, JDS; Pimentel Jatobá, V, 2023) |
| "Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell malignancy, with varying prognosis after the gold standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 4.12 | A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. ( Akashi, K; Aster, JC; Iwasaki, H; Kato, K; Kikushige, Y; Kunisaki, Y; Kuo, FC; Maeda, T; Miyamoto, T; Miyawaki, K; Miyoshi, H; Mori, Y; Ohshima, K; Sasaki, K; Semba, Y; Sugio, T, 2022) |
| "Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP)." | 4.12 | Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. ( Choi, YS; Do, YR; Eom, HS; Hyun, SY; Jeong, SH; Jo, JC; Kang, HJ; Kim, HJ; Kim, MK; Kim, SH; Kim, SJ; Kim, WS; Koh, Y; Kwak, JY; Kwon, JH; Lee, GW; Lee, HS; Lee, WS; Oh, SY; Park, BB; Park, Y; Shin, HJ; Sohn, BS; Suh, C; Won, JH; Yang, DH; Yi, JH; Yi, SY; Yoo, KH; Yoon, DH; Yun, HJ, 2022) |
| "Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method." | 4.12 | Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. ( Agbetiafa, K; Ahearne, M; Barlow, BR; Calimeri, T; Cheah, CY; Choquet, S; Clavert, A; Cwynarski, K; Durot, E; Ebsworth, TJ; El Galaly, TC; Elliot, J; Eyre, TA; Fernandez, R; Ferreri, AJM; Forgeard, N; Fox, CP; Gounder, P; Guidetti, A; Hamad, N; Htut, TW; Khwaja, J; Kirkwood, AA; Ku, M; Lebras, L; Lees, C; Lewis, KL; Liu, Q; Lombion, N; Lopez-Garcia, A; Manos, K; Martinez-Calle, N; McIlroy, G; McKay, P; Miall, F; Moles-Moreau, MP; Narkhede, M; O'Mahony, D; Preston, G; Renaud, L; Ricard, L; Roulin, L; Rusconi, C; Santarsieri, A; Schorb, E; Scott, H; Shah, N; Smith, J; Soussain, C; Strüßmann, T; Tchernonog, E; Vassallo, F; Wilson, MR; Wong Doo, N; Zayac, AS; Øvlisen, AK, 2022) |
| "Maintaining relative dose intensity (RDI) of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the prognosis of patients with diffuse large B-cell lymphoma (DLBCL)." | 4.12 | Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. ( Kageyama, A; Kanemasa, Y; Morita, Y; Nakamura, S; Ohigashi, A; Omuro, Y; Sasaki, Y; Shimoyama, T; Tamura, T; Yagi, Y, 2022) |
| "Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia." | 4.12 | Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. ( Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Putri, S; Saldi, SRF; Sari, ER; Sastroasmoro, S; Setiawan, E, 2022) |
| "In patients with treatment-naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study (A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone [R-CHP] Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [R-CHOP] in Participants With Diffuse Large B-Cell Lymphoma) reported a 6." | 4.12 | Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. ( Budde, LE; Danilov, AV; Forman, SJ; Herrera, AF; Kambhampati, S; Kwak, LW; Mei, MG; Pak, S; Popplewell, LL; Rosen, ST; Saumoy, M; Schneider, Y; Siddiqi, T; Thiruvengadam, NR; Wen, YP; Zain, J, 2022) |
| "The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years with an aaIPI (age-adjusted International Prognostic Index) score ≥1 (registered as NCT00144755)." | 4.12 | Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. ( Belot, A; Bosly, A; Camus, V; Casasnovas, O; Delarue, R; Feugier, P; Fitoussi, O; Fruchart, C; Ghesquières, H; Haioun, C; Joubert, C; Michot, JM; Molina, TJ; Nicolas-Virelizier, E; Oberic, L; Sibon, D; Thieblemont, C; Tilly, H, 2022) |
| " Most patients with diffuse large B-cell lymphoma (DLBCL) are successfully treated with the current standard chemotherapeutic regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 4.12 | [Therapeutic developments and advances in B-cell lymphoma]. ( Miyazaki, K, 2022) |
| "Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P)." | 4.12 | Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. ( Böhmer, L; Brink, M; Diepstra, A; Huls, GA; Jansen, PM; Kersten, MJ; Meeuwes, FO; Mutsaers, PGNJ; Nijland, M; Oostvogels, R; Plattel, WJ; Snijders, TJF; van der Poel, MWM; Vermaat, JSP; Visser, O; Woei-A-Jin, S; Wondergem, M, 2022) |
| "The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 4.02 | Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP. ( Bang, SM; Kang, M; Kim, ES; Kim, HB; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Song, KH; Suh, KJ, 2021) |
| " He had a history of chronic lymphocytic leukemia with transformation to diffuse large B-cell lymphoma for which he was started on dose-adjusted rituximab, etoposide, prednisone vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH)." | 4.02 | Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report. ( Abou-Ghanem, N; Agab, M; Egoryan, G; Filipiuk, D; Gidron, A; Ibrahim, R; Murguia-Fuentes, R; Pyakuryal, B; Rodriguez-Nava, G; Trelles-Garcia, DP; Yanez-Bello, MA, 2021) |
| "Outcomes of diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from indolent lymphoma, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone are described in retrospective studies." | 4.02 | Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma. ( Baez-Sosa, V; Chaturvedi, M; Desai, S; Hameed, R; Shenoy, AG, 2021) |
| "Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear." | 4.02 | Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. ( Batlevi, CL; Bobillo, S; Caron, PC; Dogan, A; Ghione, P; Hamilton, A; Hamlin, PA; Horwitz, SM; Joffe, E; Kumar, A; Matasar, MJ; Mondello, P; Moskowitz, A; Noy, A; Owens, CN; Palomba, ML; Sermer, D; Seshan, VE; Straus, D; von Keudell, G; Younes, A; Zelenetz, AD, 2021) |
| "Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP." | 4.02 | Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. ( Abou Dalle, I; Al Chami, F; Bazarbachi, A; Charafeddine, M; El Cheikh, J; El Darsa, H; El Sayed, R; Ibrahim, A; Kort, J, 2021) |
| " Nine years earlier, the patient had been diagnosed with diffuse large B-cell lymphoma (DLBCL) and undergone rituximab, cyclophosphamide, doxorubicin hydrochloride, oncovin, prednisone (R-CHOP) therapy." | 3.96 | Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. ( Fukuda, H; Fukuda, S; Fukunaga, A; Hirai, F; Irie, M; Kunimoto, H; Morihara, D; Sakisaka, S; Sakurai, K; Shakado, S; Takata, K; Takeyama, Y; Tanaka, T; Umeda, K; Yamauchi, R; Yokoyama, K, 2020) |
| "Other iatrogenic immunodeficiency-associated lymphoproliferative disorders induced by immunosuppressive drugs, such as methotrexate (MTX-LPD), exhibit numerous pathological findings." | 3.96 | Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer. ( Carreras, J; Kikuti, YY; Kondo, Y; Moriya, K; Nakamura, N; Shiraiwa, S, 2020) |
| "In diffuse large B-cell lymphoma (DLBCL), there is an unmet medical need to select patients who would benefit from intensified frontline treatments such as adding etoposide to an R-CHOP regimen." | 3.96 | Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment. ( Bloigu, R; Haapasaari, KM; Hakalahti, A; Honkavaara, P; Kari, EJM; Karihtala, P; Kuittinen, O; Kuusisto, MEL; Pirinen, R; Teppo, HR; Turpeenniemi-Hujanen, T, 2020) |
| " Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab(R-CHOP) as front line therapy for PLHIV with diffuse large B-cell lymphoma (DLBCL) receiving modern combined antiretroviral therapy (cART)." | 3.96 | Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. ( Chen, J; Liu, L; Qi, TK; Shen, YZ; Song, W; Sun, JJ; Tang, Y; Wang, JR; Wang, ZY; Zhang, RF, 2020) |
| "One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy." | 3.96 | A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. ( Arroyo-Solera, I; Casanova, I; Céspedes, MV; Falgàs, A; Gallardo, A; Mangues, MA; Mangues, R; Moreno, MJ; Pallarès, V; Sierra, J; Unzueta, U; Vázquez, E; Villaverde, A, 2020) |
| "A 52-year-old woman was treated for colorectal diffuse large B-cell lymphoma (DLBCL) after a prolonged treatment period of azathioprine (AZA) and infliximab (IFX) for Crohn's disease (CD)." | 3.96 | Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine. ( Daikuhara, S; Hirayama, A; Sato, K; Suga, T; Tanaka, E; Uehara, T, 2020) |
| "Addition of rituximab (R) to "CHOP" (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients." | 3.91 | CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. ( Ammatuna, E; Bouwstra, R; Bremer, E; Cendrowicz, E; de Boer, J; Fehrmann, RSN; He, Y; Huls, G; Kooistra, H; Nijland, M; van Meerten, T; Zu Eulenburg, C, 2019) |
| "About one third of patients with diffuse large B-cell lymphoma (DLBCL) relapse after receiving first-line (1L) treatment of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.91 | Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. ( Broder, MS; Purdum, A; Reddy, SR; Tieu, R, 2019) |
| "We compared treatment outcomes between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy alone with R-CHOP followed by consolidative radiation therapy (RT) in diffuse large B-cell lymphoma (DLBCL)." | 3.91 | A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02). ( Cho, WK; Chung, MJ; Eom, KY; Kim, JH; Kim, WC; Lee, JH; Oh, D, 2019) |
| "Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype." | 3.88 | Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. ( Ayer, T; Chen, Q; Flowers, CR; Goldstein, DA; Koff, JL; Staton, AD, 2018) |
| " We aimed at evaluating the NLR as predictive for complete response (CR) and prognostic for progression-free (PFS) and overall survival (OS) in a study cohort of 121 Peruvian patients with diffuse large B-cell lymphoma (DLCBL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 3.88 | The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. ( Beltrán, BE; Castillo, JJ; Cotrina, E; Paredes, S; Sotomayor, EM, 2018) |
| "Acute biochemical changes, hepatotoxicity, nephrotoxicity and frequency of infections are common in diffuse large B-cell Lymphoma patients undergoing Cyclophosphamide, Doxorubicin, Oncovin (Vincristine) Prednisone (CHOP) and Rituximab plus CHOP chemo cycles." | 3.88 | Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab. ( Adil, SO; Ali, K; Ansari, SH; Baig, MT; Shamsi, TS; Sial, AA, 2018) |
| "To investigate the effectiveness of 2 chemotherapeutic regimens, bendamustine plus rituximab (BR) or reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (RD-R-CHOP), in elderly patients with treatment-naïve diffuse large B-cell lymphoma." | 3.88 | Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. ( Cheng, CL; Chou, SC; Liu, JH; Tang, JL; Tien, HF; Yao, M, 2018) |
| "Aberrant microRNA (miRNAs) have recently been proposed as important regulators in acquiring resistance to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in diffuse large B-cell lymphoma (DLBCL)." | 3.88 | Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. ( Guo, WJ; He, MQ; Huang, H; Huang, YY; Lin, XJ; Ruan, YJ; Su, T; Sun, N; Sun, YQ; Wang, CY; Yao, RX; Zhou, XH, 2018) |
| "Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL)." | 3.88 | Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. ( Ansell, SM; Castellino, A; Cavallo, F; Chiappella, A; Ciccone, G; Congiu, A; Foran, JM; Gaidano, G; Habermann, TM; Inghirami, G; King, RL; LaPlant, BR; Macon, WR; Molinari, AL; Nowakowski, GS; Pavone, V; Pederson, LD; Reeder, CB; Rivera, CE; Spina, M; Tucci, A; Vitolo, U; Witzig, TE, 2018) |
| " Since the impact of polymorphisms of the VEGF on non-Hodgkin lymphoma prognosis has not been fully elucidated, we investigated 149 diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at the National Cancer Center, Korea." | 3.85 | Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma. ( Eom, HS; Kim, MJ; Kim, MK; Kong, SY; Lee, H; Park, WS; Sohn, JY; Yoon, KA, 2017) |
| "Prognostic models for primary diffuse large B-cell lymphoma (DLBCL) resistant to or relapsing after initial therapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) have not been well-established." | 3.85 | Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. ( Fukuda, T; Miura, O; Watanabe, K; Yamamoto, M, 2017) |
| "No randomised study in the rituximab era has been performed specifically to evaluate addition of etoposide to treatment of diffuse large B-cell lymphoma (DLBCL)." | 3.85 | Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. ( Hartman, L; Jerkeman, M; Székely, E; Wästerlid, T, 2017) |
| " The principal objective of this study was to determine whether the tumors' microenvironment expressions of CD11c and FOXP3 are predictive of clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients receiving treatment with rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy." | 3.85 | Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. ( Jeong, JS; Ju, MH; Kim, DH; Kim, HJ; Kim, SH; Kim, SY; Koh, MS; Kwak, JY; Lee, JH; Lee, S; Oh, SY; Pak, MG, 2017) |
| "A few recent studies investigated the prognostic impact of CD30 expression in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone." | 3.85 | CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. ( Desai, P; Li, S; Lin, P; Medeiros, LJ; Oki, Y; Saksena, A; Tang, G; Thakral, B; Xu, J; Yin, CC; You, MJ, 2017) |
| "To assess the benefit of rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) regimen as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) presenting with unfavorable or aggressive features, and autologous stem cell transplantation (ASCT) as a part of the first-line treatment for selected DLBCL patients with additional aggressive features." | 3.85 | Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. ( Ajduković, R; Jakšić, O; Kušec, R; Lucijanić, M; Mitrović, Z; Pejša, V; Piršić, M; Prka, Ž, 2017) |
| "There is a lack of data on the effect of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy on brain glucose metabolism of diffuse large B-cell lymphoma (DLBCL) patients, as measured by 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)." | 3.83 | Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects. ( Adams, HJ; de Klerk, JM; Dubois, SV; Fijnheer, R; Heggelman, BG; Kwee, TC; Nievelstein, RA, 2016) |
| " In this study, we assessed rearrangements and expression of MYC, BCL2 and BCL6 in 898 patients with de novo diffuse large B-cell lymphoma treated with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab)." | 3.83 | Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. ( Bhagat, G; Chiu, A; Choi, WW; Deng, L; Dybkær, K; Ferreri, AJ; Hsi, ED; Hu, S; Huh, J; Manyam, GC; Medeiros, LJ; Montes-Moreno, S; Møller, MB; Orazi, A; Parsons, BM; Piris, MA; Ponzoni, M; Richards, KL; Tzankov, A; van Krieken, JH; Visco, C; Wang, X; Winter, JN; Xu-Monette, ZY; Ye, Q; Young, KH; Zhang, L; Zu, Y, 2016) |
| "The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)." | 3.83 | CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. ( Giampietro, P; Gregory, SA; Horner, TJ; Leonard, JP; Lin, TS; Smith, H; Williams, VC, 2016) |
| "We evaluated the prognostic impact of cell-of-origin classification as well as intratumoral regulatory T cells (Tregs), macrophages, and microvessel density (MVD) on 115 patients (74 in the training set and 41 in the validation set) diagnosed with de novo diffuse large B-cell lymphoma (DLBCL) and uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy." | 3.83 | Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy. ( Gomez-Gelvez, JC; Inamdar, KV; Leavitt, M; Perkins, SL; Salama, ME, 2016) |
| "Diffuse large B-cell lymphoma (DLBCL) patients with high Ki-67 expression receive limited benefits from R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy." | 3.83 | A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution. ( Bi, XW; Huang, JJ; Jiang, WQ; Li, ZM; Lin, TY; Liu, PP; Sun, P; Wang, Y; Xia, Y, 2016) |
| "We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP)." | 3.83 | The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. ( Fujimaki, K; Fujisawa, S; Fujita, H; Hagihara, M; Hashimoto, C; Kawamoto, K; Kawasaki, R; Koharazawa, H; Miyashita, K; Motohashi, K; Motomura, S; Sakai, R; Sone, H; Suzuki, T; Tachibana, T; Taguchi, J; Takasaki, H; Takemura, S; Takizawa, J; Tomita, N; Yamamoto, W; Yamazaki, E, 2016) |
| " We evaluated the association of sarcopenia with febrile neutropenia hospitalization, treatment-related mortality, and ability to complete standard number of cycles in a retrospective cohort of United States veterans diagnosed with DLBCL between 1998 and 2008 and treated with cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab." | 3.83 | Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. ( Carson, KR; Ganti, A; Liu, W; Luo, S; Lynch, RC; O'Brian, K; Riedell, P; Sanfilippo, KM; Xiao, DY, 2016) |
| "We evaluated the prognostic value of total lesion glycolysis (TLG) measured in baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.83 | Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. ( Chen, Y; Huang, G; Huang, H; Liu, J; Zhou, M; Zhou, X, 2016) |
| "This study evaluated the efficacy of central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell lymphoma (DLBCL)." | 3.81 | Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. ( Fujimaki, K; Hagihara, M; Hashimoto, C; Ishibashi, D; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Kishimoto, K; Koyama, S; Motomura, S; Numata, A; Ohshima, R; Sakai, R; Tachibana, T; Taguchi, J; Takahashi, H; Takasaki, H; Takemura, S; Tomita, N; Watanabe, R, 2015) |
| "We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions." | 3.81 | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lympho ( Ahn, JS; Bae, SH; Do, YR; Go, SI; Hong, J; Kang, HJ; Kim, HJ; Kim, JS; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, WS; Kim, YR; Lee, B; Lee, GW; Lee, H; Lee, SI; Lee, WS; Oh, S; Oh, SY; Song, MK; Suh, C; Yhim, HY, 2015) |
| "Addition of etoposide to the R-CHOP chemotherapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOEP) has resulted in improved survival in young patients with high-risk diffuse large B-cell lymphoma (DLBCL)." | 3.81 | Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. ( Brown, P; Gang, AO; Høgdall, E; Klausen, TW; Knudsen, H; Lauritzen, AF; Nielsen, SL; Nørgaard, P; Pedersen, M; Pedersen, MØ, 2015) |
| " We retrospectively analyzed 148 Taiwanese patients with newly diagnosed diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)-like regimens from January 2001 to December 2010 at the Tri-Service General Hospital." | 3.81 | Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. ( Chang, PY; Chen, JH; Chen, YC; Dai, MS; Ho, CL; Huang, TC; Lu, CS; Wu, YY, 2015) |
| "The purpose of this study was to analyze the pre- and post-treatment neutrophil to lymphocyte ratio (pre- and post-NLR) in combination with immunologic profiles in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 3.81 | Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. ( Ha, H; Heo, DS; Jeon, YK; Keam, B; Kim, CW; Kim, DW; Kim, TM; Lee, SH, 2015) |
| "This study evaluated the effect of age and cell of origin on the prognostic significance of Ki-67 labeling index (Ki-67 LI) on overall survival (OS) of diffuse large B-cell lymphoma (DLBCL) in a cohort of 697 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 3.81 | Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. ( Huh, J; Hwang, HS; Koh, YW; Park, CS; Suh, C; Yoon, DH, 2015) |
| "Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in patients aged >80 years are less clear." | 3.81 | Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. ( Flowers, CR; Koff, JL; Lipscomb, J; Nastoupil, LJ; Rai, A; Williams, JN, 2015) |
| "The purpose of this study was to evaluate the role of involved-lesion radiation therapy (ILRT) after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy in limited stage diffuse large B-cell lymphoma (DLBCL) by comparing outcomes of R-CHOP therapy alone with R-CHOP followed by ILRT." | 3.81 | Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. ( Heo, DS; Kim, BH; Kim, IH; Kim, TM; Kwon, J, 2015) |
| "We analysed data from 380 patients enrolled in a French multi-centre regional cohort, with diffuse large B-cell lymphoma receiving first-line treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or R-CHOP-like regimens." | 3.81 | A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. ( Bauvin, E; Borel, C; Compaci, G; Delpierre, C; Despas, F; Jeanneau, P; Lamy, S; Laurent, G; Nogaro, JC; Récher, C, 2015) |
| "The aim of this retrospective analysis was to investigate the efficacy and safety of nonpegylated liposomal doxorubicin (NPLD) as part of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL) and preexisting cardiac diseases." | 3.81 | Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases. ( Aurich, M; Ho, AD; Rohlfing, S; Schöning, T; Witzens-Harig, M, 2015) |
| " The assay was then applied to pretreatment formalin-fixed paraffin-embedded tissue (FFPET) biopsies from 344 patients with de novo diffuse large B-cell lymphoma (DLBCL) uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at the British Columbia Cancer Agency." | 3.81 | Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. ( Abrisqueta, P; Barry, GS; Ben-Neriah, S; Boyle, M; Connors, JM; Ennishi, D; Farinha, P; Gascoyne, RD; Hother, C; Kridel, R; Meissner, B; Mottok, A; Rimsza, LM; Savage, KJ; Scott, DW; Sehn, LH; Slack, GW; Staudt, LM; Steidl, C; Telenius, A; Wright, GW, 2015) |
| " The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear." | 3.81 | Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. ( Bhagat, G; Cao, X; Chiu, A; Choi, WW; Dybkær, K; Ferreri, AJ; Hsi, ED; Huh, J; Li, X; Liu, Z; Manyam, GC; Medeiros, LJ; Montes-Moreno, S; Møller, MB; O'Malley, DP; Orazi, A; Parsons, BM; Piris, MA; Ponzoni, M; Richards, KL; Sun, R; Tzankov, A; van Krieken, JH; Visco, C; Wang, X; Winter, JN; Xia, Y; Xu-Monette, ZY; Young, KH; Zhang, L; Zu, Y, 2015) |
| "Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has greatly improved clinical outcomes in patients with diffuse large B-cell lymphoma (DLBCL) compared with CHOP." | 3.81 | Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. ( Gribben, JG; Hao, J; Jia, L; Jiang, W; Li, J; Li, Y; Liu, P; Ren, H; Wang, X; Yan, F; Zhao, T, 2015) |
| "R-CHOP immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is a standard first-line treatment for diffuse large B-cell lymphoma (DLBCL)." | 3.81 | Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group. ( Boguradzki, P; Giza, A; Górecki, T; Joks, M; Jurczak, W; Knopińska-Posłuszny, W; Ochrem, B; Stella-Hołowiecka, B; Walewski, J; Wróbel, T; Zaucha, JM; Zimowska-Curyło, D, 2015) |
| " We have previously shown that low HIP1R protein expression was associated with poorer survival in diffuse large B-cell lymphoma (DLBCL) patients from Denmark treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 3.81 | Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. ( Banham, AH; Ch'ng, ES; Gaafar, A; Green, TM; Husin, A; Lawrie, CH; Loo, SK; Muruzabal, MA; Møller, MB; Pedersen, LM; Pomposo, MP; Wong, KK, 2015) |
| "To study expression of CD68, cyclin D1 protein and rearrangement of bcl-6 gene impact on the prognosis of diffuse large B-cell lymphoma (DLBCL)." | 3.81 | [Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma]. ( Bai, W; Liang, X; Sun, R; Wang, J, 2015) |
| "We evaluated the prognostic impact of the absolute lymphocyte count (ALC), absolute monocyte count (AMC), and lymphocyte/monocyte ratio (LMR) in 359 diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.80 | Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. ( Fujimaki, K; Fujisawa, S; Hashimoto, C; Hattori, Y; Ishibashi, D; Ishigatsubo, Y; Itabashi, M; Koyama, S; Miyashita, K; Motohashi, K; Motomura, S; Nakajima, Y; Ohshima, R; Sakai, R; Takahashi, H; Takasaki, H; Tomita, N; Watanabe, R; Yamamoto, E; Yamazaki, E, 2014) |
| "About 60% of patients with diffuse large B-cell lymphoma (DLBCL) may be cured by primary chemotherapy with an R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen." | 3.80 | Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. ( Benelli, G; Bosi, A; Brugia, M; Del Fava, E; Di Lollo, S; Di Rocco, A; Doria, M; Finolezzi, E; Landini, I; Martelli, M; Mini, E; Napoli, C; Nobili, S; Perrone, G; Puccini, B; Rigacci, L, 2014) |
| "In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes." | 3.80 | Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. ( Bhagat, G; Choi, WW; Dirnhofer, S; Dybkaer, K; Farnen, JP; Ferreri, AJ; Gerhard, M; Gisin, N; Hsi, ED; McDonnell, T; Medeiros, LJ; Møller, MB; Orazi, A; Piris, MA; Ponzoni, M; Richards, KL; Tzankov, A; van Krieken, JH; Visco, C; Winter, JN; Xu-Monette, ZY; Ye, Q; You, MJ; Young, KH, 2014) |
| ", we analyzed 262 patients who had been treated with Ruximab-cyclophosphamide, doxorubicin, vincristine, and prednisone for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and for whom data were available regarding pretreatment nutritional status." | 3.80 | Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. ( Cho, JW; Han, B; Kim, S; Kim, SJ; Kim, WS; Park, S; Woo, SY, 2014) |
| "An observational population-based cohort study was performed to investigate the role of comorbidity on outcome and treatment-related toxicity in patients with newly diagnosed advanced-stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 3.80 | Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. ( Beerden, T; Boslooper, K; Hoogendoorn, M; Joosten, P; Kibbelaar, RE; Kluin-Nelemans, HC; Storm, H; van Kamp, H; van Rees, B; van Roon, EN; Veeger, NJ; Veldhuis, GJ; Wieringa, A, 2014) |
| "Summary We report a case of a 56-year-old woman with a high-grade diffuse large B-cell lymphoma who unexpectedly developed toxic plasma levels of methotrexate (MTX) following the first cycle of rituximab-cyclophosphamide, hydroxydanorubicin, oncovin, prednisolone (R-CHOP) with a high-dose MTX chemotherapy protocol." | 3.80 | The utility of online haemodiafiltration in methotrexate poisoning. ( Abdelsalam, MS; Alfurayh, O; Althaf, MM; Maghfoor, I, 2014) |
| "The first-line standard treatment for diffuse large B-cell lymphoma (DLBCL) is the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 3.80 | R-CHOP versus R-COMP: are they really equally effective? ( Fiegl, M; Gamerith, G; Jäger, T; Linkesch, W; Melchardt, T; Mian, M; Mondello, P; Wasle, I, 2014) |
| "Recent studies provide convincing evidence that a combined immunohistochemical or fluorescence in situ hybridization (FISH) score of MYC, BCL2, BCL6 proteins and MYC translocations predicted outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.80 | MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. ( Cheng, J; Cheng, Y; Liu, YH; Luo, DL; Luo, XL; Xu, J; Yan, LX; Zhang, F; Zhuang, HG, 2014) |
| "Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable therapeutic responses and alternative therapies are needed for patients with unfavourable treatment outcomes after standard treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 3.80 | CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. ( Gascoyne, RD; Sehn, LH; Slack, GW; Steidl, C, 2014) |
| "Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL)." | 3.80 | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. ( Ahn, MS; Choi, JH; Choi, YW; Jeong, SH; Jin, UR; Kang, SY; Lee, HW; Park, JS, 2014) |
| "Long-term observation has identified a pattern of continuing relapse in limited stage diffuse large B-cell lymphoma (DLBCL) treated by three cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus involved-field irradiation." | 3.79 | R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. ( Fujimaki, K; Fujisawa, S; Fujita, A; Hagihara, M; Hashimoto, C; Ishigatsubo, Y; Kishimoto, K; Koharazawa, H; Kuwabara, H; Matsuura, S; Miyashita, K; Numata, A; Ogusa, E; Ohshima, R; Sakai, R; Taguchi, J; Takasaki, H; Takemura, S; Tomita, N; Yamazaki, E, 2013) |
| "Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is regarded as the first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), but it is often necessary to reduce the dose or prolong the intervals between doses." | 3.79 | Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. ( Aoki, K; Ishikawa, T; Kurata, M; Matsushita, A; Nagai, K; Tabata, S; Takahashi, T, 2013) |
| "Subtypes of diffuse large B-cell lymphoma (DLBCL) that have inferior outcomes after front-line therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) have been identified." | 3.79 | Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large ( Agress, H; Bhattacharyya, P; Chow, KF; Feldman, T; Gadaletta, G; Goy, A; Howlett, C; Mato, A; Panush, D; Pecora, A; Rosario, M; Singavi, A; Waksmundzki, K; Yang, X; Zielonka, T, 2013) |
| "The role of consolidative radiation therapy (RT) after complete response (CR) to rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for stage III-IV diffuse large B-cell lymphoma (DLBCL) patients is unclear." | 3.79 | Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy. ( Chen, Z; Das, S; Esiashvili, N; Flowers, C; Jiang, K; Khan, MK; Nastoupil, LJ; Okwan-Duodu, D; Shi, Z; Wang, X, 2013) |
| "We assessed the prognostic impact of occult bone marrow involvement, determined by flow cytometry and/or polymerase chain reaction, in a population of 117 consecutive patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)." | 3.79 | Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. ( Arima, H; Imai, Y; Ishikawa, T; Kurata, M; Maruoka, H; Matsushita, A; Nasu, K; Tabata, S; Takahashi, T, 2013) |
| "Use of combination antiretroviral therapy (cART) and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with or without rituximab for treatment of diffuse large B-cell lymphoma (DLBCL) in HIV substantially increases response rates but may also increase toxicity, possibly due to antiretroviral-antineoplastic drug interactions." | 3.79 | Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. ( Kukreti, V; Laroche, M; Lemieux, B; Marcotte, S; Rouleau, D; Routy, JP; Seki, JT; Sheehan, NL; Tseng, A; Wong, AY, 2013) |
| "High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse large B-cell lymphomas (DLBCL), independent of the international prognostic index (IPI)." | 3.79 | Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. ( Bhagat, G; Dirnhofer, S; Dybkær, K; Frei, E; Go, RS; Hsi, ED; Møller, MB; Orazi, A; Piris, MA; Ponzoni, M; Tzankov, A; van Krieken, JH; Visco, C; Xu-Monette, ZY; Young, KH, 2013) |
| " Using the redox scanner that collects the fluorescence signals from both the oxidized flavoproteins (Fp) and the reduced form of nicotinamide adenine dinucleotide (NADH) in snap-frozen tumor tissues, we investigated the effects of chemotherapy on mouse xenografts of a human diffuse large B-cell lymphoma cell line (DLCL2)." | 3.79 | Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice. ( Choe, R; Farhad, N; Feng, M; Glickson, JD; Lee, SC; Li, LZ; Mir, TA; Xu, HN, 2013) |
| "Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)." | 3.79 | Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. ( Barbui, A; Carella, AM; Cesaretti, M; Chiappella, A; de Souza, CA; di Rocco, A; Federico, M; Gaidano, G; Guida, A; Hohaus, S; Luminari, S; Marcheselli, L; Merli, F; Miranda, EC; Puccini, B; Rigacci, L; Rossi, A; Spina, M; Stelitano, C, 2013) |
| " In the present study, we investigated whether miR-21 is involved in regulating the sensitivity of the diffuse large B-cell lymphoma (DLBCL) cell line CRL2631 to the cyclophosphamide, vincristine, Adriamycin, and prednisone (CHOP) chemotherapeutic regimen." | 3.79 | MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. ( Bai, H; Deng, C; Wang, C; Wei, J; Xu, R; Yang, X, 2013) |
| "MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and rituximab (R)-CHOP treated patients." | 3.79 | MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. ( Barth, TF; Becher, C; Bernd, HW; Cogliatti, S; Feller, AC; Hansmann, ML; Horn, H; Hummel, M; Klapper, W; Loeffler, M; Möller, P; Ott, G; Pfreundschuh, M; Rosenwald, A; Schmelter, C; Schmitz, N; Siebert, R; Stein, H; Trümper, L; Ziepert, M, 2013) |
| "Diffuse large B-cell lymphoma primary of lung (DLBCL-PL) is a rare presentation of extranodal lymphoma, in most cases chemotherapy-based anthracyclines: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the treatment, with excellent outcome." | 3.79 | Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung. ( Aviles, A; Huerta-Guzman, J; Nambo, MJ; Neri, N; Silva, L, 2013) |
| "The prognosis of diffuse large B-cell lymphoma (DLBCL) has improved significantly since the introduction of immunochemotherapy (rituximab [R] with cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP])." | 3.78 | Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. ( Andersson, PO; Hansson, U; Hasselblom, S; Lewerin, C; Nilsson-Ehle, H; Sender, M; Stenson, M; Werlenius, O, 2012) |
| "We report the largest study to date assessing FCGR3A-V158F polymorphisms in diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/Oncovin (vincristine)/prednisone/rituximab (CHOP-R)." | 3.78 | Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. ( Crooks, P; Gandhi, MK; Keane, C; Lea, RA; Mollee, P; Mutsando, H; Nguyen-Van, D; Nourse, JP, 2012) |
| "As lymphocytes play an active role in tumor control and as targets for immunochemotherapy, the prognostic significance of the absolute lymphocyte count (ALC) and its changes after rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) were investigated in patients with early-stage diffuse large B-cell lymphoma (DLBCL)." | 3.78 | Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. ( Chae, YS; Kang, BW; Kim, JG; Lee, JJ; Lee, SJ; Moon, JH; Park, TI; Shin, H; Sohn, SK; Yang, DH, 2012) |
| "When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor." | 3.78 | [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012) |
| "A decision model was developed to compare the clinical outcomes, costs, and cost effectiveness of three HBV screening strategies for patients with lymphoma before R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy: screen all patients for hepatitis B surface antigen (HBsAg; Screen-All), screen patients identified as being at high risk for HBV infection (Screen-HR), and screen no one (Screen-None)." | 3.78 | Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. ( Bell, CM; Chan, KK; Feld, JJ; Hicks, LK; Krahn, M; Woo, G; Zurawska, U, 2012) |
| "Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.78 | Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. ( Ben-Neriah, S; Braziel, RM; Brunhoeber, P; Campo, E; Chan, WC; Connors, JM; Cook, JR; Delabie, J; Gascoyne, RD; Grogan, TM; Holcroft, C; Iqbal, J; Jaffe, ES; Johnson, NA; Lenz, G; Meyer, PN; Ott, G; Rimsza, LM; Rogic, S; Rosenwald, A; Savage, KJ; Scott, DW; Sehn, LH; Slack, GW; Staudt, LM; Steidl, C; Tan, KL; Tubbs, RR; Valentino, C; Weisenburger, DD; Wright, G, 2012) |
| "TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy." | 3.78 | Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. ( Abruzzo, LV; Ai, W; Bhagat, G; Chiu, A; Choi, WW; Dybkaer, K; Ferreri, AJ; Go, RS; Hsi, ED; Huang, Q; Huh, J; Kahl, BS; Li, J; Li, Y; Liu, WM; Medeiros, LJ; Miranda, RN; Montes-Moreno, S; Møller, MB; Orazi, A; Piris, MA; Ponzoni, M; Richards, KL; Tai, YC; Tzankov, A; van Krieken, JH; Visco, C; Winter, JN; Wu, L; Xu, W; Xu-Monette, ZY; Young, KH; Zhao, X; Zhao, XF; Zhou, F; Zu, Y, 2012) |
| "Development of resistance to the CHOP chemotherapeutic regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) remains a major cause of treatment failure and mortality in approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL)." | 3.77 | Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. ( Bayless, KJ; Cherry, EM; Maxwell, SA, 2011) |
| " Using xenografts of the most common form of human NHL, diffuse large B-cell lymphoma (DLBCL), we have detected therapeutic response within one cycle of therapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), rituximab plus CHOP (RCHOP) or radiation (15 Gy) through detection of a decrease in lactic acid (Lac) or total choline (tCho) and an increase of apparent diffusion coefficients (ADC)." | 3.77 | NMR metabolic and physiological markers of therapeutic response. ( Delikatny, EJ; Glickson, JD; Goldstein, SC; Lee, SC; Loevner, LA; Mellon, EA; Nasta, SD; Nelson, DS; Pickup, S; Poptani, H; Reddy, R; Schuster, SJ; Svoboda, J; Wallace, SG, 2011) |
| " This study investigated the effects of statins in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-based chemoimmunotherapy, and the impact of commonly used drugs, metformin and aspirin, on the clinical outcomes of patients receiving chemoimmunotherapy." | 3.77 | Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. ( Ha, T; Koo, YX; Lim, ST; Ong, WS; Quek, R; Tai, DW; Tan, DS; Tan, IB; Tao, M, 2011) |
| "Activation of the endoplasmic reticulum (ER) stress pathway is associated with poor response to doxorubicin-containing regimens, such as rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine and prednisone (R-CHOP), in patients with diffuse large B-cell lymphoma (DLBCL)." | 3.77 | The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. ( Campo, E; Colomer, D; Jares, P; López-Guillermo, A; Martinez, A; Mozos, A; Roué, G, 2011) |
| "The addition of rituximab to CHOP (R-CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B-cell lymphoma (DLBCL)." | 3.76 | Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. ( Connors, JM; Gascoyne, RD; Savage, KJ; Sehn, LH; Shenkier, TN; Villa, D, 2010) |
| "We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)." | 3.76 | Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. ( Asai, H; Ennishi, D; Hatake, K; Ikeda, K; Maeda, Y; Matsuo, K; Shinagawa, K; Takeuchi, K; Tanimoto, M; Terui, Y; Yokoyama, M; Yoshino, T, 2010) |
| "The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL)." | 3.76 | Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. ( Ahn, HK; Kim, JH; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Won, YW; Yi, JH; Yun, J, 2010) |
| " We retrospectively studied the risk factors for CNS involvement in patients with diffuse large B-cell lymphoma (DLBCL) treated by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab (R) -CHOP chemotherapy." | 3.76 | Central nervous system involvement in diffuse large B-cell lymphoma. ( Hashimoto, C; Hattori, Y; Hyo, R; Ishigatsubo, Y; Motomura, S; Nakajima, Y; Tomita, N; Watanabe, R; Yamamoto, W, 2010) |
| " In this study, we investigated the influence of the genetic polymorphisms GSTM1, GSTT1, and GSTP1 on treatment response in 94 Korean patients with de novo diffuse large B-cell lymphoma, who had received rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) as a front-line regimen." | 3.76 | Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. ( Cho, HJ; Eom, HS; Kim, HJ; Kim, IS; Kong, SY; Lee, GW, 2010) |
| " Thus, we studied absolute lymphocyte count (ALC) as a marker of poststandard chemotherapy (rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP)) NHL relapse in patients with diffuse large B-cell lymphoma (DLBCL)." | 3.76 | Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. ( Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; Markovic, SN; Micallef, IN; Nowakowski, GS; Porrata, LF; Rsitow, K; Thompson, CA; Witzig, TE, 2010) |
| "The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.76 | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. ( Dabaja, BS; Fayad, L; Fowler, N; Horace, P; Mazloom, A; Medeiros, LJ; Phan, J; Reed, V; Rodriguez, MA; Shihadeh, F; Wogan, C; Zreik, TG, 2010) |
| "Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (R-CHOP) has improved survival in patients with diffuse large B-cell lymphoma (DLBCL) and weakened the prognostic power of the international prognostic index (IPI)." | 3.76 | Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma. ( Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Sohn, BS; Suh, C; Yoo, C; Yoon, DH, 2010) |
| "Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy." | 3.75 | Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. ( Asai, H; Ennishi, D; Hatake, K; Ikeda, K; Komatsu, H; Mishima, Y; Sakajiri, S; Takahashi, S; Takeuchi, K; Tanimoto, M; Terui, Y; Yokoyama, M, 2009) |
| "We performed this study to reassess the prognostic factors of diffuse large B-cell lymphoma (DLBCL) in the era of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Chinese population." | 3.75 | Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. ( Hui-Jin, Z; Jian-Hua, Y; Jian-Qing, M; Jun-Min, L; Li, W; Qiu-Sheng, C; Shu, C; Wei-Li, Z; Yan, W; Yang, S; Yu, C; Yu, Y; Zhi-Xiang, S, 2009) |
| "We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan." | 3.75 | The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. ( Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Ishimaru, F; Kataoka, I; Kiguchi, T; Maeda, Y; Makita, M; Matsuo, K; Nawa, Y; Nishimori, H; Sezaki, N; Shinagawa, K; Sugiyama, H; Sunami, K; Tabayashi, T; Tabuchi, T; Takeuchi, M; Takimoto, H; Tanimoto, M; Togitani, K; Yamane, H; Yamasuji, Y; Yano, T; Yoshino, T, 2009) |
| "The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab." | 3.75 | Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? ( Kang, JH; Kim, DC; Kim, HG; Kim, IS; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Song, DH; Yang, JW, 2009) |
| " We therefore evaluated the impact of the ABCG2 V12M and Q141K polymorphisms on the therapeutic outcomes and toxicities of primary rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) therapy in 145 Korean patients with diffuse large B-cell lymphoma (DLBCL)." | 3.74 | ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. ( Eom, HS; Hwang, SH; Kim, DC; Kim, HG; Kim, IS; Kong, SY; Lee, EY; Lee, GW; Shin, HJ, 2008) |
| "This study was designed to assess the efficacy and safety of an infusional DA-EPOCH (dose-adjusted etoposide/vincristine/doxorubicin/bolus cyclophosphamide/prednisone) and rituximab (DA-EPOCH-R) regimen for patients with poor prognosis diffuse large B-cell lymphoma (DLBCL)." | 3.74 | Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. ( Arribas, I; Bañas, H; Burgaleta, C; De Miguel, D; García-Suárez, J; Pascual, T, 2007) |
| " For acute myelogenous leukemia, cytarabine with anthracycline agent is believed to be the standard treatment in first remission induction therapy." | 3.74 | [The standard treatments for patients with hematological malignancies in Japan]. ( Ishizawa, K, 2007) |
| "The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000." | 3.74 | Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. ( Berneman, Z; Bosly, A; Bron, D; Dauwe, M; De Bock, R; Ferrant, A; Kaufman, L; Van Hoof, A; Verhoef, G, 2008) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| " In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP." | 3.73 | The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. ( Feliu, E; Lloveras, N; Mate, JL; Navarro, JT; Oriol, A; Ribera, JM, 2005) |
| "For more than two decades, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the standard therapy for diffuse large B-cell lymphoma (DLBCL)." | 3.73 | Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. ( Chhanabhai, M; Connors, JM; Donaldson, J; Fitzgerald, C; Gascoyne, RD; Gill, K; Klasa, R; MacPherson, N; O'Reilly, S; Sehn, LH; Spinelli, JJ; Sutherland, J; Wilson, KS, 2005) |
| " Of 33 SL cases, 14 consecutive diffuse large B-cell lymphomas were treated with CHOP (adriamycin, cyclophosphamide, vincristine and prednisone) or CHOP-like chemotherapy regimen." | 3.73 | Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. ( Assaf, E; Azoulay, R; Bosq, J; Cainap, C; Jabbour, E; Koscielny, S; Lapusan, S; Oprea, C; Ribrag, V; Vanel, D, 2005) |
| "The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been shown to improve the outcome in all age groups with newly diagnosed diffuse large B-cell lymphoma (DLBCL)." | 3.73 | Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. ( Bang, YJ; Do, YR; Heo, DS; Kang, YK; Kim, DH; Kim, HJ; Kim, JK; Kim, SY; Kim, YK; Lee, JJ; Lee, KH; Lee, WS; Oh, SJ; Park, YH; Ryoo, BY; Ryu, MH; Sohn, SK; Song, HS; Suh, CW; Yang, SH, 2006) |
| " A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy." | 3.73 | Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. ( Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M, 2006) |
| "One-hundred and ninety-four adult patients with histologically proven stage III and IV non-Hodgkin's lymphomas, treated with CVP (cyclophosphamide, vincristine and prednisone) alternated with ABP (adriamycin, bleomycin and prednisone), were analyzed to test the validity of the clinicoprognostic correlation offered by the working formulation in comparison with the Rappaport and Kiel classifications." | 3.67 | A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. ( Bajetta, E; Buzzoni, R; Canetta, R; Giardini, R; Monfardini, S; Rilke, F; Valagussa, P; Viviani, S, 1984) |
| " A 64-year-old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytoxan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)-Bleo." | 3.67 | Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome. ( Floyd, M; Lieber, IH; McGuffin, WL; Stoneburner, SD, 1984) |
| "The combination of cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) alternating with total body irradiation (TBI) has been shown earlier to be effective therapy in patients with malignant lymphoma who have received prior chemotherapy and/or radiation therapy." | 3.66 | The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation. ( Antunez, A; Dixon, D; Fabian, CJ; Kraus, TA; Weick, JK, 1983) |
| "Two hundred and fifty-two patients with advanced stages of favorable non-Hodgkin's lymphoma (NHL) subtypes (nodular histiocytic (NH), and diffuse well-differentiated lymphocytic (DLWD)) were analyzed for response and survival to moderate (cyclophosphamide-prednisone (CP)) vs." | 3.66 | Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report. ( Berard, C; Costello, WG; Ezdinli, EZ; Hartsock, RJ; Silverstein, MN; Sokal, JE, 1980) |
| "Three patients with Hodgkin disease, eight with non-Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four-drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym "BOAP." | 3.66 | A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients. ( Braine, HG; Coltman, CA; Kerr, RO; Rossof, AH, 1978) |
| "The results of a chemotherapy regimen utilizing adriamycin in combination with vincristine, prednisone plus or minus cyclophosphamide (CHOP-HOP) for the treatment of non-Hodgkin lymphoma are compared to those of a non-adriamycin containing combination (COP)." | 3.66 | Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. ( Cabanillas, F; Freireich, EJ; Rodriguez, V, 1978) |
| "Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vincristine, and prednisone) and HOP (Adrimycin, vincristine, and prednisone, was used as treatment for patients with pathologically staged, advanced non-Hodgkin's lymphoma." | 3.65 | Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. ( Coltman, C; Gamble, JF; Gottlieb, JA; Grozea, PN; Gutterman, J; Haut, A; Jones, SE; Lane, M; McKelvey, EM; Moon, TE; Stephens, R; Talley, RW; Wilson, HE, 1976) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 3.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "Management of acquired immunodeficiency syndrome (AIDS)-related diffuse large B-cell (DLBCL) and plasmablastic lymphomas (PBL) poses significant challenges." | 3.30 | Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. ( Agarwal, A; Alahari, A; Bagal, B; Gota, V; Gujral, S; Gupta, H; Jain, H; Kannan, S; Kumar, S; Laskar, SS; Menon, H; Nayak, L; Rangarajan, V; Sengar, M; Sharma, N; Shet, T; Sridhar, E; Thorat, J, 2023) |
| "Richter syndrome (RS) of chronic lymphocytic leukemia (CLL) is typically chemoresistant, with a poor prognosis." | 3.11 | Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. ( Brown, JR; Davids, MS; Fisher, DC; Ihuoma, U; Jacobson, CA; Lehmberg, TZ; Montegaard, J; Parry, EM; Pazienza, S; Renner, SK; Rogers, KA; Thompson, PA; Tyekucheva, S; Wang, Z; Wu, CJ, 2022) |
| " We present population pharmacokinetics (PopPK) and exposure-response (ER) analyses for venetoclax (a selective BCL-2 inhibitor) administered with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with relapsed/refractory (R/R) and previously untreated (1L) non-Hodgkin lymphoma (NHL) from the phase 1b/2 CAVALLI study, to confirm dose selection for future studies." | 3.11 | Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. ( Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022) |
| "Lenalidomide has response rates of 45% in relapsed transformed DLBCL." | 3.01 | Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. ( Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE, 2021) |
| "2%) were subject to dosing adjustments." | 3.01 | The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma. ( Brown, AB; Carty, SA; Kaminski, MS; Phillips, TJ; Runge, JS; Wilcox, RA, 2023) |
| "The shocking fact was that re-biopsy of lymphadenopathy revealed peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL)." | 3.01 | Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review. ( Chen, B; Chen, P; Huang, F; Jin, X; Li, J; Liang, Y; Liu, H; Xiao, X; Yuan, X, 2023) |
| "We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas." | 3.01 | Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. ( Bair, SM; Ballard, H; Barta, SK; Bogusz, AM; Chong, E; Dwivedy Nasta, S; Filicko-O'Hara, J; Gaballa, S; Gerson, J; Hung, SS; Khan, N; King, C; Landsburg, DJ; Lim, M; Maity, A; Mitnick, S; Nagle, SJ; Nakamura, H; Nejati, R; Plastaras, JP; Ruella, M; Schuster, SJ; Steidl, C; Strelec, L; Svoboda, J; Waite, TS; Youngman, M, 2021) |
| "The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis." | 3.01 | Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. ( Appleby, N; Cabes, M; Campo, E; Dreau, H; Ehinger, M; Eyre, TA; Klintman, J; Knight, SJL; Månsson, R; Martín-Subero, JI; Pascua, LL; Popitsch, N; Ridout, K; Robbe, P; Rossi, D; Schuh, A; Stamatopoulos, B; Taylor, JC; Vavoulis, DV, 2021) |
| " No organ-oriented toxicity increased with tazemetostat dosage escalation (severity and incidence)." | 2.94 | A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. ( Cullières-Dartigues, P; Dubois, R; Dubois, S; Herbaux, C; Jardin, F; Karlin, L; Le Gouill, S; Michot, JM; Molina, T; Morschhauser, F; Picquenot, JM; Ribrag, V; Salles, G; Sarkozy, C; Suttle, B; Tilly, H, 2020) |
| " We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)- EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) combined with high-dose methotrexate (HD-MTX) in newly diagnosed patients with CD5+ DLBCL." | 2.94 | DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. ( Asano, N; Igarashi, T; Izutsu, K; Katayama, N; Kato, K; Kinoshita, T; Miyawaki, K; Miyazaki, K; Nishikawa, M; Nishikori, M; Nishimura, Y; Ohata, K; Ohshima, K; Okamoto, M; Sakai, R; Sunami, K; Suzumiya, J; Takahashi, N; Tamaru, S; Yamada, T; Yamaguchi, M; Yamamoto, G; Yano, H; Yoshida, I, 2020) |
| "Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL." | 2.94 | Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. ( Arens, AIJ; Bakunina, K; Beeker, A; Bilgin, YM; Boersma, RS; Bohmer, LH; Burggraaff, CN; Chamuleau, MED; de Jong, D; de Jongh, E; Diepstra, A; Dierickx, D; Durian, MF; Hijmering, N; Hoekstra, O; Huijbregts, J; Kersten, MJ; Koene, HR; Lugtenburg, PJ; Mandigers, C; Marijt, EAF; Mous, R; Nijland, M; Schouten, HC; Snijders, TJF; Tick, LW; van den Berg, A; van Imhoff, GW; van Rees, B; Vermaat, JSP; Visser, O; Zijlstra, JM, 2020) |
| "Everolimus has single-agent activity in lymphoma." | 2.87 | Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. ( Belada, D; Bermudez Silva, CD; Bouabdallah, K; Cavalli, F; Costa, LJ; Fan, J; Fayad, L; Hino, M; Ikeda, T; Kattan, JG; Kim, WS; Kuruvilla, J; Larouche, JF; Louveau, AL; Mayer, J; Ogura, M; Ozcan, M; Rigacci, L; Shi, Y; Tobinai, K; Vanazzi, A; Voi, M; Witzig, TE; Wu, C; Zhu, J, 2018) |
| " S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)." | 2.87 | A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. ( Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018) |
| "Follicular lymphoma is an indolent lymphoma that remains incurable with standard approaches." | 2.82 | Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose? ( Ngu, H; Okosun, J; Phillips, T; Sehn, LH; Takiar, R, 2022) |
| "Lenalidomide 10 mg/d was identified as the MTD because, in the 15 mg cohort, one patient experienced dose-limiting toxicity (grade 3 angioedema) and two patients had mobilization failure." | 2.82 | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. ( Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A, 2016) |
| " Pharmacokinetic sampling was performed at pre-dose, post-infusion, 24, 48 h, 7 and 21 days." | 2.82 | Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ( Gota, V; Karanam, A; Menon, H; Nair, R; Rath, S; Sengar, M; Subramanian, P; Tembhare, P; Yadav, A, 2016) |
| " These patients were followed up for 18 months, and the total effective rate, the survival rate and the adverse reaction rate were compared between these two groups." | 2.82 | [Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL]. ( Li, ZH; Wang, Y; Xing, MT; Zhan, XR; Zhang, YP, 2016) |
| "The CHOP-OR study is a prospective phase II study to evaluate the safety, feasibility and activity of a CHOP chemotherapy in combination with ofatumumab in induction and subsequent maintenance for patients with newly diagnosed RS." | 2.80 | Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome. ( Boyle, L; Clifford, R; Dutton, SJ; Eyre, TA; Francis, A; Roberts, C; Schuh, A, 2015) |
| "Sarcopenia is an independent prognostic factor in male patients with DLBCL." | 2.80 | Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. ( Goto, N; Hara, T; Kanemura, N; Kitagawa, J; Kito, Y; Matsumoto, T; Miyazaki, T; Nakamura, H; Nakamura, N; Ninomiya, S; Shibata, Y; Shimizu, M; Shiraki, M; Takeuchi, T; Tsurumi, H, 2015) |
| " Fifty-three patients withdrew after cycle 1; 10 for grade 3 or 4 IRRs and one for a grade 3 adverse event." | 2.79 | Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. ( Brewster, M; Chai, A; Dakhil, S; Gregory, SA; Hermann, R; Hurst, D; Monte, M; Richards, P; Schreeder, MT; Windsor, KS, 2014) |
| "Lenalidomide has high activity in relapsed or refractory aggressive B-cell lymphomas." | 2.79 | Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. ( Baldi, I; Botto, B; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; Congiu, A; Dreyling, M; Fattori, PP; Franceschetti, S; Gaidano, G; Gaudiano, M; Inghirami, G; Ladetto, M; Liberati, AM; Molinari, AL; Pavone, V; Rossi, G; Salvi, F; Spina, M; Vitolo, U; Zaccaria, A; Zanni, M; Zinzani, P, 2014) |
| " Two toxic deaths were observed." | 2.78 | High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. ( Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013) |
| " The adverse events in R-CHOP group were similar with that in CHOP group." | 2.77 | [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up]. ( Cao, JN; Chen, FY; Cheng, YF; Cheng, ZX; Li, F; Li, JM; Wang, C; Wang, JM; Wei, Z; Zou, SH, 2012) |
| " Neutropenia (48%) was the most frequent grade 3 to 4 adverse event (AE); no grade 3 to 4 cardiac AEs were observed." | 2.76 | Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. ( Ardizzoni, A; Boggiani, D; Franciosi, V; Musolino, A; Panebianco, M; Salvagni, S; Vasini, G, 2011) |
| "As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients." | 2.76 | Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. ( Anglaret, B; Belhadj, K; Brechignac, S; Casasnovas, O; Ferme, C; Feugier, P; Fitoussi, O; Gabarre, J; Ghesquieres, H; Gisselbrecht, C; Haioun, C; Herbrecht, R; Janvier, M; Morschhauser, F; Mounier, N; Parrens, M; Salles, G; Tilly, H; Van Den Neste, E; Ysebaert, L, 2011) |
| "Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL)." | 2.76 | Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. ( Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE, 2011) |
| "To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)." | 2.74 | [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. ( Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009) |
| " The major adverse events in combination group were infusion-related responses which could be well tolerated in patients, and hematological toxicities which were similar to those in CHOP group." | 2.73 | [Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. ( Li, JY; Lu, H; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W; Zhang, ZH, 2008) |
| "The objective of this study is to evaluate the long-term efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in Chinese patients with newly diagnosed diffuse large B cell lymphoma (DLBCL)." | 2.73 | Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. ( Chen, QS; Chen, Y; Li, JM; Qian, Y; Shen, Y; Shen, ZX; Wang, L; Xia, ZG; You, JH; Zeng, XY, 2007) |
| "A 31-year-old man with Crohn's disease in remission after 6-year treatment with infliximab developed nasopharyngeal diffuse large B cell lymphoma." | 2.72 | Long-term endoscopic remission in Crohn's disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma: case report and literature review. ( Fukuhara, N; Handa, T; Ichikawa, S; Inomata, Y; Kakuta, Y; Kuroha, M; Masamune, A; Moroi, R; Sato, Y; Shiga, H; Shimoyama, Y; Takahashi, T, 2021) |
| " Severe adverse events occurred on 12 occasions (4% of cycles), involving 11 patients (22% of total); the most frequent severe adverse event was interstitial pneumonia which occurred in seven patients (14% of total)." | 2.72 | Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. ( Brusamolino, E; Fava, S; Gargantini, L; Lazzarino, M; Montalbetti, L; Morra, E; Pagnucco, G; Pascutto, C; Pinotti, G; Rigacci, L; Rusconi, C; Uziel, L, 2006) |
| "Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL)." | 2.72 | Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. ( Guan, ZZ; He, YJ; Lin, JY; Lui, DG; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years." | 2.71 | Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). ( Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A, 2003) |
| "DNA aneuploidy was shown in 57% of cases, but was not predictive of clinical outcome." | 2.68 | Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. ( Andersen, J; Bauer, KD; Fisher, RI; Gordon, LI; Jiang, S; Neiman, RS; Oken, MM; Variakojis, D; Winter, JN, 1996) |
| "They also discuss treatment for relapsed disease including targeted therapies." | 2.66 | Perspectives on chemotherapy for the management of double-hit lymphoma. ( Al-Juhaishi, T; Mckay, J; Sindel, A; Yazbeck, V, 2020) |
| " The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients." | 2.65 | Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. ( Bodey, GP; Cabanillas, F; Freireich, EJ; Rodriguez, V, 1979) |
| "The response rate and survival in diffuse histiocytic lymphoma have improved since the first study." | 2.64 | Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. ( Coltman, CA; Jones, SE; Luce, JK; McKelvey, EM; Moon, TE, 1977) |
| " However, among patients with DLBCL toxic effects due to therapy treatment are still very frequent, as well as inter-individual differences in the outcomes of patients even having similar stage, histological grade and histopathological type of the tumor." | 2.55 | How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. ( Allegra, A; Cimino, F; Falduto, A; Gangemi, S; Musolino, C; Saija, A; Speciale, A, 2017) |
| "was diagnosed with chronic lymphocytic leukemia (CLL)." | 2.52 | Richter syndrome: an aggressive transformation. ( Streu, E, 2015) |
| "Here we report two cases of follicular lymphoma that transformed to CD30 positive diffuse large B cell lymphoma and review the literature on this topic." | 2.52 | CD 30-positive transformed follicular lymphoma: two case reports and literature review. ( Batlle, A; Climent, F; Colorado, M; Conde, E; Espiga, CR; González Barca, EM; González de Villambrosía, S; Insunza, A; Martin-Sánchez, G; Montes-Moreno, S; Pané-Foix, M; Piris, MA, 2015) |
| "Also, both the lymphoma and colon cancer stained positive for vascular endothelial growth factor (VEGF)." | 2.52 | [RS3PE syndrome associated with senile Epstein-Barr virus-positive diffuse large B cell lymphoma of a patient with colon cancer]. ( Fujii, S; Fujita, M; Iyama, S; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Nakano, T; Sakamoto, H; Shimoyama, S; Usami, M; Yamada, M; Yoshida, M, 2015) |
| "Diffuse large B-cell lymphoma and Burkitt lymphoma are two distinct lymphoma entities recognized by the current World Health Organization classification of lymphoid neoplasms." | 2.48 | New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. ( Dörken, B; Frick, M; Lenz, G, 2012) |
| "A pathological diagnosis of follicular lymphoma (FL), grade 3A, was made based on a biopsy specimen from the right inguinal lymph node." | 2.47 | CD5-positive follicular lymphoma: a case report and literature review. ( Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Wakabayashi, M, 2011) |
| "For the management of multiple myeloma, high-dose chemotherapy, mainly melphalan with autologous stem cell transplantation, has become the standard treatment even for elderly patients less than 65 years of age." | 2.44 | [Hematological malignancies]. ( Usui, N, 2007) |
| " This analysis focused on patient characteristics, underlying disease, rituximab dosing schedule, and R-ILD characteristic-like symptoms, diagnosis, treatment, and outcomes." | 2.44 | Rituximab-induced interstitial lung disease. ( Laber, DA; Mehta, AC; Wagner, SA, 2007) |
| "Although MALT lymphoma is the most common primary pulmonary lymphoma, it was present in only one of our patients, while seven patients had aggressive lymphoma." | 2.44 | Non-Hodgkin's lymphoma presenting as an endobronchial tumor: report of eight cases and literature review. ( Ben-Arieh, Y; Goralnik, L; Rowe, JM; Solomonov, A; Yigla, M; Zuckerman, T, 2008) |
| "The fistula was observed during upper gastrointestinal endoscopy (gastroscopy) and confirmed by CT scan with contrast." | 2.40 | Gastrosplenic fistulas: a case report and review of the literature. ( Carolin, KA; Prakash, SH; Silva, YJ, 1997) |
| "The previously published cases of Gaucher's disease associated with NHL as well as the possible mechanisms leading to this association are reviewed here." | 2.40 | Non-Hodgkin's lymphoma associated with Gaucher's disease. ( Cervantes, F; Cobo, F; Montserrat, E; Perales, M, 1998) |
| "Patients with malignant lymphoma, diffuse type, have an unfavorable prognosis when compared to those patients with modular patterns." | 2.36 | Chemotherapy of non-Hodgkin lymphoma: the diffuse types. ( Sweet, DL; Ultmann, JE, 1978) |
| " Heterogeneous dosing practices were observed." | 1.91 | A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. ( Cerdeña, S; Cortese, MJ; Grover, NS; Haverkos, B; Hill, BT; Hughes, ME; Jodon, G; Kahl, BS; Kaiser, J; Kamdar, M; Landsburg, DJ; Namoglu, E; Olson, M; Orellana-Noia, V; Portell, C; Rainey, M; Rudoni, J; Snow, A; Sohail, M; Voorhees, T; Watkins, MP; Wei, W, 2023) |
| "Past medical conditions included type 2 diabetes." | 1.91 | Primary esophageal diffuse large B-cell lymphoma. ( Álvarez Martínez, P; Del Caño Cerdán, C; García González, P; García Riesco, E; Nieto-Jara, A; Ramos Martínez, PJ, 2023) |
| " In unfit older patients, a dynamic dosing strategy is often applied." | 1.91 | How I treat older patients with DLBCL in the frontline setting. ( Lugtenburg, PJ; Mutsaers, PGNJ, 2023) |
| "Frailty is a significant risk factor for poor outcomes among older patients with diffuse large B-cell lymphoma (DLBCL)." | 1.72 | Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma. ( Chan, H; Disperati, P; Elinder-Camburn, A; Leitch, S; Merriman, E; Zhang, J, 2022) |
| " The frequency of severe adverse events from the two regimens was similar." | 1.72 | Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma. ( Cai, R; Guan, J; Huang, H; Huang, J; Lu, S; Que, Y; Sun, F; Sun, X; Wang, J; Xia, Z; Zhang, Y; Zhen, Z; Zhu, J; Zhu, X, 2022) |
| "Here, we report two cases of aplastic anemia in which diffuse large B-cell lymphoma developed during treatment with CsA." | 1.72 | [Systemic chemotherapy combined with thrombopoietin receptor agonist for the treatment of diffuse large B-cell lymphoma complicated with aplastic anemia]. ( Edahiro, Y; Fukuda, Y; Furuya, C; Hamano, Y; Koike, M; Komatsu, N; Shirane, S; Takaku, T, 2022) |
| "Gastrosplenic fistula is a rare and potentially fatal clinical entity unknown to most healthcare providers." | 1.72 | Successful multidisciplinary management of an asymptomatic gastrosplenic fistula in a diffuse large B cell lymphoma patient. ( Assane, C; Malo, FC; Mansouri, S, 2022) |
| "Follicular lymphoma is the second most common type of non-Hodgkin lymphoma, and the disease course is usually characterized by an indolent clinical course." | 1.72 | Management of elderly patients with malignant lymphoma. ( Miyazaki, K, 2022) |
| " The results showed that SCR is safe and feasible in terms of a high compliance rate and stable nutritional status." | 1.62 | Safety, Feasibility, and Effects of Short-Term Calorie Reduction during Induction Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Pilot Study. ( Huang, TC; Lee, CY; Lin, JM; Tang, CC; Tien, FM; Yeh, YC, 2021) |
| "Composite lymphoma is a rare entity where two or more distinct subtypes of lymphoma coexist within a single organ or tissue." | 1.62 | Composite lymphoma of T-cell rich, histiocyte-rich diffuse large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma: a case report. ( Alhoulaiby, S; Alshehabi, Z; Esper, A; Zuhri Yafi, R, 2021) |
| "Although the standard treatment for relapsed DLBCL is high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), the efficacy of this approach for primary refractory DLBCL is not well understood." | 1.62 | Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. ( Fukuhara, S; Hatta, S; Ito, Y; Izutsu, K; Kobayashi, Y; Makita, S; Maruyama, D; Miyagi-Maeshima, A; Munakata, W; Nomoto, J; Suzuki, T; Tajima, K; Taniguchi, H; Tobinai, K; Yuda, S, 2021) |
| "However, chromosomal abnormalities are neither included as a prognostic factor nor are they considered in the IPI risk classification category." | 1.56 | Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, SS; Shin, SH; Yahng, SA; Yoon, JH, 2020) |
| "After 6 courses of chemotherapy treatment, the duodenal ulcer was completely healed by reviewing the UGIE." | 1.56 | Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report. ( Jia, N; Li, Y; Tang, Y, 2020) |
| "Systemic infections have also been suggested as beneficial promotors of immunological responses." | 1.56 | Prognostic significance of infectious episodes occurring during first-line therapy for diffuse large B-cell lymphoma - A nationwide cohort study. ( Clausen, MR; d'Amore, F; Gørløv, JS; Iversen, B; Josefsson, PL; Juul, MB; Madsen, J; Nørgaard, M; Pedersen, PT; Pedersen, RS; Poulsen, CB; Ulrichsen, SP, 2020) |
| "Prednisone was again prescribed and his symptoms and the pulmonary opacities gradually disappeared." | 1.56 | Progressive dyspnea and diffuse ground-glass opacities after treatment for lymphoma with rituximab-containing chemotherapy: A case report. ( Feng, R; Huang, H; Li, J; Liu, P; Shao, C; Sun, Y; Xu, K; Zhang, Y, 2020) |
| "Risk for breast and thyroid cancers, in Arab and Jewish females respectively, were higher in the pre-rituximab era [SIR(95%CI) 5." | 1.56 | Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen. ( Avivi, I; Neeman, Y; Perry, C; Silverman, B; Waintraub, N, 2020) |
| " High-dose chemotherapy regimens such as DA-EPOCH should be administered to young patients in combination with rituximab." | 1.56 | Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma. ( Chen, Z; Li, Y; Tian, C, 2020) |
| "Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited." | 1.56 | Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen. ( Chinen, S; Ishizu, M; Mogi, A; Nakashima, Y; Sasaki, H; Takamatsu, Y; Takata, T; Tanaka, T, 2020) |
| "We report a patient with chronic lymphocytic leukemia who presented with a large and rapidly evolving ulcer, revealed to be a high-grade cutaneous lymphoma." | 1.56 | Ulcerated cutaneous Richter syndrome. ( De Mello, RB; Do Vale, ECS, 2020) |
| "To analyze the efficacy of rituximab combined with CHOP/EPOCH regimen for treatment of diffuse large B-cell lymphoma（DLBCL） patients, and to explore the high risk factors of refractory and relapsed patients." | 1.56 | [Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen]. ( Chen, BA; Gao, C; Gu, Y; Wu, X; Zhang, J, 2020) |
| "We experienced a pregnant woman with superior vena cava syndrome at 15 weeks of pregnancy who was diagnosed with primary mediastinal large B-cell lymphoma and given chemotherapy." | 1.51 | Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy. ( Hashimoto, Y; Nakamoto, S; Omura, H; Tanaka, T; Tokuyasu, Y, 2019) |
| "With suspected recurrence of DLBCL, FDG-PET/CT was performed that showed no lymphadenopathy or abnormal FDG uptake." | 1.51 | [Diffuse large B-cell lymphoma relapsing with intravascular large B-cell lymphoma-like perivascular and intravascular lesions]. ( Fukumi, T; Ishikawa, T; Makita, M; Moriyama, T; Murakami, H; Nagakita, K; Shinno, Y; Sunami, K; Yoshioka, T, 2019) |
| "Unfortunately, pulmonary thromboembolism occurred 2 weeks later, and the patient's condition was not alleviated through active treatment." | 1.51 | Application of contrast-enhanced ultrasonography in the diagnosis of post-kidney transplant lymphoproliferative disorder in native kidney- a case report. ( Lan, HX; Lei, YY; Lu, MD; Ma, L; Wang, W; Xie, XY; Zhang, JC; Zhao, HJ, 2019) |
| "Vitamin D deficiency has been reported to be a negative prognostic factor in elderly patients with aggressive B-cell lymphomas." | 1.48 | Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. ( Alma, E; Basile, U; Bellesi, S; Corrente, F; Cuccaro, A; D'Alo', F; De Stefano, V; Hohaus, S; Larocca, LM; Maiolo, E; Tartaglia, G; Tisi, MC, 2018) |
| "Seventy patients with primary follicular lymphomawere in our hospital were treated with R-CHOP chemotherapy, the ALC/AMC value of peripheral blood was recorded, and the prognosis was assessed by the international prognostic index." | 1.48 | [ALC/AMC Value and Prognosis in Patients with Primary Follicular Lymphoma Treated with R-CHOP Chemotherapy]. ( Cui, Y; Shi, P, 2018) |
| "Tacrolimus therapy was stopped due to the possibility of immunodeficiency-related lymphoproliferative disease; however, the lesion did not improve." | 1.48 | A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors. ( Hamada, Y; Horiki, N; Inoue, H; Katsurahara, M; Miura, H; Nakamura, M; Okuse, H; Sakuno, T; Shiono, Y; Takei, Y; Takeuchi, T; Tanaka, K; Yamada, R, 2018) |
| "Hyperfibrinogenemia was demonstrated to be able to predict poor outcome in DLBCL, especially for patients with advanced stage and high NCCN-IPI score." | 1.48 | Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma. ( Cao, L; Li, JY; Liang, JH; Lu, RN; Niu, JY; Tian, T; Wang, L; Wu, W; Xu, W; Zhu, HY, 2018) |
| "Cardiotoxicity is a known risk of anthracycline treatment." | 1.48 | Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. ( Baech, J; Brown, PN; El-Galaly, TC; Haaber, J; Hansen, SM; Josefsson, P; Juul, MB; Jørgensen, J; Lund, PE; Poulsen, CB; Soegaard, P; Starklint, J; Torp-Pedersen, C, 2018) |
| "Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL)." | 1.46 | A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. ( Go, SI; Kang, JH; Kang, MH; Kim, HG; Kim, HR; Lee, GW; Park, MJ; Song, HN, 2017) |
| "However, a primary presentation of acute kidney failure due to lymphoma localization is extremely rare." | 1.46 | Clinical case report: a rare cause of acute kidney failure - tissue is the issue. ( Claes, K; Evenepoel, P; Heggermont, WA; Lerut, E; Sprangers, B; Tousseyn, T; Verhoef, G, 2017) |
| "Relapse was confirmed by biopsy or consecutive imaging." | 1.43 | Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma. ( Avivi, I; Bar-Shalom, R; Benyamini, N; Dann, EJ; Farbstein, D; Lavi, N; Shapira, G; Zilberlicht, A, 2016) |
| "(2) Burkitt's lymphoma was the most common (34/43, 79." | 1.43 | [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia]. ( Gao, J; Guo, J; Guo, X; Jia, CS; Li, Q; Zhou, CY; Zhu, YP, 2016) |
| "Sarcopenia is known to be related to an increased risk of chemotherapy toxicity and to a poor prognosis in patients with malignancy." | 1.43 | Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. ( Go, SI; Kang, MH; Kim, HG; Kim, RB; Kim, Y; Lee, GW; Lee, HR; Lee, SI; Park, MJ; Song, HN, 2016) |
| "We treated 4 with a diagnosis of diffuse large B cell lymphoma involving the gastrointestinal tract with rituximab combined with adjusted dose EPOCH (R-DA-EPOCH) scheme based on a comprehensive analysis of the onset process, clinical and pathological features, and prognosis of the patients, and evaluated their treatment response." | 1.43 | [Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases]. ( Guo, YX; Hu, RH; Hui, WH; Su, L; Sun, WL; Wan, SG; Zhao, H, 2016) |
| "The median duration from initiation of treatment to relapse was 14." | 1.42 | Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. ( Advani, RH; Hiniker, SM; Hoppe, RT; Khodadoust, MS; Kozak, MM; Pollom, EL; Quon, A; Xu, G, 2015) |
| "Patients suffering from cancer are often treated with a range of chemotherapeutic agents, but the treatment efficacy varies greatly between patients." | 1.42 | Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. ( Bødker, JS; Bøgsted, M; Dybkær, K; El-Galaly, TC; Falgreen, S; Johnsen, HE; Kjeldsen, MK; Laursen, MB; Nyegaard, M; Schmitz, A; Xu-Monette, ZY; Young, KH, 2015) |
| "Acute liver failure is a rare but life-threatening illness with an incidence of 2-8 per million population." | 1.42 | Diffuse large B-cell lymphoma causing acute liver failure: a rare case of survival. ( Kapuria, D; Qasem, A; Strasser, K, 2015) |
| "This syncope was considered to be neurally mediated syncope caused by the compression of the carotid sinus by the cervical malignant lymphoma." | 1.42 | [A Case of Neurally Mediated Syncope Caused by Cervical Malignant Lymphoma]. ( Matsuzaki, T; Nishimoto, K; Ushikai, M; Yoshifuku, K, 2015) |
| "A biopsy of the tumors indicated MALT lymphoma, and the patient was referred to our hospital." | 1.42 | [A Case of MALT Lymphoma of the Rectum Treated with Intersphincteric Resection (ISR)]. ( Morita, T; Murata, A; Nishikawa, S; Takahashi, K; Tokura, T; Umehara, M; Umehara, Y, 2015) |
| "Sarcopenia is a relevant and predictive factor in elderly patients with DLBCL treated with rituximab plus chemotherapy." | 1.40 | Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. ( Clatot, F; Jardin, F; Kraut-Tauzia, J; Lanic, H; Leprêtre, S; Mareschal, S; Modzelewski, R; Picquenot, JM; Stamatoullas, A; Tilly, H, 2014) |
| " Patients with documented HBV reactivation were treated with entecavir at a dosage of 0." | 1.40 | Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. ( Chang, CS; Chen, PJ; Cheng, AL; Chiu, CF; Hsu, C; Hwang, WL; Kao, WY; Lin, J; Lin, SF; Lin, SJ; Liu, TW; Tien, HF; Tsou, HH; Wang, MC; Yao, M, 2014) |
| "Cyclin D1 expression has been reported in a subset of patients with diffuse large B-cell leukemia (DLBCL), but studies have been few and generally small, and they have demonstrated no obvious clinical implications attributable to cyclin D1 expression." | 1.40 | Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. ( Bhagat, G; Dybkaer, K; Farnen, JP; Han van Krieken, J; Hsi, ED; Medeiros, LJ; Montes-Moreno, S; Møller, MB; O'Malley, DP; Ok, CY; Orazi, A; Piris, MA; Ponzoni, M; Richards, KL; Tzankov, A; Visco, C; Winter, JN; Xu-Monette, ZY; Young, KH; Zu, Y, 2014) |
| "People living with HIV/AIDS (PLWHA) are at a higher risk of developing non-Hodgkin lymphoma (NHL)." | 1.40 | Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era. ( Adamski, M; Gunthel, C; Mosunjac, M; Nguyen, ML; Silverton, A, 2014) |
| "A rare cause of trigeminal neuralgia is malignant lymphoma which spread along the trigeminal nerve." | 1.40 | [Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia]. ( Arakawa, T; Kobayashi, Y; Mano, T; Matsuo, K; Ozawa, H, 2014) |
| "Lymphomatoid granulomatosis is a rare lymphoproliferative disorder composed of rare-to-abundant atypical Epstein Barr virus infected B-cells admixed with numerous reactive T-cells." | 1.39 | Lymphomatoid granulomatosis: a case report with unique clinical and histopathologic features. ( Boone, JM; Fan, F; Zhang, D, 2013) |
| "Long-term survival for patients with AIDS-related diffuse large B-cell lymphoma (DLBCL) is feasible in settings with available combination antiretroviral therapy (cART)." | 1.39 | Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa. ( de Witt, P; Maartens, DJ; Sissolak, G; Uldrick, TS, 2013) |
| "Primary bone lymphoma is a rare disease, representing less than 5% of all extra-nodal non-Hodgkin lymphomas." | 1.39 | Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center. ( Bakiri, M; Briasoulis, A; Harhalakis, N; Karmiris, T; Matikas, A; Oikonomopoulou, D; Tzannou, I, 2013) |
| " In this study we assessed cytotoxicity of ONC in combination with currently used anticancer drugs on a human diffuse large B-cell lymphoma (DLBCL)-derived cell line (Toledo)." | 1.39 | In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line. ( Bogusz, J; Cebula-Obrzut, B; Darzynkiewicz, Z; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P; Witkowska, M; Zwolińska, M, 2013) |
| "Finally, a genomic instability gene signature was highlighted in gene expression profiles of patients belonging to the high-risk GERS-defined group." | 1.38 | Gene expression-based risk score in diffuse large B-cell lymphoma. ( Bret, C; Klein, B; Moreaux, J, 2012) |
| "Early relapse is a parameter that affects clinical outcomes in relapsed diffuse large B cell lymphoma (DLBCL)." | 1.38 | Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. ( Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T, 2012) |
| "Given the overall low rate of CNS recurrence and lack of prophylaxis-associated survival benefit, the current data called into question the practice of CNS prophylaxis in the rituximab era." | 1.38 | Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. ( Abel, GA; Crosby, AL; Czuczman, MS; Friedberg, JW; Gordon, LI; Kumar, A; LaCasce, AS; Lepisto, E; Millenson, M; Nademanee, A; Niland, J; Rodriguez, MA; Vanderplas, A; Zelenetz, AD, 2012) |
| " No guidelines exist for chemotherapy dosing in the elderly population, and a clear assessment of treatment toxicity and benefits has not been previously reported." | 1.38 | Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. ( Greer, JP; Huntington, SF; Morgan, DS; Reddy, N; Talbott, MS, 2012) |
| "Physical examination showed hemiparesis and cerebellar ataxia." | 1.38 | Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs. ( Beyne-Rauzy, O; Brechemier, D; Dugert, E; Hitzel, A; Julian, A; Le Guellec, S; Wagner, T, 2012) |
| "A part of MALT lymphoma is characterized by chromosomal translocations, t(11;18), t(1;14) or t(14;18) that is poor response factors to the eradication." | 1.38 | [Gastric malignant lymphoma]. ( Sugiyama, T; Yoshita, H, 2012) |
| "However, her facial palsy did not resolve, and she died 6 months after diagnosis with pneumonia and sepsis." | 1.38 | Multifocal cranial plasmablastic lymphoma as a rare manifestation of posttransplant lymphoproliferative disorder. ( Bastani, B; Ghods, AJ; Jabbari, M; Jenabi, A; Mooraki, A; Shayanfar, N; Ziari, MB, 2012) |
| "He had no previous history of convulsion." | 1.38 | Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma. ( Baniasadi, S; Fahimi, F; Foroughinia, F; Seifi, S, 2012) |
| "Orbital lymphoma is a very rare type of primary Non-Hodgkin lymphoma." | 1.37 | Treatment of a patient with adnexal lymphoma with Rituximab. ( Bilgir, F; Bilgir, O; Calan, M; Oztekin, O; Sari, F; Yuksel, A, 2011) |
| "Primary breast lymphoma is a rare disease entity." | 1.37 | [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases]. ( Fu, L; Fu, XL; Jin, ZJ; Lang, RG; Liu, FF; Lü, AJ; Wang, XF; Wang, Y; Yang, H, 2011) |
| "A patient was diagnosed with autoimmune thrombocytopenia and concurrent diffuse large B-cell lymphoma (DLBCL)." | 1.37 | Diffuse large B-cell lymphoma complicated with autoimmune thrombocytopenia. ( Ikeda, T; Sato, K; Uchiyama, M, 2011) |
| "This study was purposed to investigate the changes of serum immunoglobulin (Ig) level during treatment of diffuse large B cell lymphoma by using rituximab (RTX) combined with CHOP." | 1.37 | [Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy]. ( Gao, CJ; Huang, WR; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y, 2011) |
| "There were no CNS recurrences in the three patients who received CNS prophylaxis." | 1.37 | Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. ( Fukuhara, S; Kim, SW; Kobayashi, Y; Maeshima, AM; Maruyama, D; Matsuno, Y; Mori, M; Munakata, W; Taniguchi, H; Tanosaki, R; Tobinai, K; Watanabe, T, 2011) |
| "Composite lymphoma is defined as two or more distinct types of lymphoma in a single anatomical site." | 1.37 | Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma. ( Fujioka, Y; Fukayama, M; Ichikawa, M; Kamikubo, Y; Kurokawa, M; Nakamura, F; Nannya, Y; Ota, S; Shinozaki, A; Yamamoto, G; Yamazaki, S, 2011) |
| "While hypercalcemia is one of the complications of various types of cancerous diseases, it has rarely been reported as the first presentation of IVLBCL." | 1.37 | Intravascular B-cell lymphoma with hypercalcemia as the initial presentation. ( Chinen, Y; Horiike, S; Kiyota, M; Kuroda, J; Nakao, M; Sugitani-Yamamoto, M; Taniwaki, M, 2011) |
| "The risk of infection with Pneumocystis jirovecii pneumonia (PCP) in patients undergoing chemotherapy is closely related to the intensity of corticosteroid exposure." | 1.36 | High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. ( Filshie, R; Kamel, S; Lee, N; Nandurkar, H; O'Connor, S; Tam, CS, 2010) |
| "CHOP-like regimen combined with rituximab is a standard chemotherapy for diffuse large B-cell lymphoma (DLBCL)." | 1.36 | Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. ( Dan, K; Gomi, S; Hirakawa, T; Inokuchi, K; Yamaguchi, H; Yokose, N, 2010) |
| "The diagnosis was Hodgkin's disease." | 1.36 | Hodgkin's lymphoma variant of Richter's syndrome. ( Curić-Jurić, S; Kelcec, IB; Kojić-Katović, S; Maricević, I; Tomas, D; Vasilj, A; Zokvić, E, 2010) |
| "Although prophylaxis against CNS recurrence with either intrathecal or intravenous methotrexate is commonly used for such patients, to the authors' knowledge, there is no standard of care." | 1.36 | Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. ( Abramson, JS; Barnes, JA; Hammerman, P; Hellmann, M; Hochberg, EP; Muzikansky, A; Takvorian, T; Toomey, C, 2010) |
| "The prognosis and management of acute exacerbations of hepatitis-B in patients with lymphoma after chemotherapy in combination with rituximab remain unclear." | 1.36 | Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. ( Chen, ZH; Dong, M; Li, X; Lin, Q; Ma, XK; Wei, L; Wen, JY; Wu, XY, 2010) |
| "Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve lymphoma-free survival of primary mediastinal large B-cell lymphoma (PMLBCL)." | 1.35 | Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. ( Broccoli, A; Brusamolino, E; Cabras, MG; Chiappella, A; Finolezzi, E; Martelli, M; Rossi, A; Salvi, F; Stefoni, V; Zinzani, PL, 2009) |
| " This case suggests that long-term administration of an LMWH contributes to the primary improvement and secondary prevention of VTE even in patients who are at high risk for thrombosis." | 1.35 | Long-term administration of a low-molecular-weight heparin contributed to successful treatment in a patient with primary mediastinal large B-cell lymphoma and venous thromboembolism. ( Asaka, M; Hashino, S; Ibata, M; Imamura, M; Masauzi, N; Mashiko, S; Mori, A; Morioka, M; Tsutsumi, Y, 2008) |
| "The dose-dense CHOP-14 regimen is efficient and safe in elderly patients with diffuse large B-cell lymphoma (DLBCL)." | 1.34 | Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. ( de Nully Brown, P; Hansen, M; Jurlander, J; Tholstrup, D, 2007) |
| "In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test." | 1.34 | Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. ( Gergely, L; Illes, A; Kiss, E; Ress, Z; Simon, Z; Tarr, T, 2007) |
| "Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27." | 1.34 | [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. ( Koffi, G; Kouakou, B; Ndathz, E; Ndiaye, FS; Sangare, A; Sanogo, I, 2007) |
| "Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL." | 1.33 | Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Best, JH; Hornberger, JC, 2005) |
| "Adult rhabdomyoma is a rare mesenchymal tumor, which generally grows slowly and is mainly localized in the head and neck area." | 1.33 | Cervical adult rhabdomyoma presenting as a rapidly growing mass in a patient with diffuse large B-cell non-Hodgkin's lymphoma. ( Burg, JE; Hansen, T; Kirkpatrick, CJ; Koutsimpelas, D; Mann, WJ, 2005) |
| "Two of the patients died of disease progression." | 1.33 | Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. ( Ishikura, S; Kitadai, Y; Kobayashi, Y; Matsuno, Y; Mera, K; Nakamura, S; Ochiai, A; Oda, I; Ohtsu, A; Suzumiya, J; Tobinai, K; Yokoi, T; Yoshino, T, 2006) |
| "Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course." | 1.32 | A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003) |
| "The outcome of acquired immunodeficiency syndrome-related lymphomas (ARLs) has improved since the era of highly active antiretroviral therapy, but median survival remains low." | 1.32 | Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. ( Franchini, G; Grant, N; Gutierrez, M; Jaffe, ES; Kavlick, MF; Little, RF; Mitsuya, H; Pittaluga, S; Raffeld, M; Shearer, G; Steinberg, SM; Wilson, WH; Yarchoan, R, 2003) |
| "Grade 3-4 leukopenia was observed in 61% of patients with 11% of febrile neutropenia." | 1.32 | ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma. ( Cavalli, F; Cocorocchio, E; Conconi, A; De Luzio, K; Ferrucci, PF; Martinelli, G; Mazzetta, C; Mingrone, W; Peccatori, FA; Santoro, P; Zucca, E, 2003) |
| "A diagnosis of seronegative Wegener's granulomatosis was made and the patient received a combination of prednisone and cyclophosphamide with clinical improvement and clearance of the radiological lesions in the lungs." | 1.32 | Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis. ( Amariglio, N; Amir, G; Cohen, Y; Polliack, A; Schibi, G, 2004) |
| "At the age of 26 there was a transitory recurrence of the goitre during a pregnancy, during which time the thyroid peroxidase antibodies became strongly positive." | 1.32 | [A pregnant woman with autoimmune thyroiditis and recurrent goiter]. ( Berghout, A; Muller, AF; Santoe, MF; Van Houten, AA, 2004) |
| "Lymphomatoid papulosis is associated with primary cutaneous ALCL and other lymphoproliferative malignancies, but is rarely associated with extranodal systemic ALCL." | 1.32 | Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. ( Duvic, M; Jones, DM; Perna, AG, 2004) |
| "Pancreatic lymphoma is a rare neoplasm." | 1.31 | Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma? ( Abrams, RA; Cameron, JL; Colemann, J; Koniaris, LG; Lillemoe, KD; Nakeeb, A; Pitt, H; Yeo, CJ, 2000) |
| "The acute tumor lysis syndrome is a rare condition that has most frequently been documented in patients with rapidly dividing myeloproliferative and lymphoproliferative malignancies." | 1.31 | Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome. ( Grootendorst, AF; Van Der Klooster, JM; Van Der Wiel, HE; Van Saase, JL, 2000) |
| "Two patients presented with anasarca, fevers and sweats." | 1.31 | Non-Hodgkin's lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha). ( Burgess, R; Day, DS; Jillella, AP; Kallab, AM; Severson, K, 2000) |
| "9 mg/m2/week (90% of ideal CHOP dosing for both drugs)." | 1.31 | Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. ( Bertino, J; Donnelly, GB; Glassman, J; Long, C; Moskowitz, CH; O'Brien, JP; Portlock, CS; Straus, DJ; Torres, P; Zelenetz, AD, 2000) |
| "Low-grade relapse is not uncommon in patients who initially presented with diffuse large cell lymphoma." | 1.30 | Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. ( Connors, JM; Gascoyne, RD; Hoskins, PJ; Klasa, R; Le, N; O'Reilly, S; Shenkier, T, 1997) |
| "Although chemotherapy rendered the cardiac tumor indistinct on MRI and UCG images, gallium-67 scintigraphy still demonstrated abnormal cardiac uptake." | 1.30 | [Sick sinus syndrome after chemotherapy for malignant lymphoma with right atrial tumor at initial presentation]. ( Fujii, S; Fujiwara, T; Kikuchi, T; Miyata, A; Osada, T, 1998) |
| "Castleman's disease is a rare entity which is characterized by its histologic features: hyperplasia of lymph nodes and capillary proliferation." | 1.30 | [Localized Castleman's disease associated with high-grade lymphoma]. ( de Prada, I; Guerra Vales, JM; Guillén Camargo, V; Martínez, MA; Sanz García, RM, 1999) |
| "Two had cutaneous non-Hodgkin's lymphoma while one had Hodgkin's lymphoma." | 1.30 | HIV-associated lymphoma: report of three cases. ( Mwangi, JW, 1999) |
| "We describe a patient with acquired immunodeficiency syndrome (AIDS) and non-Hodgkin's lymphoma of the duodenum manifested as obstructive jaundice." | 1.29 | Primary small bowel lymphoma manifested as obstructive jaundice in a patient with AIDS. ( Bresalier, RS; Schoeppner, HL; Wong, DK, 1995) |
| "Spinal cord compression has been reported in 5% of patients with solid tumors." | 1.29 | [Spinal cord compression as the presenting form of non-Hodgkin's lymphoma]. ( Amigo, ML; Caballero, D; del Cañizo, C; Revilla, R; San Miguel, JF; Sánchez, C, 1995) |
| "Lymphoma is an unusual cause of tracheoesophageal fistula (TEF)." | 1.29 | Tracheoesophageal fistula developing during chemotherapy for non-Hodgkins lymphoma. ( Bierman, PJ; Galbraith, TA; Lackner, RP, 1996) |
| "The development of multiple myeloma has not been reported previously during a course of malignant lymphoma." | 1.28 | [Multiple myeloma in a patient in remission from malignant lymphoma]. ( Aotuka, N; Asai, T; Hashimoto, S; Hirasawa, A; Itoh, K; Kawano, E; Morio, S; Nakamura, H; Oh, H; Yoshida, S, 1992) |
| "A case of primary histiocytic lymphoma in the uterine cervix of a 22-year-old nulligravid woman is reported." | 1.28 | Successful pregnancy following treatment of primary malignant lymphoma of the uterine cervix. ( Lote, K; Sandvei, R; Svendsen, E; Thunold, S, 1990) |
| "A patient had cutaneous polyarteritis nodosa associated with Crohn's disease." | 1.27 | Cutaneous polyarteritis nodosa. Report of a case associated with Crohn's disease. ( Goslen, JB; Graham, W; Lazarus, GS, 1983) |
| "Fifty-six patients with malignant lymphoma of aggressive histologic type (51 large cell, three diffuse undifferentiated, and two nodular mixed) were treated with three non-cross-resistant combination chemotherapy regimens that were introduced sequentially according to the response to therapy." | 1.27 | Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ, 1983) |
| "Seventy-five patients with diffuse histiocytic lymphoma (DHL) ranging in age from 33 to 94 years were treated with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP)." | 1.26 | Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). ( Armitage, JO; Corder, MP; Dick, FR; Garneau, SC; Platz, CE; Slymen, DJ, 1982) |
| "We grouped 162 patients wtih advanced, diffuse histiocytic lymphoma (DHL) into various morphological subtypes to ascertain whether there were any significant differences in survival among them." | 1.26 | The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group. ( Byrne, GE; Coltman, CA; Dixon, DO; Hartsock, RJ; Jones, SE; Kim, H; Nathwani, BN; Rappaport, H; Rebuck, JW; Sheehan, WW, 1982) |
| "Long-term survivors of advanced diffuse histiocytic lymphoma treated with comparable chemotherapy, who served as a control population, had significantly higher percentages of E rosettes and no reduction in mitogen-induced lymphocyte proliferation." | 1.26 | Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. ( Bostick, F; DeVita, VT; Fisher, RI; Howser, DM; Hubbard, SM; Vanhaelen, C; Young, RC, 1980) |
| "A patient with histiocytic lymphoma had abdominal masses, hypophosphatemia, normocalcemia, and a normal serum parathyroid hormone value." | 1.26 | Hypophosphatemia in a patient with lymphoma in leukemic phase. ( Matzner, Y; Polliack, A; Popovtzer, MM; Prococimer, M; Rubinger, D, 1981) |
| "15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC." | 1.26 | Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations. ( Donner, L; Klener, P, 1977) |
| "Low-grade malignant lymphomas are treated best with conventional doses of an alkylating agent." | 1.26 | [Chemotherapy in non-Hodgkin's lymphomas (author's transl)]. ( Schmidt, CG, 1977) |
| "The response rates for lymphocytic and histiocytic lymphomas were 82 and 86%." | 1.26 | Combination of cyclophosphamide, vincristine, and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with non-Hodgkin's lymphomas. ( David, R; Duhamel, G; Gorin, NC; Najman, A; Stachowiak, J, 1977) |
| "Fifteen patients with stage III and IV diffuse histiocytic lymphoma were treated with combination chemotherapy: cyclophosphamide, vincristine sulfate, prednisone, and procarbazine hydrochloride (COPP)." | 1.26 | Diffuse histiocytic lymphoma. The need for aggressive restaging. ( Babick, T; Levitt, M; Weinerman, BH, 1977) |
| "Twenty-three patients with diffuse histiocytic lymphoma who had not had prior chemotherapy were treated with CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone)." | 1.26 | Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). ( Elias, L; Portlock, CS; Rosenberg, SA, 1978) |
| "Four patients suffering spinal cord compression resulting from epidural metastases were treated with adrenocorticosteroid hormones." | 1.26 | "Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. ( Cvitkovic, E; Howieson, J; Posner, JB, 1977) |
| "The response rates for lymphocytic and histiocytic lymphomas were 80 and 86%." | 1.26 | [Cyclophosphamide-vincristine-prednisone combination in the treatment of lympho- and reticulosarcomas in adults (60 cases)]. ( David, R; Duhamel, G; Gorin, NC; Najman, A; Stachowiak, J, 1976) |
| "Twenty-seven patients with advanced diffuse histiocytic lymphoma (reticulum-cell sarcoma) were treated with combination chemotherapy utilising nitrogen mustard (or cyclophosphamide), procarbazine, vincristine, and prednisone." | 1.25 | Advanced diffuse histiocytic lymphoma, a potentially curable disease. ( Canellos, GP; Chabner, B; DeVita, VT; Hubbard, SP; Schein, P; Young, RC, 1975) |
| "A patient with nodular histiocytic lymphoma was treated with bleomycin; she later developed interstitial pneumonitis documented by lung biopsy." | 1.25 | Reversible interstitial pneumonitis associated with low dose bleomycin. ( Kardinal, CG; O'Neill, TJ; Tierney, LM, 1975) |
| "The survival was longer for nodular lymphosarcoma patients (25% are alive at 7 years for Stages III and IV) than for diffuse lymphosarcomata and reticulosarcomata (10%)." | 1.25 | Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV. ( Amiel, JL; Hayat, M; Mathé, G; Pouillart, P; Schwarzenberg, L; Tubiana, M, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a histologically proven complete remission after 6 months of treatment without maintenance have remained disease-free whereas those with nodular poorly differentiated lymphocytic and diffuse well-differentiated lymphocytic lymphomas have demonstrated a pattern of continuous late recurrence." | 1.25 | Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. ( Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RC, 1975) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 1.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a complete remission after 6 months of treatment without maintenance have remained disease-free, whereas those with nodular poorly differentiated lymphocytic and diffuse well differentiated lymphocytic lymphomata demonstrate a pattern of continuous late recurrence." | 1.25 | Results of combination chemotherapy of non-Hodgkin's lymphoma. ( Berard, C; Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RD, 1975) |
| "Clinical recurrence of the histiocytic lymphoma has not occurred." | 1.25 | Successful use of combination chemotherapy in pure red cell aplasia associated with malignant lymphoma, histiocytic type. ( Hunt, FA; Lander, CM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 153 (6.52) | 18.7374 |
| 1990's | 143 (6.10) | 18.2507 |
| 2000's | 421 (17.95) | 29.6817 |
| 2010's | 1194 (50.90) | 24.3611 |
| 2020's | 435 (18.54) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, MC | 5 |
| Musuraca, G | 8 |
| Battistini, R | 2 |
| Casaroli, I | 3 |
| Zoli, V | 2 |
| Anticoli-Borza, P | 1 |
| Arcari, A | 6 |
| Naso, V | 1 |
| di Landro, F | 2 |
| Fabbri, F | 2 |
| Tafuri, A | 2 |
| Bocci, G | 2 |
| Merli, F | 9 |
| Pelliccia, S | 3 |
| Marcheselli, L | 9 |
| Borza, PA | 1 |
| Patti, C | 6 |
| Di Napoli, A | 3 |
| Caridi, M | 1 |
| Ulu, BU | 1 |
| Yiğenoğlu, TN | 3 |
| Başcı, S | 3 |
| Bakırtaş, M | 3 |
| Şahin, D | 3 |
| Darçın, T | 1 |
| Yaman, S | 2 |
| Bozan, E | 1 |
| Seçilmiş, S | 1 |
| Candır, BA | 1 |
| Yıldız, J | 2 |
| İskender, D | 1 |
| Baysal, NA | 1 |
| Çakar, MK | 1 |
| Dal, MS | 3 |
| Altuntaş, F | 3 |
| Knörr, F | 1 |
| Zimmermann, M | 1 |
| Attarbaschi, A | 1 |
| Kabíčková, E | 1 |
| Maecker-Kolhoff, B | 1 |
| Ruf, S | 1 |
| Kühnle, I | 1 |
| Ebinger, M | 1 |
| Garthe, AK | 1 |
| Simonitsch-Klupp, I | 2 |
| Oschlies, I | 1 |
| Klapper, W | 7 |
| Burkhardt, B | 1 |
| Woessmann, W | 1 |
| Tekinalp, A | 1 |
| Kars, TU | 1 |
| Dikici, HZ | 1 |
| Yılmaz, PD | 1 |
| Demircioğlu, S | 1 |
| Çeneli, Ö | 1 |
| Desai, SH | 1 |
| LaPlant, B | 5 |
| Macon, WR | 10 |
| King, RL | 4 |
| Wang, Y | 18 |
| Inwards, DJ | 10 |
| Micallef, I | 1 |
| Johnston, PB | 9 |
| Porrata, LF | 7 |
| Ansell, SM | 13 |
| Habermann, TM | 22 |
| Witzig, TE | 20 |
| Nowakowski, GS | 20 |
| Burke, GAA | 1 |
| Minard-Colin, V | 2 |
| Aupérin, A | 3 |
| Alexander, S | 2 |
| Pillon, M | 2 |
| Delgado, R | 1 |
| Zsíros, J | 1 |
| Uyttebroeck, A | 1 |
| Dartigues, P | 2 |
| Miles, RR | 1 |
| Kazanowska, B | 1 |
| Chiang, AK | 1 |
| Haouy, S | 2 |
| Bollard, CM | 2 |
| Csoka, M | 1 |
| Wheatley, K | 1 |
| Barkauskas, DA | 1 |
| Adamson, PC | 1 |
| Vassal, G | 1 |
| Patte, C | 4 |
| Gross, TG | 1 |
| Tang, CC | 1 |
| Huang, TC | 3 |
| Tien, FM | 1 |
| Lin, JM | 1 |
| Yeh, YC | 1 |
| Lee, CY | 1 |
| Hounsome, L | 1 |
| Eyre, TA | 13 |
| Ireland, R | 1 |
| Hodson, A | 1 |
| Walewska, R | 1 |
| Ardeshna, K | 1 |
| Chaganti, S | 2 |
| McKay, P | 3 |
| Davies, A | 5 |
| Fox, CP | 6 |
| Kalakonda, N | 2 |
| Fields, PA | 3 |
| Ensor, AM | 1 |
| Sanchez, CG | 1 |
| Ensor, JE | 1 |
| Anand, K | 1 |
| Dlouhy, I | 3 |
| Karube, K | 1 |
| Enjuanes, A | 1 |
| Salaverria, I | 1 |
| Nadeu, F | 1 |
| Ramis-Zaldivar, JE | 1 |
| Valero, JG | 1 |
| Rivas-Delgado, A | 1 |
| Magnano, L | 1 |
| Martin-García, D | 1 |
| Pérez-Galán, P | 1 |
| Clot, G | 1 |
| Rovira, J | 2 |
| Jares, P | 3 |
| Balagué, O | 1 |
| Giné, E | 2 |
| Mozas, P | 1 |
| Briones, J | 7 |
| Sancho, JM | 9 |
| Salar, A | 10 |
| Mercadal, S | 2 |
| Alcoceba, M | 2 |
| Valera, A | 1 |
| Campo, E | 15 |
| López-Guillermo, A | 16 |
| Miyawaki, K | 5 |
| Kato, K | 8 |
| Sugio, T | 2 |
| Sasaki, K | 4 |
| Miyoshi, H | 3 |
| Semba, Y | 1 |
| Kikushige, Y | 2 |
| Mori, Y | 1 |
| Kunisaki, Y | 1 |
| Iwasaki, H | 2 |
| Miyamoto, T | 4 |
| Kuo, FC | 1 |
| Aster, JC | 2 |
| Ohshima, K | 10 |
| Maeda, T | 1 |
| Akashi, K | 3 |
| Ho, G | 1 |
| Tan, C | 1 |
| de Mel, S | 3 |
| Poon, L | 1 |
| Chan, EHL | 3 |
| Lee, J | 3 |
| Liu, X | 15 |
| Chng, WJ | 1 |
| Chee, YL | 2 |
| Soon, YY | 1 |
| Jeyasekharan, AD | 4 |
| Kaddu-Mulindwa, D | 2 |
| Lesan, V | 2 |
| Berdel, C | 1 |
| Stilgenbauer, S | 2 |
| Bewarder, M | 2 |
| Thurner, L | 2 |
| Witzens-Harig, M | 5 |
| Viardot, A | 2 |
| Soekler, M | 1 |
| Keller, U | 3 |
| Truemper, L | 3 |
| Christofyllakis, K | 2 |
| Fleser, O | 1 |
| Bittenbring, JT | 4 |
| Poeschel, V | 7 |
| Held, G | 10 |
| Jagoda, P | 1 |
| Puckrin, R | 1 |
| Ghosh, S | 1 |
| Peters, A | 1 |
| Stewart, D | 2 |
| Ceriani, L | 2 |
| Milan, L | 1 |
| Cascione, L | 2 |
| Gritti, G | 3 |
| Dalmasso, F | 1 |
| Esposito, F | 1 |
| Pirosa, MC | 1 |
| Schär, S | 1 |
| Bruno, A | 1 |
| Dirnhofer, S | 8 |
| Giovanella, L | 2 |
| Hayoz, S | 1 |
| Mamot, C | 7 |
| Rambaldi, A | 4 |
| Chauvie, S | 1 |
| Zucca, E | 12 |
| Ren, M | 1 |
| Liu, Y | 13 |
| Wilson, WH | 22 |
| Wright, GW | 2 |
| Huang, DW | 2 |
| Hodkinson, B | 3 |
| Balasubramanian, S | 6 |
| Fan, Y | 2 |
| Vermeulen, J | 5 |
| Shreeve, M | 1 |
| Staudt, LM | 14 |
| Roh, J | 3 |
| Cho, H | 7 |
| Pak, HK | 3 |
| Lee, YS | 4 |
| Lee, SW | 7 |
| Ryu, JS | 4 |
| Chae, EJ | 2 |
| Kim, KW | 3 |
| Huh, J | 35 |
| Choi, YS | 4 |
| Jeong, SH | 7 |
| Suh, C | 34 |
| Yoon, DH | 26 |
| Park, CS | 12 |
| Fleming, M | 1 |
| Huang, Y | 4 |
| Dotson, E | 1 |
| Bond, DA | 2 |
| Reneau, J | 1 |
| Epperla, N | 3 |
| Alinari, L | 4 |
| Brammer, J | 1 |
| Christian, BA | 1 |
| Baiocchi, RA | 1 |
| Maddocks, K | 1 |
| Sawalha, Y | 1 |
| Davids, MS | 1 |
| Rogers, KA | 1 |
| Tyekucheva, S | 1 |
| Wang, Z | 9 |
| Pazienza, S | 1 |
| Renner, SK | 1 |
| Montegaard, J | 1 |
| Ihuoma, U | 1 |
| Lehmberg, TZ | 1 |
| Parry, EM | 1 |
| Wu, CJ | 1 |
| Jacobson, CA | 1 |
| Fisher, DC | 2 |
| Thompson, PA | 1 |
| Brown, JR | 1 |
| Willenbacher, W | 2 |
| Greil, R | 8 |
| Larsen, TS | 6 |
| Patel, K | 1 |
| Jäger, U | 2 |
| Manges, RF | 1 |
| Trümper, L | 7 |
| Everaus, H | 1 |
| Brown, P | 4 |
| Jørgensen, JM | 2 |
| Cunningham, D | 9 |
| Dell'Aringa, J | 1 |
| Fox, B | 1 |
| Rubio, ND | 1 |
| Kilavuz, N | 1 |
| Casadebaig, ML | 2 |
| Manzke, O | 1 |
| Munoz, J | 1 |
| Major, A | 1 |
| Smith, SM | 11 |
| Morgenstern, Y | 1 |
| Aumann, S | 1 |
| Goldschmidt, N | 3 |
| Gatt, ME | 2 |
| Nachmias, B | 1 |
| Horowitz, NA | 2 |
| Samineni, D | 2 |
| Huang, W | 4 |
| Gibiansky, L | 1 |
| Ding, H | 3 |
| Zhang, R | 2 |
| Li, C | 4 |
| Sinha, A | 2 |
| Rajwanshi, R | 1 |
| Humphrey, K | 2 |
| Bazeos, A | 2 |
| Salem, AH | 1 |
| Miles, D | 1 |
| Dunleavy, K | 10 |
| Tilly, H | 38 |
| Morschhauser, F | 14 |
| Sehn, LH | 54 |
| Friedberg, JW | 18 |
| Trněný, M | 11 |
| Sharman, JP | 4 |
| Herbaux, C | 2 |
| Burke, JM | 5 |
| Matasar, M | 2 |
| Rai, S | 4 |
| Izutsu, K | 9 |
| Mehta-Shah, N | 2 |
| Oberic, L | 7 |
| Chauchet, A | 1 |
| Jurczak, W | 10 |
| Song, Y | 14 |
| Mykhalska, L | 1 |
| Bergua-Burgués, JM | 1 |
| Cheung, MC | 5 |
| Pinto, A | 3 |
| Shin, HJ | 18 |
| Hapgood, G | 1 |
| Munhoz, E | 1 |
| Abrisqueta, P | 6 |
| Gau, JP | 7 |
| Hirata, J | 2 |
| Jiang, Y | 3 |
| Yan, M | 1 |
| Lee, C | 3 |
| Flowers, CR | 14 |
| Salles, G | 21 |
| Zhang, J | 10 |
| Disperati, P | 1 |
| Elinder-Camburn, A | 1 |
| Merriman, E | 1 |
| Leitch, S | 1 |
| Chan, H | 1 |
| Rajabto, W | 1 |
| Angkasa, YK | 1 |
| Harahap, AS | 1 |
| Ham, MF | 1 |
| Brahma, B | 1 |
| Hawkes, EA | 8 |
| Barraclough, A | 3 |
| Chiappella, A | 22 |
| Diop, F | 2 |
| Agostinelli, C | 2 |
| Novo, M | 2 |
| Nassi, L | 5 |
| Evangelista, A | 1 |
| Ciccone, G | 6 |
| Di Rocco, A | 11 |
| Martelli, M | 17 |
| Melle, F | 1 |
| Moia, R | 1 |
| Motta, G | 1 |
| Righi, S | 1 |
| Santambrogio, E | 1 |
| Tucci, A | 12 |
| Balzarotti, M | 7 |
| Ladetto, M | 7 |
| Pileri, SA | 6 |
| Gaidano, G | 15 |
| Vitolo, U | 26 |
| João, M | 1 |
| Bento-Miranda, M | 1 |
| Gravito-Soares, E | 1 |
| Gravito-Soares, M | 1 |
| Figueiredo, P | 1 |
| Rajendran, T | 1 |
| Kini, JR | 1 |
| Abna, A | 1 |
| Prasad, K | 1 |
| Kim, DY | 4 |
| Nam, J | 1 |
| Chung, JS | 10 |
| Jeon, BE | 2 |
| Lee, JH | 17 |
| Jo, JC | 4 |
| Kim, SW | 9 |
| Kim, SJ | 31 |
| Park, Y | 9 |
| Kang, HJ | 13 |
| Koh, Y | 5 |
| Lee, GW | 18 |
| Lee, WS | 12 |
| Yang, DH | 14 |
| Do, YR | 8 |
| Kim, MK | 11 |
| Yoo, KH | 3 |
| Yun, HJ | 2 |
| Yi, JH | 3 |
| Eom, HS | 12 |
| Kwak, JY | 7 |
| Park, BB | 1 |
| Hyun, SY | 3 |
| Yi, SY | 1 |
| Kwon, JH | 5 |
| Oh, SY | 14 |
| Kim, HJ | 15 |
| Sohn, BS | 6 |
| Won, JH | 5 |
| Kim, SH | 8 |
| Lee, HS | 4 |
| Kim, WS | 28 |
| Wilson, MR | 1 |
| Kirkwood, AA | 4 |
| Wong Doo, N | 1 |
| Soussain, C | 2 |
| Choquet, S | 2 |
| Martinez-Calle, N | 4 |
| Preston, G | 1 |
| Ahearne, M | 1 |
| Schorb, E | 1 |
| Moles-Moreau, MP | 1 |
| Ku, M | 1 |
| Rusconi, C | 3 |
| Khwaja, J | 1 |
| Narkhede, M | 1 |
| Lewis, KL | 2 |
| Calimeri, T | 1 |
| Durot, E | 2 |
| Renaud, L | 2 |
| Øvlisen, AK | 2 |
| McIlroy, G | 1 |
| Ebsworth, TJ | 1 |
| Elliot, J | 1 |
| Santarsieri, A | 1 |
| Ricard, L | 1 |
| Shah, N | 3 |
| Liu, Q | 5 |
| Zayac, AS | 2 |
| Vassallo, F | 1 |
| Lebras, L | 2 |
| Roulin, L | 3 |
| Lombion, N | 1 |
| Manos, K | 2 |
| Fernandez, R | 4 |
| Hamad, N | 1 |
| Lopez-Garcia, A | 1 |
| O'Mahony, D | 1 |
| Gounder, P | 1 |
| Forgeard, N | 1 |
| Lees, C | 1 |
| Agbetiafa, K | 1 |
| Strüßmann, T | 2 |
| Htut, TW | 1 |
| Clavert, A | 1 |
| Scott, H | 1 |
| Guidetti, A | 3 |
| Barlow, BR | 1 |
| Tchernonog, E | 1 |
| Smith, J | 1 |
| Miall, F | 1 |
| Cheah, CY | 4 |
| El Galaly, TC | 1 |
| Ferreri, AJM | 2 |
| Cwynarski, K | 4 |
| Guan, J | 1 |
| Sun, F | 2 |
| Wang, J | 21 |
| Huang, J | 5 |
| Lu, S | 2 |
| Zhu, J | 23 |
| Zhu, X | 3 |
| Huang, H | 17 |
| Xia, Z | 8 |
| Que, Y | 1 |
| Cai, R | 1 |
| Zhen, Z | 2 |
| Sun, X | 7 |
| Zhang, Y | 20 |
| Jiang, J | 3 |
| Liu, L | 3 |
| Yu, B | 3 |
| Zhang, Q | 17 |
| Ji, D | 4 |
| Lv, F | 5 |
| Hong, X | 12 |
| Song, S | 1 |
| Cao, J | 12 |
| Zhou, X | 4 |
| Li, X | 14 |
| Harris, W | 1 |
| Bataillard, EJ | 1 |
| Choi, Y | 1 |
| El-Galaly, TC | 13 |
| Cuchelkar, V | 1 |
| Henneges, C | 1 |
| Kwan, A | 1 |
| Schneider, DJ | 1 |
| Paulson, JN | 2 |
| Nielsen, TG | 3 |
| Chatzidimitriou, C | 1 |
| Rondogianni, P | 4 |
| Arapaki, M | 3 |
| Liaskas, A | 1 |
| Plata, E | 2 |
| Angelopoulou, MK | 7 |
| Tsirigotis, P | 5 |
| Vassilakopoulos, TP | 7 |
| Jakobsen, LH | 4 |
| Severinsen, MT | 3 |
| Bæch, J | 1 |
| Kragholm, KH | 1 |
| Glimelius, I | 2 |
| Gang, AO | 6 |
| Frederiksen, H | 3 |
| Poulsen, CB | 4 |
| Clausen, MR | 6 |
| Pedersen, PT | 3 |
| Pedersen, RS | 3 |
| Torp-Pedersen, C | 2 |
| Eloranta, S | 2 |
| Spinner, MA | 1 |
| Advani, RH | 8 |
| Harkins, RA | 1 |
| Patel, SP | 1 |
| Lee, MJ | 1 |
| Switchenko, JM | 1 |
| Bartlett, NL | 13 |
| Blum, KA | 6 |
| Cashen, AF | 2 |
| Casulo, C | 3 |
| Kahl, BS | 17 |
| Leonard, JP | 18 |
| Link, BK | 4 |
| Lossos, IS | 10 |
| Martin, P | 4 |
| Maurer, MJ | 6 |
| Reagan, PM | 1 |
| Westin, JR | 5 |
| Koff, JL | 3 |
| Runge, JS | 1 |
| Brown, AB | 1 |
| Phillips, TJ | 3 |
| Kaminski, MS | 4 |
| Carty, SA | 1 |
| Wilcox, RA | 2 |
| Lucijanic, M | 4 |
| Huzjan Korunic, R | 1 |
| Sedinic, M | 1 |
| Kovacevic, S | 1 |
| Atic, A | 1 |
| Pejsa, V | 4 |
| Kusec, R | 4 |
| Albitar, M | 1 |
| Zhang, H | 10 |
| Goy, A | 5 |
| Xu-Monette, ZY | 25 |
| Bhagat, G | 18 |
| Visco, C | 23 |
| Tzankov, A | 22 |
| Fang, X | 3 |
| Zhu, F | 2 |
| Dybkaer, K | 12 |
| Chiu, A | 14 |
| Tam, W | 3 |
| Zu, Y | 16 |
| Hsi, ED | 29 |
| Hagemeister, FB | 9 |
| Ponzoni, M | 24 |
| Møller, MB | 27 |
| Parsons, BM | 5 |
| van Krieken, JH | 16 |
| Piris, MA | 27 |
| Winter, JN | 22 |
| Li, Y | 28 |
| Xu, B | 6 |
| Young, KH | 27 |
| Zhong, KL | 1 |
| Cao, BP | 1 |
| Guo, XC | 1 |
| Huang, LF | 1 |
| Wang, WX | 1 |
| Wang, B | 3 |
| Zhang, WJ | 2 |
| Fukuda, Y | 1 |
| Edahiro, Y | 1 |
| Takaku, T | 1 |
| Furuya, C | 1 |
| Shirane, S | 1 |
| Hamano, Y | 1 |
| Koike, M | 2 |
| Komatsu, N | 3 |
| Arai, K | 1 |
| Mitsuhashi, K | 2 |
| Honjo, Y | 1 |
| Kurachi, M | 1 |
| Komiya, Y | 2 |
| Arao, T | 1 |
| Sato, H | 1 |
| Xue, H | 1 |
| Song, W | 2 |
| Xiao, S | 1 |
| Jing, F | 1 |
| Dong, T | 1 |
| Wang, L | 26 |
| Dourthe, ME | 1 |
| Phulpin, A | 1 |
| Bosq, J | 4 |
| Couec, ML | 1 |
| Ducassou, S | 1 |
| Garnier, N | 1 |
| Leblanc, T | 1 |
| Leruste, A | 1 |
| Paillard, C | 1 |
| Rigaud, C | 1 |
| Simonin, M | 1 |
| Snider, JT | 1 |
| McMorrow, D | 1 |
| Song, X | 2 |
| Diakun, D | 1 |
| Wade, SW | 1 |
| Cheng, P | 1 |
| Mansouri, S | 1 |
| Assane, C | 1 |
| Malo, FC | 1 |
| Durmaz, M | 2 |
| Visser, O | 4 |
| Posthuma, EFM | 1 |
| Brouwer, RE | 4 |
| Issa, DE | 4 |
| de Jong, D | 6 |
| Lam, KH | 3 |
| Blijlevens, NMA | 1 |
| Zijlstra, JM | 4 |
| Chamuleau, MED | 5 |
| Lugtenburg, PJ | 11 |
| Kersten, MJ | 7 |
| Dinmohamed, AG | 3 |
| Nelles, R | 1 |
| Morris, K | 3 |
| Scott, A | 1 |
| Kennedy, G | 1 |
| Rubalcava Lara, LF | 1 |
| Aviles-Salas, A | 3 |
| Candelaria, M | 3 |
| Sirivisoot, S | 1 |
| Kasantikul, T | 1 |
| Techangamsuwan, S | 1 |
| Radtanakatikanon, A | 1 |
| Chen, K | 2 |
| Lin, TY | 14 |
| Rungsipipat, A | 1 |
| Lakhotia, R | 1 |
| Melani, C | 3 |
| Roschewski, M | 4 |
| Segawa, R | 1 |
| Natazuka, T | 2 |
| Jin, J | 8 |
| Xue, K | 5 |
| Gu, JJ | 3 |
| Guo, Y | 8 |
| Miyazaki, K | 11 |
| Juul, MB | 6 |
| Jelicic, J | 1 |
| Anru, PL | 1 |
| Engberg, H | 2 |
| Hammershøj Jensen, P | 1 |
| Kristensen, HB | 2 |
| Baech, J | 3 |
| Munksgaard, L | 2 |
| Stauffer Larsen, T | 1 |
| Morita, Y | 3 |
| Kanemasa, Y | 8 |
| Sasaki, Y | 8 |
| Ohigashi, A | 2 |
| Tamura, T | 2 |
| Nakamura, S | 12 |
| Yagi, Y | 2 |
| Kageyama, A | 2 |
| Omuro, Y | 7 |
| Shimoyama, T | 8 |
| Putri, S | 1 |
| Setiawan, E | 1 |
| Saldi, SRF | 1 |
| Khoe, LC | 1 |
| Sari, ER | 1 |
| Megraini, A | 1 |
| Nadjib, M | 1 |
| Sastroasmoro, S | 1 |
| Armansyah, A | 1 |
| Miura, K | 3 |
| Takahashi, H | 7 |
| Nakagawa, M | 2 |
| Hamada, T | 1 |
| Uchino, Y | 2 |
| Iizuka, K | 1 |
| Ohtake, S | 2 |
| Iriyama, N | 3 |
| Hatta, Y | 3 |
| Nakamura, H | 9 |
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 2 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Rudresha, AH | 1 |
| Hassan, SA | 1 |
| Sreevalli, A | 1 |
| Lokanatha, D | 1 |
| Babu, MCS | 1 |
| Lokesh, KN | 1 |
| Rajeev, LK | 1 |
| Saldanha, S | 2 |
| Thottian, AGF | 1 |
| Sharma, K | 1 |
| Jacob, LA | 2 |
| Gui, A | 1 |
| Chen, G | 3 |
| Yang, L | 6 |
| Bonnet, A | 1 |
| Bossard, C | 1 |
| Gabellier, L | 1 |
| Rohmer, J | 1 |
| Laghmari, O | 1 |
| Parrens, M | 5 |
| Sarkozy, C | 3 |
| Dulery, R | 1 |
| Roland, V | 1 |
| Llamas-Gutierrez, F | 1 |
| Fornecker, LM | 1 |
| Bounaix, L | 1 |
| Villemagne, B | 1 |
| Szablewski, V | 2 |
| Bouabdallah, K | 3 |
| Traverse-Glehen, A | 1 |
| Mohty, M | 2 |
| Sanhes, L | 2 |
| Houot, R | 2 |
| Gastinne, T | 1 |
| Leux, C | 1 |
| Le Gouill, S | 6 |
| Ngu, H | 1 |
| Takiar, R | 1 |
| Phillips, T | 2 |
| Okosun, J | 1 |
| Ruiz, IC | 1 |
| Sellam, G | 3 |
| Bottos, A | 1 |
| Klingbiel, D | 4 |
| Kostakoglu, L | 4 |
| Özbalak, M | 2 |
| Güzel Mastanzade, M | 1 |
| Özlük, Ö | 1 |
| Tiryaki, TO | 1 |
| Erdem, S | 1 |
| Özbalak, EP | 1 |
| Elverdi, T | 2 |
| Yönal Hindilerden, İ | 1 |
| Altay, AY | 1 |
| Yeğen, G | 1 |
| Eşkazan, AE | 2 |
| Ar, MC | 2 |
| Yenerel, MN | 1 |
| Soysal, T | 3 |
| Nalçacı, M | 2 |
| Ferhanoğlu, B | 5 |
| Kalayoğlu Beşışık, S | 1 |
| He, ZY | 1 |
| Yu, WJ | 2 |
| Suo, SS | 1 |
| Wang, JH | 1 |
| Meng, HT | 1 |
| Mai, WY | 1 |
| Wei, JY | 2 |
| Yang, M | 1 |
| Mao, LP | 1 |
| Qu, S | 1 |
| Liao, LS | 1 |
| Zheng, ZH | 1 |
| Xie, Y | 4 |
| Chen, WM | 1 |
| Chen, BY | 1 |
| Zhang, HL | 1 |
| Uticul, A | 1 |
| Xu, XW | 1 |
| Shi, YW | 1 |
| Ogiso, A | 1 |
| Mizuno, T | 1 |
| Ito, K | 1 |
| Mizokami, F | 1 |
| Tomita, A | 3 |
| Yamada, S | 2 |
| Kambhampati, S | 1 |
| Saumoy, M | 1 |
| Schneider, Y | 1 |
| Pak, S | 1 |
| Budde, LE | 1 |
| Mei, MG | 1 |
| Siddiqi, T | 1 |
| Popplewell, LL | 2 |
| Wen, YP | 1 |
| Zain, J | 1 |
| Forman, SJ | 1 |
| Kwak, LW | 6 |
| Rosen, ST | 2 |
| Danilov, AV | 1 |
| Herrera, AF | 1 |
| Thiruvengadam, NR | 1 |
| Camus, V | 5 |
| Belot, A | 2 |
| Sibon, D | 2 |
| Ghesquières, H | 7 |
| Thieblemont, C | 23 |
| Fruchart, C | 8 |
| Casasnovas, O | 10 |
| Michot, JM | 2 |
| Molina, TJ | 13 |
| Bosly, A | 10 |
| Joubert, C | 2 |
| Haioun, C | 27 |
| Nicolas-Virelizier, E | 1 |
| Feugier, P | 12 |
| Fitoussi, O | 8 |
| Delarue, R | 9 |
| Manosroi, W | 1 |
| Chirayucharoensak, J | 1 |
| Chai-Adisaksopha, C | 1 |
| Phinyo, P | 1 |
| Zhao, J | 3 |
| Zhang, W | 13 |
| Zhou, D | 5 |
| Jobanputra, K | 1 |
| Nayak, L | 2 |
| Jain, H | 3 |
| Shet, T | 2 |
| Epari, S | 2 |
| Bonda, VNA | 1 |
| Thorat, J | 2 |
| Bagal, B | 3 |
| Laskar, S | 3 |
| Rangarajan, V | 2 |
| Agrawal, A | 1 |
| Gujral, S | 2 |
| Khanna, N | 2 |
| Goda, JS | 3 |
| Sengar, M | 5 |
| Ting, CY | 2 |
| Tan, SY | 3 |
| Gan, GG | 3 |
| Zain, SM | 1 |
| Pung, YF | 1 |
| Ong, DB | 1 |
| Bee, PC | 3 |
| Othman, T | 1 |
| Penaloza, J | 1 |
| Zhang, S | 3 |
| Daniel, CE | 1 |
| Gaut, D | 1 |
| Oliai, C | 1 |
| Brem, EA | 2 |
| Baweja, A | 1 |
| Ly, J | 1 |
| Reid, J | 2 |
| Pinter-Brown, L | 2 |
| Lee, M | 1 |
| Abdulhaq, H | 1 |
| Tuscano, J | 1 |
| Higo, R | 1 |
| Kojima, M | 4 |
| Itoh, S | 1 |
| Noguchi, M | 3 |
| Izumi, H | 1 |
| Takeuchi, K | 13 |
| Park, S | 11 |
| Go, SI | 8 |
| Rapiti, N | 1 |
| Abdelatif, N | 1 |
| Rapiti, A | 1 |
| Moosa, MY | 1 |
| Yang, F | 1 |
| Abraham, A | 1 |
| Yan, JT | 1 |
| Hammer, RD | 1 |
| Prime, MS | 1 |
| Wang, X | 17 |
| Hong, Y | 2 |
| Meng, S | 1 |
| Gong, W | 1 |
| Ren, T | 1 |
| Zhang, T | 1 |
| Li, L | 18 |
| Qiu, L | 3 |
| Qian, Z | 2 |
| Zhou, S | 6 |
| Zhao, M | 1 |
| Zhai, Q | 1 |
| Meng, B | 3 |
| Ren, X | 1 |
| Al-Sarayfi, D | 1 |
| Meeuwes, FO | 2 |
| Beeker, A | 4 |
| van Rhenen, A | 1 |
| Mutsaers, PGNJ | 5 |
| Böhmer, LH | 4 |
| van der Poel, MWM | 2 |
| Te Boome, L | 1 |
| van Meerten, T | 5 |
| Brink, M | 2 |
| Nijland, M | 8 |
| Pasvolsky, O | 2 |
| Berger, T | 1 |
| Geiger, KR | 1 |
| Akirov, A | 1 |
| Bshara, E | 1 |
| Raanani, P | 4 |
| Gafter-Gvili, A | 4 |
| Shochat, T | 2 |
| Rozovski, U | 1 |
| Gurion, R | 5 |
| Sheng, R | 1 |
| Clarke, D | 1 |
| Laver, T | 1 |
| Meichner, K | 1 |
| Northrup, N | 1 |
| Tarigo, J | 1 |
| Zduniak, A | 2 |
| Lévêque, E | 1 |
| Perdrix, A | 1 |
| Etancelin, P | 1 |
| Ménard, AL | 2 |
| Lenain, P | 2 |
| Contentin, N | 2 |
| Pépin, LF | 2 |
| Leprêtre, S | 5 |
| Lemasle, E | 2 |
| Lanic, H | 4 |
| Stamatoullas-Bastard, A | 2 |
| Kammoun-Quique, L | 1 |
| Bauer, F | 1 |
| Jardin, F | 15 |
| Kilani, Y | 1 |
| Sohail, H | 1 |
| Lim, CY | 1 |
| Payette, A | 1 |
| Kamal, SAF | 1 |
| Afzal, A | 1 |
| Khan, T | 1 |
| Paracha, N | 1 |
| Muppidi, MR | 1 |
| Sittler, D | 1 |
| Zhan, J | 1 |
| Yang, S | 8 |
| Wang, W | 11 |
| Wei, C | 2 |
| Yamaguchi, M | 8 |
| Wondergem, M | 1 |
| Böhmer, L | 1 |
| Woei-A-Jin, S | 1 |
| Oostvogels, R | 1 |
| Jansen, PM | 1 |
| Diepstra, A | 4 |
| Snijders, TJF | 2 |
| Plattel, WJ | 1 |
| Huls, GA | 1 |
| Vermaat, JSP | 3 |
| Ito, A | 1 |
| Miyaoka, M | 1 |
| Tomita, S | 1 |
| Ikoma, H | 1 |
| Hiraiwa, S | 1 |
| Carreras, J | 3 |
| Kikuti, YY | 3 |
| Kawada, H | 2 |
| Nakamura, N | 11 |
| Sabljic, A | 1 |
| Sedinic Lacko, M | 1 |
| Zhang, N | 1 |
| Xu, D | 1 |
| Liu, B | 3 |
| Shi, X | 2 |
| Xie, X | 1 |
| Younes, A | 10 |
| Cheson, BD | 8 |
| Diefenbach, CS | 1 |
| Ferrari, S | 2 |
| Hahn, UH | 1 |
| Khan, C | 2 |
| Tani, M | 7 |
| Yuen, S | 1 |
| Raval, A | 1 |
| Shivhare, M | 1 |
| Zhu, H | 2 |
| Li, F | 8 |
| Chang, Y | 1 |
| Sun, Y | 5 |
| Wang, N | 1 |
| Wang, R | 3 |
| Vijenthira, A | 1 |
| Kuruvilla, J | 3 |
| Crump, M | 5 |
| Jain, M | 2 |
| Prica, A | 2 |
| Cortese, MJ | 1 |
| Wei, W | 3 |
| Cerdeña, S | 1 |
| Watkins, MP | 1 |
| Olson, M | 1 |
| Jodon, G | 1 |
| Kaiser, J | 1 |
| Haverkos, B | 2 |
| Hughes, ME | 2 |
| Namoglu, E | 1 |
| Grover, NS | 1 |
| Snow, A | 1 |
| Orellana-Noia, V | 1 |
| Rainey, M | 1 |
| Sohail, M | 1 |
| Rudoni, J | 1 |
| Portell, C | 1 |
| Voorhees, T | 1 |
| Landsburg, DJ | 6 |
| Kamdar, M | 2 |
| Hill, BT | 3 |
| Sridhar, E | 1 |
| Gota, V | 2 |
| Laskar, SS | 1 |
| Alahari, A | 1 |
| Agarwal, A | 1 |
| Sharma, N | 1 |
| Gupta, H | 1 |
| Kannan, S | 1 |
| Kumar, S | 1 |
| Menon, H | 2 |
| Hiroi, T | 1 |
| Hosoi, H | 1 |
| Kuriyama, K | 1 |
| Murata, S | 1 |
| Morimoto, M | 1 |
| Mushino, T | 1 |
| Nishikawa, A | 1 |
| Tamura, S | 1 |
| Sonoki, T | 1 |
| Zhao, X | 12 |
| Yang, J | 7 |
| Wang, H | 7 |
| Piao, Y | 2 |
| Tyryshkin, K | 1 |
| Moore, A | 1 |
| Good, D | 1 |
| Popov, J | 1 |
| Crocker, S | 1 |
| Rauh, MJ | 1 |
| Baetz, T | 1 |
| LeBrun, DP | 1 |
| Cabrera, ME | 1 |
| Peña, C | 1 |
| Leon, P | 2 |
| Lois, V | 1 |
| Rojas, H | 1 |
| Vega, V | 1 |
| Pizarro, A | 1 |
| Calderon, S | 1 |
| Rojas, C | 1 |
| Aspillaga, A | 1 |
| Gonzalez, ML | 1 |
| Intriago, M | 1 |
| Rojas, B | 1 |
| Hales, C | 1 |
| Oliva, J | 1 |
| Romero, M | 1 |
| Capurro, M | 1 |
| Castillo, JJ | 9 |
| Álvarez Martínez, P | 1 |
| Ramos Martínez, PJ | 1 |
| García González, P | 1 |
| Nieto-Jara, A | 1 |
| Del Caño Cerdán, C | 1 |
| García Riesco, E | 1 |
| Cherng, HJ | 2 |
| Alig, SK | 1 |
| Oki, Y | 15 |
| Nastoupil, LJ | 4 |
| Fayad, L | 7 |
| Neelapu, SS | 2 |
| Turturro, F | 2 |
| Hagemeister, F | 1 |
| Craig, AFM | 1 |
| Macaulay, CW | 1 |
| Rodriguez, MA | 11 |
| Lee, HJ | 3 |
| McDonnell, TJ | 3 |
| Vega, F | 3 |
| Green, MR | 3 |
| Feng, L | 2 |
| Kurtz, DM | 3 |
| Alizadeh, AA | 5 |
| Davis, RE | 4 |
| Warnnissorn, N | 3 |
| Kanitsap, N | 3 |
| Niparuck, P | 3 |
| Boonsakan, P | 3 |
| Kulalert, P | 3 |
| Limvorapitak, W | 3 |
| Bhoopat, L | 3 |
| Saengboon, S | 3 |
| Chantrathammachart, P | 3 |
| Puavilai, T | 3 |
| Chuncharunee, S | 3 |
| Turot, M | 3 |
| Aspas Requena, G | 3 |
| Lim, SK | 3 |
| Peng, CC | 3 |
| Low, S | 3 |
| Vijay, V | 3 |
| Budiman, A | 3 |
| Phang, BH | 3 |
| Lim, JQ | 3 |
| Lim, ST | 10 |
| Ong, CK | 3 |
| Tan, SM | 4 |
| Kim, DW | 6 |
| Byun, JM | 4 |
| Lee, JO | 6 |
| Kim, JK | 3 |
| Lynch, RC | 5 |
| Poh, C | 2 |
| Ujjani, CS | 3 |
| Warren, EH | 2 |
| Smith, SD | 7 |
| Shadman, M | 3 |
| Lee, S | 11 |
| Rasmussen, H | 2 |
| Ottemiller, S | 2 |
| Shelby, M | 2 |
| Keo, S | 2 |
| Verni, K | 2 |
| Chabon, JJ | 2 |
| Hogan, GJ | 2 |
| Schulz, A | 2 |
| Gooley, T | 2 |
| Voutsinas, JM | 2 |
| Gopal, AK | 7 |
| Matsumoto, M | 3 |
| Kasahara, K | 1 |
| Nagakawa, Y | 1 |
| Katsumata, K | 1 |
| Tsuchida, A | 1 |
| Ludvigsen Al-Mashhadi, A | 1 |
| Cederleuf, H | 1 |
| Kuhr Jensen, R | 1 |
| Holm Nielsen, T | 1 |
| Bjerregård Pedersen, M | 1 |
| Bech Mortensen, T | 1 |
| Relander, T | 2 |
| Jerkeman, M | 13 |
| Ortved Gang, A | 1 |
| Kristensen, AL | 1 |
| Roost Clausen, M | 1 |
| de Nully Brown, P | 7 |
| Tang Severinsen, M | 1 |
| Ellin, F | 1 |
| Zhang, L | 22 |
| Hong, H | 3 |
| Chen, Y | 15 |
| Ren, Q | 1 |
| Yao, Y | 2 |
| Chen, Z | 6 |
| Pan, F | 1 |
| Chen, M | 3 |
| Lin, T | 5 |
| Goto, H | 5 |
| Terui, Y | 10 |
| Feng, J | 6 |
| Kim, TM | 9 |
| Tsai, XC | 1 |
| Koh, H | 3 |
| Yang, Y | 6 |
| Li, W | 9 |
| Ando, K | 4 |
| Bu, L | 1 |
| Vaughan, J | 1 |
| Wiggill, T | 1 |
| Lawrie, D | 1 |
| Machaba, M | 1 |
| Patel, M | 2 |
| Lin, Y | 5 |
| Li, Z | 5 |
| Wu, Y | 3 |
| Yang, Z | 2 |
| Gao, S | 1 |
| Lin, F | 1 |
| Zaidi, B | 1 |
| Mukhopadhyay, A | 3 |
| Ramos-Vara, JA | 2 |
| Dhawan, D | 1 |
| Ruple, A | 2 |
| Childress, MO | 2 |
| Czarny, J | 1 |
| Andrzejewska, M | 1 |
| Zając-Spychała, O | 1 |
| Latos-Grażyńska, E | 1 |
| Pastorczak, A | 1 |
| Wypyszczak, K | 1 |
| Szczawińska-Popłonyk, A | 1 |
| Niewiadomska-Wojnałowicz, I | 1 |
| Wziątek, A | 1 |
| Marciniak-Stępak, P | 1 |
| Dopierała, M | 1 |
| Małdyk, J | 1 |
| Jończyk-Potoczna, K | 1 |
| Derwich, K | 1 |
| Johnson, PWM | 3 |
| Shreeve, SM | 3 |
| Sun, S | 5 |
| Srinivasan, S | 1 |
| Steele, AJ | 1 |
| Altmann, B | 4 |
| Frontzek, F | 1 |
| Chartier, L | 4 |
| Ketterer, N | 5 |
| Récher, C | 8 |
| Glass, B | 2 |
| Mounier, N | 17 |
| Rosenwald, A | 20 |
| Ott, G | 15 |
| Lenz, G | 10 |
| Molina, T | 7 |
| Ziepert, M | 10 |
| Schmitz, N | 11 |
| Kim, YR | 6 |
| Chang, MH | 4 |
| Lim, SN | 5 |
| Kim, IH | 2 |
| Mun, YC | 6 |
| Kim, JS | 10 |
| Tabanelli, V | 3 |
| Merli, M | 4 |
| Zilioli, VR | 2 |
| Fabbri, A | 4 |
| Cavallo, F | 5 |
| Casaluci, GM | 1 |
| Puccini, B | 6 |
| Pennese, E | 3 |
| Zanni, M | 6 |
| Flenghi, L | 4 |
| Gini, G | 4 |
| Sartori, R | 2 |
| Usai, SV | 2 |
| Marino, D | 3 |
| Arcaini, L | 3 |
| Vallisa, D | 3 |
| Spina, M | 8 |
| Liang, Y | 2 |
| Wei, L | 2 |
| Portugues, C | 1 |
| Paget, J | 1 |
| Cony-Makhoul, P | 1 |
| Kos, IA | 1 |
| Pfreundschuh, M | 28 |
| Loeffler, M | 8 |
| Hou, J | 1 |
| Guo, P | 1 |
| Lu, Y | 3 |
| Jin, X | 5 |
| Liang, K | 1 |
| Zhao, N | 1 |
| Xue, S | 1 |
| Zhou, C | 2 |
| Wang, G | 6 |
| Lu, H | 2 |
| Xu, C | 2 |
| Han, Y | 3 |
| Cai, S | 1 |
| Isaksen, KT | 1 |
| Galleberg, R | 1 |
| Mastroianni, MA | 1 |
| Rinde, M | 1 |
| Rusten, LS | 1 |
| Barzenje, D | 1 |
| Ramslien, F | 1 |
| Fluge, O | 2 |
| Slaaen, M | 1 |
| Meyer, P | 1 |
| Liestol, K | 1 |
| Smeland, EB | 2 |
| Lingjarde, OC | 1 |
| Holte, H | 5 |
| Brodtkorb, M | 1 |
| Chong, G | 3 |
| Keane, C | 4 |
| Lee, ST | 2 |
| Smith, C | 1 |
| Churilov, L | 1 |
| McKendrick, J | 1 |
| Renwick, W | 2 |
| Blombery, P | 1 |
| Burgess, M | 1 |
| Nelson, NE | 1 |
| Fancourt, T | 2 |
| Hawking, J | 1 |
| Lin, W | 1 |
| Scott, AM | 1 |
| Wight, J | 2 |
| Grigg, A | 2 |
| Fong, CY | 1 |
| Yu, L | 2 |
| Jiang, X | 1 |
| Ding, K | 1 |
| Cooper, A | 1 |
| Kline, J | 1 |
| Sakai, R | 11 |
| Iwaki, N | 2 |
| Yamamoto, G | 6 |
| Murayama, K | 4 |
| Nishikori, M | 4 |
| Sunami, K | 7 |
| Yoshida, I | 4 |
| Yano, H | 2 |
| Takahashi, N | 5 |
| Okamoto, A | 2 |
| Munemoto, S | 2 |
| Sawazaki, A | 2 |
| Suehiro, Y | 4 |
| Fukuhara, N | 5 |
| Wake, A | 1 |
| Arai, A | 1 |
| Masaki, Y | 3 |
| Toyama, K | 4 |
| Yokoyama, A | 1 |
| Tsunemine, H | 1 |
| Hasegawa, Y | 1 |
| Matsumoto, K | 3 |
| Yamada, T | 11 |
| Nishimura, Y | 2 |
| Tamaru, S | 2 |
| Asano, N | 2 |
| Kinoshita, T | 9 |
| Suzuki, R | 5 |
| Katayama, N | 5 |
| Liang, X | 3 |
| Hu, R | 1 |
| Li, Q | 8 |
| Wang, C | 8 |
| Mitrovic, Z | 5 |
| Dujmovic, D | 1 |
| Jaksic, O | 2 |
| Kinda, SB | 2 |
| Gacina, P | 1 |
| Perisa, V | 1 |
| Prka, Z | 2 |
| Dreta, B | 1 |
| Galusic, D | 1 |
| Holik, H | 1 |
| Aurer, I | 4 |
| Ernst, M | 1 |
| Dührsen, U | 3 |
| Hellwig, D | 1 |
| Skoetz, N | 2 |
| Borchmann, P | 2 |
| Sheng, Z | 1 |
| Li, D | 3 |
| Chen, B | 12 |
| Zhao, C | 1 |
| Ding, B | 1 |
| Davies, AJ | 1 |
| Barrans, S | 5 |
| Stanton, L | 1 |
| Caddy, J | 2 |
| Wilding, S | 1 |
| Saunders, G | 1 |
| Novak, U | 2 |
| McMillan, A | 11 |
| Fields, P | 5 |
| Collins, GP | 7 |
| Stephens, R | 2 |
| Cucco, F | 2 |
| Sha, C | 2 |
| van Hoppe, M | 2 |
| Tooze, R | 3 |
| Davies, JR | 1 |
| Griffiths, G | 1 |
| Schuh, A | 6 |
| Burton, C | 5 |
| Westhead, DR | 2 |
| Du, MQ | 3 |
| Nakayama, K | 1 |
| Terasaki, S | 1 |
| Matsumura, I | 3 |
| Kanaya, S | 1 |
| Iino, H | 1 |
| Noguchi, H | 1 |
| Tahara, K | 1 |
| Yoshida, T | 2 |
| Saito, A | 2 |
| Suzaki, K | 1 |
| Kobayashi, M | 1 |
| Kosugi, N | 1 |
| Musimar, Z | 1 |
| Mpetani, M | 1 |
| Abramson, JS | 10 |
| Chabner, BA | 11 |
| Mohamed, Z | 1 |
| Yoon, J | 1 |
| Kim, KH | 3 |
| Hong, J | 8 |
| Shin, DY | 5 |
| Kim, I | 2 |
| Yoon, SS | 3 |
| Heo, DS | 8 |
| Park, H | 1 |
| Park, JH | 4 |
| Ma'koseh, M | 1 |
| Farfoura, H | 1 |
| Abufara, A | 1 |
| Elmusa, R | 1 |
| Hushki, A | 1 |
| Faqeer, N | 1 |
| Ghatasheh, H | 1 |
| Shahin, O | 1 |
| Alawabdeh, T | 1 |
| Al-Rwashdeh, M | 1 |
| Halahleh, K | 1 |
| Al-Ibraheem, A | 1 |
| Alrabi, K | 1 |
| Belia, M | 1 |
| Drandakis, I | 1 |
| Lakiotaki, E | 1 |
| Panitsas, F | 2 |
| Triantafyllou, EF | 1 |
| Siakantaris, MP | 4 |
| Korkolopoulou, P | 3 |
| Goto, S | 2 |
| Yamamura, Y | 1 |
| Ishimine, K | 1 |
| Hayashi, Y | 4 |
| Mino, M | 1 |
| Okuya, T | 2 |
| Acar, R | 1 |
| Paydaş, S | 1 |
| Yıldırım, M | 1 |
| Kılıçarslan, E | 1 |
| Sahın, U | 1 |
| Dogan, A | 7 |
| Guven, DC | 1 |
| Ekıncı, O | 1 |
| Tıglıoglu, M | 1 |
| Erdogan, I | 2 |
| Elıbol, T | 1 |
| Kızıloz, H | 1 |
| Aykan, MB | 1 |
| Sayın, S | 1 |
| Kaptan, K | 1 |
| Soydan, E | 1 |
| Gokmen, A | 1 |
| Esen, R | 1 |
| Barısta, I | 2 |
| Albayrak, M | 2 |
| Erturk, I | 1 |
| Yıldız, B | 1 |
| Keskın, GY | 1 |
| Aylı, M | 1 |
| Karadurmus, N | 1 |
| Ibrahim, EM | 1 |
| Refat, S | 1 |
| El-Ashwah, S | 1 |
| Fahmi, MW | 1 |
| Ibrahiem, AT | 1 |
| Bock, AM | 1 |
| Ayers, EC | 2 |
| Girton, M | 1 |
| Hu, M | 1 |
| Beckman, AK | 1 |
| Li, S | 12 |
| Medeiros, LJ | 30 |
| Chang, JE | 3 |
| Stepanovic, A | 1 |
| Kurt, H | 1 |
| Sandoval-Sus, J | 1 |
| Ansari-Lari, MA | 1 |
| Kothari, SK | 1 |
| Kress, A | 1 |
| Xu, ML | 1 |
| Torka, P | 1 |
| Sundaram, S | 1 |
| Naresh, KN | 1 |
| Karimi, YH | 1 |
| Farooq, U | 1 |
| Saad, M | 1 |
| Evens, AM | 5 |
| Pandya, K | 1 |
| Naik, SG | 1 |
| Karmali, R | 5 |
| Oh, TS | 1 |
| Vose, JM | 17 |
| Nutsch, H | 1 |
| Rubinstein, PG | 1 |
| Chaudhry, A | 1 |
| Olszewski, AJ | 2 |
| Rovsing, AB | 1 |
| Thomsen, EA | 2 |
| Nielsen, I | 1 |
| Skov, TW | 1 |
| Luo, Y | 3 |
| Mikkelsen, JG | 2 |
| Park, J | 9 |
| Chung, SW | 2 |
| Lee, YB | 1 |
| Shin, H | 3 |
| Hur, MH | 1 |
| Park, MK | 1 |
| Youk, J | 1 |
| Lee, JY | 6 |
| Yu, SJ | 1 |
| Kim, YJ | 5 |
| Yoon, JH | 3 |
| de Jonge, AV | 1 |
| van Werkhoven, E | 1 |
| Zwinderman, AH | 1 |
| Bossuyt, PM | 1 |
| Veldhuis, MS | 1 |
| Rutten, EGGM | 1 |
| Mous, R | 2 |
| Sandberg, Y | 1 |
| de Jongh, E | 4 |
| Bilgin, YM | 3 |
| Boersma, R | 1 |
| Koene, H | 1 |
| Zhou, N | 1 |
| Choi, J | 2 |
| Grothusen, G | 1 |
| Kim, BJ | 1 |
| Ren, D | 1 |
| Cao, Z | 1 |
| Inamdar, A | 1 |
| Beer, T | 1 |
| Tang, HY | 1 |
| Perkey, E | 1 |
| Maillard, I | 1 |
| Bonasio, R | 1 |
| Shi, J | 5 |
| Ruella, M | 2 |
| Wan, L | 2 |
| Busino, L | 1 |
| Wang, P | 1 |
| Ni, Z | 1 |
| Shang, N | 1 |
| Meng, W | 1 |
| Han, B | 2 |
| Yim, J | 1 |
| Lim, S | 1 |
| Na, S | 1 |
| Paik, JH | 2 |
| Kim, S | 10 |
| Jeon, YK | 5 |
| Lantz, J | 1 |
| Portell, CA | 1 |
| He, MY | 1 |
| Kayamori, K | 2 |
| Lee, JE | 1 |
| Jung, H | 1 |
| Park, EG | 1 |
| Lee, DH | 6 |
| Seo, YS | 1 |
| Kim, HS | 2 |
| Rigacci, L | 11 |
| Luminari, S | 7 |
| Mahmoud, AM | 1 |
| Botto, B | 7 |
| Hohaus, S | 7 |
| Tarantini, G | 1 |
| Pagani, C | 1 |
| Dessì, D | 1 |
| Ferrero, S | 2 |
| Cencini, E | 2 |
| Bernuzzi, P | 1 |
| Mammi, C | 3 |
| Jeong, S | 1 |
| Hwang, S | 1 |
| Kim, DE | 1 |
| Choi, HS | 1 |
| Kim, H | 4 |
| Park, JS | 6 |
| Han, JH | 3 |
| Shi, ZY | 1 |
| Shi, Q | 6 |
| Wang, S | 14 |
| Zhang, MC | 3 |
| Shen, R | 2 |
| He, Y | 9 |
| Qiu, HL | 1 |
| Yi, HM | 2 |
| Dong, L | 3 |
| Cheng, S | 5 |
| Xu, PP | 6 |
| Zhao, WL | 9 |
| Belada, D | 8 |
| Kopeckova, K | 1 |
| Bergua Burgues, JM | 1 |
| Stevens, D | 1 |
| André, M | 6 |
| Persona, EP | 1 |
| Pichler, P | 1 |
| Staber, PB | 1 |
| Duell, J | 2 |
| Waldron-Lynch, M | 1 |
| Wagner, S | 1 |
| Dirnberger-Hertweck, M | 1 |
| Mu, RJ | 1 |
| Jiang, XF | 2 |
| Fu, D | 3 |
| Qin, W | 1 |
| Song, Q | 2 |
| Chen, SJ | 3 |
| Kumar, A | 6 |
| Abutalib, SA | 1 |
| Awan, FT | 1 |
| Chen, YB | 2 |
| Holter-Chakrabarty, J | 1 |
| Kekre, N | 1 |
| Lee, CJ | 1 |
| Lekakis, L | 1 |
| Mei, M | 1 |
| Nathan, S | 1 |
| Nastoupil, L | 2 |
| Oluwole, O | 1 |
| Phillips, AA | 1 |
| Reid, E | 1 |
| Rezvani, AR | 1 |
| Trotman, J | 6 |
| Zurko, J | 1 |
| Kharfan-Dabaja, MA | 1 |
| Sauter, CS | 1 |
| Perales, MA | 1 |
| Locke, FL | 1 |
| Carpenter, PA | 1 |
| Hamadani, M | 1 |
| Kiamos, A | 1 |
| Boldig, K | 1 |
| Gagadam, V | 1 |
| Gujarathi, R | 1 |
| Liu, H | 11 |
| Li, J | 27 |
| Xiao, X | 2 |
| Yuan, X | 1 |
| Chen, P | 4 |
| Huang, F | 4 |
| Masaquel, A | 1 |
| Hossain, F | 1 |
| Zhou, SQ | 1 |
| Ng, CD | 1 |
| Hahn, CK | 1 |
| Palmer, AC | 1 |
| Weinstock, DM | 1 |
| Sharma, A | 2 |
| Das, A | 1 |
| Bal, A | 1 |
| Srinivasan, R | 1 |
| Malhotra, P | 3 |
| Prakash, G | 3 |
| Kumar, R | 1 |
| Lim, KJC | 1 |
| Filshie, R | 3 |
| Moraes de Brito, MC | 1 |
| Guedes, MMV | 1 |
| Nascimento, JDS | 1 |
| Pimentel Jatobá, V | 1 |
| Alves Junior, MP | 1 |
| Lira, AC | 1 |
| Gouveia, PADC | 1 |
| Turdo, A | 1 |
| Gaggianesi, M | 1 |
| D'Accardo, C | 1 |
| Porcelli, G | 1 |
| Bella, SD | 1 |
| Cricchio, D | 1 |
| Pillitteri, I | 1 |
| Porcasi, R | 1 |
| Lo Iacono, M | 1 |
| Verona, F | 1 |
| Modica, C | 1 |
| Roozafzay, N | 1 |
| Florena, AM | 1 |
| Stassi, G | 1 |
| Mancuso, S | 1 |
| Todaro, M | 1 |
| Skelin, M | 1 |
| Miketic, T | 1 |
| Hashimoto, Y | 2 |
| Omura, H | 1 |
| Tokuyasu, Y | 1 |
| Nakamoto, S | 2 |
| Tanaka, T | 6 |
| Satoh, T | 1 |
| Arai, E | 1 |
| Kayano, H | 1 |
| Sakaguchi, H | 2 |
| Tsukasaki, K | 4 |
| Yasuda, M | 1 |
| Cruickshank, A | 1 |
| Koury, J | 1 |
| Bouwstra, R | 2 |
| de Boer, J | 1 |
| Kooistra, H | 1 |
| Cendrowicz, E | 1 |
| Fehrmann, RSN | 2 |
| Ammatuna, E | 4 |
| Zu Eulenburg, C | 1 |
| Huls, G | 3 |
| Bremer, E | 2 |
| Morrison, VA | 7 |
| Hamilton, L | 1 |
| Ogbonnaya, A | 1 |
| Raju, A | 1 |
| Hennenfent, K | 1 |
| Galaznik, A | 1 |
| Deol, A | 1 |
| Uberti, J | 1 |
| Codacci-Pisanelli, G | 1 |
| Honeywell, RJ | 1 |
| Asselin, N | 1 |
| Bellettini, G | 1 |
| Peters, GJ | 1 |
| Giovannetti, E | 1 |
| Peccatori, FA | 2 |
| Pang, A | 1 |
| Au-Yeung, R | 1 |
| Leung, RYY | 1 |
| Kwong, YL | 3 |
| Shao, C | 2 |
| Xu, K | 2 |
| Malachowski, SJ | 1 |
| Sun, J | 3 |
| Chen, PL | 1 |
| Seminario-Vidal, L | 1 |
| Philippe, L | 1 |
| Lancar, R | 1 |
| Laurent, C | 3 |
| Algarte-Genin, M | 1 |
| Chassagne-Clément, C | 1 |
| Fabiani, B | 7 |
| Pierre Chenard, M | 1 |
| Lazure, T | 3 |
| Charlotte, F | 2 |
| Delattre, C | 1 |
| Gibault, L | 1 |
| Capron, F | 1 |
| Goubin-Versini, I | 1 |
| Petitjean, B | 1 |
| Boué, F | 2 |
| Costello, R | 2 |
| Costagliola, D | 1 |
| Prevot, S | 1 |
| Besson, C | 3 |
| Liu, R | 2 |
| Zhao, G | 1 |
| Gu, Y | 3 |
| Han, Q | 1 |
| Djebbari, F | 2 |
| Weis, TM | 2 |
| Perissinotti, AJ | 2 |
| Nachar, VR | 2 |
| Brown, AM | 2 |
| Marini, BL | 2 |
| Jiang, S | 5 |
| Zhen, H | 1 |
| Jiang, H | 2 |
| Lee, JW | 3 |
| Oh, D | 2 |
| Eom, KY | 2 |
| Kim, JH | 8 |
| Kim, WC | 2 |
| Chung, MJ | 2 |
| Ohmachi, K | 5 |
| Poon, F | 1 |
| Ieremia, E | 1 |
| Collins, G | 1 |
| Matin, RN | 1 |
| Malenda, A | 1 |
| Kołkowska-Leśniak, A | 1 |
| Puła, B | 1 |
| Długosz-Danecka, M | 3 |
| Chełstowska, M | 1 |
| Końska, A | 1 |
| Giza, A | 3 |
| Lech-Marańda, E | 3 |
| Warzocha, K | 3 |
| Tian, Y | 1 |
| Tully, S | 1 |
| Feng, Z | 2 |
| Grindrod, K | 1 |
| McFarlane, T | 1 |
| Chan, KKW | 2 |
| Wong, WWL | 1 |
| Salas, MQ | 1 |
| Domingo Domenech, E | 1 |
| Oliveira, AC | 1 |
| Encuentra, M | 1 |
| Climent, F | 2 |
| Andrade Campos, M | 1 |
| Aguilera, C | 1 |
| Fernández de Sevilla, A | 3 |
| Sureda, A | 3 |
| González-Barca, E | 13 |
| Ishikawa, T | 4 |
| Fukumi, T | 1 |
| Moriyama, T | 1 |
| Murakami, H | 3 |
| Nagakita, K | 1 |
| Yoshioka, T | 1 |
| Makita, M | 2 |
| Shinno, Y | 1 |
| Howlett, S | 1 |
| Casasnovas, RO | 4 |
| Perrot, A | 3 |
| Daguindau, N | 1 |
| van Eygen, K | 2 |
| Bouabdallah, R | 7 |
| Pica, GM | 2 |
| Nicolas-Virezelier, E | 1 |
| Abraham, J | 2 |
| Snauwaert, S | 2 |
| Eisenmann, JC | 1 |
| Lionne-Huyghe, P | 1 |
| Bron, D | 2 |
| Tricot, S | 1 |
| Deeren, D | 1 |
| Gonzalez, H | 3 |
| Le Du, K | 4 |
| da Silva, MG | 2 |
| Grosicki, S | 1 |
| Catalano, J | 3 |
| Caballero, D | 12 |
| Cohen, AM | 2 |
| Gaulard, P | 17 |
| Takeshita, K | 1 |
| Coiffier, B | 34 |
| Lu, TX | 4 |
| Wu, S | 2 |
| Zhou, XY | 1 |
| Hong, TT | 1 |
| Cai, DY | 1 |
| Hua, HY | 1 |
| Qi, XW | 1 |
| Wu, XH | 1 |
| Schmelz, JL | 1 |
| Navsaria, L | 1 |
| Goswamy, R | 1 |
| Chuang, HH | 2 |
| Miranda, RN | 11 |
| van Ettekoven, CN | 1 |
| Heijink, DM | 1 |
| Matsuyama, A | 1 |
| Bienzle, D | 1 |
| Richardson, D | 1 |
| Deravi, N | 1 |
| Hwang, MH | 1 |
| Darzentas, N | 1 |
| Keller, SM | 1 |
| Yoon, SE | 3 |
| Zhang, JC | 1 |
| Lan, HX | 1 |
| Zhao, HJ | 2 |
| Lei, YY | 1 |
| Ma, L | 1 |
| Xie, XY | 1 |
| Lu, MD | 1 |
| Nakayama, S | 3 |
| Espinoza, JL | 1 |
| Taniguchi, Y | 1 |
| Taniguchi, T | 2 |
| Miyake, Y | 1 |
| Tanaka, H | 3 |
| Ashida, T | 1 |
| Oka, S | 4 |
| Ono, K | 1 |
| Nohgawa, M | 1 |
| Bento, L | 3 |
| Díaz-López, A | 2 |
| Barranco, G | 2 |
| Martín-Moreno, AM | 1 |
| Baile, M | 3 |
| Martín, A | 8 |
| García, O | 4 |
| Rodríguez, M | 2 |
| Sánchez-Pina, JM | 1 |
| Novelli, S | 2 |
| Bastos, M | 2 |
| Rodríguez-Salazar, MJ | 2 |
| González de Villambrosia, S | 4 |
| Córdoba, R | 6 |
| García-Recio, M | 2 |
| Martínez-Serra, J | 2 |
| Del Campo, R | 2 |
| Luzardo, H | 2 |
| García, D | 2 |
| Hong, A | 1 |
| Sastre-Serra, J | 2 |
| Roca, P | 1 |
| Rodríguez, J | 4 |
| Gutiérrez, A | 3 |
| Chia, AXF | 1 |
| Zhao, Z | 1 |
| Lim, SL | 1 |
| de Jong, MRW | 2 |
| Langendonk, M | 1 |
| Reitsma, B | 1 |
| van den Berg, A | 3 |
| Visser, L | 2 |
| Sanchez Pina, JM | 1 |
| Bastos-Oreiro, M | 1 |
| de la Cruz, F | 3 |
| Queizan, JA | 2 |
| López, A | 6 |
| Garcia, JF | 2 |
| Montalban, C | 4 |
| Cabanillas, F | 9 |
| Viswabandya, A | 2 |
| Shah, S | 1 |
| Nagarkar, RV | 1 |
| Batra, SS | 1 |
| Lopez-Lazaro, L | 1 |
| Kankanwadi, S | 1 |
| Srivastava, A | 1 |
| Yousif, P | 1 |
| Kotecha, A | 1 |
| Thakur, A | 1 |
| Ismail, HM | 1 |
| Zhang, F | 6 |
| Luo, DL | 4 |
| Liu, J | 6 |
| Luo, LQ | 1 |
| He, J | 4 |
| Yan, JH | 1 |
| Xu, J | 8 |
| Luo, XL | 5 |
| Liu, YH | 5 |
| Batta, N | 1 |
| Shukla, M | 1 |
| Pandey, M | 1 |
| Yamaguchi, K | 2 |
| Kubota, Y | 2 |
| Kishimori, C | 1 |
| Ohno, H | 2 |
| Kidoguchi, K | 1 |
| Kizuka-Sano, H | 1 |
| Nishioka, A | 1 |
| Katsuya, H | 1 |
| Ando, T | 1 |
| Kimura, S | 4 |
| Pan, H | 2 |
| Xiao, Y | 1 |
| Liu, T | 3 |
| Wu, G | 1 |
| Brown, J | 1 |
| Devata, S | 1 |
| Yamamoto, M | 6 |
| Suzuki, I | 2 |
| Yokoyama, M | 14 |
| Marangon, AV | 1 |
| Colli, CM | 1 |
| Cardozo, DM | 1 |
| Visentainer, JEL | 1 |
| Sell, AM | 1 |
| Guimaraes, F | 1 |
| Marques, SBD | 1 |
| Lieber, SR | 1 |
| Aranha, FJP | 1 |
| Zulli, R | 1 |
| de Souza, VH | 1 |
| de Souza, CA | 5 |
| Anusim, N | 1 |
| Ionescu, F | 1 |
| Afolayan-Oloye, O | 1 |
| Gaikazian, SS | 1 |
| He, HS | 1 |
| Hu, QF | 1 |
| Kang, J | 2 |
| Chae, H | 1 |
| Hong, JY | 6 |
| Fujita, K | 3 |
| Negoro, E | 3 |
| Morishita, T | 2 |
| Oiwa, K | 2 |
| Tsukasaki, H | 2 |
| Kinoshita, K | 2 |
| Kawai, Y | 1 |
| Ueda, T | 3 |
| Yamauchi, T | 4 |
| Qasrawi, A | 1 |
| Arora, R | 1 |
| Ramlal, R | 1 |
| Munker, R | 2 |
| Hildebrandt, GC | 1 |
| Yang, C | 3 |
| Cai, H | 1 |
| Cao, X | 5 |
| Zhuang, J | 1 |
| Zhu, T | 1 |
| Duan, M | 1 |
| Dirani, D | 1 |
| Sedana, M | 1 |
| Wahyuni, S | 1 |
| Ardianto, C | 1 |
| Alderman, C | 1 |
| Christin, A | 1 |
| de Leval, L | 1 |
| Obeid, M | 1 |
| Liu, JL | 1 |
| Khoury, JD | 3 |
| Tang, G | 4 |
| Schlette, E | 1 |
| Yin, CC | 3 |
| Bueso-Ramos, CE | 5 |
| Lin, P | 3 |
| Yamauchi, R | 1 |
| Takeyama, Y | 1 |
| Takata, K | 2 |
| Fukunaga, A | 2 |
| Sakurai, K | 2 |
| Fukuda, H | 1 |
| Fukuda, S | 2 |
| Kunimoto, H | 1 |
| Umeda, K | 1 |
| Morihara, D | 1 |
| Yokoyama, K | 1 |
| Irie, M | 1 |
| Shakado, S | 1 |
| Sakisaka, S | 1 |
| Hirai, F | 1 |
| Vercellino, L | 1 |
| Cottereau, AS | 1 |
| Ribrag, V | 7 |
| Simon, M | 1 |
| Sebban, C | 5 |
| Corront, B | 3 |
| Choufi, B | 2 |
| Godmer, P | 2 |
| Briere, J | 21 |
| Meignan, M | 4 |
| Páscoa Pinheiro, J | 1 |
| Rato, J | 1 |
| Rebelo, O | 1 |
| Costa, G | 1 |
| Min, GJ | 1 |
| Jeon, YW | 3 |
| Park, SS | 1 |
| Shin, SH | 2 |
| Yahng, SA | 2 |
| Lee, SE | 4 |
| Cho, BS | 1 |
| Eom, KS | 2 |
| Min, CK | 2 |
| Cho, SG | 5 |
| Kil, WJ | 1 |
| Tian, T | 2 |
| Xue, T | 1 |
| Jia, N | 2 |
| Tang, Y | 4 |
| Till, BG | 2 |
| Shadman, MS | 1 |
| Cowan, AJ | 1 |
| Wu, QV | 1 |
| Voutsinas, J | 1 |
| Rasmussen, HA | 1 |
| Blue, K | 1 |
| Shustov, A | 2 |
| Cassaday, RD | 2 |
| Fromm, JR | 1 |
| Park, EH | 1 |
| Kang, EH | 1 |
| Lee, YJ | 2 |
| Ha, YJ | 1 |
| Gao, Y | 2 |
| Sun, B | 1 |
| Hu, J | 2 |
| Ren, H | 3 |
| Zhou, H | 2 |
| Chen, L | 4 |
| Ogura, S | 1 |
| Nakazato, T | 2 |
| Al-Juhaishi, T | 2 |
| Mckay, J | 1 |
| Sindel, A | 1 |
| Yazbeck, V | 1 |
| Jain, MD | 1 |
| Lam, R | 1 |
| Liu, Z | 6 |
| Stubbins, RJ | 1 |
| Kahlon, A | 1 |
| Kansara, R | 5 |
| Goswami, R | 1 |
| Humar, A | 1 |
| Slack, GW | 14 |
| Savage, KJ | 18 |
| Peters, AC | 1 |
| Xia, Y | 16 |
| Zhang, X | 6 |
| Drozd-Sokolowska, J | 1 |
| Zaucha, JM | 2 |
| Biecek, P | 1 |
| Kobylinska, K | 1 |
| Joks, M | 2 |
| Wrobel, T | 4 |
| Kumiega, B | 1 |
| Knopinska-Posluszny, W | 1 |
| Spychalowicz, W | 1 |
| Romejko-Jarosinska, J | 1 |
| Fischer, J | 1 |
| Wiktor-Jedrzejczak, W | 1 |
| Dlugosz-Danecka, M | 1 |
| Giebel, S | 1 |
| Sparano, JA | 1 |
| Kaplan, LD | 3 |
| Ramos, JC | 1 |
| Ambinder, RF | 2 |
| Wachsman, W | 1 |
| Aboulafia, D | 1 |
| Noy, A | 6 |
| Henry, DH | 1 |
| Ratner, L | 1 |
| Cesarman, E | 2 |
| Chadburn, A | 5 |
| Mitsuyasu, R | 1 |
| Ashrafi, F | 1 |
| Klein, C | 1 |
| Poorpooneh, M | 1 |
| Sherkat, R | 1 |
| Khoshnevisan, R | 1 |
| Dubois, S | 2 |
| Cullières-Dartigues, P | 1 |
| Suttle, B | 1 |
| Karlin, L | 1 |
| Picquenot, JM | 4 |
| Dubois, R | 1 |
| Ryu, KJ | 2 |
| Ko, YH | 12 |
| Wang, HY | 4 |
| Yao, ZH | 2 |
| Yao, SN | 2 |
| Chu, JF | 1 |
| Yan, Z | 1 |
| Wang, K | 1 |
| Liu, YY | 3 |
| Hartert, KT | 1 |
| Wenzl, K | 1 |
| Krull, JE | 1 |
| Manske, M | 1 |
| Sarangi, V | 1 |
| Asmann, Y | 1 |
| Larson, MC | 1 |
| Slager, S | 1 |
| Feldman, AL | 1 |
| Gandhi, AK | 1 |
| Yang, ZZ | 1 |
| Cerhan, JR | 2 |
| Novak, AJ | 2 |
| Hashimoto, I | 1 |
| Abe, Y | 3 |
| Nagasawa, S | 1 |
| Tamagawa, H | 1 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Rier, HN | 1 |
| Kharagjitsing, H | 1 |
| van Rosmalen, J | 1 |
| van Vugt, J | 1 |
| Westerweel, PE | 1 |
| Kock, M | 1 |
| Levin, MD | 1 |
| Wästerlid, T | 3 |
| Harrysson, S | 1 |
| Andersson, TM | 1 |
| Ekberg, S | 1 |
| Enblad, G | 9 |
| Andersson, PO | 4 |
| Smedby, KE | 2 |
| Omidvar, N | 2 |
| Tekin, N | 2 |
| Conget, P | 2 |
| Bruna, F | 2 |
| Timar, B | 2 |
| Gagyi, E | 2 |
| Basak, R | 2 |
| Auewarakul, C | 2 |
| Sritana, N | 1 |
| Cerci, JJ | 1 |
| Dimamay, MP | 2 |
| Gyorke, T | 1 |
| Redondo, F | 1 |
| Nair, R | 3 |
| Gorospe, C | 1 |
| Paez, D | 2 |
| Fanti, S | 3 |
| Ozdag, H | 2 |
| Padua, RA | 2 |
| Carr, R | 2 |
| Nagata, A | 1 |
| Funasaka, C | 1 |
| Moriya, K | 1 |
| Kondo, Y | 1 |
| Shiraiwa, S | 1 |
| Charifa, A | 1 |
| Paulson, N | 1 |
| Levy, L | 1 |
| Perincheri, S | 1 |
| Lee, A | 3 |
| McNiff, JM | 1 |
| Ko, CJ | 1 |
| Schöder, H | 4 |
| Polley, MC | 2 |
| Knopp, MV | 1 |
| Hall, N | 1 |
| Higley, HR | 1 |
| Kelloff, G | 1 |
| Zelenetz, AD | 13 |
| Wagner-Johnston, N | 2 |
| Schwartz, LH | 1 |
| Ruppert, AS | 1 |
| Dixon, JG | 1 |
| Wall, A | 1 |
| Flament, J | 2 |
| Flowers, C | 3 |
| Eule, C | 1 |
| Arora, N | 1 |
| Li, HC | 2 |
| Sadeghi, N | 2 |
| Ulrichsen, SP | 2 |
| Iversen, B | 1 |
| Madsen, J | 2 |
| Josefsson, PL | 3 |
| Gørløv, JS | 2 |
| Nørgaard, M | 2 |
| d'Amore, F | 3 |
| Frosch, ZAK | 1 |
| Kari, EJM | 1 |
| Kuusisto, MEL | 1 |
| Honkavaara, P | 1 |
| Hakalahti, A | 1 |
| Haapasaari, KM | 5 |
| Bloigu, R | 2 |
| Karihtala, P | 4 |
| Teppo, HR | 1 |
| Pirinen, R | 1 |
| Turpeenniemi-Hujanen, T | 7 |
| Kuittinen, O | 7 |
| Brody, J | 1 |
| Maly, J | 2 |
| Rizvi, S | 2 |
| Lansigan, F | 3 |
| Jing, H | 1 |
| Lue, JK | 2 |
| Luo, W | 1 |
| Han, I | 1 |
| Jivani, M | 1 |
| Heineman, T | 1 |
| Cheng, CL | 2 |
| Huang, SC | 1 |
| Chen, JH | 3 |
| Wei, CH | 1 |
| Fang, WQ | 1 |
| Su, TH | 1 |
| Yuan, CT | 1 |
| Liu, JH | 8 |
| Chuang, MK | 1 |
| Tien, HF | 3 |
| Lee, K | 1 |
| Ha, JY | 1 |
| Jung, AR | 1 |
| Shi, Y | 7 |
| Qin, Y | 8 |
| Han, X | 2 |
| Wang, D | 2 |
| Jin, C | 1 |
| Jin, Z | 1 |
| Su, H | 1 |
| Yang, H | 3 |
| Fu, W | 1 |
| Zhang, M | 4 |
| Ke, X | 1 |
| Yu, D | 1 |
| Sun, T | 1 |
| Du, X | 2 |
| Cheng, Y | 5 |
| Yi, P | 1 |
| Ma, C | 4 |
| Cheng, J | 2 |
| Chai, K | 1 |
| Luk, A | 1 |
| Liu, E | 1 |
| Hardy, AJ | 1 |
| Stoica, I | 1 |
| Kearney, DE | 1 |
| O'Riordain, DS | 1 |
| Tan, IJ | 1 |
| Tan, KK | 1 |
| Chen, YK | 1 |
| Qian, WB | 1 |
| Patkar, S | 1 |
| Dutt, K | 1 |
| Shah, A | 1 |
| Goel, M | 1 |
| Kazama, R | 1 |
| Takeuchi, M | 3 |
| Nakashima, K | 1 |
| Yoshida, N | 1 |
| Kawamoto, K | 2 |
| Yanagida, E | 1 |
| Yamada, K | 2 |
| Umeno, T | 1 |
| Suzuki, T | 9 |
| Takizawa, J | 3 |
| Seto, M | 1 |
| Büyüktaş, D | 1 |
| Örnek, S | 1 |
| Tokat, F | 1 |
| Tecimer, T | 1 |
| Tomita, M | 1 |
| Oura, S | 1 |
| Nishiguchi, H | 1 |
| Makimoto, S | 1 |
| Xiao, L | 1 |
| Strati, P | 1 |
| Chen, H | 6 |
| Manyam, GC | 11 |
| Montes-Moreno, S | 25 |
| Liu, P | 13 |
| Feng, R | 7 |
| Zhao, CS | 1 |
| Ma, R | 1 |
| Yoon, SO | 2 |
| Cheong, JW | 2 |
| Chung, H | 1 |
| Jang, JE | 1 |
| Kim, Y | 3 |
| Yang, WI | 1 |
| Min, YH | 3 |
| Meng, F | 1 |
| He, X | 2 |
| Gui, L | 3 |
| Lin, J | 4 |
| Han-Zhang, H | 1 |
| Amaki, J | 2 |
| Ogiya, D | 1 |
| Svoboda, J | 4 |
| Bair, SM | 1 |
| Dwivedy Nasta, S | 1 |
| Nagle, SJ | 1 |
| Barta, SK | 2 |
| Khan, N | 2 |
| Filicko-O'Hara, J | 2 |
| Gaballa, S | 1 |
| Strelec, L | 1 |
| Chong, E | 1 |
| Mitnick, S | 1 |
| Waite, TS | 1 |
| King, C | 1 |
| Ballard, H | 1 |
| Youngman, M | 1 |
| Gerson, J | 1 |
| Plastaras, JP | 2 |
| Maity, A | 1 |
| Bogusz, AM | 1 |
| Hung, SS | 1 |
| Nejati, R | 1 |
| Steidl, C | 10 |
| Lim, M | 1 |
| Schuster, SJ | 4 |
| Kim, HG | 7 |
| Kang, MH | 5 |
| Gleeson, M | 2 |
| Counsell, N | 4 |
| Lawrie, A | 5 |
| Clifton-Hadley, L | 3 |
| Hawkes, E | 2 |
| Ardeshna, KM | 8 |
| Chadwick, N | 3 |
| Gambell, J | 4 |
| Smith, P | 6 |
| Mouncey, P | 4 |
| Pocock, C | 4 |
| Radford, J | 2 |
| Davies, J | 4 |
| Turner, D | 4 |
| Kruger, A | 4 |
| Johnson, P | 5 |
| Linch, D | 5 |
| Bai, JF | 1 |
| Han, HX | 1 |
| Li, JT | 1 |
| Wang, T | 6 |
| Zhang, CL | 2 |
| Cao, Y | 5 |
| Duan, X | 1 |
| Zhao, W | 10 |
| Asklid, A | 1 |
| Eketorp Sylvan, S | 1 |
| Mattsson, A | 1 |
| Winqvist, M | 1 |
| Johansson, H | 1 |
| Österborg, A | 2 |
| Hansson, L | 1 |
| Systchenko, T | 1 |
| Defossez, G | 1 |
| Guidez, S | 2 |
| Puyade, M | 1 |
| Debiais-Delpech, C | 2 |
| Dreyfus, B | 2 |
| Machet, A | 2 |
| Leleu, X | 2 |
| Delwail, V | 4 |
| Ingrand, P | 1 |
| McMillan, AK | 2 |
| Phillips, EH | 1 |
| Rule, S | 1 |
| Patmore, R | 2 |
| Pettengell, R | 6 |
| Montoto, S | 5 |
| Paneesha, S | 1 |
| Linch, DC | 7 |
| Cai, M | 2 |
| Xu, P | 2 |
| Marcheselli, R | 3 |
| Bari, A | 2 |
| Tadmor, T | 5 |
| Papotti, R | 2 |
| Ferrari, A | 3 |
| Baldini, L | 8 |
| Gobbi, P | 1 |
| Levy, I | 2 |
| Pugliese, G | 1 |
| Federico, M | 8 |
| Polliack, A | 8 |
| Pozzi, S | 2 |
| Sacchi, S | 3 |
| Liu, W | 8 |
| Bolen, CR | 2 |
| Knapp, A | 1 |
| Janikova, A | 2 |
| Michalka, J | 1 |
| Bortlicek, Z | 1 |
| Chloupkova, R | 1 |
| Campr, V | 4 |
| Kopalova, N | 1 |
| Klener, P | 3 |
| Benesova, K | 2 |
| Hamouzova, J | 1 |
| Prochazka, V | 2 |
| Pytlik, R | 3 |
| Pirnos, J | 1 |
| Duras, J | 1 |
| Mocikova, H | 3 |
| Malkan, UY | 1 |
| Yildiz, A | 1 |
| Maral, S | 1 |
| Afacan Ozturk, HB | 1 |
| Comert, P | 1 |
| Saitou, K | 1 |
| Tsumanuma, R | 1 |
| Okuyama, S | 1 |
| Kumagai, H | 1 |
| Omoto, E | 1 |
| Satoh, S | 2 |
| Tajima, K | 3 |
| Ednersson, SB | 1 |
| Stern, M | 2 |
| Fagman, H | 1 |
| Nilsson-Ehle, H | 2 |
| Hasselblom, S | 3 |
| Vujosevic, S | 1 |
| Toma, C | 1 |
| Muraca, A | 1 |
| Alkabes, M | 1 |
| Villani, E | 1 |
| Nucci, P | 1 |
| De Cilla, S | 1 |
| Kuitunen, H | 2 |
| Kaprio, E | 1 |
| Makkonen, V | 1 |
| Kauppila, S | 1 |
| Kuusisto, M | 1 |
| Jantunen, E | 4 |
| Prieto-Torres, L | 1 |
| Trascasa, Á | 1 |
| Manso, R | 1 |
| Machan, S | 1 |
| Cieza-Diaz, D | 1 |
| Olmedilla, G | 2 |
| García-García, M | 1 |
| Ara-Martín, M | 1 |
| Requena, L | 1 |
| Rodríguez-Pinilla, SM | 1 |
| Bee-Lan Ong, D | 1 |
| Hayden, AR | 1 |
| Tonseth, P | 2 |
| Lee, DG | 1 |
| Villa, D | 10 |
| Gerrie, AS | 4 |
| Scott, DW | 16 |
| Freeman, CL | 2 |
| Farinha, P | 10 |
| Skinnider, B | 3 |
| Yenson, PR | 1 |
| Benard, F | 2 |
| Lo, A | 2 |
| Pickles, T | 2 |
| Wilson, D | 3 |
| Connors, JM | 45 |
| Lee, AN | 1 |
| Lee, H | 6 |
| Park, WS | 3 |
| Kim, SY | 5 |
| Neeman, Y | 1 |
| Perry, C | 1 |
| Silverman, B | 1 |
| Waintraub, N | 1 |
| Avivi, I | 4 |
| Jindal, N | 1 |
| Jain, A | 1 |
| Lad, D | 1 |
| Khadwal, A | 1 |
| Mikhaeel, NG | 3 |
| Radford, JA | 3 |
| O'Doherty, MJ | 1 |
| Barrington, SF | 1 |
| Kang, KW | 1 |
| Lee, BH | 1 |
| Jeon, MJ | 1 |
| Yu, ES | 1 |
| Kim, DS | 1 |
| Lee, SR | 2 |
| Sung, HJ | 2 |
| Choi, CW | 6 |
| Kim, BS | 4 |
| Subtil, A | 1 |
| Gru, AA | 1 |
| Tian, C | 1 |
| Fan, L | 6 |
| Lin, Q | 2 |
| Shen, J | 2 |
| Persky, DO | 3 |
| Li, H | 8 |
| Stephens, DM | 3 |
| Park, SI | 1 |
| Swinnen, LJ | 3 |
| Barr, PM | 2 |
| Winegarden, JD | 1 |
| Constine, LS | 4 |
| Fitzgerald, TJ | 1 |
| LeBlanc, ML | 3 |
| Song, JY | 1 |
| Fisher, RI | 21 |
| Rimsza, LM | 9 |
| Miller, TP | 8 |
| Foo, MY | 1 |
| Lee, WP | 1 |
| Seah, CMJ | 1 |
| Kam, C | 1 |
| Su, T | 2 |
| Kang, L | 1 |
| Wang, WT | 1 |
| Liang, JH | 5 |
| Zhu, HY | 4 |
| Li, JY | 7 |
| Xu, W | 9 |
| van der Holt, B | 1 |
| D'Amore, FA | 1 |
| Koene, HR | 3 |
| Fijnheer, R | 3 |
| van Esser, JW | 1 |
| Pruijt, JF | 1 |
| Verhoef, GE | 1 |
| Hoogendoorn, M | 6 |
| Bilgin, MY | 1 |
| van der Burg-de Graauw, NC | 2 |
| Oosterveld, M | 1 |
| Jie, KG | 1 |
| van der Poel, MW | 1 |
| Leijs, MB | 1 |
| Silbermann, MH | 1 |
| van Marwijk Kooy, M | 1 |
| Doorduijn, JK | 2 |
| Tick, LW | 2 |
| Burggraaff, CN | 2 |
| de Keizer, B | 1 |
| Arens, AI | 1 |
| Hoekstra, OS | 1 |
| Zijlstra-Baalbergen, JM | 1 |
| Gaikwad, U | 1 |
| Narayan, A | 1 |
| Kurkure, D | 1 |
| Yadav, S | 1 |
| Singh, P | 1 |
| de la Cruz-Benito, B | 1 |
| Lázaro-Del Campo, P | 1 |
| Ramírez-López, A | 1 |
| de Soto-Álvarez, T | 1 |
| Sánchez-Vadillo, I | 1 |
| García-Pérez, E | 1 |
| Dos Santos-Ortas, A | 1 |
| Humala-Barbier, K | 1 |
| López-de la Guía, A | 1 |
| Casado-Abad, G | 1 |
| Jiménez-Yuste, V | 1 |
| Canales-Albendea, M | 1 |
| Kagami, Y | 8 |
| Yamamoto, K | 11 |
| Shibata, T | 1 |
| Tobinai, K | 11 |
| Imaizumi, Y | 2 |
| Uchida, T | 4 |
| Shimada, K | 6 |
| Minauchi, K | 1 |
| Kobayashi, H | 2 |
| Yamauchi, N | 4 |
| Tsujimura, H | 3 |
| Hangaishi, A | 1 |
| Tominaga, R | 1 |
| Yoshida, S | 4 |
| Inoue, Y | 2 |
| Suzuki, S | 2 |
| Tokuhira, M | 2 |
| Kusumoto, S | 2 |
| Kuroda, J | 5 |
| Yakushijin, Y | 4 |
| Takamatsu, Y | 3 |
| Nosaka, K | 3 |
| Morishima, S | 2 |
| Ogura, M | 6 |
| Maruyama, D | 9 |
| Hotta, T | 2 |
| Morishima, Y | 5 |
| Nagai, H | 3 |
| Oba, R | 1 |
| Koike, K | 1 |
| Okabe, M | 1 |
| Tsuboi, N | 1 |
| Yokoo, T | 1 |
| Zhao, F | 1 |
| Zhou, L | 2 |
| Zhong, Q | 1 |
| Zhou, Y | 5 |
| Mogi, A | 1 |
| Sasaki, H | 2 |
| Nakashima, Y | 3 |
| Chinen, S | 1 |
| Ishizu, M | 1 |
| Takata, T | 1 |
| Nishimura, N | 5 |
| Asaka, R | 1 |
| Tuyama, N | 1 |
| Inoue, N | 3 |
| Kusano, Y | 2 |
| Mishima, Y | 8 |
| Yang, B | 2 |
| Li, R | 2 |
| Lu, X | 1 |
| Habbous, S | 1 |
| Guo, H | 2 |
| Beca, J | 1 |
| Dai, WF | 1 |
| Isaranuwatchai, W | 1 |
| Cheung, M | 1 |
| Zhong, M | 3 |
| Su, QH | 1 |
| Xu, L | 4 |
| Tsutsué, S | 1 |
| Yi, J | 2 |
| Crawford, B | 1 |
| Okello, CD | 1 |
| Omoding, A | 1 |
| Ddungu, H | 1 |
| Mulumba, Y | 1 |
| Orem, J | 1 |
| Ohtsubo, K | 1 |
| Yamashita, K | 5 |
| Yanagimura, N | 1 |
| Suzuki, C | 1 |
| Tanimoto, A | 1 |
| Nishiyama, A | 1 |
| Takeuchi, S | 1 |
| Kawano, M | 1 |
| Izumozaki, A | 1 |
| Inoue, D | 1 |
| Gabata, T | 1 |
| Ikeda, H | 1 |
| Watanabe, M | 4 |
| Yano, S | 1 |
| Villa, DR | 1 |
| Srour, L | 1 |
| Brown, MJ | 1 |
| Morris, J | 1 |
| Aquino-Parsons, C | 1 |
| Wilson, DC | 1 |
| Wu, J | 3 |
| He, Z | 1 |
| Zhu, Y | 3 |
| Jiang, C | 2 |
| Deng, Y | 1 |
| Wei, B | 1 |
| Lee, HH | 1 |
| Jung, SE | 2 |
| Park, KS | 1 |
| O, JH | 1 |
| Choi, BO | 3 |
| Kang, M | 1 |
| Suh, KJ | 1 |
| Kim, JW | 5 |
| Song, KH | 1 |
| Kim, ES | 1 |
| Kim, HB | 1 |
| Lee, KW | 3 |
| Bang, SM | 2 |
| Lee, JS | 6 |
| Kang, S | 1 |
| Lee, SM | 7 |
| Runge, HFP | 1 |
| Lacy, S | 1 |
| Beer, PA | 1 |
| Painter, D | 1 |
| Smith, A | 2 |
| Roman, E | 2 |
| Crouch, S | 2 |
| Hodson, DJ | 1 |
| Torisu, T | 1 |
| Kawano, S | 1 |
| Yamamoto, H | 1 |
| Ihara, Y | 1 |
| Matsuno, Y | 4 |
| Torisu, K | 1 |
| Shimakawa, T | 1 |
| Kitazono, T | 1 |
| Klanova, M | 1 |
| Tong, J | 2 |
| Kim, E | 1 |
| Fingerle-Rowson, G | 3 |
| Nielsen, T | 2 |
| Oestergaard, MZ | 2 |
| Igarashi, T | 3 |
| Ohata, K | 1 |
| Okamoto, M | 2 |
| Nishikawa, M | 1 |
| Suzumiya, J | 5 |
| De Mello, RB | 1 |
| Do Vale, ECS | 1 |
| O'Connor, OA | 3 |
| Fang, Y | 3 |
| Zhao, Y | 10 |
| Wang, CF | 3 |
| Huang, HH | 1 |
| Hsiao, FY | 1 |
| Chen, HM | 1 |
| Wang, CY | 2 |
| Ko, BS | 1 |
| Škor, O | 1 |
| Bicanová, L | 1 |
| Wolfesberger, B | 1 |
| Fuchs-Baumgartinger, A | 1 |
| Ruetgen, B | 1 |
| Štěrbová, M | 1 |
| Schwendenwein, I | 1 |
| Kleiter, M | 1 |
| Fuji, S | 1 |
| Kida, S | 1 |
| Nakata, K | 1 |
| Morishima, T | 1 |
| Miyashiro, I | 1 |
| Ishikawa, J | 3 |
| Arumov, A | 1 |
| Liyanage, PY | 1 |
| Trabolsi, A | 1 |
| Roberts, ER | 1 |
| Ferreira, BCLB | 1 |
| Gao, Z | 1 |
| Ban, Y | 1 |
| Newsam, AD | 1 |
| Taggart, MW | 1 |
| Bilbao, D | 1 |
| Leblanc, RM | 1 |
| Schatz, JH | 2 |
| Schaffer, M | 2 |
| Chaturvedi, S | 2 |
| Davis, C | 1 |
| de Jong, J | 1 |
| Aquino, R | 1 |
| Fourneau, N | 2 |
| Klintman, J | 1 |
| Appleby, N | 2 |
| Stamatopoulos, B | 1 |
| Ridout, K | 1 |
| Robbe, P | 1 |
| Pascua, LL | 1 |
| Knight, SJL | 1 |
| Dreau, H | 1 |
| Cabes, M | 2 |
| Popitsch, N | 1 |
| Ehinger, M | 2 |
| Martín-Subero, JI | 1 |
| Månsson, R | 1 |
| Rossi, D | 4 |
| Taylor, JC | 1 |
| Vavoulis, DV | 1 |
| Lamy, T | 4 |
| Maisonneuve, H | 3 |
| Gressin, R | 4 |
| Bouhabdallah, K | 1 |
| Damaj, G | 2 |
| Fornecker, L | 2 |
| Bouhabdallah, R | 1 |
| Cartron, G | 3 |
| Bonnet, C | 3 |
| Ruminy, P | 5 |
| Kraeber-Bodéré, F | 1 |
| Bodet-Milin, C | 1 |
| Berriolo-Riedinger, A | 2 |
| Jais, JP | 12 |
| Itti, E | 2 |
| Wondergem, MJ | 1 |
| Blommestein, HM | 1 |
| Huijgens, PC | 2 |
| Zweegman, S | 1 |
| Uncu Ulu, B | 2 |
| Batgi, H | 1 |
| Kızıl Çakar, M | 2 |
| Henriques, J | 1 |
| Felisberto, R | 1 |
| Constantino-Casas, F | 1 |
| Cabeçadas, J | 4 |
| Dobson, J | 1 |
| Bakunina, K | 1 |
| Dierickx, D | 3 |
| van Imhoff, GW | 2 |
| Marijt, EAF | 1 |
| Mandigers, C | 1 |
| Durian, MF | 1 |
| van Rees, B | 3 |
| Boersma, RS | 1 |
| Schouten, HC | 3 |
| Hijmering, N | 2 |
| Arens, AIJ | 1 |
| Huijbregts, J | 1 |
| Hoekstra, O | 1 |
| Sun, JJ | 1 |
| Wang, JR | 1 |
| Shen, YZ | 1 |
| Qi, TK | 1 |
| Wang, ZY | 2 |
| Chen, J | 8 |
| Zhang, RF | 1 |
| Chong, EA | 2 |
| Porter, DL | 1 |
| Wu, X | 7 |
| Gao, C | 1 |
| Chen, BA | 1 |
| Tsai, PC | 1 |
| Mavis, C | 1 |
| Hernandez-Ilizaliturri, FJ | 3 |
| Iltar, U | 1 |
| Sözel, H | 1 |
| Sözel, YK | 1 |
| Ataş, Ü | 1 |
| Yücel, OK | 1 |
| Salim, O | 1 |
| Aydin, F | 1 |
| Undar, L | 1 |
| Li, LR | 1 |
| Wang, Q | 4 |
| Yan, H | 1 |
| Xu, Y | 6 |
| Su, Z | 1 |
| Nusrat, A | 1 |
| Nazim, SM | 1 |
| Ta, R | 1 |
| Santini, C | 1 |
| Gou, P | 1 |
| Lee, G | 1 |
| Tai, YC | 3 |
| O'Brien, C | 1 |
| Fontecha, M | 1 |
| Grant, C | 3 |
| Bacon, L | 1 |
| Finn, S | 1 |
| Vandenberghe, E | 2 |
| Quinn, F | 2 |
| Dua, R | 1 |
| Flavin, R | 2 |
| Hegazy, SK | 1 |
| El-Haggar, SM | 1 |
| Alhassanin, SA | 1 |
| El-Berri, EI | 1 |
| Westin, J | 3 |
| Yagmur, Y | 1 |
| Nakagawa, J | 1 |
| Takahata, T | 1 |
| Hyodo, R | 1 |
| Hasui, K | 1 |
| Saito, K | 3 |
| Ueno, K | 2 |
| Hosoi, K | 1 |
| Terui, K | 1 |
| Sato, A | 2 |
| Niioka, T | 1 |
| Xie, S | 1 |
| Fan, W | 1 |
| Lei, W | 1 |
| Tong, X | 1 |
| Iwamoto, K | 1 |
| Nozaki, R | 1 |
| Saiki, Y | 1 |
| Tanaka, M | 3 |
| Fukunaga, M | 1 |
| Marshall, S | 1 |
| Yamauchi, H | 1 |
| Tsuyama, N | 4 |
| Ogasawara, T | 1 |
| Mori, N | 2 |
| Ogawa, T | 4 |
| Sakura, H | 1 |
| Senousy, MA | 1 |
| El-Abd, AM | 1 |
| Abdel-Malek, RR | 1 |
| Rizk, SM | 1 |
| Khanal, S | 1 |
| Bradley, T | 1 |
| Bolaman, AZ | 1 |
| Selim, C | 1 |
| Karaman, C | 1 |
| Yavaşoğlu, İ | 1 |
| Fernández-Alvarez, R | 1 |
| Gual-Capllonch, F | 1 |
| González-García, E | 1 |
| Grande, C | 9 |
| Gutiérrez, N | 1 |
| Peñarrubia, MJ | 2 |
| Batlle-López, A | 2 |
| Guinea, JM | 1 |
| Gimeno, E | 3 |
| Peñalver, FJ | 2 |
| Fuertes, M | 1 |
| Hernández-Rivas, JÁ | 1 |
| Moraleda, JM | 3 |
| Sorigué, M | 1 |
| Jung, J | 1 |
| Heo, JY | 1 |
| Lee, E | 2 |
| Papageorgiou, SG | 2 |
| Chatziioannou, S | 3 |
| Prassopoulos, V | 2 |
| Karakatsanis, S | 2 |
| Mellios, Z | 1 |
| Sachanas, S | 3 |
| Kalpadakis, C | 4 |
| Katodritou, E | 3 |
| Leonidopoulou, T | 3 |
| Kotsianidis, I | 4 |
| Hatzimichael, E | 2 |
| Kotsopoulou, M | 2 |
| Dimou, M | 3 |
| Variamis, E | 2 |
| Boutsis, D | 3 |
| Terpos, E | 3 |
| Michali, E | 2 |
| Karianakis, G | 2 |
| Tsirkinidis, P | 2 |
| Vadikolia, C | 2 |
| Poziopoulos, C | 2 |
| Pigaditou, A | 2 |
| Vrakidou, E | 2 |
| Kyrtsonis, MC | 4 |
| Symeonidis, A | 3 |
| Anargyrou, K | 2 |
| Papaioannou, M | 2 |
| Chatziharissi, E | 1 |
| Vervessou, E | 2 |
| Tsirogianni, M | 2 |
| Palassopoulou, M | 2 |
| Gainaru, G | 2 |
| Mainta, C | 1 |
| Assimakopoulou, T | 2 |
| Konstantinidou, P | 3 |
| Papadaki, H | 2 |
| Dimopoulos, MA | 5 |
| Pappa, V | 4 |
| Karmiris, T | 4 |
| Roussou, P | 3 |
| Datseris, I | 2 |
| Panayiotidis, P | 5 |
| Konstantopoulos, K | 4 |
| Pangalis, GA | 6 |
| Peng, Y | 1 |
| He, B | 4 |
| Wu, Z | 1 |
| Yoshida, M | 8 |
| Nakaya, Y | 1 |
| Shimizu, K | 1 |
| Tatsumi, N | 1 |
| Tsutsumi, M | 1 |
| Fuseya, H | 1 |
| Horiuchi, M | 2 |
| Yoshimura, T | 1 |
| Nakao, T | 3 |
| Inoue, T | 3 |
| Yamane, T | 3 |
| Flinn, IW | 4 |
| Gasiorowski, R | 1 |
| Illés, Á | 7 |
| Johnson, NA | 10 |
| Larouche, JF | 2 |
| Salles, GA | 6 |
| de Vos, S | 3 |
| Mir, F | 1 |
| Punnoose, E | 1 |
| Clark, E | 1 |
| Spielewoy, N | 1 |
| Perry, IE | 1 |
| Azam, MU | 1 |
| Yap, JE | 1 |
| Hong, F | 5 |
| Wade, JL | 1 |
| Nagargoje, GG | 1 |
| Reynolds, CM | 1 |
| Cohen, JB | 2 |
| Amengual, JE | 1 |
| Richards, KL | 17 |
| Little, RF | 6 |
| Castro, D | 2 |
| Beltrán, B | 1 |
| Quiñones, MDP | 1 |
| Pachas, C | 1 |
| Huerta, Y | 1 |
| Lalupu, K | 1 |
| Mendoza, R | 1 |
| Chen, HY | 1 |
| Zhang, WL | 1 |
| Yang, P | 3 |
| Yang, ZR | 2 |
| Pang, M | 1 |
| Yan, C | 1 |
| Xu, N | 1 |
| Xiao, XB | 1 |
| He, XH | 7 |
| Zhu, HC | 1 |
| He, C | 1 |
| Jing, HM | 2 |
| Choi, I | 1 |
| Atsuta, Y | 2 |
| Miyashita, K | 5 |
| Moriuchi, Y | 5 |
| Kubota, N | 1 |
| Kojima, K | 2 |
| Tsukamoto, N | 5 |
| Ohtsuka, E | 1 |
| Inaguma, Y | 2 |
| Ichikawa, S | 2 |
| Gomyo, H | 1 |
| Ushijima, Y | 1 |
| Kurata, M | 3 |
| Tanaka, Y | 2 |
| Ueda, R | 1 |
| Mizokami, M | 1 |
| Ogawa, G | 1 |
| Mizutani, T | 1 |
| Iida, S | 2 |
| Utsumi, T | 1 |
| Tokunaga, T | 1 |
| Murayama, T | 2 |
| Dobashi, N | 2 |
| Ishizawa, K | 4 |
| Yoshino, T | 8 |
| Sugimoto, K | 2 |
| Uejima, S | 1 |
| Uchiyama, Y | 1 |
| Yasue, R | 1 |
| Nambu, K | 1 |
| Koma, Y | 1 |
| Akita, T | 1 |
| Toh, T | 1 |
| Fujimoto, T | 1 |
| Yang, X | 3 |
| Laliberté, F | 1 |
| Germain, G | 1 |
| Raut, M | 1 |
| Duh, MS | 1 |
| Sen, SS | 1 |
| Lejeune, D | 1 |
| Desai, K | 1 |
| Armand, P | 1 |
| Zhang, XY | 4 |
| Cutter, DJ | 1 |
| Gascoyne, RD | 54 |
| Özcan, M | 2 |
| Bergua, JM | 1 |
| Piazza, F | 2 |
| Molinari, AL | 3 |
| Czuczman, M | 2 |
| Hersey, S | 1 |
| Kilcoyne, A | 1 |
| Russo, J | 1 |
| Hudak, K | 1 |
| Wade, S | 1 |
| Binkley, MS | 2 |
| Hiniker, SM | 3 |
| Younes, S | 1 |
| Yoo, C | 4 |
| Wignarajah, A | 1 |
| Jin, M | 1 |
| Guo, HH | 1 |
| Gupta, NK | 1 |
| Natkunam, Y | 8 |
| Hoppe, RT | 3 |
| Mihailescu, SD | 1 |
| Lequesne, J | 1 |
| Tamion, F | 1 |
| Hatzl, S | 1 |
| Posch, F | 1 |
| Rezai, A | 1 |
| Gornicec, M | 1 |
| Beham-Schmid, C | 1 |
| Magnes, T | 1 |
| Wangner, S | 1 |
| Deutsch, A | 1 |
| Greinix, H | 1 |
| Uhl, B | 1 |
| Prochazka, KT | 1 |
| Egle, A | 2 |
| Melchardt, T | 3 |
| Linkesch, W | 2 |
| Schulz, E | 1 |
| Neumeister, P | 1 |
| Hernández Martínez, M | 1 |
| Lizán Tudela, C | 1 |
| Saus Carreres, A | 1 |
| Freudenberger, F | 1 |
| Ohler, A | 1 |
| Theobald, M | 1 |
| Hess, G | 1 |
| Bhattacharya, P | 1 |
| Zakaria, R | 1 |
| Stonelake, S | 1 |
| Butler, B | 1 |
| Sarma, D | 1 |
| Maheswari, M | 1 |
| Zaman, S | 1 |
| Pitney, T | 1 |
| Pitney, MJ | 1 |
| Susanibar-Adaniya, S | 1 |
| Tavares, A | 1 |
| Moreira, I | 1 |
| Bettelli, S | 1 |
| Forti, E | 1 |
| Cox, MCC | 1 |
| Mansueto, GR | 1 |
| Musto, P | 2 |
| Quintini, M | 1 |
| Galimberti, S | 1 |
| Lalinga, V | 1 |
| Donati, V | 1 |
| Maiorana, A | 1 |
| Rozental, A | 2 |
| Ise, M | 1 |
| Matsuda, K | 1 |
| Shimura, A | 1 |
| Masamoto, Y | 1 |
| Kurokawa, M | 4 |
| Zhang, HZ | 1 |
| Wang, SY | 1 |
| Lim, CH | 1 |
| Hyun, SH | 1 |
| Cho, YS | 1 |
| Choi, JY | 3 |
| Lee, KH | 3 |
| Inomata, Y | 1 |
| Kuroha, M | 1 |
| Handa, T | 1 |
| Shimoyama, Y | 1 |
| Moroi, R | 1 |
| Shiga, H | 1 |
| Kakuta, Y | 1 |
| Sato, Y | 2 |
| Takahashi, T | 14 |
| Masamune, A | 1 |
| Tokola, S | 1 |
| Giyanani, N | 1 |
| Som, S | 1 |
| Egoryan, G | 1 |
| Murguia-Fuentes, R | 1 |
| Agab, M | 1 |
| Abou-Ghanem, N | 1 |
| Yanez-Bello, MA | 1 |
| Pyakuryal, B | 1 |
| Trelles-Garcia, DP | 1 |
| Ibrahim, R | 1 |
| Filipiuk, D | 1 |
| Gidron, A | 1 |
| Rodriguez-Nava, G | 1 |
| Solís-Armenta, R | 1 |
| Cacho-Díaz, B | 1 |
| Gutiérrez-Hernández, O | 1 |
| Candelaria-Hernández, M | 1 |
| Yin, J | 1 |
| Zhao, D | 2 |
| Esper, A | 1 |
| Alhoulaiby, S | 1 |
| Zuhri Yafi, R | 1 |
| Alshehabi, Z | 1 |
| Cao, YJ | 1 |
| Duan, J | 1 |
| Liu, LF | 1 |
| Wei, X | 6 |
| Ren, L | 1 |
| Zhang, LN | 1 |
| Popplewell, L | 1 |
| Chhabra, S | 1 |
| Kimball, AS | 1 |
| Beaupre, D | 1 |
| Wright, G | 4 |
| Kwei, K | 1 |
| Ping, J | 1 |
| Neuenburg, JK | 1 |
| Michail, M | 1 |
| Papageorgiou, S | 3 |
| Kourti, G | 2 |
| Dimopoulou, MN | 2 |
| Michalis, E | 1 |
| Economopoulos, T | 2 |
| Kyriazopoulou, L | 2 |
| Hatjiharissi, E | 1 |
| Stefanoudaki, E | 2 |
| Zikos, P | 1 |
| Tsourouflis, G | 1 |
| A Papadaki, H | 1 |
| Megalakaki, K | 1 |
| Umemura, M | 1 |
| Suda, G | 1 |
| Tsukamoto, S | 1 |
| Ebata, K | 1 |
| Takahash, S | 1 |
| Sasaki, T | 1 |
| Nakajima, S | 1 |
| Hirata, K | 1 |
| Ozasa, M | 1 |
| Takano, M | 1 |
| Katagiri, M | 2 |
| Sakamoto, N | 1 |
| Bouabdallah, S | 1 |
| Mariko, ML | 1 |
| Besson, J | 1 |
| Dellis, O | 1 |
| Major, C | 1 |
| Zinzani, PL | 18 |
| Carey, J | 2 |
| Gerecitano, J | 1 |
| Wilson, W | 2 |
| Abu Sabaa, A | 1 |
| Mörth, C | 2 |
| Hedström, G | 3 |
| Flogegård, M | 2 |
| Goldfinger, M | 1 |
| Cooper, DL | 2 |
| Cai, J | 1 |
| Tian, X | 1 |
| Ma, S | 1 |
| Zhong, L | 2 |
| Guo, L | 3 |
| Zhong, G | 1 |
| Su, N | 1 |
| Cai, Q | 2 |
| Tang, T | 3 |
| Saleh, L | 1 |
| Steinhardt, MJ | 1 |
| Krummenast, FC | 1 |
| Gerhard-Hartmann, E | 1 |
| Heidemeier, A | 1 |
| Einsele, H | 1 |
| Topp, MS | 2 |
| Pregnolato, F | 1 |
| Ferrarini, I | 1 |
| De Marco, B | 1 |
| Bonuomo, V | 1 |
| Sbisà, E | 1 |
| Fraenza, C | 1 |
| Bernardelli, A | 1 |
| Tanasi, I | 1 |
| Quaglia, FM | 1 |
| Krampera, M | 2 |
| Desai, S | 2 |
| Chaturvedi, M | 1 |
| Hameed, R | 1 |
| Baez-Sosa, V | 1 |
| Shenoy, AG | 1 |
| Miyagi-Maeshima, A | 1 |
| Nomoto, J | 1 |
| Ito, Y | 3 |
| Hatta, S | 1 |
| Yuda, S | 1 |
| Makita, S | 1 |
| Fukuhara, S | 2 |
| Munakata, W | 2 |
| Taniguchi, H | 2 |
| Kobayashi, Y | 10 |
| Elhagracy, R | 1 |
| Hamadah, A | 1 |
| Abd El Tawab, R | 1 |
| Pinto, K | 1 |
| Hussain, A | 1 |
| Osmani, M | 1 |
| Alshemmari, S | 1 |
| Bobillo, S | 1 |
| Joffe, E | 1 |
| Sermer, D | 1 |
| Mondello, P | 5 |
| Ghione, P | 1 |
| Caron, PC | 2 |
| Hamilton, A | 1 |
| Hamlin, PA | 4 |
| Horwitz, SM | 1 |
| Matasar, MJ | 2 |
| Batlevi, CL | 1 |
| Moskowitz, A | 1 |
| Owens, CN | 2 |
| Palomba, ML | 2 |
| Straus, D | 3 |
| von Keudell, G | 1 |
| Seshan, VE | 1 |
| Qiu, C | 1 |
| Zhang, C | 6 |
| Hou, S | 1 |
| El Sayed, R | 1 |
| El Darsa, H | 1 |
| Kort, J | 1 |
| Al Chami, F | 1 |
| Ibrahim, A | 1 |
| Charafeddine, M | 1 |
| Bazarbachi, A | 1 |
| Abou Dalle, I | 1 |
| El Cheikh, J | 1 |
| Englert, P | 1 |
| Levy, S | 1 |
| Vekemans, M | 1 |
| De Wilde, V | 1 |
| Lavacchi, D | 1 |
| Landini, I | 2 |
| Perrone, G | 2 |
| Roviello, G | 1 |
| Mini, E | 2 |
| Nobili, S | 2 |
| Azzazi, MO | 1 |
| Hegab, HM | 1 |
| El-Ghammaz, AMS | 2 |
| Saber, HM | 1 |
| Afifi, YA | 1 |
| Brito, ABC | 2 |
| Delamain, MT | 4 |
| Fanelli, MF | 2 |
| Soares, FA | 2 |
| Vassallo, J | 2 |
| Lima, CSP | 2 |
| Wai, SH | 1 |
| Shen, E | 1 |
| Berlangieri, S | 1 |
| Hannah, A | 1 |
| Leung, T | 1 |
| Yin, H | 1 |
| Wu, JZ | 1 |
| Hara, T | 10 |
| Tsurumi, H | 12 |
| Wakasa, T | 1 |
| Hanamoto, H | 1 |
| Koyama, T | 1 |
| Ohta, Y | 1 |
| Inoue, M | 2 |
| Terashita, D | 1 |
| Gakuhara, A | 1 |
| Tomihara, H | 1 |
| Ohta, K | 2 |
| Kitani, K | 1 |
| Hashimoto, K | 2 |
| Ishikawa, H | 1 |
| Hida, JI | 1 |
| Kimura, Y | 2 |
| Dodero, A | 2 |
| Marino, F | 1 |
| Barretta, F | 2 |
| Re, A | 3 |
| Carniti, C | 2 |
| Monfrini, C | 1 |
| Cabras, A | 1 |
| Facchetti, F | 4 |
| Pennisi, M | 2 |
| Rahal, D | 2 |
| Monti, V | 1 |
| Devizzi, L | 3 |
| Miceli, R | 2 |
| Cocito, F | 1 |
| Farina, L | 2 |
| Ricci, F | 1 |
| Rossi, G | 10 |
| Carlo-Stella, C | 1 |
| Corradini, P | 3 |
| Lin, RJ | 1 |
| Drill, E | 1 |
| Iannotta, A | 1 |
| Oliveros, M | 1 |
| Schick, DL | 1 |
| Gerecitano, JF | 1 |
| Drullinsky, PR | 1 |
| Moskowitz, C | 1 |
| Korc-Grodzicki, B | 1 |
| Painschab, MS | 2 |
| Kohler, R | 1 |
| Kimani, S | 1 |
| Mhango, W | 2 |
| Kaimila, B | 2 |
| Zuze, T | 2 |
| Mithi, V | 1 |
| Kasonkanji, E | 2 |
| Mumba, N | 1 |
| Nyasosela, R | 2 |
| Wheeler, S | 1 |
| Gopal, S | 2 |
| Tsugu, T | 1 |
| Nagatomo, Y | 1 |
| Matsuyama, E | 1 |
| Lancellotti, P | 1 |
| Mitamura, H | 1 |
| Miyawaki, M | 1 |
| Aoyama, R | 1 |
| Harada, K | 3 |
| Rinaldi, F | 1 |
| Marchesi, F | 2 |
| Palombi, F | 1 |
| Pelosi, A | 1 |
| Di Pace, AL | 1 |
| Sacconi, A | 1 |
| Terrenato, I | 1 |
| Annibali, O | 1 |
| Tomarchio, V | 1 |
| Marino, M | 1 |
| Cantonetti, M | 2 |
| Vaccarini, S | 1 |
| Papa, E | 1 |
| Moretta, L | 1 |
| Bertoni, F | 10 |
| Mengarelli, A | 1 |
| Regazzo, G | 1 |
| Rizzo, MG | 1 |
| Al-Kindi, SG | 1 |
| Kiyoi, H | 1 |
| Wang, XD | 1 |
| Guo, B | 1 |
| Zhai, B | 1 |
| Fan, H | 1 |
| Lu, XC | 1 |
| Li, SX | 1 |
| Zhu, HL | 1 |
| Bouroumeau, A | 1 |
| Bussot, L | 1 |
| Bonnefoix, T | 1 |
| Fournier, C | 1 |
| Chapusot, C | 1 |
| Martin, L | 1 |
| McLeer, A | 1 |
| Col, E | 1 |
| David-Boudet, L | 1 |
| Lefebvre, C | 1 |
| Algrin, C | 1 |
| Raskovalova, T | 1 |
| Jacob, MC | 1 |
| Vettier, C | 1 |
| Chevalier, S | 1 |
| Callanan, MB | 1 |
| Emadali, A | 1 |
| Sartelet, H | 1 |
| Villacampa, G | 1 |
| Dienstmann, R | 1 |
| Bosch, F | 2 |
| Yu, M | 2 |
| Xu, S | 1 |
| Yin, T | 1 |
| Denker, S | 1 |
| Bittner, A | 1 |
| Frick, M | 2 |
| Kase, J | 1 |
| Hoffmann, J | 1 |
| Trenker, C | 1 |
| Bogner, C | 1 |
| Hüttmann, A | 1 |
| Dürig, J | 1 |
| Janz, M | 1 |
| Mathas, S | 1 |
| Marks, R | 3 |
| Krohn, U | 1 |
| Na, IK | 1 |
| Bullinger, L | 1 |
| Schmitt, CA | 1 |
| Camerini, C | 1 |
| Sant'Antonio, E | 1 |
| Ginori, A | 1 |
| Pellegri, M | 1 |
| De Gaudio, C | 1 |
| Banti, E | 1 |
| Ciliberti, V | 1 |
| Parrini, M | 1 |
| Bozzoli, L | 1 |
| Simonetti, F | 1 |
| Capochiani, E | 1 |
| Harada, N | 5 |
| Tagami, M | 1 |
| Ohsawa, M | 1 |
| Hino, M | 3 |
| Nakamae, H | 1 |
| Chavez, JC | 2 |
| Reagan, JL | 2 |
| LaCasce, AS | 6 |
| Jones, J | 1 |
| Drew, J | 1 |
| Wu, C | 3 |
| Mulvey, E | 1 |
| Revuelta, MV | 1 |
| Cerchietti, L | 2 |
| Tang, J | 2 |
| He, S | 1 |
| Zhang, Z | 3 |
| Wu, P | 1 |
| Luo, L | 1 |
| Guo, Q | 2 |
| Ren, Y | 1 |
| Yu, S | 1 |
| Kraft, RM | 1 |
| Villasboas, JC | 1 |
| Bennani, NN | 1 |
| Thanarajasingam, G | 1 |
| Lester, SC | 1 |
| Macon, W | 1 |
| Micallef, IN | 11 |
| Thompson, CA | 5 |
| Paludo, J | 1 |
| Yoon, KA | 1 |
| Sohn, JY | 1 |
| Kim, MJ | 3 |
| Kong, SY | 3 |
| Petrella, T | 8 |
| Copie-Bergman, C | 8 |
| Figeac, M | 3 |
| Canioni, D | 6 |
| Leroy, K | 9 |
| Gorospe, L | 1 |
| Gallego-Rivera, JI | 1 |
| Rioja-Martín, ME | 1 |
| Chinea-Rodríguez, A | 1 |
| Park, MJ | 3 |
| Song, HN | 3 |
| Kang, JH | 3 |
| Kim, HR | 3 |
| Kanaya, M | 1 |
| Endo, T | 1 |
| Hashimoto, D | 1 |
| Endo, S | 1 |
| Takemura, R | 1 |
| Okada, K | 1 |
| Hatanaka, KC | 1 |
| Teshima, T | 3 |
| Kühnl, A | 1 |
| Qian, W | 3 |
| Jack, A | 4 |
| Johnson, PW | 2 |
| Horn, H | 5 |
| Broccoli, A | 6 |
| Casadei, B | 2 |
| Stefoni, V | 10 |
| Pellegrini, C | 6 |
| Quirini, F | 1 |
| Tonialini, L | 1 |
| Morigi, A | 1 |
| Marangon, M | 1 |
| Argnani, L | 3 |
| Yoon, N | 1 |
| Ahn, S | 1 |
| Yong Yoo, H | 1 |
| Jin Kim, S | 1 |
| Seog Kim, W | 1 |
| Hyeh Ko, Y | 1 |
| Gomes da Silva, M | 2 |
| Lazarovici, J | 1 |
| Grosicka, A | 1 |
| Van Hoof, A | 4 |
| Miranda, ECM | 1 |
| Lourenço, GJ | 1 |
| Lavi, N | 1 |
| Shapira, G | 1 |
| Zilberlicht, A | 2 |
| Benyamini, N | 1 |
| Farbstein, D | 1 |
| Dann, EJ | 5 |
| Bar-Shalom, R | 2 |
| Watanabe, K | 2 |
| Fukuda, T | 4 |
| Miura, O | 1 |
| Amin, AD | 1 |
| Peters, TL | 1 |
| Rajan, SS | 1 |
| Choudhari, R | 1 |
| Puvvada, SD | 2 |
| Cubo, AM | 1 |
| Soto, ZM | 1 |
| Cruz, MÁ | 2 |
| Doyague, MJ | 1 |
| Sancho, V | 1 |
| Fraino, A | 1 |
| Blanco, Ó | 2 |
| Puig, N | 1 |
| González, M | 5 |
| Sayagués, JM | 1 |
| Xiao, J | 1 |
| Du, S | 1 |
| Dai, G | 1 |
| Gao, G | 1 |
| Yang, D | 1 |
| Zhao, H | 4 |
| Arakaki, H | 1 |
| Osada, Y | 1 |
| Ito, C | 1 |
| Aisa, Y | 1 |
| Mori, T | 1 |
| Pantelaki, I | 1 |
| Tigges, C | 1 |
| Nußbaum, T | 1 |
| Oellig, F | 1 |
| Wieland, U | 1 |
| Kreuter, A | 1 |
| Sakata, S | 1 |
| Baba, S | 1 |
| Ueda, K | 4 |
| Hatake, K | 7 |
| Kitagawa, M | 2 |
| Ishizuka, N | 1 |
| Tomita, N | 13 |
| Staiger, AM | 2 |
| Barth, TFE | 1 |
| Bernd, HW | 3 |
| Feller, AC | 3 |
| Szczepanowski, M | 2 |
| Hummel, M | 3 |
| Stein, H | 4 |
| Lenze, D | 2 |
| Hansmann, ML | 5 |
| Hartmann, S | 1 |
| Möller, P | 4 |
| Cogliatti, S | 3 |
| Löffler, M | 1 |
| Padberg, S | 1 |
| Mick, I | 1 |
| Frenzel, C | 1 |
| Hilberath, J | 1 |
| Schaefer, C | 1 |
| Uebner, M | 1 |
| Jacobi, J | 1 |
| Schmidt, D | 1 |
| Büttner-Herold, M | 1 |
| Mackensen, A | 2 |
| Spriewald, BM | 1 |
| Takahashi, A | 1 |
| Gunji, T | 1 |
| Nitta, H | 3 |
| Yamamoto, W | 6 |
| Watanabe, R | 6 |
| Shimazu, Y | 1 |
| Tsunoda, S | 3 |
| Hashimoto, C | 9 |
| Yano, T | 6 |
| Okamoto, R | 1 |
| Kikuchi, A | 1 |
| Tamura, K | 4 |
| Sato, K | 5 |
| Shibayama, H | 1 |
| Takimoto, R | 3 |
| Ohshima, R | 4 |
| Numata, A | 4 |
| Nakajima, H | 1 |
| Miura, I | 1 |
| Saygin, C | 1 |
| Jia, X | 1 |
| Hill, B | 1 |
| Dean, R | 2 |
| Pohlman, B | 6 |
| Smith, MR | 2 |
| Jagadeesh, D | 4 |
| Zenz, T | 1 |
| Kreuz, M | 2 |
| Fuge, M | 1 |
| Winter, D | 1 |
| Helfrich, H | 1 |
| Huellein, J | 1 |
| Feller, A | 1 |
| Siebert, R | 3 |
| You, X | 1 |
| Xu, M | 3 |
| Dang, Q | 1 |
| Shi, W | 1 |
| Kim, J | 2 |
| Song, YS | 2 |
| Lee, WW | 1 |
| Kim, SE | 1 |
| Kwak, YK | 1 |
| Kang, DG | 1 |
| Lai, C | 1 |
| Pittaluga, S | 9 |
| Shovlin, M | 1 |
| Steinberg, SM | 7 |
| Pack, S | 1 |
| Jaffe, ES | 15 |
| Dong, LH | 1 |
| Chen, JL | 1 |
| Gao, X | 3 |
| Li, GP | 1 |
| Li, YF | 2 |
| Song, YP | 1 |
| Wei, XD | 2 |
| Fritsch, K | 1 |
| Baumgarten, A | 1 |
| Fietz, T | 1 |
| Engelhardt, M | 2 |
| Mertelsmann, R | 2 |
| Ihorst, G | 1 |
| Duyster, J | 1 |
| Finke, J | 2 |
| McPhail, E | 2 |
| Colgan, JP | 5 |
| Zheng, SM | 1 |
| Zhou, DJ | 1 |
| Chen, YH | 1 |
| Jiang, R | 1 |
| Wang, YX | 1 |
| Xue, HL | 1 |
| Wang, HQ | 1 |
| Mou, D | 1 |
| Zeng, WZ | 1 |
| Bauer, WM | 1 |
| Aichelburg, MC | 1 |
| Griss, J | 1 |
| Skrabs, C | 1 |
| Schiefer, AI | 1 |
| Kittler, H | 1 |
| Zeyda, M | 1 |
| Knobler, R | 1 |
| Stingl, G | 1 |
| Rinaldi, A | 2 |
| Kwee, I | 6 |
| Altenbuchinger, M | 1 |
| Kohler, C | 1 |
| Inghirami, G | 5 |
| Kagawa, K | 1 |
| Sumitani, R | 2 |
| Uemura, M | 1 |
| Takahashi, M | 1 |
| Iwasa, M | 1 |
| Fujii, S | 5 |
| Miki, H | 1 |
| Abe, M | 1 |
| Tomowiak, C | 2 |
| Michallet, AS | 3 |
| Dupuis, J | 2 |
| Hivert, B | 2 |
| Toussaint, E | 1 |
| Godet, S | 1 |
| Merabet, F | 1 |
| Van Den Neste, E | 5 |
| Ivanoff, S | 1 |
| Roussel, X | 1 |
| Zini, JM | 1 |
| Regny, C | 1 |
| Lemal, R | 1 |
| Sutton, L | 1 |
| Kanagaratnam, L | 1 |
| Morel, P | 5 |
| Leblond, V | 2 |
| Delmer, A | 3 |
| Mustafa Ali, M | 1 |
| Rybicki, L | 1 |
| Nomani, L | 1 |
| Rouphail, B | 1 |
| Dean, RM | 1 |
| Zlamalikova, L | 1 |
| Moulis, M | 2 |
| Ravcukova, B | 2 |
| Liskova, K | 1 |
| Malcikova, J | 1 |
| Salek, D | 2 |
| Jarkovsky, J | 1 |
| Svitakova, M | 1 |
| Hrabalkova, R | 2 |
| Smarda, J | 1 |
| Smardova, J | 2 |
| Kimura, K | 1 |
| Iwamuro, M | 1 |
| Terasaka, T | 1 |
| Hanayama, Y | 1 |
| Kondo, E | 2 |
| Hayashi, E | 1 |
| Otsuka, F | 1 |
| Carella, AM | 4 |
| Chua, N | 1 |
| Demeter, J | 3 |
| Flinn, I | 2 |
| Shi, YK | 8 |
| Tatsumi, Y | 1 |
| Wenger, M | 2 |
| Catalani, O | 1 |
| Tsuda, Y | 1 |
| Oguri, T | 1 |
| Kajiguchi, T | 1 |
| Kato, H | 5 |
| Yuasa, H | 2 |
| Lamos, C | 1 |
| Dippel, E | 1 |
| Vidal, L | 2 |
| Lando, S | 1 |
| Vaxman, I | 1 |
| Moon, JH | 5 |
| Won, YW | 2 |
| Kim, TS | 1 |
| Kolibaba, KS | 1 |
| Reeves, JA | 1 |
| Tulpule, A | 2 |
| Kolevska, T | 1 |
| Robles, R | 1 |
| Collins, R | 2 |
| DiBella, NJ | 1 |
| Papish, SW | 1 |
| Venugopal, P | 4 |
| Horodner, A | 1 |
| Tabatabai, A | 1 |
| Hajdenberg, J | 1 |
| Neuwirth, R | 1 |
| Mulligan, G | 1 |
| Suryanarayan, K | 1 |
| Esseltine, DL | 1 |
| Reddy, P | 1 |
| Kanan, S | 1 |
| Cowan, A | 1 |
| Warren, H | 1 |
| Till, B | 1 |
| Cassaday, R | 2 |
| Press, O | 2 |
| Gopal, A | 1 |
| Imamura, S | 1 |
| Kamiya, K | 1 |
| Tsutsumi, Y | 3 |
| Nakayama, C | 1 |
| Kamada, K | 1 |
| Kikuchi, R | 1 |
| Kudo, D | 1 |
| Ito, S | 2 |
| Matsuoka, S | 1 |
| Shiratori, S | 1 |
| Yamamoto, Y | 3 |
| Naruse, H | 1 |
| Khelfa, Y | 1 |
| Lebowicz, Y | 1 |
| Jamil, MO | 1 |
| Xu, ZZ | 2 |
| Shen, JK | 2 |
| Zhao, SQ | 2 |
| Li, JM | 7 |
| Chen-Liang, TH | 1 |
| Martín-Santos, T | 1 |
| Jerez, A | 1 |
| Rodríguez-García, G | 1 |
| Senent, L | 1 |
| Martínez-Millán, C | 1 |
| Muiña, B | 1 |
| Orero, M | 1 |
| Teruel, A | 1 |
| Gómez-Espuch, J | 1 |
| Kennedy, K | 1 |
| Benet, C | 1 |
| Raya, JM | 1 |
| Fernández-González, M | 1 |
| Guinot, M | 1 |
| Villegas, C | 1 |
| Ballester, I | 1 |
| Moya, M | 1 |
| López-Jiménez, J | 1 |
| Frutos, L | 1 |
| Navarro, JL | 1 |
| Uña, J | 1 |
| Fernández-López, R | 1 |
| Igua, C | 1 |
| Contreras, J | 1 |
| Sánchez-Vañó, R | 1 |
| Cozar, MDP | 1 |
| Tamayo, P | 2 |
| Mucientes, J | 1 |
| Sánchez-Blanco, JJ | 3 |
| Pérez-Ceballos, E | 2 |
| Ortuño, FJ | 1 |
| Hao, X | 3 |
| Wei, Q | 3 |
| Song, J | 1 |
| Wei, Y | 4 |
| Ríos León, R | 1 |
| Crespo Pérez, L | 1 |
| Martínez-Geijo Román, C | 1 |
| Barbado Cano, A | 1 |
| García-Cosío Piqueras, M | 1 |
| Sánchez Rodríguez, E | 1 |
| de la Filia Molina, IG | 1 |
| Flores de Miguel, Á | 1 |
| Guerrero García, A | 1 |
| López-Jiménez, FJ | 1 |
| Mena Mateos, A | 1 |
| Albillos Martínez, A | 1 |
| Soubeyran, P | 1 |
| Gyan, E | 2 |
| Cornillon, J | 1 |
| Banos, A | 2 |
| Benchalal, M | 1 |
| Moles, MP | 1 |
| Fleury, J | 1 |
| Deconinck, E | 2 |
| Laribi, K | 3 |
| Marolleau, JP | 4 |
| Tournilhac, O | 2 |
| Branger, B | 1 |
| Devillers, A | 1 |
| Vuillez, JP | 1 |
| Fest, T | 2 |
| Colombat, P | 1 |
| Costes, V | 1 |
| Béné, MC | 1 |
| Chen, Q | 3 |
| Staton, AD | 1 |
| Ayer, T | 2 |
| Goldstein, DA | 1 |
| Loo, SK | 2 |
| Ch'ng, ES | 2 |
| Lawrie, CH | 3 |
| Muruzabal, MA | 2 |
| Gaafar, A | 2 |
| Pomposo, MP | 2 |
| Husin, A | 2 |
| Md Salleh, MS | 1 |
| Banham, AH | 7 |
| Pedersen, LM | 9 |
| Green, TM | 9 |
| Wong, KK | 5 |
| Giulino-Roth, L | 1 |
| O'Donohue, T | 1 |
| LaCasce, A | 5 |
| Martin-Doyle, W | 1 |
| Barth, MJ | 1 |
| Davies, K | 1 |
| Christian, B | 4 |
| Godfrey, J | 1 |
| Termuhlen, A | 1 |
| Oberley, MJ | 1 |
| Weitzman, S | 4 |
| Appel, B | 1 |
| Mizukawa, B | 1 |
| Afify, Z | 1 |
| Pauly, M | 1 |
| Dave, H | 1 |
| Gardner, R | 1 |
| Zeitler, WA | 1 |
| Forlenza, C | 1 |
| Levine, J | 1 |
| Williams, ME | 2 |
| Sima, JL | 1 |
| Boslooper, K | 3 |
| van Imhoff, G | 1 |
| Kibbelaar, R | 2 |
| Joosten, P | 3 |
| Storm, H | 3 |
| van Roon, EN | 2 |
| Kluin-Nelemans, HC | 3 |
| Pedersen, MØ | 3 |
| Pedersen, M | 5 |
| Knudsen, H | 3 |
| Nielsen, SL | 3 |
| Poulsen, T | 1 |
| Wirenfeldt Klausen, T | 1 |
| Høgdall, E | 3 |
| Nørgaard, P | 4 |
| Fan, X | 1 |
| Qian, Y | 3 |
| Ou-Yang, BS | 1 |
| Leboeuf, C | 2 |
| Janin, A | 2 |
| Ding, N | 4 |
| Mi, L | 1 |
| Ping, L | 3 |
| Ying, Z | 4 |
| Deng, L | 6 |
| Hu, X | 2 |
| Zeng, M | 2 |
| Yang, SE | 1 |
| Ding, SS | 1 |
| Wen, SJ | 1 |
| Cho, KM | 1 |
| Keam, B | 2 |
| Ha, H | 2 |
| Kim, M | 2 |
| Jung, JW | 1 |
| Song, WJ | 1 |
| Kang, HR | 1 |
| Kim, CW | 4 |
| Sierra Matiz, OR | 1 |
| Santilli, J | 1 |
| Anai, LA | 1 |
| Da Silva, MCL | 1 |
| Sueiro, FA | 1 |
| Sequeira, JL | 1 |
| Magalhães, LF | 1 |
| Magalhães, GM | 1 |
| Tinucci Costa, M | 1 |
| Calazans, SG | 1 |
| Butler, MJ | 1 |
| Aguiar, RCT | 1 |
| Chen, AI | 1 |
| Leonard, JT | 1 |
| Okada, CY | 1 |
| Gay, ND | 1 |
| Chansky, K | 1 |
| Fan, G | 1 |
| Dunlap, JB | 1 |
| Raess, PW | 1 |
| Braziel, RM | 8 |
| Stentz, A | 1 |
| Maziarz, RT | 2 |
| Lee, T | 1 |
| Park, BG | 1 |
| You, E | 1 |
| Cho, YU | 2 |
| Jang, S | 4 |
| Park, CJ | 4 |
| Arima, H | 3 |
| Fujimoto, M | 1 |
| Kitano, T | 1 |
| Kishimoto, W | 1 |
| Hishizawa, M | 2 |
| Kondo, T | 2 |
| Hirata, M | 1 |
| Haga, H | 1 |
| Takaori-Kondo, A | 1 |
| Ikeda, T | 3 |
| Vanazzi, A | 2 |
| Mayer, J | 1 |
| Costa, LJ | 3 |
| Bermudez Silva, CD | 1 |
| Kattan, JG | 1 |
| Fan, J | 1 |
| Louveau, AL | 1 |
| Voi, M | 1 |
| Cavalli, F | 8 |
| Bane, CL | 1 |
| Von Gehr, A | 1 |
| LeBlanc, M | 3 |
| Tisi, MC | 6 |
| Bellesi, S | 3 |
| Maiolo, E | 3 |
| Alma, E | 3 |
| Tartaglia, G | 1 |
| Corrente, F | 1 |
| Cuccaro, A | 1 |
| D'Alo', F | 2 |
| Basile, U | 1 |
| Larocca, LM | 3 |
| De Stefano, V | 1 |
| Ding, Z | 1 |
| Vollmer, K | 1 |
| Hunter, NB | 1 |
| Vogt, S | 1 |
| Hernández-Aragüés, I | 1 |
| Baniandrés-Rodríguez, O | 1 |
| Vilas-Boas, PT | 1 |
| Conde-Montero, E | 1 |
| Suárez-Fernández, R | 1 |
| Rajendra, A | 1 |
| Devasia, AJ | 2 |
| Francis, NR | 1 |
| Turaka, VP | 1 |
| Meng, X | 1 |
| Çetin, B | 1 |
| Akyürek, N | 2 |
| Metin, Y | 1 |
| Karaca, F | 1 |
| Bilgetekin, İ | 1 |
| Özet, A | 2 |
| Ohzato, Y | 1 |
| Murakami, M | 1 |
| Shimizu, J | 1 |
| Koga, C | 1 |
| Marukawa, D | 1 |
| Yoshida, Y | 1 |
| Yasuyama, A | 1 |
| Matsumura, T | 1 |
| Takada, A | 1 |
| Kameda, C | 1 |
| Kawabata, R | 1 |
| Hirota, M | 1 |
| Noura, S | 1 |
| Miwa, H | 1 |
| Hasegawa, J | 1 |
| Cui, Y | 1 |
| Shi, P | 3 |
| Li, JD | 1 |
| Han, XL | 1 |
| Sun, L | 3 |
| Choi, SJ | 1 |
| Lim, J | 1 |
| Ng, AK | 3 |
| Yahalom, J | 3 |
| Pinnix, CC | 4 |
| Kelsey, CR | 4 |
| Hoppe, B | 1 |
| Oguchi, M | 1 |
| Suh, CO | 1 |
| Wirth, A | 2 |
| Qi, S | 1 |
| Moskowitz, CH | 5 |
| Mauch, PM | 2 |
| Specht, L | 1 |
| Illidge, T | 2 |
| Hishima, T | 5 |
| Ji, H | 1 |
| Niu, X | 1 |
| Yin, L | 4 |
| Huang, L | 1 |
| Xuan, Q | 1 |
| An, W | 1 |
| Mizuno, Y | 1 |
| Tsukamoto, T | 1 |
| Kawata, E | 1 |
| Uoshima, N | 2 |
| Uchiyama, H | 1 |
| Yokota, I | 1 |
| Maegawa, S | 1 |
| Takimoto, T | 1 |
| Tanba, K | 1 |
| Matsumura-Kimoto, Y | 1 |
| Kuwahara-Ota, S | 1 |
| Fujibayashi, Y | 1 |
| Yamamoto-Sugitani, M | 1 |
| Chinen, Y | 2 |
| Shimura, Y | 1 |
| Horiike, S | 2 |
| Taniwaki, M | 4 |
| Kobayashi, T | 8 |
| Beltrán, BE | 4 |
| Paredes, S | 2 |
| Cotrina, E | 2 |
| Sotomayor, EM | 3 |
| Quera, R | 1 |
| Flores, L | 1 |
| Simian, D | 1 |
| Kronberg, U | 1 |
| Vial, MT | 1 |
| de Guevara, DL | 1 |
| García-Rodríguez, MJ | 1 |
| van Vugt, M | 1 |
| van Rijn, RS | 1 |
| Vellenga, E | 1 |
| Yamada, R | 1 |
| Sakuno, T | 1 |
| Inoue, H | 1 |
| Miura, H | 1 |
| Takeuchi, T | 5 |
| Shiono, Y | 1 |
| Okuse, H | 1 |
| Nakamura, M | 2 |
| Katsurahara, M | 1 |
| Hamada, Y | 1 |
| Tanaka, K | 2 |
| Horiki, N | 1 |
| Takei, Y | 1 |
| Hanna, F | 1 |
| Prakash, A | 1 |
| Allan, E | 1 |
| Khalafallah, AA | 1 |
| Moore, AS | 1 |
| Frimberger, AE | 1 |
| Ali, K | 1 |
| Sial, AA | 1 |
| Baig, MT | 1 |
| Ansari, SH | 1 |
| Adil, SO | 1 |
| Shamsi, TS | 1 |
| Lakshmaiah, KC | 2 |
| Asati, V | 1 |
| Babu K, G | 1 |
| D, L | 1 |
| M C, SB | 1 |
| K N, L | 1 |
| L K, R | 1 |
| A H, R | 1 |
| Koppaka, D | 1 |
| Patidar, R | 1 |
| C S, P | 1 |
| Linnik, Y | 1 |
| Nicka, C | 1 |
| Loo, E | 1 |
| Hager, S | 1 |
| Füllgraf, H | 1 |
| Südkamp, NP | 1 |
| Herget, GW | 1 |
| Chin, V | 1 |
| Fulham, M | 1 |
| Hertzberg, M | 3 |
| Jackson, M | 1 |
| Lindeman, R | 1 |
| Brighton, T | 1 |
| Kidson-Gerber, G | 1 |
| Wegner, EA | 1 |
| Cheung, C | 1 |
| MacCallum, S | 1 |
| Williams, J | 1 |
| Thompson, SR | 1 |
| Yan, X | 1 |
| Zhou, M | 5 |
| Lou, Z | 1 |
| Mu, Q | 1 |
| Sheng, L | 1 |
| Zhang, P | 1 |
| Ouyang, G | 1 |
| Chou, SC | 1 |
| Yao, M | 2 |
| Tang, JL | 1 |
| Konishi, H | 1 |
| Taguchi, Y | 1 |
| Nukui, T | 1 |
| Dougu, N | 1 |
| Nakatsuji, Y | 1 |
| Beygi, S | 1 |
| Sadashiv, S | 1 |
| Reilly, JB | 1 |
| Lister, J | 1 |
| Pál, I | 1 |
| Gergely, L | 6 |
| Pál, T | 1 |
| Radnay, Z | 1 |
| Szekanecz, Z | 1 |
| Zilahi, E | 2 |
| Váróczy, L | 3 |
| Pardal, E | 3 |
| Díez Baeza, E | 1 |
| Salas, Q | 1 |
| García, T | 1 |
| Monzón, E | 1 |
| Rodríguez, MJ | 1 |
| Navarro, B | 1 |
| Hernández, JA | 1 |
| Díez, R | 1 |
| Vahi, M | 1 |
| Viguria, MC | 1 |
| Canales, M | 4 |
| González-López, TJ | 1 |
| Liu, DL | 1 |
| Zhu, YD | 1 |
| Yan, F | 2 |
| Que, X | 1 |
| Gao, Q | 1 |
| Ma, K | 1 |
| Xi, Y | 1 |
| Zhou, J | 1 |
| Gou, Z | 1 |
| Tumati, V | 1 |
| Trivedi, L | 1 |
| Patel, P | 2 |
| Scaglioni, PP | 1 |
| Vusirikala, M | 1 |
| Chen, W | 3 |
| Wachsmann, J | 1 |
| Desai, NB | 1 |
| Hiraga, J | 1 |
| Suzuki, N | 1 |
| Takagi, Y | 1 |
| Narita, M | 1 |
| Yang, JJ | 1 |
| Chen, XC | 3 |
| Shen, K | 1 |
| Xie, LP | 1 |
| Moon, K | 1 |
| Seo, J | 3 |
| Zhang, WH | 1 |
| Li, GY | 2 |
| Ma, YJ | 1 |
| Li, ZC | 1 |
| Chang, J | 1 |
| Hao, SG | 1 |
| Tao, R | 2 |
| Zou, H | 1 |
| Zou, Y | 1 |
| Lei, L | 1 |
| Song, L | 2 |
| Biccler, JL | 1 |
| Brown, PN | 4 |
| Bøgsted, M | 8 |
| Mészáros Jørgensen, J | 1 |
| Christensen, JH | 1 |
| Wahlin, BE | 1 |
| Tariq, A | 1 |
| Aziz, MT | 1 |
| Mehmood, Y | 1 |
| Asghar, SA | 1 |
| Khurshid, A | 1 |
| Lu, L | 1 |
| Shi, HZ | 1 |
| Xiao, ZJ | 1 |
| Li, CL | 1 |
| Niu, JY | 1 |
| Wu, W | 2 |
| Cao, L | 3 |
| Lu, RN | 1 |
| Gadallah, HA | 1 |
| Kamal, G | 1 |
| Maher, MM | 1 |
| Mohamad, MA | 1 |
| Yoshikawa, T | 4 |
| Sawada, M | 5 |
| Fukuno, K | 3 |
| Kasahara, S | 7 |
| Shibata, Y | 3 |
| Matsumoto, T | 5 |
| Mabuchi, R | 2 |
| Ninomiya, S | 4 |
| Kitagawa, J | 3 |
| Kanemura, N | 7 |
| Nannya, Y | 2 |
| Katsumura, N | 2 |
| Kito, Y | 4 |
| Takami, T | 9 |
| Miyazaki, T | 2 |
| Shimizu, M | 7 |
| Drott, K | 2 |
| Hagberg, H | 2 |
| Papworth, K | 1 |
| Miyata, Y | 1 |
| Saito, AM | 1 |
| Jensen, PH | 1 |
| Wehberg, S | 1 |
| Dessau-Arp, A | 1 |
| Haziri, D | 1 |
| Schurmann, L | 2 |
| Valentin, R | 1 |
| Knudsen, LM | 1 |
| Hall, KH | 1 |
| Panjic, EH | 1 |
| Valla, K | 1 |
| Ayed, AO | 1 |
| Pederson, L | 1 |
| Laplant, BR | 2 |
| Congiu, AG | 1 |
| Witzig, T | 1 |
| Sun, N | 2 |
| Sun, YQ | 1 |
| Ruan, YJ | 1 |
| Huang, YY | 1 |
| Zhou, XH | 2 |
| Guo, WJ | 1 |
| He, MQ | 1 |
| Yao, RX | 1 |
| Lin, XJ | 1 |
| Jbeli, AH | 1 |
| Sunassee, A | 1 |
| Sanford, A | 1 |
| Elshami, A | 1 |
| Bleeker, J | 1 |
| Swan, CD | 1 |
| Gottlieb, T | 1 |
| Lin, Z | 1 |
| Chen, X | 2 |
| Fang, Z | 1 |
| Cao, YW | 1 |
| Chen, S | 2 |
| Castrillo, A | 1 |
| Cerdan, D | 1 |
| Eguizabal, J | 1 |
| Mendoza-Rodriguez, A | 1 |
| Rodriguez, MF | 1 |
| Zamora, T | 1 |
| Sonlleva, A | 1 |
| Duarte, J | 1 |
| Wei, Z | 3 |
| Gao, R | 1 |
| Matsuda, M | 2 |
| Adachi, T | 1 |
| Sueda, S | 1 |
| Ohashi, Y | 1 |
| Awaji, S | 1 |
| Hashimoto, S | 2 |
| Park, SW | 1 |
| Hwang, HS | 6 |
| Valachis, A | 1 |
| Sabaa, AA | 1 |
| Molin, D | 1 |
| Shono, K | 1 |
| Onoda, M | 2 |
| Yokota, A | 2 |
| Abid, MB | 1 |
| Loi, HY | 1 |
| Poon, LM | 1 |
| Owattanapanich, W | 1 |
| Sirinvaravong, S | 1 |
| Suphadirekkul, K | 1 |
| Wannachalee, T | 1 |
| Conconi, A | 5 |
| Margiotta-Casaluci, G | 1 |
| Darling, K | 1 |
| Hasse, B | 1 |
| Battegay, M | 1 |
| Staehelin, C | 1 |
| Schmid, P | 1 |
| Scherrer, A | 1 |
| Bernasconi, E | 1 |
| Kamal, WSA | 1 |
| Affandi, AM | 1 |
| Bhullar, A | 1 |
| Kamal, WSZ | 1 |
| Fraz, MA | 1 |
| Usman, M | 1 |
| Malik, SU | 1 |
| Ijaz, A | 1 |
| Durer, C | 1 |
| Durer, S | 1 |
| Tariq, MJ | 1 |
| Khan, AY | 1 |
| Qureshi, A | 1 |
| Faridi, W | 1 |
| Nasar, A | 1 |
| Anwer, F | 1 |
| Umino, K | 1 |
| Fujiwara, SI | 1 |
| Minakata, D | 1 |
| Yamamoto, C | 1 |
| Meguro, A | 1 |
| Matsuyama, T | 1 |
| Ohmine, K | 1 |
| Izumi, T | 1 |
| Muroi, K | 1 |
| Kanda, Y | 2 |
| Gutsch, J | 1 |
| Werthmann, PG | 1 |
| Kienle, GS | 1 |
| Feng, Y | 2 |
| Zeng, S | 2 |
| Bernard, S | 1 |
| Rutherford, SC | 1 |
| Forero-Torres, A | 1 |
| Inhorn, L | 1 |
| Kelly, K | 1 |
| Bessudo, A | 1 |
| Fayad, LE | 7 |
| Mundt, KE | 1 |
| Sandmann, T | 1 |
| Vignal, C | 1 |
| Mobasher, M | 1 |
| Ye, S | 3 |
| Zhan, H | 1 |
| Xie, D | 1 |
| Peng, J | 2 |
| Pu, X | 1 |
| Guo, C | 1 |
| Lin, S | 2 |
| Peroja, P | 2 |
| Mantere, T | 1 |
| Peltonen, J | 1 |
| Böhm, J | 1 |
| Rapakko, K | 1 |
| Soini, Y | 2 |
| Vasala, K | 1 |
| Yunce, M | 1 |
| Muganlinskaya, N | 1 |
| Selinger, S | 1 |
| Ma, X | 3 |
| Pan, Z | 1 |
| Song, JL | 1 |
| Wei, XL | 1 |
| Zhang, YK | 1 |
| Hao, XX | 1 |
| Huang, WM | 1 |
| Wei, YQ | 1 |
| Avilés, A | 17 |
| Nambo, MJ | 12 |
| Neri, N | 13 |
| Yokoo, M | 1 |
| Sano, H | 1 |
| Kai, K | 1 |
| Arakawa, F | 2 |
| Matsunaga, T | 3 |
| Hansen, SM | 1 |
| Lund, PE | 1 |
| Soegaard, P | 1 |
| Haaber, J | 1 |
| Jørgensen, J | 2 |
| Starklint, J | 1 |
| Josefsson, P | 1 |
| Cho, MC | 1 |
| Chung, Y | 1 |
| Chi, HS | 2 |
| Shim, H | 3 |
| Castellino, A | 3 |
| Pederson, LD | 2 |
| Reeder, CB | 3 |
| Congiu, A | 2 |
| Foran, JM | 3 |
| Pavone, V | 4 |
| Rivera, CE | 3 |
| Matsuo, T | 1 |
| Drew, L | 1 |
| DeWeerdt, S | 1 |
| Tomoka, T | 1 |
| Nyirenda, R | 1 |
| Dhungel, BM | 1 |
| Mulenga, M | 1 |
| Chikasema, M | 1 |
| Tewete, B | 1 |
| Mtangwanika, A | 1 |
| Chiyoyola, S | 1 |
| Chimzimu, F | 1 |
| Kampani, C | 1 |
| Krysiak, R | 1 |
| Shea, TC | 1 |
| Montgomery, ND | 1 |
| Fedoriw, Y | 1 |
| Zanelli, M | 1 |
| Zizzo, M | 1 |
| Mengoli, MC | 1 |
| Valli, R | 1 |
| Martino, G | 1 |
| Fenocchio, D | 1 |
| De Marco, L | 1 |
| Ascani, S | 3 |
| Ju, Y | 1 |
| Qu, T | 1 |
| Moccia, AA | 1 |
| Fanale, MA | 2 |
| Caimi, PF | 2 |
| Parekh, S | 1 |
| Hayslip, JW | 1 |
| Nagpal, S | 1 |
| Lechowicz, MJ | 1 |
| Gaur, R | 1 |
| Lucas, A | 1 |
| Kahl, B | 2 |
| Pannu, AK | 1 |
| Jandial, A | 1 |
| Kopp, CR | 1 |
| Kumari, S | 1 |
| Bentley, MA | 1 |
| Care, MA | 1 |
| Cummin, T | 1 |
| Kennedy, H | 1 |
| Thompson, JS | 1 |
| Uddin, R | 1 |
| Worrillow, L | 1 |
| Chalkley, R | 1 |
| Ahmed, S | 2 |
| Maishman, T | 1 |
| Ennishi, D | 8 |
| Jiang, A | 1 |
| Boyle, M | 4 |
| Collinge, B | 1 |
| Grande, BM | 1 |
| Ben-Neriah, S | 6 |
| Rushton, C | 1 |
| Thomas, N | 1 |
| Miyata-Takata, T | 1 |
| Craig, J | 1 |
| Mottok, A | 5 |
| Meissner, B | 3 |
| Saberi, S | 1 |
| Bashashati, A | 5 |
| Kridel, R | 5 |
| Mungall, AJ | 2 |
| Marra, MA | 3 |
| Shah, SP | 2 |
| Morin, RD | 3 |
| Impellizeri, JA | 1 |
| Gavazza, A | 1 |
| Greissworth, E | 1 |
| Crispo, A | 1 |
| Montella, M | 1 |
| Ciliberto, G | 1 |
| Lubas, G | 1 |
| Aurisicchio, L | 1 |
| Delage, L | 1 |
| Manzoni, D | 1 |
| Quinquenet, C | 1 |
| Fontaine, J | 1 |
| Maarek, A | 1 |
| Chabane, K | 1 |
| Mosnier, I | 1 |
| Hayette, S | 1 |
| Callet-Bauchu, E | 2 |
| Grange, B | 1 |
| Plesa, A | 1 |
| Sujobert, P | 1 |
| Frigeni, M | 1 |
| Alric, L | 1 |
| Mannelli, L | 1 |
| Pirisi, M | 1 |
| Loustaud-Ratti, V | 1 |
| Sica, A | 1 |
| Goldaniga, M | 1 |
| Gentile, M | 1 |
| Benanti, F | 1 |
| Rumi, MG | 1 |
| Ferretti, VV | 1 |
| Grossi, P | 1 |
| Gotti, M | 1 |
| Sciarra, R | 1 |
| Cano, I | 1 |
| Zuccaro, V | 1 |
| Passamonti, F | 2 |
| Magnoli, F | 1 |
| Bernasconi, B | 1 |
| Vivian, L | 1 |
| Proserpio, I | 3 |
| Pinotti, G | 3 |
| Campiotti, L | 3 |
| Mazzucchelli, L | 1 |
| Sessa, F | 1 |
| Tibiletti, MG | 2 |
| Uccella, S | 4 |
| Killock, D | 1 |
| Prusila, REI | 1 |
| Passi, A | 1 |
| Pellegrinelli, A | 1 |
| Pruneri, G | 3 |
| Testi, A | 1 |
| Di Chio, MC | 1 |
| Matteucci, P | 1 |
| Ma, Y | 5 |
| Yu, K | 2 |
| Tojaga, S | 1 |
| Zhao, R | 3 |
| Shu, X | 2 |
| Cheng, L | 2 |
| Heffes, V | 1 |
| Darawshy, F | 1 |
| Mashiach, T | 1 |
| Shaulov, A | 1 |
| Cheung, CY | 1 |
| Chak, WL | 1 |
| Gabeeva, NG | 1 |
| Zvonkov, EE | 3 |
| Koroleva, DA | 1 |
| Chukavina, MM | 1 |
| Obukhova, TN | 3 |
| Kovrigina, AM | 1 |
| Godfrey, JK | 1 |
| Nabhan, C | 7 |
| Karrison, T | 1 |
| Kline, JP | 1 |
| Cohen, KS | 1 |
| Bishop, MR | 1 |
| Stadler, WM | 1 |
| Rapoport, AP | 1 |
| Çağlayan, Ç | 1 |
| Goldstein, JS | 1 |
| Rai, A | 2 |
| Wiersma, VR | 1 |
| de Jong, M | 1 |
| Jan Lourens, H | 1 |
| Fehrmann, R | 1 |
| de Bruyn, M | 1 |
| Islam, P | 1 |
| Goldstein, J | 1 |
| Kadota, T | 1 |
| Seo, S | 5 |
| Fuse, H | 1 |
| Ishii, G | 1 |
| Itoh, K | 5 |
| Kaneko, K | 1 |
| Mohamed, G | 1 |
| Talima, S | 1 |
| Rudzki, Z | 2 |
| Allam, RM | 1 |
| Simmons, W | 1 |
| Tao, Q | 1 |
| Murray, PG | 1 |
| Szmit, S | 1 |
| Ogórka, T | 1 |
| Skotnicki, AB | 4 |
| Jaime-Pérez, JC | 1 |
| Padilla-Medina, JR | 1 |
| Salazar-Cavazos, L | 1 |
| Fernández, LT | 1 |
| Gómez-Almaguer, D | 1 |
| DE Palma, D | 2 |
| Guasti, L | 1 |
| Casagrande, S | 1 |
| Schiorlin, I | 1 |
| Bolzacchini, E | 1 |
| Suter, M | 1 |
| Ogliari, F | 1 |
| Squizzato, A | 2 |
| Hildyard, C | 3 |
| Eyre, DW | 3 |
| Plaschkes, H | 3 |
| Griffith, J | 3 |
| Wolf, J | 3 |
| Gunawan, A | 3 |
| Oliver, R | 3 |
| Booth, S | 3 |
| Bishton, MJ | 2 |
| Hatton, CSR | 3 |
| Bonou, M | 1 |
| Kapelios, CJ | 1 |
| Marinakos, A | 1 |
| Adamopoulos, S | 1 |
| Diamantopoulos, P | 2 |
| Foukas, PG | 1 |
| Kaklamanis, L | 1 |
| Barbetseas, J | 1 |
| Viniou, NA | 1 |
| Casan, JM | 1 |
| Shortt, J | 1 |
| Chiche, J | 1 |
| Reverso-Meinietti, J | 1 |
| Mouchotte, A | 1 |
| Rubio-Patiño, C | 1 |
| Mhaidly, R | 1 |
| Villa, E | 3 |
| Bossowski, JP | 1 |
| Proics, E | 1 |
| Grima-Reyes, M | 1 |
| Paquet, A | 1 |
| Fragaki, K | 1 |
| Marchetti, S | 1 |
| Ambrosetti, D | 1 |
| Michiels, JF | 1 |
| Lehmann-Che, J | 1 |
| Peyrottes, I | 1 |
| Peyrade, F | 5 |
| de Kerviler, E | 1 |
| Taillan, B | 1 |
| Garnier, G | 1 |
| Verhoeyen, E | 1 |
| Paquis-Flucklinger, V | 1 |
| Shintu, L | 1 |
| Delpech-Debiais, C | 1 |
| Brisou, G | 1 |
| Nadel, B | 1 |
| Barbry, P | 1 |
| Ricci, JE | 1 |
| Vähämurto, P | 1 |
| Mannisto, S | 1 |
| Pollari, M | 1 |
| Karjalainen-Lindsberg, ML | 3 |
| Mäkitie, AA | 1 |
| Leppä, S | 11 |
| Purdum, A | 1 |
| Tieu, R | 1 |
| Reddy, SR | 1 |
| Broder, MS | 1 |
| Broadwater, G | 2 |
| James, O | 1 |
| Chino, J | 1 |
| Diehl, L | 1 |
| Beaven, AW | 3 |
| Chang, C | 1 |
| Koontz, BF | 1 |
| Prosnitz, LR | 4 |
| Voropaeva, EN | 2 |
| Pospelova, TI | 2 |
| Voevoda, MI | 2 |
| Maksimov, VN | 2 |
| Orlov, YL | 1 |
| Seregina, OB | 1 |
| Samoilova, O | 2 |
| Turgut, M | 1 |
| Yeh, SP | 2 |
| Lopez-Hernandez, A | 2 |
| Chiattone, CS | 1 |
| Liu, G | 2 |
| Zhuang, SH | 1 |
| Kim, NY | 1 |
| Park, HS | 1 |
| Gourd, E | 1 |
| Suter, MB | 1 |
| Mian, M | 8 |
| Jung, SH | 5 |
| Pitcher, BN | 1 |
| Wagner-Johnston, ND | 2 |
| Reddy, NM | 2 |
| Mathew, S | 1 |
| Coutinho, R | 3 |
| Lobato, J | 1 |
| Esteves, S | 1 |
| Due, H | 1 |
| Schönherz, AA | 1 |
| Ryø, L | 1 |
| Primo, MN | 1 |
| Jespersen, DS | 1 |
| Roug, AS | 1 |
| Xiao, M | 1 |
| Tan, X | 1 |
| Pang, Y | 1 |
| Dybkær, K | 10 |
| Bishton, M | 2 |
| McGuirt, J | 1 |
| Van Keerberghen, CA | 1 |
| Goffin, K | 1 |
| Vergote, V | 1 |
| Tousseyn, T | 2 |
| Verhoef, G | 5 |
| Laenen, A | 1 |
| Vandenberghe, P | 1 |
| Gheysens, O | 1 |
| Costa, S | 1 |
| Peacock, SJ | 1 |
| Regier, DA | 1 |
| Hu, K | 2 |
| Gao, JJ | 1 |
| Li, QH | 1 |
| Tian, L | 2 |
| Wan, W | 2 |
| Wang, JJ | 1 |
| Fu, L | 3 |
| Ide, S | 1 |
| Ohara, S | 1 |
| Hua, J | 1 |
| Hagihara, M | 4 |
| Erter, J | 1 |
| Daniel, DB | 1 |
| Mace, JR | 1 |
| Berdeja, JG | 1 |
| Aránguiz, N | 1 |
| Vega, J | 1 |
| Jackson, A | 1 |
| Boucher, R | 1 |
| Yates, F | 1 |
| Fox, S | 1 |
| Rawstron, A | 1 |
| Hillmen, P | 1 |
| Zou, L | 1 |
| Song, G | 6 |
| Gu, S | 1 |
| Kong, L | 2 |
| Cho, WC | 4 |
| Yamashita, A | 1 |
| Tokuda, M | 2 |
| Matsuo, M | 1 |
| Irie, J | 1 |
| Tateishi, Y | 1 |
| Mutsukura, K | 1 |
| Shaw, J | 1 |
| Harvey, C | 1 |
| Richards, C | 1 |
| Kim, C | 1 |
| Alkodsi, A | 1 |
| Cervera, A | 1 |
| Zhang, K | 1 |
| Louhimo, R | 1 |
| Meriranta, L | 1 |
| Pasanen, A | 1 |
| Leivonen, SK | 1 |
| Lehtonen, R | 1 |
| Hautaniemi, S | 2 |
| Pothen, L | 1 |
| Aydin, S | 1 |
| Camboni, A | 1 |
| Hainaut, P | 1 |
| Arslan, B | 1 |
| Gündüz, HM | 1 |
| Ünlü, N | 1 |
| Çavuş, G | 1 |
| Menemenlioğlu, D | 1 |
| Mercer, C | 1 |
| Nyilas, R | 1 |
| Farkas, B | 1 |
| Bicsko, RR | 1 |
| Magyari, F | 2 |
| Pinczes, LI | 1 |
| Khan, Y | 1 |
| Falgàs, A | 1 |
| Pallarès, V | 1 |
| Unzueta, U | 1 |
| Céspedes, MV | 1 |
| Arroyo-Solera, I | 1 |
| Moreno, MJ | 1 |
| Sierra, J | 3 |
| Gallardo, A | 1 |
| Mangues, MA | 1 |
| Vázquez, E | 1 |
| Villaverde, A | 1 |
| Mangues, R | 1 |
| Casanova, I | 1 |
| Cho, WK | 1 |
| Koh, LP | 1 |
| Jeyasekharan, A | 1 |
| Tao, M | 6 |
| Quek, R | 6 |
| Farid Bin Harunal Ras, M | 1 |
| Diong, C | 1 |
| Tan, D | 1 |
| Poon, LMM | 1 |
| González, DE | 1 |
| Bär, DO | 1 |
| Beniwal, SK | 1 |
| Dasappa, L | 1 |
| Flores, DH | 1 |
| Querol, J | 1 |
| Guan, TS | 1 |
| Lipatov, ON | 1 |
| Volodicheva, EM | 1 |
| Safaee Nodehi, SR | 1 |
| Paravisini, A | 1 |
| Perez Diaz, L | 1 |
| Berenschot, HW | 1 |
| Herbers, AHE | 1 |
| Chiţu, D | 1 |
| Lacotte-Thierry, L | 1 |
| Princet, I | 1 |
| Olivier, G | 1 |
| Fleck, E | 1 |
| Corby, A | 1 |
| Motard, C | 1 |
| Barrier, J | 1 |
| Chabin, M | 1 |
| Guilhot, J | 1 |
| Knauf, W | 1 |
| Abenhardt, W | 1 |
| Mohm, J | 1 |
| Rauh, J | 1 |
| Harde, J | 1 |
| Kaiser-Osterhues, A | 1 |
| Jänicke, M | 1 |
| Marschner, N | 1 |
| Moale, A | 1 |
| Zimmerman, J | 1 |
| Jiang, SY | 1 |
| Zhou, SY | 5 |
| Zhou, LQ | 4 |
| Yang, JL | 4 |
| Wen, TY | 1 |
| Soubeyran, PL | 1 |
| Wuchter, P | 1 |
| Egerer, G | 1 |
| Kriegsmann, M | 1 |
| Mataityte, A | 1 |
| Koelsche, C | 1 |
| Kriegsmann, K | 1 |
| Suga, T | 1 |
| Hirayama, A | 1 |
| Daikuhara, S | 1 |
| Uehara, T | 2 |
| Tanaka, E | 1 |
| Chan, A | 2 |
| Shimizu-Koresawa, R | 1 |
| Chihara, D | 3 |
| Mizuta, S | 2 |
| Ikegame, K | 1 |
| Uchida, N | 1 |
| Ichinohe, T | 2 |
| Zhao, P | 1 |
| Wang, PJ | 1 |
| Wang, YY | 1 |
| Shi, CL | 1 |
| Xia, B | 2 |
| Guo, S | 3 |
| Zhan, Z | 1 |
| Leiba, R | 1 |
| Faibish, T | 2 |
| Rowe, JM | 4 |
| Takasaki, H | 8 |
| Fujisawa, S | 6 |
| Ogusa, E | 2 |
| Matsuura, S | 2 |
| Kishimoto, K | 4 |
| Fujita, A | 2 |
| Kuwabara, H | 3 |
| Takemura, S | 3 |
| Koharazawa, H | 5 |
| Yamazaki, E | 5 |
| Fujimaki, K | 6 |
| Taguchi, J | 6 |
| Ishigatsubo, Y | 10 |
| Shi, Z | 3 |
| Esiashvili, N | 4 |
| Das, S | 2 |
| Khan, MK | 4 |
| Hu, S | 5 |
| Green, T | 1 |
| Wu, L | 7 |
| Balasubramanyam, A | 2 |
| Liu, WM | 5 |
| Orazi, A | 18 |
| Choi, WW | 17 |
| Huang, Q | 9 |
| Ai, W | 8 |
| Ferreri, AJ | 28 |
| Zhou, F | 3 |
| Tu, M | 5 |
| Variakojis, D | 4 |
| Go, RS | 12 |
| Aoki, K | 3 |
| Tabata, S | 3 |
| Matsushita, A | 3 |
| Nagai, K | 1 |
| Gill, D | 3 |
| Vari, F | 2 |
| Cross, D | 1 |
| Griffiths, L | 1 |
| Gandhi, M | 2 |
| Bret, C | 1 |
| Klein, B | 1 |
| Moreaux, J | 1 |
| Suzuki, K | 6 |
| Sakajiri, S | 3 |
| Mato, A | 2 |
| Feldman, T | 3 |
| Zielonka, T | 1 |
| Singavi, A | 1 |
| Gadaletta, G | 1 |
| Waksmundzki, K | 1 |
| Bhattacharyya, P | 1 |
| Chow, KF | 1 |
| Panush, D | 1 |
| Agress, H | 1 |
| Rosario, M | 1 |
| Howlett, C | 1 |
| Pecora, A | 1 |
| Zeng, L | 1 |
| Gordon, MW | 1 |
| Zou, D | 2 |
| Wang, M | 3 |
| Ramos, KS | 1 |
| Latta, S | 1 |
| Cygan, PH | 1 |
| Fried, W | 1 |
| Tarabar, O | 1 |
| Cikota-Aleksić, B | 1 |
| Tukić, L | 1 |
| Milanović, N | 1 |
| Aleksić, A | 1 |
| Magić, Z | 1 |
| Okwan-Duodu, D | 2 |
| Jiang, K | 1 |
| Sun, XF | 3 |
| Zhen, ZJ | 3 |
| Lu, SY | 1 |
| Sun, FF | 1 |
| Li, PF | 1 |
| Cai, RQ | 1 |
| Chan, WC | 16 |
| Maruoka, H | 1 |
| Nasu, K | 1 |
| Imai, Y | 3 |
| Czuczman, MS | 4 |
| Maeda, LS | 1 |
| Advani, R | 6 |
| Chen, CC | 2 |
| Hessler, J | 1 |
| Varma, G | 1 |
| Bologna, S | 7 |
| Hacini, M | 1 |
| Ysebaert, L | 3 |
| Fermé, C | 10 |
| Thyss, A | 3 |
| Markovic, O | 6 |
| Marisavljevic, D | 4 |
| Cemerikic-Martinovic, V | 2 |
| Filipovic, B | 3 |
| Radovanović, S | 1 |
| Zdravković, M | 1 |
| Stanisavljevic, D | 2 |
| Mihaljevic, B | 5 |
| Baldolli, A | 1 |
| Chuffart, M | 1 |
| Geffray, L | 1 |
| Verneuil, L | 1 |
| Reman, O | 1 |
| George, A | 2 |
| Tam, CS | 3 |
| Seymour, JF | 7 |
| Conrad, AL | 2 |
| Gundrum, JD | 1 |
| McHugh, VL | 1 |
| Berrang, T | 1 |
| Holloway, C | 1 |
| Hart, J | 1 |
| Yee, A | 1 |
| Berry, B | 4 |
| Kotb, R | 1 |
| Oh, JI | 1 |
| Park, SH | 3 |
| Xie, WZ | 1 |
| Hu, KY | 1 |
| Huang, WJ | 1 |
| Wei, GQ | 1 |
| He, JS | 1 |
| Shi, JM | 1 |
| Zhu, JJ | 1 |
| Lin, MF | 1 |
| Ye, XJ | 1 |
| Cai, Z | 1 |
| Wong, AY | 1 |
| Marcotte, S | 1 |
| Laroche, M | 1 |
| Sheehan, NL | 1 |
| Kukreti, V | 1 |
| Routy, JP | 1 |
| Lemieux, B | 1 |
| Seki, JT | 1 |
| Rouleau, D | 1 |
| Tseng, A | 1 |
| Kolhari, VB | 1 |
| Nagesh, CM | 1 |
| Singh, Y | 1 |
| Manjunath, CN | 1 |
| Goto, N | 9 |
| Takemura, M | 5 |
| Yasuda, I | 5 |
| Seishima, M | 6 |
| Moriwaki, H | 8 |
| Mizutani, M | 2 |
| Nakamori, Y | 2 |
| Kageyama, Y | 2 |
| Oya, E | 1 |
| Ino, K | 1 |
| Sekine, T | 2 |
| Maffioli, M | 1 |
| Ferrario, A | 1 |
| Damotte, D | 1 |
| Courby, S | 1 |
| Sénécal, D | 1 |
| Quittet, P | 1 |
| Schmidt-Tanguy, A | 1 |
| Fontan, J | 1 |
| Alexis, M | 1 |
| Dreyfus, F | 1 |
| Solal-Céligny, P | 2 |
| Arakelyan, N | 1 |
| Boone, JM | 1 |
| Zhang, D | 1 |
| Fan, F | 1 |
| Li, WS | 1 |
| Xie, JL | 1 |
| Zhou, XG | 2 |
| Lu, HJ | 2 |
| Huang, YC | 3 |
| Liu, CY | 4 |
| Hung, MH | 3 |
| Hu, MH | 1 |
| Wu, CY | 1 |
| Hong, YC | 4 |
| Hsiao, LT | 5 |
| Hsu, HC | 2 |
| Chiou, TJ | 6 |
| Tzeng, CH | 5 |
| Yu, YB | 4 |
| Aviv, A | 1 |
| Zhang, HW | 1 |
| Chen, ZW | 1 |
| He, JX | 1 |
| Zheng, YP | 1 |
| Han, WE | 1 |
| Zhao, ZQ | 1 |
| Bai, W | 2 |
| Wang, JF | 2 |
| Lim, Y | 1 |
| Go, H | 2 |
| Wendtner, CM | 1 |
| Ozsan, N | 2 |
| Cagirgan, S | 1 |
| Saydam, G | 1 |
| Gunes, A | 1 |
| Hekimgil, M | 1 |
| Veeger, NJ | 2 |
| Hovenga, S | 1 |
| Woolthuis, G | 1 |
| de Graaf, E | 1 |
| van Roon, E | 1 |
| Xu, X | 2 |
| Koh, YW | 2 |
| Jung, SJ | 1 |
| Park, C | 2 |
| Foppoli, M | 3 |
| Citterio, G | 2 |
| Donadoni, G | 2 |
| Govi, S | 2 |
| Fujita, H | 4 |
| Ishii, Y | 4 |
| Motomura, S | 8 |
| Kos, Z | 1 |
| Burns, BF | 1 |
| Gomes, MM | 1 |
| Sekhon, HS | 1 |
| Frei, E | 2 |
| Liu, HT | 3 |
| Chen, PM | 4 |
| Kraut-Tauzia, J | 1 |
| Modzelewski, R | 1 |
| Clatot, F | 2 |
| Mareschal, S | 4 |
| Stamatoullas, A | 2 |
| Wu, B | 1 |
| Zou, S | 4 |
| de Witt, P | 1 |
| Maartens, DJ | 1 |
| Uldrick, TS | 1 |
| Sissolak, G | 2 |
| Baldi, I | 3 |
| Orsucci, L | 4 |
| Salvi, F | 7 |
| Liberati, AM | 6 |
| Bottelli, C | 5 |
| Rossini, B | 1 |
| Perticone, S | 1 |
| De Masi, P | 1 |
| Palumbo, A | 1 |
| Zhao, SX | 1 |
| Zhu, Q | 2 |
| Sun, AN | 1 |
| Jin, ZM | 2 |
| Qiu, HY | 1 |
| Tang, XW | 1 |
| Fu, ZZ | 1 |
| He, GS | 1 |
| Miao, M | 1 |
| Wu, DP | 2 |
| Varga, C | 1 |
| Holcroft, C | 2 |
| Kezouh, A | 2 |
| Bucatel, S | 1 |
| Johnson, N | 4 |
| Petrogiannis-Haliotis, T | 2 |
| Assouline, S | 2 |
| Xu, HN | 1 |
| Mir, TA | 1 |
| Lee, SC | 3 |
| Feng, M | 1 |
| Farhad, N | 1 |
| Choe, R | 1 |
| Glickson, JD | 3 |
| Li, LZ | 1 |
| Yonetani, N | 1 |
| Cortés, M | 1 |
| Vidal, MJ | 3 |
| Oriol, A | 4 |
| Bargay, J | 4 |
| Bello, JL | 3 |
| Sánchez, JJ | 1 |
| Tomás, JF | 2 |
| Donato, E | 1 |
| Ferrer, S | 2 |
| Gascoyne, DM | 3 |
| Brown, PJ | 2 |
| Soilleux, EJ | 3 |
| Snell, C | 1 |
| Lyne, L | 3 |
| Pulford, K | 2 |
| Murphy, D | 1 |
| Sellami-Dhouib, R | 1 |
| Nasfi, A | 1 |
| Mejri, NT | 1 |
| Doghri, R | 1 |
| Charfi, L | 1 |
| Sassi, S | 1 |
| Abbes, I | 1 |
| Mrad, K | 1 |
| Ben Hamida, N | 1 |
| Driss, MP | 1 |
| Ben Romdhane, K | 1 |
| Campbell, BA | 1 |
| Afshan, A | 1 |
| Sadaf, N | 1 |
| Tanaka, S | 2 |
| Nagata, N | 2 |
| Mine, S | 1 |
| Igari, T | 1 |
| Sugihara, J | 1 |
| Honda, H | 1 |
| Teruya, K | 2 |
| Kikuchi, Y | 2 |
| Uemura, N | 2 |
| Krawczyk, K | 1 |
| Zauska-Giza, A | 1 |
| Dzietczenia, J | 2 |
| Duman, AE | 1 |
| Oğütmen Koç, D | 1 |
| Korkmaz, U | 1 |
| Tohumcu, A | 1 |
| Celebi, A | 1 |
| Sentürk, O | 1 |
| Hülagü, S | 1 |
| Erçin, C | 1 |
| Boschini, C | 2 |
| Delaini, F | 2 |
| Oldani, E | 1 |
| Rossi, A | 6 |
| Barbui, AM | 2 |
| Caracciolo, D | 1 |
| Gueli, A | 1 |
| De Crescenzo, A | 1 |
| Passera, R | 2 |
| Gianni, AM | 2 |
| Tarella, C | 3 |
| Wood, L | 1 |
| Smith, L | 2 |
| Chan, JW | 1 |
| Armitage, J | 1 |
| Jacobs, P | 2 |
| Herbrecht, R | 4 |
| Cernohous, P | 1 |
| Engert, A | 3 |
| Macdonald, D | 1 |
| Machida, C | 1 |
| Myint, H | 1 |
| Saleh, A | 1 |
| Singer, J | 1 |
| Wilhelm, M | 1 |
| van der Jagt, R | 1 |
| Hu, W | 1 |
| Kristensen, L | 1 |
| Wang, SA | 2 |
| Huang, S | 1 |
| Zheng, ZX | 1 |
| Xu, Q | 1 |
| Yuan, XH | 1 |
| Hsu, C | 2 |
| Tsou, HH | 1 |
| Lin, SJ | 1 |
| Wang, MC | 1 |
| Hwang, WL | 1 |
| Kao, WY | 1 |
| Chiu, CF | 1 |
| Lin, SF | 2 |
| Chang, CS | 1 |
| Liu, TW | 1 |
| Chen, PJ | 1 |
| Cheng, AL | 2 |
| Matikas, A | 1 |
| Briasoulis, A | 1 |
| Tzannou, I | 1 |
| Oikonomopoulou, D | 1 |
| Bakiri, M | 1 |
| Harhalakis, N | 1 |
| Yoon, HH | 1 |
| Ahn, HK | 5 |
| Sym, SJ | 3 |
| Park, PW | 3 |
| Ahn, JY | 4 |
| Cho, EK | 3 |
| Shin, DB | 3 |
| Hatsuse, M | 2 |
| Shimazaki, C | 1 |
| Yumiba, T | 1 |
| Jung, CW | 1 |
| Wong, GB | 1 |
| Spadafora, S | 1 |
| Barbon, N | 1 |
| Caputo, M | 1 |
| Ramkumar, B | 1 |
| Hutchison, R | 1 |
| Khadim, H | 1 |
| Gajra, A | 1 |
| Lowry, L | 2 |
| Kristensen, LS | 2 |
| Treppendahl, MB | 1 |
| Asmar, F | 1 |
| Girkov, MS | 1 |
| Nielsen, HM | 1 |
| Kjeldsen, TE | 1 |
| Ralfkiaer, E | 1 |
| Hansen, LL | 1 |
| Grønbæk, K | 3 |
| Goto, D | 1 |
| Otani, T | 1 |
| Tomioka, A | 1 |
| Maruyama, Y | 1 |
| Chuang, H | 1 |
| Fowler, N | 6 |
| Neelapu, S | 2 |
| McLaughlin, P | 6 |
| Romaguera, JE | 4 |
| Fanale, M | 2 |
| Orlowski, RZ | 1 |
| Ouzounian, ST | 1 |
| Samaniego, F | 3 |
| Culpin, RE | 1 |
| Sieniawski, M | 1 |
| Angus, B | 1 |
| Menon, GK | 1 |
| Proctor, SJ | 1 |
| Milne, P | 1 |
| McCabe, K | 1 |
| Mainou-Fowler, T | 1 |
| Iványi, JL | 1 |
| Marton, E | 1 |
| Plander, M | 1 |
| Engert, ZV | 1 |
| Tóth, C | 1 |
| Lee, JA | 1 |
| Jeong, WK | 1 |
| Min, JH | 1 |
| Li, YL | 1 |
| Pan, YY | 1 |
| Jiao, Y | 1 |
| Ning, J | 1 |
| Fan, YG | 1 |
| Zhai, ZM | 1 |
| Bo, J | 1 |
| Shi, YN | 1 |
| Stewart, DA | 2 |
| Kloiber, R | 1 |
| Owen, C | 1 |
| Bahlis, NJ | 1 |
| Duggan, P | 1 |
| Mansoor, A | 3 |
| Bence-Bruckler, I | 1 |
| Barnes, JA | 2 |
| Kim, YS | 3 |
| Ji, JH | 2 |
| Lunning, MA | 3 |
| Kutty, S | 1 |
| Rome, ET | 1 |
| Padiyath, A | 1 |
| Loberiza, F | 1 |
| Bociek, RG | 5 |
| Bierman, PJ | 6 |
| Armitage, JO | 15 |
| Porter, TR | 1 |
| Viveka, BK | 1 |
| Anil Kumar, N | 1 |
| Saini, ML | 1 |
| Sinha, S | 1 |
| Saini, KS | 1 |
| Huang, X | 2 |
| Iqbal, J | 5 |
| Ding, BB | 1 |
| Perry, AM | 3 |
| Cao, W | 1 |
| Smith, LM | 7 |
| Bi, C | 1 |
| Greiner, TC | 12 |
| Weisenburger, DD | 11 |
| Rimsza, L | 3 |
| Delabie, J | 9 |
| Cook, JR | 5 |
| Tubbs, RR | 3 |
| McKeithan, TW | 1 |
| Ye, BH | 2 |
| Fu, K | 10 |
| Zheng, W | 5 |
| Lin, N | 2 |
| Yimamu, M | 1 |
| Mao, M | 1 |
| Aisimitula, A | 1 |
| Nie, Y | 1 |
| Itabashi, M | 1 |
| Ishibashi, D | 2 |
| Yamamoto, E | 1 |
| Koyama, S | 2 |
| Nakajima, Y | 2 |
| Hattori, Y | 2 |
| Motohashi, K | 2 |
| Napoli, C | 1 |
| Brugia, M | 1 |
| Benelli, G | 1 |
| Doria, M | 2 |
| Finolezzi, E | 4 |
| Del Fava, E | 1 |
| Di Lollo, S | 2 |
| Bosi, A | 4 |
| Gu, MJ | 1 |
| Ha, JO | 1 |
| Weiss, L | 1 |
| Habringer, S | 1 |
| Boekstegers, A | 1 |
| Hufnagl, C | 1 |
| Neureiter, D | 1 |
| Hopfinger, G | 1 |
| Shin, DH | 6 |
| Kim, KB | 1 |
| Shin, N | 1 |
| Park, WY | 3 |
| Choi, KU | 1 |
| Kim, JY | 1 |
| Lee, CH | 1 |
| Sol, MY | 1 |
| Xu, FP | 2 |
| Yan, LX | 2 |
| Zhuang, HG | 4 |
| Bi, CF | 4 |
| Zhang, WY | 3 |
| Yang, QP | 1 |
| Liu, WP | 5 |
| Huang, WT | 1 |
| Lü, N | 2 |
| Mulay, K | 1 |
| Kaustubh, M | 1 |
| Nair, AG | 1 |
| Aggarwal, E | 1 |
| White, VA | 1 |
| Honavar, SG | 1 |
| Zhao, Q | 1 |
| Liu, HP | 1 |
| Gu, YJ | 1 |
| Cong, WM | 1 |
| Hashimoto, A | 1 |
| Fujimi, A | 1 |
| Kanisawa, Y | 1 |
| Matsuno, T | 2 |
| Okuda, T | 1 |
| Minami, S | 1 |
| Doi, T | 1 |
| Ishikawa, K | 1 |
| Jyomen, Y | 1 |
| Tomaru, U | 1 |
| Gerhard, M | 1 |
| Gisin, N | 1 |
| Ye, Q | 2 |
| Farnen, JP | 6 |
| You, MJ | 2 |
| McDonnell, T | 1 |
| Inano, S | 1 |
| Iwasaki, M | 1 |
| Iwamoto, Y | 1 |
| Sueki, Y | 1 |
| Yanagita, S | 1 |
| Arima, N | 1 |
| Köksal, AR | 1 |
| Alkim, H | 1 |
| Ergun, M | 1 |
| Boga, S | 1 |
| Bayram, M | 1 |
| Alkim, C | 1 |
| Eryilmaz, OT | 1 |
| Oliver, C | 1 |
| Guillermo, C | 1 |
| Martínez, P | 1 |
| Díaz, L | 1 |
| Senapati, J | 1 |
| Sudhakar, S | 1 |
| Yokohama, A | 1 |
| Saitoh, A | 1 |
| Nakahashi, H | 1 |
| Mitsui, T | 1 |
| Koiso, H | 1 |
| Saitoh, T | 1 |
| Handa, H | 2 |
| Uchiumi, H | 1 |
| Jinbo, T | 1 |
| Sawamura, M | 2 |
| Karasawa, M | 2 |
| Hirato, J | 1 |
| Nojima, Y | 2 |
| Majchrzak, A | 1 |
| Witkowska, M | 1 |
| Mędra, A | 1 |
| Zwolińska, M | 1 |
| Bogusz, J | 1 |
| Cebula-Obrzut, B | 1 |
| Darzynkiewicz, Z | 1 |
| Robak, T | 3 |
| Smolewski, P | 1 |
| Nam, SJ | 1 |
| Cho, JW | 1 |
| Woo, SY | 1 |
| Cao, XX | 1 |
| Duan, MH | 1 |
| Shen, T | 3 |
| Zhou, DB | 1 |
| Guirguis, HR | 3 |
| Piliotis, E | 2 |
| Spaner, D | 1 |
| Berinstein, NL | 1 |
| Imrie, K | 1 |
| Buckstein, R | 4 |
| Pria, AD | 1 |
| Gandhi, S | 2 |
| Bailey, K | 1 |
| Wilson, A | 2 |
| Papanastasopoulos, P | 1 |
| Tenant-Flowers, M | 2 |
| Webb, A | 1 |
| Burns, F | 2 |
| Marcus, RE | 1 |
| Orkin, C | 1 |
| Bower, M | 2 |
| Gallicchio, R | 1 |
| Mansueto, G | 1 |
| Simeon, V | 1 |
| Nardelli, A | 1 |
| Guariglia, R | 1 |
| Capacchione, D | 1 |
| Soscia, E | 1 |
| Pedicini, P | 1 |
| Gattozzi, D | 1 |
| Storto, G | 1 |
| Liu, YC | 2 |
| Yen, CC | 3 |
| Chao, TC | 2 |
| Yan-Li, L | 1 |
| Kang-Sheng, G | 1 |
| Yue-Yin, P | 1 |
| Zhi-Min, Z | 1 |
| Rong, YF | 1 |
| He, LM | 1 |
| Zhang, YS | 1 |
| Feng, YZ | 1 |
| Cheng, Z | 1 |
| Chen, F | 5 |
| Dakhil, S | 1 |
| Hermann, R | 1 |
| Schreeder, MT | 1 |
| Gregory, SA | 4 |
| Monte, M | 1 |
| Windsor, KS | 1 |
| Hurst, D | 1 |
| Chai, A | 1 |
| Brewster, M | 1 |
| Richards, P | 1 |
| Alvarado-Bernal, Y | 1 |
| Laurini, JA | 1 |
| Tan, KL | 3 |
| Aoun, P | 3 |
| Wang, YP | 3 |
| Hao, YY | 1 |
| Zheng, Y | 5 |
| He, RQ | 1 |
| Li, ZY | 1 |
| Kobayashi, S | 3 |
| Yokose, T | 1 |
| Ristow, KM | 1 |
| Nowakowski, G | 1 |
| Markovic, SN | 3 |
| Gordon, LI | 8 |
| Hochster, H | 1 |
| Stiff, PJ | 1 |
| Horning, SJ | 11 |
| Okamura, A | 1 |
| Yakushijin, K | 1 |
| Matsuoka, H | 1 |
| Minami, H | 1 |
| Mullen, EC | 1 |
| Sengupta, S | 1 |
| Benkers, T | 1 |
| Blitstein, M | 1 |
| Palmer, E | 1 |
| Plotkin, SR | 1 |
| Ok, CY | 4 |
| Dybaer, K | 1 |
| Rund, D | 1 |
| Dalia, S | 2 |
| Chavez, J | 1 |
| Little, B | 1 |
| Bello, C | 2 |
| Fisher, K | 1 |
| Chervenick, P | 1 |
| Sokol, L | 1 |
| Sotomayor, E | 1 |
| Shah, B | 1 |
| Avigdor, A | 2 |
| Sirotkin, T | 1 |
| Kedmi, M | 2 |
| Ribakovsy, E | 1 |
| Berkowicz, M | 1 |
| Davidovitz, Y | 1 |
| Kneller, A | 1 |
| Merkel, D | 1 |
| Volchek, Y | 1 |
| Davidson, T | 1 |
| Goshen, E | 1 |
| Apter, S | 1 |
| Shimoni, A | 1 |
| Ben-Bassat, I | 1 |
| Nagler, A | 2 |
| Lapa, C | 1 |
| Knott, M | 1 |
| Rasche, L | 1 |
| Herrmann, K | 2 |
| Buck, AK | 2 |
| Zaky, AH | 1 |
| Bakry, R | 1 |
| El-sayed, MI | 1 |
| Elwanis, MA | 1 |
| Nabih, O | 1 |
| Vaidya, R | 1 |
| Subramaniam, R | 1 |
| Chin, EF | 1 |
| Abdul-Halim, H | 1 |
| Tai, MC | 1 |
| O'Malley, DP | 2 |
| Han van Krieken, J | 2 |
| Ghose, A | 1 |
| Kundu, R | 1 |
| Latif, T | 1 |
| Sagüés, M | 1 |
| Paredes, V | 1 |
| Altés, J | 1 |
| Scarpino, S | 1 |
| Salerno, G | 1 |
| Tatarelli, C | 1 |
| Talerico, C | 1 |
| Lombardi, M | 1 |
| Monarca, B | 2 |
| Amadori, S | 5 |
| Ruco, L | 1 |
| Silverton, A | 1 |
| Gunthel, C | 1 |
| Adamski, M | 1 |
| Mosunjac, M | 1 |
| Nguyen, ML | 1 |
| Cirillo, M | 1 |
| Bianchi, A | 1 |
| Gately, M | 1 |
| Olimpieri, OM | 1 |
| Cerchiara, E | 1 |
| Renzi, D | 1 |
| Micera, A | 1 |
| Balzamino, BO | 1 |
| Bonini, S | 1 |
| Onetti Muda, A | 1 |
| Avvisati, G | 1 |
| Nomani, AZ | 1 |
| Wazir, M | 1 |
| Kashmir, SB | 1 |
| Qureshi, MS | 1 |
| Ouyang, J | 3 |
| Xu, JY | 3 |
| Zhang, QG | 3 |
| Zhou, RF | 3 |
| Yang, YG | 3 |
| Shao, XY | 1 |
| Chen, YM | 1 |
| Fan, XS | 1 |
| Wu, HY | 1 |
| Dabaja, BS | 6 |
| Hess, K | 1 |
| Shihadeh, F | 3 |
| Podoloff, DA | 1 |
| Mawlawi, O | 1 |
| Arzu, I | 2 |
| Reed, VK | 2 |
| Kedir, A | 1 |
| Wogan, CF | 2 |
| Rodriguez, A | 3 |
| Zhao, T | 2 |
| Kuroda, H | 4 |
| Jomen, W | 1 |
| Yamada, M | 4 |
| Sato, M | 3 |
| Abe, T | 2 |
| Sakurai, T | 2 |
| Maeda, M | 4 |
| Fujita, M | 3 |
| Nagashima, K | 1 |
| Nojiri, S | 1 |
| Arihara, Y | 1 |
| Kato, J | 4 |
| Unger, JM | 4 |
| Burack, WR | 1 |
| Raju, RN | 1 |
| Nademanee, AP | 2 |
| Press, OW | 2 |
| Ludwig, E | 1 |
| Wieringa, A | 1 |
| Beerden, T | 1 |
| Kibbelaar, RE | 1 |
| Veldhuis, GJ | 1 |
| van Kamp, H | 1 |
| Yang, XY | 1 |
| Zhai, YP | 1 |
| Liu, HN | 1 |
| Yu, YP | 1 |
| Song, P | 1 |
| An, ZM | 1 |
| Wang, LP | 1 |
| Batlle, A | 3 |
| de Villambrosía, SG | 2 |
| Sánchez-Espiridión, B | 1 |
| Cereceda, L | 1 |
| Purroy, N | 2 |
| Mazorra, F | 1 |
| Insunza, A | 2 |
| Quero, C | 1 |
| Aguiar, D | 1 |
| Rueda, A | 2 |
| Llanos, M | 2 |
| Codina, JG | 1 |
| Arroyo, FR | 1 |
| Conde, E | 7 |
| Provencio, M | 4 |
| Piris, M | 1 |
| Augustin, F | 1 |
| Kocher, F | 1 |
| Gunsilius, E | 1 |
| Zabernigg, A | 1 |
| Zangerl, G | 1 |
| Oexle, H | 1 |
| Schreieck, S | 1 |
| Schnallinger, M | 1 |
| Fiegl, M | 2 |
| Hartl, J | 1 |
| Werner, T | 1 |
| Schramm, C | 1 |
| Tapan, U | 1 |
| Pestana, JB | 1 |
| Lee, JC | 1 |
| Lerner, A | 1 |
| Stelitano, C | 3 |
| Brusamolino, E | 4 |
| Cabras, MG | 6 |
| Oerlemans, S | 1 |
| van den Broek, EC | 1 |
| Nijziel, MR | 1 |
| Coebergh, JW | 1 |
| Mols, F | 1 |
| van de Poll-Franse, LV | 1 |
| Masuda, A | 1 |
| Wang, YH | 1 |
| Shiseki, M | 1 |
| Motoji, T | 1 |
| Franceschetti, S | 7 |
| Zinzani, P | 1 |
| Fattori, PP | 1 |
| Zaccaria, A | 2 |
| Dreyling, M | 1 |
| Gaudiano, M | 1 |
| Winer, ES | 2 |
| Hanna, DM | 1 |
| Fellowes, A | 1 |
| Vedururu, R | 1 |
| Mechinaud, F | 1 |
| Hansford, JR | 1 |
| Pariente, A | 1 |
| Gu, L | 3 |
| Tang, Z | 2 |
| Pan, Y | 4 |
| Abdelsalam, MS | 1 |
| Althaf, MM | 1 |
| Alfurayh, O | 1 |
| Maghfoor, I | 2 |
| Diem, S | 1 |
| Ess, S | 1 |
| Cerny, T | 1 |
| Früh, M | 1 |
| Hitz, F | 3 |
| Vicente-Dueñas, C | 1 |
| Romero-Camarero, I | 1 |
| Long Liu, C | 1 |
| Dai, B | 1 |
| González-Herrero, I | 1 |
| García-Ramírez, I | 1 |
| Alonso-Escudero, E | 1 |
| Campos-Sanchez, E | 1 |
| Orfao, A | 1 |
| Pintado, B | 1 |
| Flores, T | 2 |
| Jiménez, R | 1 |
| Martínez-Climent, JA | 1 |
| Criado, FJ | 1 |
| Cenador, MB | 1 |
| Zhao, S | 6 |
| Majeti, R | 1 |
| Melnick, A | 2 |
| Cobaleda, C | 1 |
| Sánchez-García, I | 1 |
| Csinady, E | 1 |
| Moore, N | 1 |
| Dozzo, M | 1 |
| Zaja, F | 2 |
| Volpetti, S | 1 |
| Chiozzotto, M | 1 |
| Puglisi, S | 1 |
| Mazzucco, M | 1 |
| Perali, G | 1 |
| Fanin, R | 1 |
| Ishiyama, Y | 1 |
| Tachibana, T | 2 |
| Odejide, OO | 1 |
| Cronin, AM | 1 |
| Davidoff, AJ | 1 |
| Abel, GA | 3 |
| Murawski, N | 4 |
| Zeynalova, S | 3 |
| Hänel, M | 1 |
| Schmidt, C | 1 |
| Hallek, M | 1 |
| Rixecker, T | 2 |
| Zwick, C | 5 |
| Wasle, I | 1 |
| Gamerith, G | 1 |
| Jäger, T | 1 |
| Wu, PY | 1 |
| Zhang, XD | 1 |
| Guo, XY | 1 |
| Ríos, A | 1 |
| Rodríguez, JM | 1 |
| Febrero, B | 1 |
| Parrilla, P | 1 |
| Wen, JJ | 1 |
| Zhou, JL | 1 |
| Liu, ZB | 1 |
| Xu, CG | 1 |
| Salah-Eldin, MA | 1 |
| Ebrahim, MA | 1 |
| El-Sadda, W | 1 |
| Pertovaara, H | 1 |
| Korkola, P | 1 |
| Vornanen, M | 1 |
| Järvenpää, R | 1 |
| Dastidar, P | 1 |
| Eskola, H | 1 |
| Kellokumpu-Lehtinen, PL | 1 |
| Ahn, JS | 4 |
| Kim, YK | 3 |
| Lee, JJ | 9 |
| Achenbach, M | 2 |
| Regitz, E | 3 |
| Numata, H | 1 |
| Ohgiya, D | 1 |
| Tazume, K | 1 |
| Moriuchi, M | 1 |
| Miyamoto, M | 1 |
| Aoyama, Y | 1 |
| Kawai, H | 2 |
| Ichiki, A | 1 |
| Hara, R | 1 |
| Ogawa, Y | 3 |
| Schuster, T | 1 |
| Abbrederis, K | 1 |
| Blümel, C | 1 |
| Santi, I | 1 |
| Rudelius, M | 1 |
| Wester, HJ | 1 |
| Peschel, C | 1 |
| Schwaiger, M | 1 |
| Dechow, T | 1 |
| De Stefani, A | 1 |
| Boffano, P | 1 |
| Bongioannini, G | 1 |
| Jeong, Y | 1 |
| Rancea, M | 1 |
| Will, A | 1 |
| Monsef, I | 1 |
| Eatrides, J | 1 |
| Thompson, Z | 1 |
| Oh, S | 3 |
| Lee, SI | 4 |
| Bae, SH | 2 |
| Song, MK | 12 |
| Lee, B | 1 |
| Yhim, HY | 2 |
| Vance, KK | 1 |
| Krunic, AL | 1 |
| Fishman, PM | 1 |
| Kadkol, SS | 1 |
| Nuovo, GJ | 1 |
| Ganti, A | 3 |
| Luo, S | 3 |
| Sanfilippo, KM | 3 |
| Roop, R | 1 |
| Lynch, R | 1 |
| Riedell, P | 3 |
| O'Brian, K | 3 |
| Colditz, GA | 1 |
| Carson, KR | 4 |
| Amorim, S | 1 |
| Bandyopadhyay, N | 1 |
| de Vries, R | 1 |
| Hellemans, P | 1 |
| Smit, JW | 1 |
| Liu, F | 1 |
| Papajík, T | 1 |
| Fürst, T | 1 |
| Furstova, J | 1 |
| Coronado, M | 1 |
| Marín-Niebla, A | 1 |
| Panizo, C | 1 |
| Hernández, MT | 2 |
| Arranz, R | 4 |
| Caballero, MD | 2 |
| Herbert, KE | 1 |
| O'Rourke, K | 1 |
| Kennedy, GA | 1 |
| Fedele, PL | 1 |
| Gilbertson, M | 1 |
| Ritchie, DS | 1 |
| Opat, SS | 1 |
| Prince, HM | 1 |
| Dickinson, M | 1 |
| Burbury, K | 1 |
| Wolf, M | 2 |
| Januszewicz, EH | 1 |
| Westerman, DA | 1 |
| Carney, DA | 1 |
| Harrison, SJ | 1 |
| Arasawa, S | 1 |
| Nakase, H | 1 |
| Minami, N | 1 |
| Ichikawa, K | 2 |
| Aritaka, N | 1 |
| Sekiguchi, Y | 2 |
| Sunami, Y | 1 |
| Tsutsui, M | 1 |
| Hosone, M | 1 |
| Hirano, T | 1 |
| Gotoh, A | 1 |
| Shen, Y | 7 |
| Shen, Z | 3 |
| Jelić, S | 1 |
| Martinović, T | 2 |
| Cemerikić, V | 2 |
| Ancochea, Á | 1 |
| García-Pallarols, F | 1 |
| Fernández-Rodriguez, C | 1 |
| Sánchez-González, B | 1 |
| Nelson, GD | 1 |
| Neumann, F | 1 |
| Reichrath, J | 1 |
| Geisel, J | 1 |
| Mano, T | 1 |
| Matsuo, K | 4 |
| Ozawa, H | 1 |
| Arakawa, T | 1 |
| Ni, H | 2 |
| Inaba, K | 1 |
| Okamoto, H | 1 |
| Wakita, A | 1 |
| Kobayashi, K | 4 |
| Kitaguchi, M | 1 |
| Sekii, S | 1 |
| Takahashi, K | 4 |
| Yoshio, K | 1 |
| Murakami, N | 3 |
| Morota, M | 1 |
| Sumi, M | 2 |
| Uno, T | 2 |
| Itami, J | 2 |
| Kroll-Desrosiers, AR | 1 |
| Muffly, LS | 1 |
| Winer, E | 1 |
| Nath, R | 1 |
| Woda, B | 2 |
| Yuan, T | 1 |
| Qu, F | 1 |
| Romero-Rojas, AE | 1 |
| Diaz-Perez, JA | 1 |
| Raju, S | 1 |
| Messa-Botero, O | 1 |
| Prieto-Bletan, A | 1 |
| Criollo-Palacios, F | 1 |
| Pitini, V | 2 |
| Arrigo, C | 1 |
| Derenzini, E | 5 |
| Aoki, T | 2 |
| Nakaseko, C | 2 |
| Sasaki, M | 2 |
| Mitani, K | 2 |
| Maeda, Y | 8 |
| Ishida, F | 1 |
| Niitsu, N | 5 |
| Cao, C | 1 |
| Kai, S | 1 |
| Xiang, B | 1 |
| Mertsoylu, H | 1 |
| Muallaoglu, S | 1 |
| Besen, AA | 1 |
| Erdogdu, S | 1 |
| Sezer, A | 1 |
| Sedef, AM | 1 |
| Kose, F | 1 |
| Arican, A | 1 |
| Ozyilkan, O | 1 |
| Woo, HS | 1 |
| Lee, WH | 1 |
| Kim, B | 1 |
| Kim, MS | 1 |
| Park, E | 1 |
| Saitoh, Y | 1 |
| Gotoh, M | 1 |
| Katagiri, S | 1 |
| Ohyashiki, K | 1 |
| Bruno-Ventre, M | 1 |
| Vignati, A | 1 |
| Scarfò, L | 1 |
| Sassone, M | 1 |
| Caligaris-Cappio, F | 1 |
| Ma, J | 4 |
| Hu, C | 2 |
| Zhang, G | 2 |
| Lim, SH | 1 |
| Hwang, D | 1 |
| Jang, J | 1 |
| Nikonova, A | 1 |
| Hassan, U | 1 |
| Ishtiaq, S | 1 |
| Hussain, M | 1 |
| Song, YH | 1 |
| Zhong, MZ | 1 |
| Gan, PP | 1 |
| Yi, PY | 1 |
| Tang, YH | 1 |
| Liu, YP | 2 |
| Jiang, JQ | 1 |
| Adhikari, S | 1 |
| Dongol, RM | 1 |
| Hewett, Y | 1 |
| Shah, BK | 1 |
| Shin, HC | 1 |
| Kang, BW | 3 |
| Chae, YS | 4 |
| Lee, SJ | 4 |
| Han, S | 1 |
| Seo, SK | 1 |
| Kim, JG | 5 |
| Sohn, SK | 7 |
| Park, TI | 3 |
| Lauritzen, AF | 2 |
| Klausen, TW | 1 |
| Lu, CS | 2 |
| Wu, YY | 2 |
| Chang, PY | 1 |
| Dai, MS | 1 |
| Chen, YC | 2 |
| Ho, CL | 2 |
| Lee, SH | 2 |
| Berger, F | 5 |
| Copin, MC | 2 |
| Morschauser, F | 1 |
| Chan, FC | 1 |
| Telenius, A | 2 |
| Healy, S | 1 |
| Lim, R | 1 |
| Drake, M | 1 |
| Ding, J | 1 |
| Ha, G | 1 |
| Rogic, S | 2 |
| Sehn, L | 1 |
| Lkhoyaali, S | 1 |
| Errihani, H | 2 |
| Bhagat, P | 1 |
| Sachdeva, MU | 1 |
| Sharma, P | 1 |
| Naseem, S | 1 |
| Ahluwalia, J | 1 |
| Das, R | 1 |
| Varma, N | 1 |
| Law, A | 1 |
| Choi, YW | 2 |
| Ahn, MS | 2 |
| Lee, HW | 3 |
| Kang, SY | 2 |
| Choi, JH | 3 |
| Jin, UR | 1 |
| Clear, AJ | 1 |
| Mazzola, E | 1 |
| Owen, A | 1 |
| Greaves, P | 1 |
| Matthews, J | 1 |
| Alvarez, R | 1 |
| Neuberg, D | 4 |
| Calaminici, M | 2 |
| Gribben, JG | 2 |
| Basanta, I | 1 |
| Sevillano, C | 1 |
| Álvarez, MD | 1 |
| Ewer, MS | 1 |
| Lenihan, DJ | 1 |
| Fisch, MJ | 1 |
| Romaguera, J | 1 |
| Pro, B | 2 |
| Astrow, AB | 1 |
| Durand, JB | 1 |
| Belotti, A | 1 |
| Doni, E | 1 |
| Bolis, S | 1 |
| Rossini, F | 1 |
| Pezzatti, S | 1 |
| Pogliani, EM | 3 |
| Pioltelli, PE | 1 |
| Carey, CD | 1 |
| Gusenleitner, D | 1 |
| Chapuy, B | 1 |
| Kovach, AE | 1 |
| Kluk, MJ | 1 |
| Sun, HH | 1 |
| Crossland, RE | 1 |
| Bacon, CM | 2 |
| Rand, V | 1 |
| Dal Cin, P | 1 |
| Le, LP | 1 |
| Sohani, AR | 2 |
| Shipp, MA | 3 |
| Monti, S | 2 |
| Rodig, SJ | 1 |
| Carlson, SW | 1 |
| Aneja, S | 1 |
| Honda, K | 1 |
| Cooper, KD | 1 |
| Vanderplas, AM | 1 |
| Crosby-Thompson, AL | 1 |
| Kaminski, M | 1 |
| Niland, J | 2 |
| Millenson, M | 2 |
| Zelenetz, A | 1 |
| Kim, IS | 6 |
| Boyle, J | 1 |
| Diehl, LF | 2 |
| Hagberg, O | 1 |
| Bergua, J | 1 |
| Gallur, L | 1 |
| Prieto, J | 1 |
| Lopez, LA | 1 |
| García-Marco, JA | 2 |
| Castellví, J | 1 |
| Carnicero, F | 1 |
| Ferrando-Lamana, L | 1 |
| Cho, SH | 2 |
| Kim, HK | 1 |
| Chung, YH | 1 |
| Huang, CE | 1 |
| Chen, YY | 2 |
| Lu, CH | 1 |
| Chen, PT | 1 |
| Lee, KD | 1 |
| Sikov, WM | 1 |
| Advani, P | 1 |
| Paulus, A | 1 |
| Murray, P | 1 |
| Jiang, L | 2 |
| Goff, R | 1 |
| Pooley, R | 1 |
| Garner, H | 1 |
| Foran, J | 1 |
| Shen, W | 3 |
| Huntington, SF | 2 |
| Nasta, SD | 2 |
| Doshi, JA | 1 |
| Marton, A | 1 |
| Fowler, NH | 1 |
| Kubuschok, B | 1 |
| Williams, JN | 1 |
| Lipscomb, J | 1 |
| Lin, B | 2 |
| Chen, C | 1 |
| Kim, SS | 2 |
| Knudsen, S | 1 |
| Hother, C | 2 |
| Jensen, T | 1 |
| Hansen, A | 1 |
| Mazin, W | 1 |
| Dahlgaard, J | 1 |
| Ralfkiær, E | 1 |
| Brown, Pde N | 2 |
| Shen, Q | 1 |
| Martinez-Lopez, A | 1 |
| Pham, L | 1 |
| Qiao, W | 1 |
| Elbedewy, TA | 1 |
| Elashtokhy, HE | 1 |
| Rabee, ES | 1 |
| Kheder, GE | 1 |
| Kwon, J | 1 |
| Kim, BH | 1 |
| Lim, EL | 1 |
| Trinh, DL | 1 |
| Chu, A | 1 |
| Krzywinski, M | 1 |
| Robertson, AG | 1 |
| Schein, J | 1 |
| Czader, M | 2 |
| Baptista, MJ | 1 |
| Morgades, M | 3 |
| Miralles, P | 3 |
| Abella, E | 3 |
| Moreno, M | 1 |
| Feliu, E | 3 |
| Ribera, JM | 7 |
| Navarro, JT | 3 |
| Shibata, S | 1 |
| Akasaka, H | 1 |
| Wakiya, T | 1 |
| Yamanaka, Y | 1 |
| Narita, J | 1 |
| Sutou, T | 1 |
| Iino, C | 1 |
| Harano, M | 1 |
| Kato, T | 1 |
| Yoshida, K | 2 |
| Sato, D | 1 |
| Choda, Y | 1 |
| Tokumoto, N | 1 |
| Kanazawa, T | 1 |
| Matsukawa, H | 1 |
| Ojima, Y | 1 |
| Idani, H | 1 |
| Shiozaki, S | 1 |
| Okajima, M | 1 |
| Ninomiya, M | 1 |
| Tsang, M | 1 |
| Shanafelt, TD | 1 |
| Call, TG | 1 |
| Ding, W | 1 |
| Chanan-Khan, A | 1 |
| Leis, JF | 1 |
| Bowen, D | 1 |
| Conte, M | 1 |
| Schwager, SM | 1 |
| Slager, SL | 2 |
| Kay, NE | 1 |
| Hanson, CA | 1 |
| Parikh, SA | 1 |
| Allen, PK | 2 |
| Dabaja, B | 2 |
| Gong, QX | 2 |
| Zhang, ZH | 3 |
| Clifford, R | 1 |
| Roberts, C | 1 |
| Boyle, L | 1 |
| Francis, A | 1 |
| Dutton, SJ | 1 |
| Kurita, D | 2 |
| Sakagami, M | 1 |
| Kiso, S | 1 |
| Hojo, A | 2 |
| Kodaira, H | 1 |
| Yagi, M | 1 |
| Hirabayashi, Y | 1 |
| Kura, Y | 2 |
| Sugitani, M | 1 |
| Takei, M | 1 |
| Streu, E | 1 |
| Bozzoli, V | 2 |
| Voso, MT | 3 |
| Leone, G | 3 |
| Quon, A | 3 |
| Gascoyne, R | 4 |
| Ranheim, EA | 1 |
| Courtney, MJ | 1 |
| Chattopadhyay, D | 1 |
| Rao, M | 1 |
| Light, D | 1 |
| Gopinath, B | 1 |
| Cuzzocrea, S | 1 |
| Aloisi, C | 1 |
| Adams, HJ | 4 |
| Nievelstein, RA | 3 |
| Kwee, TC | 4 |
| Athar, S | 1 |
| Siddiqui, N | 2 |
| Rai, SR | 1 |
| Muzaffar, N | 2 |
| Hameed, A | 2 |
| Pollom, EL | 1 |
| Khodadoust, MS | 1 |
| Kozak, MM | 1 |
| Xu, G | 1 |
| Ahmed, MA | 1 |
| Costelloe, C | 1 |
| Reed, V | 2 |
| Nieto, Y | 1 |
| Khouri, IF | 1 |
| Jegadeesh, N | 2 |
| Rajpara, R | 1 |
| Pósfai, É | 1 |
| Nagy, K | 1 |
| Marton, I | 1 |
| Bánfalvi, A | 1 |
| Kocsis, L | 1 |
| Cserni, G | 1 |
| Huerta-Guzmàn, J | 11 |
| Silva, L | 2 |
| Guo, X | 3 |
| Pan, J | 1 |
| Brauner, S | 1 |
| Zhou, W | 2 |
| Backlin, C | 1 |
| Folkersen, L | 1 |
| Ivanchenko, M | 1 |
| Löfström, B | 1 |
| Møller Pedersen, L | 2 |
| Boe Møller, M | 1 |
| Sundström, C | 3 |
| Baecklund, E | 1 |
| Wahren-Herlenius, M | 1 |
| Falgreen, S | 2 |
| Laursen, MB | 1 |
| Bødker, JS | 1 |
| Kjeldsen, MK | 1 |
| Schmitz, A | 1 |
| Nyegaard, M | 1 |
| Johnsen, HE | 9 |
| Borel, C | 1 |
| Lamy, S | 1 |
| Compaci, G | 1 |
| Jeanneau, P | 1 |
| Nogaro, JC | 1 |
| Bauvin, E | 1 |
| Despas, F | 1 |
| Delpierre, C | 1 |
| Laurent, G | 3 |
| Rohlfing, S | 1 |
| Aurich, M | 1 |
| Schöning, T | 1 |
| Ho, AD | 3 |
| Bautista-Gili, AM | 1 |
| Garcia, F | 2 |
| Sanchez, B | 1 |
| Martorell, C | 1 |
| Gines, J | 1 |
| Garcia, L | 1 |
| Ferraro, M | 1 |
| Perez, A | 1 |
| Vercher, J | 1 |
| Scaff, M | 1 |
| Pacheco, A | 1 |
| Ballester, C | 1 |
| Ramos, R | 1 |
| Besalduch, J | 1 |
| Deng, C | 2 |
| Zou, W | 1 |
| Poulsen, TS | 1 |
| De Sousa Lages, A | 1 |
| Esperto, H | 1 |
| Santos, L | 1 |
| Carvalho, A | 1 |
| Wei, ZL | 1 |
| Huang, DP | 1 |
| Su, GP | 1 |
| Wang, XH | 1 |
| Jiang, YZ | 1 |
| Huang, LQ | 1 |
| González Barca, EM | 1 |
| Pané-Foix, M | 1 |
| Colorado, M | 1 |
| Martin-Sánchez, G | 1 |
| Espiga, CR | 1 |
| Hainsworth, JD | 2 |
| Arrowsmith, ER | 1 |
| McCleod, M | 1 |
| Hamid, O | 1 |
| Lin, BK | 1 |
| Kapuria, D | 1 |
| Strasser, K | 1 |
| Qasem, A | 1 |
| Galani, Z | 1 |
| Variami, E | 1 |
| Kokkini, G | 1 |
| Tsatalas, C | 1 |
| Sotiropoulos, V | 1 |
| Meletis, J | 2 |
| Apostolidis, J | 1 |
| Zeng, H | 1 |
| Zhou, Q | 2 |
| Wagner, H | 1 |
| Jandali, A | 1 |
| Kabach, A | 1 |
| Al Halabi, S | 1 |
| Alraies, MC | 1 |
| Usami, M | 2 |
| Shimoyama, S | 2 |
| Wakabayashi, Y | 1 |
| Tsukamoto, K | 2 |
| Kanari, Y | 2 |
| Takada, K | 1 |
| Min, WS | 1 |
| Park, CW | 1 |
| Maguire, A | 1 |
| Castriciano, G | 1 |
| Walker, J | 1 |
| Molloy, K | 1 |
| Osman, N | 1 |
| Jeffers, M | 1 |
| Gaffney, E | 1 |
| Seo, YH | 1 |
| Seo, JY | 2 |
| Jeong, JH | 2 |
| Furuta, M | 1 |
| Hirayanagi, K | 1 |
| Nagamine, S | 1 |
| Makioka, K | 1 |
| Ikeda, Y | 1 |
| Ramachandran, R | 1 |
| Kanakry, JA | 1 |
| Kritharis, A | 1 |
| Kroll, A | 1 |
| Petrich, AM | 3 |
| Al-Mansour, Z | 1 |
| Adeimy, C | 1 |
| Hemminger, J | 1 |
| Klein, AK | 1 |
| Fabregas, JC | 1 |
| Fenske, TS | 2 |
| Guo, W | 1 |
| Liu, C | 3 |
| Bai, O | 2 |
| Leu, N | 1 |
| Muenst, S | 1 |
| Juskevicius, D | 2 |
| Kawamura, K | 2 |
| Wada, A | 1 |
| Wang, JY | 1 |
| Ishii, A | 1 |
| Takagi, T | 4 |
| Itami, M | 1 |
| Tada, Y | 2 |
| Tatsumi, K | 1 |
| Shimada, H | 1 |
| Hiroshima, K | 1 |
| Tagawa, M | 1 |
| Ueda, H | 1 |
| Hagihara, K | 1 |
| Kanashima, H | 2 |
| Sakamoto, E | 2 |
| Hirai, M | 1 |
| Nakane, T | 1 |
| Chen, YG | 1 |
| Lloret-Ruiz, C | 1 |
| Molés-Poveda, P | 1 |
| Barrado-Solís, N | 1 |
| Gimeno-Carpio, E | 1 |
| Tsuda, M | 1 |
| Ikeda, M | 1 |
| Shimada, S | 2 |
| Nomura, M | 1 |
| Matsushima, T | 1 |
| Takahashi, S | 4 |
| Aishima, S | 1 |
| Oda, Y | 1 |
| Shiratsuchi, M | 1 |
| Takayanagi, R | 1 |
| Hu, Y | 2 |
| Chen, SL | 1 |
| Huang, ZX | 1 |
| Gao, W | 1 |
| An, N | 1 |
| Renner, C | 2 |
| Pabst, T | 2 |
| Driessen, C | 1 |
| Mey, U | 1 |
| Pless, M | 1 |
| Bargetzi, M | 1 |
| Krasniqi, F | 1 |
| Gigli, F | 1 |
| Hany, T | 1 |
| Samarin, A | 1 |
| Biaggi, C | 1 |
| Rusterholz, C | 1 |
| Martinelli, G | 6 |
| Mittra, ES | 1 |
| Tashiro, R | 1 |
| Kanamori, M | 1 |
| Suzuki, H | 2 |
| Utsunomiya, A | 3 |
| Meguro, K | 1 |
| Uenohara, H | 1 |
| Tominaga, T | 1 |
| Rabah, F | 1 |
| Elmanzalawy, A | 1 |
| Bhuyan, D | 1 |
| El-Banna, N | 1 |
| Beshlawi, I | 1 |
| Song, CG | 1 |
| Huang, JJ | 7 |
| Li, YJ | 4 |
| Bi, XW | 2 |
| Jiang, WQ | 13 |
| Huang, HQ | 14 |
| Li, ZM | 8 |
| Salisbury, R | 1 |
| Watson, C | 1 |
| Hatton, CS | 1 |
| Offner, F | 3 |
| Osmanov, E | 1 |
| Raposo, J | 1 |
| Pavlov, V | 1 |
| Ricci, D | 1 |
| Zhu, E | 1 |
| van de Velde, H | 1 |
| Enny, C | 1 |
| Rizo, A | 1 |
| Barry, GS | 1 |
| Hoskins, P | 6 |
| Moccia, A | 1 |
| Shenkier, T | 7 |
| Klasa, R | 11 |
| Sun, R | 4 |
| Alzahrani, M | 1 |
| Hansen, JW | 3 |
| Loft, A | 1 |
| Iyer, V | 1 |
| Hutchings, M | 2 |
| Mendes, F | 1 |
| Domingues, C | 1 |
| Teixo, R | 1 |
| Abrantes, AM | 1 |
| Gonçalves, AC | 1 |
| Nobre-Gois, I | 1 |
| Jacobetty, M | 1 |
| Sarmento, AB | 1 |
| Botelho, MF | 1 |
| Rosa, MS | 1 |
| Dias, LM | 1 |
| Thodima, V | 1 |
| Friedman, J | 1 |
| Guttapalli, A | 1 |
| Mendiratta, G | 1 |
| Siddiqi, IN | 1 |
| Syrbu, S | 1 |
| Chaganti, RS | 1 |
| Houldsworth, J | 1 |
| Öztürk, E | 1 |
| Berk, S | 1 |
| Avşar, E | 1 |
| Dolgun, A | 1 |
| Çetiner, M | 1 |
| Mandel, NM | 1 |
| Yalnız, FF | 1 |
| Salihoğlu, A | 1 |
| Öngören, Ş | 2 |
| Başlar, Z | 2 |
| Aydın, Y | 2 |
| de Klerk, JM | 2 |
| Heggelman, BG | 2 |
| Dubois, SV | 2 |
| Tian, F | 1 |
| Jiang, W | 1 |
| Jia, L | 1 |
| Hao, J | 1 |
| Büyükkurt, N | 1 |
| Özcan, MA | 1 |
| Ergene, Ü | 1 |
| Payzın, B | 1 |
| Tunalı, S | 1 |
| Demirkan, F | 1 |
| Özsan, H | 1 |
| Pişkin, Ö | 1 |
| Ündar, B | 1 |
| Chong, SY | 1 |
| Do, Y | 1 |
| Rao, HL | 2 |
| Bi, X | 1 |
| Sun, P | 2 |
| Guan, ZZ | 8 |
| Ochrem, B | 1 |
| Zimowska-Curyło, D | 1 |
| Górecki, T | 1 |
| Boguradzki, P | 1 |
| Knopińska-Posłuszny, W | 1 |
| Stella-Hołowiecka, B | 1 |
| Walewski, J | 4 |
| Yoshifuku, K | 1 |
| Nishimoto, K | 1 |
| Matsuzaki, T | 1 |
| Ushikai, M | 1 |
| Millar, A | 1 |
| Ellis, M | 1 |
| Mollee, P | 2 |
| Cochrane, T | 1 |
| Fletcher, J | 1 |
| Caudron, A | 1 |
| Webster, B | 1 |
| Habib, G | 1 |
| Nashashibi, M | 1 |
| Hartman, L | 1 |
| Székely, E | 1 |
| Hodgson, DC | 3 |
| Cuillière-Dartigues, P | 1 |
| Baia, M | 2 |
| Belhadj, K | 5 |
| Nagel, I | 1 |
| Gajendra, S | 1 |
| Jha, B | 1 |
| Goel, S | 1 |
| Sahni, T | 1 |
| Dorwal, P | 1 |
| Sachdev, R | 1 |
| Shiraki, M | 1 |
| Dorokhina, EI | 1 |
| Magomedova, AU | 5 |
| Shevelev, AA | 3 |
| Kulikov, SM | 2 |
| Gitis, MK | 1 |
| Vedernikov, AV | 1 |
| Vorobyev, AI | 1 |
| Kravchenko, SK | 6 |
| Rashidi, A | 1 |
| Oak, E | 1 |
| Kreisel, F | 1 |
| Clark Schneider, KM | 1 |
| Banks, PM | 1 |
| Collie, AM | 1 |
| Lanigan, CP | 1 |
| Manilich, E | 1 |
| Durkin, LM | 1 |
| Utsu, Y | 1 |
| Takaishi, K | 1 |
| Inagaki, S | 1 |
| Arai, H | 1 |
| Masuda, S | 1 |
| Matsuura, Y | 1 |
| Aotsuka, N | 1 |
| Wakita, H | 1 |
| Ikebe, T | 1 |
| Saburi, Y | 1 |
| Ogata, M | 2 |
| Migliacci, JC | 1 |
| Cupelli, E | 1 |
| Santangelo, R | 1 |
| Giachelia, M | 3 |
| Martini, M | 2 |
| D'Alò, F | 2 |
| Pompili, M | 1 |
| Iioka, F | 1 |
| Izumi, K | 1 |
| Kamoda, Y | 1 |
| Akasaka, T | 1 |
| Du, H | 1 |
| Xiao, TW | 1 |
| Liu, JZ | 1 |
| Liu, GZ | 1 |
| Wang, JX | 1 |
| Wang, LX | 1 |
| Vega, GG | 1 |
| Chalapud, JR | 1 |
| Martinez-Paniagua, M | 1 |
| Pelayo, R | 1 |
| Mayani, H | 1 |
| Hernandez-Pando, R | 1 |
| Martinez-Maza, O | 1 |
| Huerta-Yepez, S | 1 |
| Bonavida, B | 1 |
| Vega, MI | 1 |
| Peng, W | 1 |
| Du, J | 1 |
| Li, G | 1 |
| Felce, SL | 1 |
| Spearman, H | 2 |
| Niroula, R | 1 |
| Butera, J | 1 |
| Song, K | 1 |
| Jaso, J | 1 |
| Yang, DT | 2 |
| Hughes, S | 1 |
| Richardson, F | 1 |
| James, E | 1 |
| Bessell, E | 1 |
| Sovani, V | 1 |
| Ganatra, R | 1 |
| Haynes, AP | 1 |
| Dhakal, S | 2 |
| Ha, CS | 2 |
| Hoppe, BS | 1 |
| Mendenhall, NP | 1 |
| Metzger, ML | 1 |
| Roberts, KB | 1 |
| Shapiro, R | 1 |
| Terezakis, SA | 1 |
| Winkfield, KM | 1 |
| Sheen, SS | 1 |
| Newman, KA | 1 |
| Ahlman, MA | 1 |
| Hughes, M | 1 |
| Malayeri, AA | 1 |
| Pratt, D | 1 |
| Grayson, PC | 1 |
| Hernández-Belmonte, A | 1 |
| Amorós-Martínez, F | 1 |
| Fernández-García, PL | 1 |
| Navarro-López, V | 1 |
| Kim, A | 1 |
| Byun, BH | 3 |
| Moon, H | 1 |
| Ko, YJ | 1 |
| Lee, HR | 2 |
| Na, II | 1 |
| Lee, SS | 2 |
| Yang, SH | 2 |
| Montanaro, C | 1 |
| Loiacono, F | 1 |
| Fragasso, G | 1 |
| De Cobelli, F | 1 |
| Margonato, A | 1 |
| Sakamoto, H | 2 |
| Nakano, T | 1 |
| Iyama, S | 3 |
| Jesionek-Kupnicka, D | 2 |
| Bojo, M | 1 |
| Prochorec-Sobieszek, M | 1 |
| Szumera-Ciećkiewicz, A | 1 |
| Jabłońska, J | 2 |
| Kalinka-Warzocha, E | 1 |
| Kordek, R | 2 |
| Młynarski, W | 1 |
| Cao, KA | 1 |
| Han, E | 1 |
| Hicks, RJ | 2 |
| Crooks, P | 2 |
| Gould, C | 1 |
| Jones, K | 1 |
| Griffiths, LR | 1 |
| Talaulikar, D | 1 |
| Jain, S | 2 |
| Tobin, J | 1 |
| Gandhi, MK | 3 |
| Sleddering, MA | 1 |
| Vlasveld, LT | 1 |
| Fukuba, N | 1 |
| Moriyama, I | 1 |
| Ishihara, S | 1 |
| Sonoyama, H | 1 |
| Yamashita, N | 1 |
| Oka, A | 1 |
| Oshima, N | 1 |
| Yuki, T | 1 |
| Kawashima, K | 4 |
| Kinoshita, Y | 1 |
| Wang, XP | 2 |
| Ping, LY | 1 |
| Wang, GQ | 2 |
| Song, YQ | 2 |
| Pagé, M | 1 |
| Grasso, AE | 1 |
| Carpenter, JP | 1 |
| Sheppard, MN | 1 |
| Karwatowski, SP | 1 |
| Mohiaddin, RH | 1 |
| Cassidy, RJ | 1 |
| Switchenko, J | 1 |
| Danish, H | 1 |
| Tokura, T | 1 |
| Nishikawa, S | 1 |
| Umehara, M | 1 |
| Umehara, Y | 1 |
| Murata, A | 1 |
| Morita, T | 2 |
| Viailly, PJ | 1 |
| Bohers, E | 2 |
| Bertrand, P | 2 |
| Maingonnat, C | 2 |
| Peyrouze, P | 1 |
| Desmots, F | 1 |
| Fu, R | 1 |
| Tu, W | 1 |
| Smith, H | 1 |
| Horner, TJ | 1 |
| Williams, VC | 1 |
| Giampietro, P | 1 |
| Lin, TS | 1 |
| Redondo, AM | 1 |
| Ocio, EM | 1 |
| Shin, S | 1 |
| Pak, KJ | 1 |
| Kwon, SY | 1 |
| Shim, HK | 1 |
| Choi, BH | 1 |
| Kim, SG | 3 |
| He, H | 1 |
| Monsalvo, S | 1 |
| Serrano, C | 1 |
| Prieto, E | 1 |
| Fernández-Sanz, G | 1 |
| Puente, MC | 1 |
| Rodriguez-Pinilla, M | 1 |
| Garcia Raso, A | 1 |
| Llamas, P | 1 |
| Dong, X | 1 |
| Ye, Z | 1 |
| Xiang, R | 1 |
| Sawada, T | 5 |
| Francisco, M | 1 |
| Malatxeberria, S | 1 |
| Sáez, A | 1 |
| Sánchez, L | 1 |
| Garcia, J | 1 |
| Ruiz-Marcellan, MC | 1 |
| Mollejo, M | 1 |
| Guo, J | 1 |
| Zhu, YP | 1 |
| Gao, J | 1 |
| Jia, CS | 1 |
| Zhou, CY | 1 |
| Deng, Q | 1 |
| Wang, XX | 1 |
| Liang, H | 1 |
| Koga, T | 1 |
| Mizokami, A | 1 |
| Nakashima, M | 1 |
| Shimizu, T | 1 |
| Chiwata, M | 1 |
| Daisuke, N | 1 |
| Kawakami, A | 1 |
| Ko, YB | 1 |
| Kwon, BS | 1 |
| Song, IH | 1 |
| Kim, DH | 4 |
| Koh, MS | 1 |
| Pak, MG | 1 |
| Ju, MH | 1 |
| Jeong, JS | 1 |
| Ferreiro-Martínez, JJ | 1 |
| Ferrer-Bordes, S | 1 |
| García-Frade, J | 2 |
| Peñalver, J | 1 |
| Bello-López, JL | 1 |
| Hedermann, G | 1 |
| Marquart, HV | 1 |
| Vissing, J | 1 |
| Nakamura, T | 2 |
| Chino, O | 1 |
| Yokoyama, D | 1 |
| Hanashi, T | 1 |
| Kikuchi, M | 2 |
| Tajima, T | 1 |
| Sadahiro, S | 1 |
| Kondoh, Y | 1 |
| Makuuchi, H | 1 |
| Hua, F | 1 |
| Zuo, C | 1 |
| Guan, Y | 1 |
| Okumura, H | 1 |
| Uike, N | 4 |
| Hidaka, T | 1 |
| Takatsuka, Y | 1 |
| Eto, T | 5 |
| Tsuda, H | 4 |
| Fujisaki, T | 4 |
| Tsuneyoshi, N | 1 |
| Nagafuji, K | 4 |
| Harada, M | 3 |
| Repici, J | 1 |
| Tong, AK | 1 |
| Neo, SH | 1 |
| Kok, TY | 1 |
| Wu, M | 1 |
| Du, T | 1 |
| Leng, X | 1 |
| Yönal-Hindilerden, İ | 1 |
| Hindilerden, F | 1 |
| Arslan, S | 1 |
| Doğan, İÖ | 1 |
| Öneç, B | 1 |
| Öneç, K | 1 |
| Esbah, AÜ | 1 |
| Esbah, O | 1 |
| de Oliveira, C | 1 |
| Silvia Passos Lima, C | 1 |
| Kim, RB | 1 |
| Basit, A | 1 |
| Awan, UK | 1 |
| Bashir, H | 1 |
| Khan, SA | 1 |
| Gomez-Gelvez, JC | 1 |
| Salama, ME | 1 |
| Perkins, SL | 2 |
| Leavitt, M | 1 |
| Inamdar, KV | 1 |
| Nan, X | 1 |
| Adike, A | 1 |
| Rice, L | 1 |
| Bunin, V | 1 |
| Song, F | 1 |
| Sriskandarajah, P | 1 |
| Davies, R | 1 |
| Ciochetto, C | 1 |
| Ansuinelli, M | 1 |
| Gandolfi, L | 3 |
| Bryk, AH | 1 |
| Mensah, P | 1 |
| Gałązka, K | 1 |
| Trofimiuk-Müldner, M | 1 |
| Wyrobek, Ł | 1 |
| Sawiec, A | 1 |
| Liu, PP | 1 |
| Canales, MA | 1 |
| Domingo-Domenech, E | 1 |
| Gardella, S | 3 |
| Asensio, A | 1 |
| Barrington, S | 2 |
| Linton, K | 1 |
| Stern, S | 1 |
| Peggs, K | 2 |
| Jensen, AK | 1 |
| Holst, R | 1 |
| de Stricker, K | 1 |
| Plesner, T | 1 |
| Mourits-Andersen, T | 3 |
| Frederiksen, M | 2 |
| Schnell, F | 1 |
| Rifkin, R | 1 |
| Smith, S | 1 |
| Nguyen, T | 1 |
| Hahka-Kemppinen, M | 1 |
| Thornton, D | 1 |
| Habermann, T | 2 |
| Roncador, G | 1 |
| He, A | 1 |
| Xiao, F | 1 |
| Zhong, H | 1 |
| Ni, B | 1 |
| Shen, L | 1 |
| Zheng, L | 1 |
| Qiu, H | 1 |
| Yuan, J | 1 |
| Lu, J | 1 |
| Gao, L | 1 |
| Lv, S | 1 |
| Heggermont, WA | 1 |
| Evenepoel, P | 1 |
| Sprangers, B | 1 |
| Lerut, E | 1 |
| Claes, K | 1 |
| Teramura, Y | 1 |
| Kameda, K | 1 |
| Kanda, J | 1 |
| Gomyo, A | 1 |
| Hayakawa, J | 1 |
| Akahoshi, Y | 1 |
| Ugai, T | 1 |
| Ishihara, Y | 1 |
| Sakamoto, K | 1 |
| Wada, H | 2 |
| Terasako-Saito, K | 1 |
| Nakasone, H | 1 |
| Kako, S | 1 |
| Mori, K | 1 |
| Sekimoto, E | 1 |
| Shibata, H | 1 |
| Noda, T | 1 |
| Shikiji, T | 1 |
| Shigekiyo, T | 1 |
| Ozaki, S | 1 |
| de Oliveira Costa, R | 1 |
| Hallack Neto, A | 1 |
| Siqueira, S | 1 |
| Lage, LA | 1 |
| de Paula, HM | 1 |
| Coutinho, AM | 1 |
| Pereira, J | 3 |
| Chun, K | 1 |
| Jeong, J | 1 |
| Delforoush, M | 1 |
| Berglund, M | 3 |
| Edqvist, PH | 1 |
| Gullbo, J | 1 |
| Kawasaki, R | 1 |
| Sone, H | 1 |
| Karanam, A | 1 |
| Rath, S | 1 |
| Yadav, A | 1 |
| Tembhare, P | 1 |
| Subramanian, P | 1 |
| Huang, YQ | 1 |
| Zheng, RJ | 1 |
| Wu, RJ | 1 |
| Ma, XD | 1 |
| Lu, GQ | 1 |
| Tan, JP | 1 |
| Li, ZH | 1 |
| Xing, MT | 1 |
| Zhang, YP | 1 |
| Zhan, XR | 1 |
| Xiao, DY | 2 |
| Tamura, M | 3 |
| Kang, B | 1 |
| Fehniger, TA | 1 |
| Nickelsen, M | 1 |
| Persky, D | 1 |
| Chai, Y | 1 |
| Xiao, Z | 2 |
| Miao, K | 1 |
| Porpaczy, E | 1 |
| Mayerhoefer, M | 1 |
| Salzer-Muhar, U | 1 |
| Jaeger, U | 7 |
| Jodra, S | 1 |
| Arcos, DA | 1 |
| Cordovilla, R | 1 |
| Barrueco, M | 1 |
| Falkiewicz, MK | 1 |
| Chu, BA | 1 |
| Behdad, A | 1 |
| Bast, MA | 1 |
| Kruczek, KR | 1 |
| Smith, SE | 1 |
| Hernandez-Ilizaliturri, F | 1 |
| Rajguru, S | 1 |
| Maly, JJ | 1 |
| Vanslambrouck, C | 1 |
| Chan, TS | 1 |
| Khong, PL | 1 |
| Nolasco-Medina, D | 1 |
| Reynoso-Noveron, N | 1 |
| Mohar-Betancourt, A | 1 |
| García-Perez, O | 1 |
| Denizon, N | 1 |
| Bolle, D | 1 |
| Truong, C | 1 |
| Besançon, A | 1 |
| Sandrini, J | 1 |
| Anghel, A | 1 |
| Farhi, J | 1 |
| Ghnaya, H | 1 |
| Baugier de Materre, A | 1 |
| Curran, KM | 1 |
| Schaffer, PA | 1 |
| Frank, CB | 1 |
| Lana, SE | 1 |
| Hamil, LE | 1 |
| Burton, JH | 1 |
| Labadie, J | 1 |
| Ehrhart, EJ | 1 |
| Avery, PR | 1 |
| Tada, K | 1 |
| Maeshima, AM | 3 |
| Hiraoka, N | 2 |
| Watanabe, T | 3 |
| Heike, Y | 1 |
| Yuba, T | 1 |
| Kodama, M | 1 |
| Uda, S | 1 |
| Yoshimura, A | 1 |
| Kurisu, N | 1 |
| Huang, HW | 1 |
| Jiang, YB | 1 |
| Fu, TW | 1 |
| Xu, T | 1 |
| Kim, KM | 3 |
| Lim, I | 1 |
| Kim, BI | 1 |
| Lim, SM | 1 |
| Soltani, Z | 1 |
| Davatchi, F | 1 |
| Kristensen, SS | 1 |
| Tholstrup, D | 3 |
| Harsløf, LB | 1 |
| Pedersen, OB | 1 |
| César, A | 1 |
| Calistru, A | 1 |
| Pardal, J | 1 |
| Magina, S | 1 |
| Mota, A | 1 |
| Azevedo, F | 1 |
| Chan, DYC | 1 |
| Chan, DTM | 1 |
| Poon, WS | 1 |
| Wong, GKC | 1 |
| Zhai, L | 1 |
| Peng, S | 1 |
| Zhu, K | 1 |
| Yu, R | 1 |
| Lin, L | 4 |
| Cai, QQ | 2 |
| Hu, LY | 1 |
| Geng, QR | 1 |
| Lu, ZH | 2 |
| Xia, ZJ | 6 |
| Moling, O | 1 |
| Piccin, A | 2 |
| Tauber, M | 1 |
| Marinello, P | 1 |
| Canova, M | 1 |
| Casini, M | 1 |
| Negri, G | 2 |
| Raffeiner, B | 1 |
| Binazzi, R | 1 |
| Gandini, L | 1 |
| Vecchiato, C | 1 |
| Rimenti, G | 1 |
| Billio, A | 3 |
| Choi, JC | 1 |
| Hu, RH | 1 |
| Sun, WL | 1 |
| Hui, WH | 1 |
| Guo, YX | 1 |
| Wan, SG | 1 |
| Su, L | 1 |
| Bolshinsky, M | 1 |
| Luan, J | 1 |
| Hong, JS | 1 |
| Kim, JA | 3 |
| Kong, JH | 2 |
| Jun, HJ | 1 |
| Park, EK | 2 |
| Zhong, HJ | 2 |
| Morris, T | 1 |
| Naik, O | 1 |
| Srithana, N | 1 |
| Natividad, F | 1 |
| Chung, JK | 1 |
| Belder, N | 1 |
| Kuzu, I | 1 |
| Svendsen, P | 1 |
| Shekhrajka, N | 1 |
| Nielsen, KL | 1 |
| Vestergaard, P | 1 |
| Poulsen, MØ | 1 |
| Vistisen, AK | 1 |
| Munksgaard, PS | 2 |
| Jensen, P | 2 |
| Frøkjær, JB | 1 |
| Telio, D | 1 |
| Tan, K | 1 |
| Wang, XJ | 1 |
| Desai, P | 3 |
| Reddy, N | 2 |
| Yoon, S | 1 |
| Lee, JB | 2 |
| Lee, Y | 1 |
| How, J | 1 |
| Blattner, M | 1 |
| Fowler, S | 1 |
| Wang-Gillam, A | 1 |
| Schindler, SE | 1 |
| Zahiu, DC | 1 |
| Mocanu, C | 1 |
| Rimbaş, M | 1 |
| Saksena, A | 1 |
| Thakral, B | 2 |
| Liu, D | 1 |
| Dong, M | 4 |
| Guan, S | 1 |
| Sun, H | 1 |
| Wu, N | 1 |
| Bai, J | 1 |
| Sun, D | 1 |
| Jin, Y | 1 |
| Angrili, F | 1 |
| DeCosta, L | 1 |
| Wetten, S | 1 |
| Huang, G | 1 |
| Pauly, F | 1 |
| Fjordén, K | 1 |
| Björkholm, M | 2 |
| Fluge, Ø | 1 |
| Eriksson, M | 2 |
| Isinger-Ekstrand, A | 1 |
| Borrebaeck, CA | 1 |
| Wingren, C | 1 |
| Deng, T | 1 |
| Bendtsen, MD | 1 |
| Bekric, E | 1 |
| Brieghel, C | 1 |
| Nielsen, KB | 1 |
| Tawara, I | 2 |
| Imai, H | 2 |
| Ono, R | 1 |
| Nosaka, T | 1 |
| Weller, EA | 6 |
| Peterson, BA | 5 |
| Baizer, L | 1 |
| Maloney, DG | 2 |
| Meissner, J | 1 |
| Finel, H | 1 |
| Dietrich, S | 2 |
| Boumendil, A | 1 |
| Kanfer, E | 1 |
| Laboure, G | 1 |
| Abecasis, M | 1 |
| Cornelissen, J | 1 |
| Delage, J | 1 |
| Hess, U | 1 |
| Ludwig, H | 2 |
| Pioltelli, P | 1 |
| Robinson, S | 1 |
| Samaras, P | 2 |
| Dreger, P | 1 |
| Ke, XY | 1 |
| Loghavi, S | 1 |
| Hu, B | 1 |
| Park, YH | 5 |
| Yi, HG | 1 |
| Lee, MH | 3 |
| Kim, CS | 1 |
| Lim, JH | 1 |
| Arboe, B | 1 |
| Højberg, L | 1 |
| Bergmann, OJ | 1 |
| Lassen, T | 1 |
| Spaccarotella, E | 1 |
| Rasi, S | 3 |
| Deambrogi, C | 1 |
| Spina, V | 1 |
| Bruscaggin, A | 2 |
| Favini, C | 1 |
| Serra, R | 1 |
| Ramponi, A | 2 |
| Boldorini, R | 1 |
| Foà, R | 2 |
| Hong, M | 1 |
| Tang, L | 1 |
| Liang, B | 1 |
| Nako, Y | 1 |
| Yamazaki, S | 2 |
| Kitade, T | 1 |
| Hariu, T | 1 |
| Wakasa, M | 1 |
| Nakanishi, M | 1 |
| Sonoyama, T | 1 |
| Iwahara, Y | 1 |
| Shinohara, T | 1 |
| Naruse, K | 1 |
| Komatsu, Y | 1 |
| Butcher, B | 1 |
| Taper, J | 1 |
| Johnston, A | 1 |
| Ho, SJ | 1 |
| Cull, G | 1 |
| Fay, K | 1 |
| Lewis, ID | 1 |
| Milliken, S | 1 |
| Hahn, U | 1 |
| Kannourakis, G | 1 |
| Watson, AM | 1 |
| Warburton, P | 1 |
| Hofman, MS | 1 |
| Huang, YH | 2 |
| Gao, XD | 1 |
| Huang, JY | 1 |
| Bashash, M | 1 |
| Schuetz, JM | 1 |
| Leach, S | 3 |
| Berry, BR | 1 |
| Hu, H | 1 |
| Brooks-Wilson, AR | 1 |
| Spinelli, JJ | 3 |
| Gifford, G | 1 |
| Gabrielli, S | 1 |
| Gill, A | 1 |
| Greenwood, M | 1 |
| Wong, K | 1 |
| Best, G | 1 |
| Nevell, D | 1 |
| McIlroy, K | 1 |
| Kliman, D | 1 |
| Ilmay-Gillespie, L | 1 |
| Tiley, C | 1 |
| Miranda, S | 1 |
| Armytage, T | 1 |
| Stevenson, W | 1 |
| Cortelazzo, S | 2 |
| Di Nicola, M | 1 |
| Mulé, A | 1 |
| Castellino, C | 1 |
| Di Raimondo, F | 1 |
| Benedetti, F | 1 |
| La Nasa, G | 1 |
| Trentin, L | 1 |
| Frezzato, M | 1 |
| Falorio, S | 1 |
| Chilosi, M | 2 |
| Bruna, R | 2 |
| Pileri, S | 5 |
| Masciulli, A | 1 |
| Jia, J | 1 |
| Michaelsen, TY | 1 |
| Smith, D | 1 |
| Rady, K | 1 |
| Mylam, KJ | 1 |
| Holmberg, S | 1 |
| Cordua, S | 1 |
| Jensen, KB | 1 |
| Piršić, M | 1 |
| Ajduković, R | 4 |
| Falduto, A | 1 |
| Cimino, F | 1 |
| Speciale, A | 1 |
| Musolino, C | 1 |
| Gangemi, S | 1 |
| Saija, A | 1 |
| Allegra, A | 1 |
| Patel, RD | 1 |
| Walker, C | 1 |
| Canter, DJ | 1 |
| Wang, JW | 1 |
| Chen, JY | 1 |
| Lu, C | 1 |
| Tang, X | 1 |
| Cho, SF | 1 |
| Hsiao, HH | 1 |
| Huang, CT | 1 |
| Tsai, YF | 1 |
| Wang, HC | 1 |
| Liu, TC | 1 |
| Bechir, A | 1 |
| Asma, A | 1 |
| Haifa, R | 1 |
| Nesrine, A | 1 |
| Yosra, BY | 1 |
| Badreddine, S | 1 |
| Abderrahim, K | 1 |
| Jucker, D | 1 |
| Choi, IY | 1 |
| Yu, W | 1 |
| Yokote, T | 2 |
| Akioka, T | 2 |
| Takubo, T | 2 |
| Tsuji, M | 2 |
| Hanafusa, T | 2 |
| Reiter, A | 1 |
| Grogan, TM | 3 |
| Martel, RR | 1 |
| Sabalos, CM | 1 |
| Seligmann, B | 1 |
| Visani, G | 2 |
| Ferrara, F | 2 |
| Alesiani, F | 2 |
| Ronconi, S | 1 |
| Catarini, M | 2 |
| D'adamo, F | 1 |
| Guiducci, B | 2 |
| Bernardi, D | 1 |
| Barulli, S | 1 |
| Piccaluga, P | 1 |
| Rocchi, M | 1 |
| Isidori, A | 2 |
| Asai, H | 4 |
| Komatsu, H | 2 |
| Ikeda, K | 5 |
| Tanimoto, M | 4 |
| Rickman, DS | 1 |
| de Reynies, A | 2 |
| Gisselbrecht, C | 16 |
| Reyes, F | 7 |
| Labouyrie, E | 1 |
| Bastard, C | 3 |
| Terano, T | 1 |
| Andhavarapu, S | 1 |
| Tolentino, AM | 1 |
| Jha, C | 1 |
| Ravi, J | 1 |
| Carlson, R | 1 |
| Nair, GR | 1 |
| Fotis, MA | 1 |
| Perry, KD | 1 |
| Hans, CP | 4 |
| Kuwatsuka, Y | 2 |
| Taji, H | 4 |
| Chang, PM | 1 |
| Hsieh, SL | 1 |
| Wang, WS | 2 |
| Yang, MH | 1 |
| Dognini, GP | 2 |
| Bairey, O | 1 |
| Szomor, A | 1 |
| Horvath, B | 1 |
| Uziel, L | 3 |
| Soffietti, R | 1 |
| Ambrosetti, A | 3 |
| Willemze, R | 3 |
| Candoni, A | 1 |
| De Renzo, A | 4 |
| Doglioni, C | 2 |
| Qiu, HX | 1 |
| Qian, SX | 1 |
| Wu, HX | 1 |
| Sheng, RL | 1 |
| Momose, S | 2 |
| Tamaru, J | 3 |
| Kishi, H | 1 |
| Mikata, I | 1 |
| Mori, M | 3 |
| Toyozumi, Y | 1 |
| Itoyama, S | 2 |
| Guo, HY | 1 |
| Zhao, XM | 1 |
| Cao, JN | 3 |
| Hu, XC | 2 |
| Yin, JL | 1 |
| Hong, XN | 3 |
| Kremenetskaia, AM | 4 |
| Makhinia, VA | 1 |
| Kaplanskaia, IB | 5 |
| Samoĭlova, RS | 3 |
| Bariakh, EA | 1 |
| Krasil'nikova, BB | 1 |
| Gubkin, AV | 2 |
| Iliushkina, EA | 1 |
| Mar'in, DS | 2 |
| Morozova, AK | 1 |
| Gemdzhian, EG | 3 |
| Vorob'ev, AI | 1 |
| Zamiatina, VI | 1 |
| Giliazitdinova, EA | 2 |
| Vorob'ev, IA | 2 |
| Gotman, LN | 2 |
| Kesel'man, SA | 1 |
| Sakhibov, IaD | 1 |
| Egorova, EK | 1 |
| Shutova, NA | 1 |
| Galstian, GM | 1 |
| Savenko, TA | 1 |
| Kremenetskia, AM | 1 |
| Kovalenko, AV | 1 |
| Kliasova, GA | 1 |
| Kozlova, SIu | 1 |
| Massoud, M | 1 |
| Koscielny, S | 2 |
| Lapusan, S | 2 |
| Gleissner, B | 2 |
| Chen, QS | 3 |
| You, JH | 2 |
| Shen, ZX | 4 |
| Yokoyama, H | 1 |
| Miura, Y | 1 |
| Nishizawa, M | 1 |
| Kaneko, H | 2 |
| Tsudo, M | 2 |
| Akbayir, O | 1 |
| Güngördük, K | 1 |
| Gülkilik, A | 1 |
| Yavuz, E | 1 |
| Tekirdağ, AI | 1 |
| Odabaş, E | 1 |
| Zhang, HY | 1 |
| Book, L | 1 |
| Naganuma, T | 1 |
| Iizawa, Y | 1 |
| Isaji, S | 1 |
| Dai, CW | 1 |
| Zhang, GS | 1 |
| Pei, MF | 1 |
| Brooks-Wilson, A | 2 |
| Chhanabhai, M | 10 |
| Brinkman, RR | 2 |
| Weng, AP | 3 |
| Kim, DC | 2 |
| Hwang, SH | 1 |
| Lee, EY | 1 |
| Dave, SS | 1 |
| Xiao, W | 1 |
| Powell, J | 1 |
| Tan, B | 1 |
| Vose, J | 3 |
| Bast, M | 3 |
| Kyle, A | 1 |
| May, L | 1 |
| Troen, G | 1 |
| Kvaloy, S | 3 |
| Martinez, A | 3 |
| Montserrat, E | 4 |
| Sweetenham, J | 1 |
| Hartmann, E | 1 |
| Muller-Hermelink, HK | 2 |
| Wrench, D | 1 |
| Lister, TA | 2 |
| Eng, C | 1 |
| Sar, A | 1 |
| Perizzolo, M | 1 |
| Difrancesco, LM | 1 |
| Demetrick, DJ | 1 |
| Rozenbaum, M | 1 |
| Slobodin, G | 1 |
| Boulman, N | 1 |
| Feld, J | 1 |
| Avshovich, N | 1 |
| Ben-Arieh, Y | 2 |
| Rosner, I | 1 |
| Rahmouni, A | 1 |
| Hemery, F | 1 |
| Lin, C | 1 |
| El Gnaoui, T | 1 |
| Gaillard, I | 1 |
| Kuhnowski, F | 1 |
| Fujita, Y | 1 |
| Ikebuchi, M | 1 |
| Tarui, S | 1 |
| Irie, H | 1 |
| Zaragoza, V | 1 |
| Martínez, L | 1 |
| Pérez-Ferriols, A | 1 |
| Alegre, V | 1 |
| Ben Salah, H | 1 |
| Ghorbel, L | 1 |
| Krichen, MS | 1 |
| Bellaaj, H | 1 |
| Elloumi, M | 2 |
| Frikha, M | 1 |
| Daoud, J | 2 |
| Chargari, C | 1 |
| Gillion, N | 1 |
| Ghalibafian, M | 1 |
| Girinsky, T | 1 |
| Magné, N | 1 |
| Di Tommaso, L | 1 |
| Bossi, P | 1 |
| Roncalli, M | 1 |
| Yun, SJ | 1 |
| Yang, DW | 1 |
| Won, YH | 1 |
| Seol, YM | 3 |
| Choi, YJ | 5 |
| Cho, GJ | 3 |
| Serrano-Navarro, I | 1 |
| Rodríguez-López, JF | 1 |
| Navas-Espejo, R | 1 |
| Pérez-Jacoiste, MA | 1 |
| Martínez-González, MA | 1 |
| Prieto, S | 1 |
| Yu, Y | 1 |
| Jun-Min, L | 1 |
| Jian-Qing, M | 1 |
| Qiu-Sheng, C | 1 |
| Yu, C | 1 |
| Wei-Li, Z | 1 |
| Jian-Hua, Y | 1 |
| Hui-Jin, Z | 1 |
| Yan, W | 1 |
| Shu, C | 1 |
| Zhi-Xiang, S | 1 |
| Woolcock, B | 1 |
| deLeeuw, RJ | 1 |
| Song, HS | 2 |
| Jung, JS | 1 |
| Grange, F | 1 |
| Maubec, E | 1 |
| Bagot, M | 2 |
| Beylot-Barry, M | 1 |
| Joly, P | 1 |
| Dalle, S | 1 |
| Delaporte, E | 1 |
| Dereure, O | 1 |
| Bachelez, H | 1 |
| Vergier, B | 1 |
| D'Incan, M | 1 |
| Nishimori, H | 1 |
| Nawa, Y | 1 |
| Togitani, K | 1 |
| Takimoto, H | 1 |
| Hiramatsu, Y | 1 |
| Kiguchi, T | 1 |
| Yamane, H | 2 |
| Tabayashi, T | 1 |
| Sezaki, N | 1 |
| Yamasuji, Y | 1 |
| Sugiyama, H | 1 |
| Tabuchi, T | 1 |
| Kataoka, I | 1 |
| Fujii, N | 1 |
| Ishimaru, F | 1 |
| Shinagawa, K | 2 |
| Hara, M | 1 |
| Ueda, Y | 1 |
| Marusawa, H | 1 |
| Kadowaki, N | 1 |
| Uchiyama, T | 1 |
| Chiba, T | 1 |
| Rajnics, P | 1 |
| Csomor, J | 2 |
| Krenács, L | 1 |
| Pajor, L | 2 |
| Kollár, B | 2 |
| Kertész, Z | 1 |
| Egyed, M | 2 |
| Zechmann, CM | 1 |
| Buchheidt, D | 1 |
| Hildenbrand, R | 1 |
| Teubner, J | 1 |
| Ilic, I | 3 |
| Nola, M | 1 |
| Sonicki, Z | 1 |
| Basic-Kinda, S | 1 |
| Radman, I | 3 |
| Labar, B | 3 |
| Lai, GG | 1 |
| Chen, CY | 1 |
| Wu, CC | 1 |
| Hsiao, CW | 1 |
| Chen, CW | 1 |
| Jin, JS | 1 |
| Jao, SW | 1 |
| Capello, D | 3 |
| Castelli, A | 1 |
| De Paoli, L | 2 |
| Colovic, N | 1 |
| Jurisic, V | 1 |
| Terzic, T | 1 |
| Atkinson, HD | 1 |
| Colovic, M | 1 |
| Al-Katib, AM | 1 |
| Aboukameel, A | 4 |
| Mohammad, R | 1 |
| Bissery, MC | 1 |
| Zuany-Amorim, C | 1 |
| Robledo, C | 1 |
| García, JL | 1 |
| García, E | 1 |
| Sáez, AI | 1 |
| Gutiérrez, NC | 1 |
| Hernández, JM | 1 |
| Lee, SG | 1 |
| Sug, LJ | 1 |
| Shi, YX | 2 |
| Gentles, AJ | 1 |
| Levy, R | 3 |
| Hirata, Y | 1 |
| Miyoshi, T | 1 |
| Iwaki, K | 1 |
| Takayama, A | 1 |
| Moruzzo, D | 1 |
| Bindi, M | 1 |
| Bongiorni, MG | 1 |
| Castiglioni, M | 1 |
| Bahlis, N | 1 |
| Borlenghi, E | 1 |
| Drera, M | 1 |
| Emile, JF | 3 |
| Ranta, D | 2 |
| Gabarre, J | 3 |
| Morchhauser, F | 1 |
| Hosoi, M | 1 |
| Kim, SN | 1 |
| Do, C | 1 |
| Lamant, L | 2 |
| Delsol, G | 3 |
| Brousset, P | 1 |
| Biswas, T | 1 |
| Chen, R | 1 |
| Hyrien, O | 1 |
| Bernstein, S | 1 |
| Liesveld, J | 1 |
| Phillips, G | 1 |
| Seki, R | 4 |
| Kawano, F | 3 |
| Gondo, H | 3 |
| Makino, S | 3 |
| Taguchi, F | 3 |
| Kamimura, T | 4 |
| Ogawa, R | 2 |
| Shimoda, K | 3 |
| Suzushima, H | 2 |
| Tsukazaki, K | 2 |
| Higuchi, M | 2 |
| Iwahashi, M | 2 |
| Imamura, Y | 2 |
| Okamura, T | 6 |
| Mazur, G | 1 |
| Poreba, R | 1 |
| Jaźwiec, B | 1 |
| Kuliczkowski, K | 1 |
| Xia, ZG | 2 |
| Ding, F | 1 |
| Hu, JP | 1 |
| Hayashi, A | 1 |
| Miyakawa, Y | 1 |
| Bokuda, K | 1 |
| Kimura, T | 1 |
| Nakashima, E | 1 |
| Irie, R | 1 |
| Sugiura, H | 1 |
| Ohsone, Y | 1 |
| Akizuki, S | 1 |
| Horsman, DE | 2 |
| Geng, H | 1 |
| Li, M | 3 |
| Jaye, DL | 1 |
| Dietrich, PY | 1 |
| Deisch, J | 1 |
| Fuda, FB | 1 |
| Karandikar, N | 1 |
| Arbini, AA | 1 |
| Zhou, XJ | 1 |
| Sanchez, A | 1 |
| Maximiano, C | 1 |
| Cantos, B | 1 |
| Méndez, M | 1 |
| Bonilla, F | 1 |
| Kaderli, AA | 1 |
| Baran, I | 1 |
| Aydin, O | 1 |
| Bicer, M | 1 |
| Akpinar, T | 1 |
| Ozkalemkas, F | 1 |
| Yesilbursa, D | 1 |
| Gullulu, S | 1 |
| Kan, E | 1 |
| Benharroch, D | 1 |
| Juweid, ME | 1 |
| Wiseman, G | 1 |
| Rodenburg, EM | 1 |
| Maartense, E | 1 |
| Posthuma, EF | 1 |
| Yu, GH | 1 |
| Qu, GM | 1 |
| Yao, WD | 1 |
| Lang, ZQ | 1 |
| Laszlo, D | 1 |
| Andreola, G | 1 |
| Radice, D | 1 |
| Calabrese, L | 1 |
| Rafaniello, PR | 1 |
| Sammassimo, S | 1 |
| Alietti, A | 1 |
| Agazzi, A | 1 |
| Shustik, J | 1 |
| Han, G | 1 |
| Ben Neriah, S | 1 |
| Yi, SH | 1 |
| Zou, DH | 1 |
| An, G | 1 |
| Zhao, YZ | 1 |
| Qi, JY | 1 |
| Qiu, LG | 1 |
| Kyllönen, H | 1 |
| Pasanen, AK | 2 |
| Fina, MP | 1 |
| Venturini, F | 1 |
| Petti, MC | 2 |
| Perrotti, A | 1 |
| Baccarani, M | 7 |
| Gratzinger, D | 2 |
| Talreja, N | 2 |
| Tibshirani, RJ | 1 |
| Shyam, R | 1 |
| Horning, S | 2 |
| Yang, HY | 1 |
| Ke, HY | 1 |
| Hong, GJ | 1 |
| Tsai, YT | 1 |
| Lin, CY | 1 |
| Li, CY | 1 |
| Tsai, CS | 1 |
| Cleto, S | 4 |
| Ko, GH | 1 |
| Song, DH | 1 |
| Yang, JW | 1 |
| Schneider, T | 1 |
| Molnár, Z | 1 |
| Deák, B | 1 |
| Várady, E | 1 |
| Tóth, E | 1 |
| Matolcsy, A | 2 |
| Lovey, J | 1 |
| Lengyel, Z | 1 |
| Petri, K | 1 |
| Gaudi, I | 1 |
| Rosta, A | 1 |
| Shenkier, TN | 1 |
| Marín García, D | 1 |
| Cárdenas Lafuente, F | 1 |
| Utrilla Ayala, Mdel C | 1 |
| Galán Jurado, MV | 1 |
| Jiménez Martín, JJ | 1 |
| García Ordóñez, MA | 1 |
| Jovanović, MP | 1 |
| Jaković, L | 1 |
| Bogdanović, A | 1 |
| Martinović, VC | 1 |
| Morley, AM | 1 |
| Verity, DH | 1 |
| Meligonis, G | 1 |
| Rose, GE | 1 |
| Salemis, NS | 1 |
| Gourgiotis, S | 1 |
| Tsiambas, E | 1 |
| Karagkiouzis, G | 1 |
| Nakos, G | 1 |
| Karathanasis, V | 1 |
| Yun, J | 2 |
| Kim, K | 2 |
| Montanini, A | 1 |
| Notter, M | 1 |
| Dyer, MJS | 1 |
| Petrini, M | 1 |
| Barbato, A | 1 |
| Kayitalire, L | 1 |
| Han, XH | 1 |
| Ren, HY | 1 |
| Cen, XN | 1 |
| Wang, JM | 2 |
| Han, MZ | 1 |
| Shen, XM | 1 |
| Fulco, PP | 1 |
| Hynicka, L | 1 |
| Rackley, D | 1 |
| Nelson, BP | 1 |
| Raji, A | 1 |
| Brakman, A | 1 |
| Parimi, V | 1 |
| Schumacker, PT | 1 |
| Yu, JI | 1 |
| Nam, H | 1 |
| Ahn, YC | 1 |
| Park, K | 1 |
| Bayraktar, S | 1 |
| Bassini, W | 1 |
| Goodman, M | 1 |
| Guyot, A | 1 |
| Ortonne, N | 1 |
| Valeyrie-Allanore, L | 1 |
| Grant, N | 4 |
| Wayne, AS | 1 |
| Carrasquillo, JA | 1 |
| Yarchoan, R | 2 |
| Ine, S | 1 |
| Onoda, H | 2 |
| Riihijärvi, S | 1 |
| Koivula, S | 2 |
| Nyman, H | 3 |
| Rydström, K | 3 |
| Bienvenu, J | 1 |
| Broussais-Guillaumot, F | 2 |
| Heider, H | 1 |
| Haile, SR | 1 |
| Petrausch, U | 1 |
| Schaefer, NG | 1 |
| Siciliano, RD | 1 |
| Meisel, A | 1 |
| Mischo, A | 1 |
| Zweifel, M | 1 |
| Knuth, A | 1 |
| Stenner-Liewen, F | 1 |
| Teruya-Feldstein, J | 1 |
| Sima, C | 1 |
| Iasonos, A | 1 |
| Portlock, CS | 7 |
| Horwitz, S | 2 |
| Weaver, SA | 1 |
| Meikle, JL | 1 |
| Filippa, DA | 1 |
| Caravelli, JF | 1 |
| Pastor, DM | 1 |
| Eggers, AD | 1 |
| Drabick, JJ | 1 |
| Loughran, TP | 1 |
| Bayerl, MG | 1 |
| Shope, TR | 1 |
| Hyo, R | 2 |
| Cho, HJ | 1 |
| Wen, MC | 1 |
| Jan, YJ | 1 |
| Li, MC | 1 |
| Lin, A | 1 |
| Kamel, S | 1 |
| O'Connor, S | 1 |
| Lee, N | 1 |
| Nandurkar, H | 1 |
| Hochberg, EP | 2 |
| Rawal, B | 1 |
| Motyckova, G | 1 |
| McAfee, SL | 1 |
| Spitzer, TR | 1 |
| Troutaud, D | 1 |
| Petit, B | 1 |
| Bellanger, C | 1 |
| Marin, B | 1 |
| Gourin-Chaury, MP | 1 |
| Petit, D | 1 |
| Olivrie, A | 1 |
| Feuillard, J | 1 |
| Jauberteau, MO | 1 |
| Bordessoule, D | 5 |
| Aurora, V | 1 |
| Nelson, B | 1 |
| Krajewska, M | 2 |
| Felgar, RE | 2 |
| Weick, JK | 3 |
| Reed, JC | 2 |
| Laatiri, MA | 1 |
| Ali, ZB | 1 |
| Ben Othmen, T | 1 |
| Msadek, F | 1 |
| Toumi, N | 1 |
| Bouaouina, N | 1 |
| Maalej, M | 1 |
| Ghannem, H | 1 |
| Meddeb, B | 1 |
| Hirakawa, T | 1 |
| Yamaguchi, H | 1 |
| Yokose, N | 1 |
| Gomi, S | 1 |
| Inokuchi, K | 1 |
| Dan, K | 1 |
| Sung-Yong, O | 1 |
| Yun, EY | 1 |
| Skugor, ND | 1 |
| Perić, Z | 1 |
| Vrhovac, R | 1 |
| Radić-Kristo, D | 1 |
| Kardum-Skelin, I | 2 |
| Jaksić, B | 3 |
| Parmentier, F | 1 |
| Vasilj, A | 1 |
| Kojić-Katović, S | 1 |
| Maricević, I | 1 |
| Zokvić, E | 1 |
| Kelcec, IB | 1 |
| Tomas, D | 1 |
| Curić-Jurić, S | 1 |
| Mazloom, A | 2 |
| Iyengar, P | 1 |
| Horace, P | 2 |
| Tabareau, F | 1 |
| Ragage, F | 1 |
| Berger, N | 1 |
| Guterman, R | 1 |
| Bruch, JF | 1 |
| Kriwalsky, MS | 1 |
| Schroers, R | 1 |
| Stricker, I | 1 |
| Hollstein, S | 1 |
| Kunkel, M | 1 |
| Choi, DR | 1 |
| Ahn, HJ | 1 |
| Park, BH | 2 |
| Bolwell, BJ | 1 |
| Rybicki, LA | 1 |
| Kang, T | 1 |
| Advani, A | 1 |
| Thakkar, S | 1 |
| Sobecks, R | 1 |
| Kalaycio, M | 1 |
| Sweetenham, JW | 1 |
| Rsitow, K | 1 |
| Koudaira, M | 1 |
| Katsube, A | 1 |
| Saotome, T | 1 |
| Gutiérrez-García, G | 1 |
| Colomo, L | 2 |
| Villamor, N | 1 |
| Arenillas, L | 1 |
| Cardesa, T | 1 |
| García-Herrera, A | 1 |
| Setoain, X | 1 |
| Rodríguez, S | 1 |
| Ghita, G | 1 |
| Turner, K | 1 |
| Owen, R | 1 |
| Montini, GC | 1 |
| Fina, M | 3 |
| Lepeu, G | 2 |
| Plantier, I | 1 |
| Castaigne, S | 3 |
| Lefort, S | 1 |
| Marit, G | 2 |
| Macro, M | 2 |
| Hellmann, M | 1 |
| Hammerman, P | 1 |
| Toomey, C | 1 |
| Takvorian, T | 1 |
| Muzikansky, A | 1 |
| Sbitti, Y | 1 |
| Ismaili, N | 1 |
| Bensouda, Y | 1 |
| Kadiri, H | 1 |
| Ichou, M | 1 |
| Linderoth, J | 2 |
| Joost, P | 1 |
| Bendahl, PO | 1 |
| Hiramoto, K | 1 |
| Kuroki, M | 1 |
| Shoji, H | 1 |
| Matsumura, Y | 1 |
| Miura, A | 1 |
| Hirakawa, H | 1 |
| Kimura, J | 1 |
| Wang, XQ | 3 |
| Zhang, LX | 1 |
| Luo, TY | 3 |
| Min, M | 3 |
| He, GX | 1 |
| Pe'er, J | 1 |
| Frenkel, S | 1 |
| Furman, RR | 3 |
| Ruan, J | 2 |
| Cheung, YK | 1 |
| Elstrom, R | 2 |
| Coleman, M | 5 |
| Phan, J | 1 |
| Zreik, TG | 1 |
| Wogan, C | 1 |
| Thorns, C | 2 |
| Frank, M | 1 |
| Barth, TF | 2 |
| Abruzzese, E | 1 |
| Bacci, F | 3 |
| Hui, D | 1 |
| Proctor, B | 1 |
| Donaldson, J | 2 |
| Savage, K | 1 |
| Wen, JY | 1 |
| Ma, XK | 1 |
| Chen, ZH | 1 |
| Wu, XY | 1 |
| Xia, QX | 1 |
| Yang, SJ | 1 |
| Munck, JN | 1 |
| Quesnel, B | 2 |
| Scandurra, M | 1 |
| Rancoita, PM | 1 |
| De Campos, CP | 1 |
| Chigrinova, E | 2 |
| Nomdedeu, JF | 1 |
| Lambotte, O | 3 |
| Kim, JE | 2 |
| Hagiwara, Y | 1 |
| Tanae, K | 1 |
| Kohri, M | 1 |
| Asano, H | 1 |
| Ota, S | 2 |
| Fukayama, M | 2 |
| Ristow, K | 1 |
| Dotlić, S | 1 |
| Seker, M | 1 |
| Bilici, A | 1 |
| Ustaalioglu, BO | 1 |
| Yilmaz, B | 1 |
| Ozturk, B | 1 |
| Ünal, A | 1 |
| Dane, F | 1 |
| Ozdemir, NY | 1 |
| Elkiran, ET | 1 |
| Kalender, ME | 1 |
| Gumus, M | 1 |
| Benekli, M | 2 |
| Shikata, H | 1 |
| Takaoka, I | 1 |
| Horikawa, T | 1 |
| Yamanouchi, J | 1 |
| Azuma, T | 1 |
| Narumi, H | 1 |
| Hato, T | 1 |
| Yasukawa, M | 2 |
| Hanzawa, K | 1 |
| Higashi, M | 1 |
| Kajino, K | 1 |
| Hino, O | 1 |
| Kizaki, M | 1 |
| Hoshi, M | 1 |
| Ito, H | 2 |
| Hirose, Y | 1 |
| Musolino, A | 1 |
| Boggiani, D | 1 |
| Panebianco, M | 1 |
| Vasini, G | 1 |
| Salvagni, S | 1 |
| Franciosi, V | 1 |
| Ardizzoni, A | 1 |
| Horiguchi, K | 1 |
| Hashizume, M | 1 |
| Masuo, T | 1 |
| Suto, M | 1 |
| Okajo, J | 1 |
| Kaneko, Y | 1 |
| Yokoo, H | 1 |
| Sasaki, A | 1 |
| Okada, S | 1 |
| Nakazato, Y | 1 |
| Werndli, JE | 1 |
| Bottner, WA | 1 |
| Rodrigues, GA | 1 |
| Sanchez, FA | 1 |
| Saphner, TJ | 1 |
| Longo, WL | 1 |
| Chen, DB | 2 |
| Song, QJ | 1 |
| Shen, DH | 2 |
| Tanizawa, Y | 1 |
| Terashima, M | 1 |
| Tokunaga, M | 1 |
| Bando, E | 1 |
| Kawamura, T | 1 |
| Kondo, J | 1 |
| Waragai, M | 1 |
| Motegi, Y | 1 |
| Sugisawa, N | 1 |
| Ohshima, N | 1 |
| Taki, Y | 1 |
| Makuuchi, R | 1 |
| Miki, Y | 1 |
| Yamakawa, Y | 1 |
| Kinugasa, Y | 1 |
| Kanemoto, H | 1 |
| Uesaka, K | 1 |
| Onozawa, Y | 1 |
| Waisbourd, M | 1 |
| Leibovitch, I | 1 |
| Sayar, D | 1 |
| Elhasid, R | 1 |
| Tay, K | 1 |
| Tai, D | 1 |
| Ha, TC | 1 |
| Wobser, M | 1 |
| Kneitz, H | 1 |
| Bröcker, EB | 1 |
| Becker, JC | 1 |
| Wang, MY | 1 |
| Xu, LC | 1 |
| Gu, SY | 1 |
| Meyer, PN | 4 |
| Kwon, JM | 1 |
| Hwang, IG | 1 |
| Forconi, F | 1 |
| Gloghini, A | 2 |
| Fangazio, M | 1 |
| Lobetti Bodoni, C | 1 |
| Lauria, F | 1 |
| Carbone, A | 2 |
| Chu, DT | 1 |
| Thomas, LC | 1 |
| Adonizio, C | 1 |
| Golshayan, AR | 1 |
| Morris, GJ | 1 |
| Greiner, T | 1 |
| Braziel, R | 2 |
| Staudt, L | 3 |
| Chan, W | 1 |
| Jo, J | 1 |
| Chang, H | 3 |
| Hung, YS | 3 |
| Lin, TL | 3 |
| Wang, PN | 3 |
| Kuo, MC | 3 |
| Tang, TC | 3 |
| Wu, JH | 3 |
| Dunn, P | 3 |
| Shih, LY | 3 |
| Cheung, K | 1 |
| Morrison, J | 1 |
| Ely, S | 1 |
| Perunicic, M | 1 |
| Savic, S | 1 |
| Tamaru, JI | 1 |
| Kashimura, M | 1 |
| Kosugi, H | 3 |
| Yujiri, T | 1 |
| Giardino, AA | 2 |
| O'Regan, K | 1 |
| Jagannathan, JP | 1 |
| Elco, C | 1 |
| Ramaiya, N | 1 |
| Müldür, E | 1 |
| Chott, A | 4 |
| Mirzaei, S | 1 |
| Zojer, N | 1 |
| Takeuchi, J | 1 |
| Potemski, P | 1 |
| Kowalik, A | 1 |
| Sygut, J | 1 |
| Tai, WM | 2 |
| Chung, J | 1 |
| Tang, PL | 1 |
| Koo, YX | 3 |
| Hou, X | 1 |
| Tay, KW | 2 |
| Jurlander, J | 2 |
| Bekker Jeppesen, P | 1 |
| Groenvold, M | 1 |
| Quah, D | 1 |
| Yap, SP | 1 |
| Tan, SH | 1 |
| Febbri, A | 1 |
| Gozzetti, A | 1 |
| Valo, E | 1 |
| Raunio, A | 1 |
| Bilgir, O | 1 |
| Bilgir, F | 1 |
| Calan, M | 1 |
| Yuksel, A | 1 |
| Sari, F | 1 |
| Oztekin, O | 1 |
| Maxwell, SA | 1 |
| Cherry, EM | 1 |
| Bayless, KJ | 1 |
| Hamilton, AS | 1 |
| Ageberg, M | 1 |
| Lindén, O | 1 |
| Han, EJ | 1 |
| Sohn, HS | 1 |
| Park, G | 1 |
| Lee, SN | 1 |
| Yang, SW | 1 |
| Han, K | 1 |
| Park, SY | 1 |
| Eun, CS | 1 |
| Byun, YS | 1 |
| Yoon, JY | 1 |
| Jeon, YC | 1 |
| Han, DS | 1 |
| Sohn, JH | 1 |
| Oh, YH | 1 |
| Balduzzi, C | 1 |
| Yantorno, M | 1 |
| Mosca, I | 1 |
| Apraiz, M | 1 |
| Velázquez, MJ | 1 |
| Puente, Mdel C | 1 |
| Moragrega, V | 1 |
| Ligorría, R | 1 |
| Ottino, A | 1 |
| Belloni, R | 1 |
| Barbero, R | 1 |
| Jmelniztky, A | 1 |
| Chopita, N | 1 |
| Ruskova, A | 1 |
| Berkahn, L | 1 |
| Lang, RG | 1 |
| Liu, FF | 1 |
| Wang, XF | 1 |
| Jin, ZJ | 1 |
| Lü, AJ | 1 |
| Fu, XL | 2 |
| Poptani, H | 2 |
| Delikatny, EJ | 2 |
| Pickup, S | 2 |
| Nelson, DS | 2 |
| Goldstein, SC | 1 |
| Wallace, SG | 1 |
| Loevner, LA | 1 |
| Mellon, EA | 1 |
| Reddy, R | 1 |
| Zhu, YJ | 4 |
| Strøm, C | 1 |
| Bukh, A | 1 |
| Pedersen, BB | 1 |
| Moeller, MB | 1 |
| Mortensen, LS | 1 |
| Gadeberg, OV | 2 |
| Ingeberg, S | 1 |
| Pulczynski, S | 1 |
| Brown, PDN | 1 |
| Blanc, M | 2 |
| Janvier, M | 3 |
| Salles, B | 1 |
| Fournier, M | 1 |
| Testoni, M | 1 |
| Wakabayashi, M | 1 |
| Tamaki, T | 1 |
| Bardet, S | 1 |
| Julian, A | 2 |
| Vera, P | 2 |
| Alencar, AJ | 1 |
| Malumbres, R | 2 |
| Kozloski, GA | 1 |
| Chinichian, S | 1 |
| Tibshirani, R | 3 |
| Kuo, TT | 1 |
| Xie, W | 1 |
| Sander, B | 1 |
| Lister, A | 1 |
| Raemaekers, J | 1 |
| Hagenbeek, A | 1 |
| Weller, E | 1 |
| Park, SJ | 1 |
| Park, KH | 1 |
| Jung, KY | 1 |
| Anglaret, B | 2 |
| Brechignac, S | 1 |
| Okines, AF | 1 |
| Plummer, C | 1 |
| Niino, D | 1 |
| Ohsaki, K | 1 |
| Watanabe, J | 1 |
| Kiyasu, J | 1 |
| Sugita, Y | 1 |
| Dong, W | 1 |
| Wang, DS | 1 |
| Akagi, T | 1 |
| Murai, K | 1 |
| Kameoka, Y | 1 |
| Kameoka, J | 1 |
| Kato, Y | 1 |
| Noji, H | 1 |
| Shichishima, T | 1 |
| Itoh, J | 1 |
| Ichinohasama, R | 1 |
| Harigae, H | 1 |
| Ishida, Y | 1 |
| Sawada, K | 2 |
| Uchiyama, M | 1 |
| Yang, Q | 1 |
| Geng, W | 1 |
| Alaoua, A | 1 |
| Gilbert, G | 1 |
| Ghannouchi, N | 1 |
| Houchlef, M | 1 |
| Letaief, A | 1 |
| Bahri, F | 1 |
| Gomez, H | 1 |
| Novero, D | 2 |
| Ricardi, U | 1 |
| Storti, S | 1 |
| Gospodarowicz, MK | 1 |
| Sarris, AH | 2 |
| Croles, FN | 1 |
| Hebeda, KM | 1 |
| Kats-Ugurlu, G | 1 |
| Hermans, JJ | 1 |
| Bonenkamp, HJ | 1 |
| van der Velden, WJ | 1 |
| Tan, DS | 1 |
| Tan, IB | 1 |
| Tai, DW | 1 |
| Ha, T | 1 |
| Ong, WS | 1 |
| Găman, A | 1 |
| Bold, A | 1 |
| Găman, G | 1 |
| Fabisiewicz, A | 1 |
| Paszkiewicz-Kozik, E | 1 |
| Osowiecki, M | 1 |
| Siedlecki, JA | 1 |
| Liardo, EV | 1 |
| Morabito, F | 1 |
| Brugiatelli, M | 2 |
| Di Renzo, N | 1 |
| Gyetvai, A | 1 |
| Kajtár, B | 1 |
| Sipka, S | 1 |
| Larson, ML | 2 |
| Wooldridge, JE | 1 |
| O'Brien, T | 1 |
| Shammo, JM | 1 |
| Bueschel, K | 1 |
| Corazzelli, G | 1 |
| Frigeri, F | 1 |
| Arcamone, M | 1 |
| Lucania, A | 1 |
| Rosariavilla, M | 1 |
| Morelli, E | 1 |
| Amore, A | 1 |
| Capobianco, G | 1 |
| Caronna, A | 1 |
| Becchimanzi, C | 1 |
| Volzone, F | 1 |
| Marcacci, G | 1 |
| Russo, F | 1 |
| De Filippi, R | 1 |
| Mastrullo, L | 1 |
| Klebig, RR | 1 |
| Wang, QS | 1 |
| Wang, SH | 1 |
| Li, HH | 1 |
| Huang, WR | 1 |
| Gao, CJ | 1 |
| Yu, G | 1 |
| Qu, G | 1 |
| Tanosaki, R | 1 |
| Morales, D | 1 |
| de Mendoza, FH | 1 |
| Quinones, P | 1 |
| Gallo, A | 1 |
| Lopez-Ilasaca, M | 1 |
| Butera, JN | 2 |
| Levy, D | 1 |
| Bellesso, M | 1 |
| Oliveira-Souza, P | 1 |
| Maciel, FV | 1 |
| Bydlowski, SP | 1 |
| Iovino, L | 1 |
| Mechken, F | 1 |
| Cornic, M | 1 |
| Rainville, V | 1 |
| Becker, S | 1 |
| Nishiyama, T | 1 |
| Imahashi, N | 1 |
| Kitamura, K | 2 |
| Hirooka, Y | 1 |
| Niwa, Y | 1 |
| Sugiura, I | 1 |
| Kotake, T | 1 |
| Takamori, H | 1 |
| Kuwayama, M | 1 |
| Hattori, H | 1 |
| Takeda, M | 1 |
| Takagi, K | 2 |
| Karasuno, T | 1 |
| Tamai, Y | 1 |
| Murakami, E | 1 |
| Ambrogi, V | 1 |
| Lanni, V | 1 |
| Cavalieri, E | 1 |
| Scopinaro, F | 1 |
| Marchetti, P | 1 |
| Spiriti, MA | 1 |
| Moore, S | 1 |
| Thomson, K | 1 |
| Ljubic, A | 1 |
| Goldstone, AH | 1 |
| Jin, MS | 1 |
| Stenson, M | 1 |
| Werlenius, O | 1 |
| Sender, M | 1 |
| Lewerin, C | 1 |
| Hansson, U | 1 |
| Stefancikova, L | 1 |
| Fabian, P | 1 |
| Vasova, I | 2 |
| Zedek, F | 1 |
| Muzik, J | 1 |
| Kuglik, P | 1 |
| Vranova, V | 1 |
| Falkova, I | 1 |
| Geng, Q | 1 |
| Nourse, JP | 1 |
| Nguyen-Van, D | 1 |
| Mutsando, H | 1 |
| Lea, RA | 1 |
| Ilariucci, F | 1 |
| Musso, M | 1 |
| Alvarez, I | 1 |
| Mazza, P | 1 |
| Fragasso, A | 1 |
| Gobbi, PG | 2 |
| Ahlgrimm, M | 1 |
| Preuss, KD | 1 |
| Bittenbring, J | 1 |
| Massini, G | 1 |
| Mozos, A | 2 |
| Roué, G | 1 |
| Colomer, D | 1 |
| Zeng, LP | 1 |
| Wen, YL | 1 |
| Xu, LL | 1 |
| Zhang, XM | 2 |
| Kuhnt, E | 2 |
| Shepherd, L | 1 |
| Gill, DS | 1 |
| Shpilberg, O | 2 |
| Stahel, R | 1 |
| Milpied, N | 1 |
| Grass, S | 1 |
| Bai, X | 1 |
| Geng, J | 1 |
| van de Schans, SAM | 1 |
| Wymenga, ANM | 1 |
| van Spronsen, DJ | 1 |
| Coebergh, JWW | 1 |
| Janssen-Heijnen, MLG | 1 |
| Menke, J | 1 |
| Unterberg-Buchwald, C | 1 |
| Schaefer, IM | 1 |
| Kertesz, A | 1 |
| Vanderplas, A | 1 |
| Crosby, AL | 1 |
| Lepisto, E | 1 |
| Nademanee, A | 1 |
| Gu, K | 1 |
| Fujioka, Y | 1 |
| Nakamura, F | 1 |
| Shinozaki, A | 1 |
| Kamikubo, Y | 1 |
| Ichikawa, M | 1 |
| Nakao, M | 1 |
| Sugitani-Yamamoto, M | 1 |
| Kiyota, M | 1 |
| Huang, BT | 1 |
| Zeng, QC | 1 |
| Yu, J | 1 |
| Li, BS | 1 |
| Ji, HB | 1 |
| Hazenberg, MD | 1 |
| Biemond, BJ | 1 |
| Pals, ST | 1 |
| Zumpolle, CM | 1 |
| Schinkel, CJ | 1 |
| Linthorst, GE | 1 |
| Hoekstra, JB | 1 |
| Vos, JM | 1 |
| Abdelhamid, T | 1 |
| Samra, M | 1 |
| Ramadan, H | 1 |
| Mehessin, M | 1 |
| Mokhtar, N | 2 |
| Johnson, HE | 1 |
| Silvestre, AS | 2 |
| Rossi, FG | 3 |
| Schwenkglenks, M | 2 |
| Bendall, K | 3 |
| Szabo, Z | 2 |
| Porcu, P | 1 |
| Hurd, D | 1 |
| Johnson, J | 1 |
| Martin, SE | 1 |
| Lai, R | 1 |
| Said, J | 1 |
| Jones, D | 1 |
| Canellos, G | 1 |
| Koo, DH | 1 |
| Mukhtar, R | 1 |
| Khattak, R | 1 |
| Mateen, A | 1 |
| Yu, H | 2 |
| Huang, JX | 1 |
| Shi, DR | 2 |
| Li, WY | 1 |
| Hardak, E | 1 |
| Oren, I | 1 |
| Yigla, M | 2 |
| Shimomura, YI | 1 |
| Takeoka, Y | 1 |
| Inaba, A | 1 |
| Fujitani, Y | 1 |
| Kosaka, S | 1 |
| Yamamura, R | 1 |
| Senzaki, H | 1 |
| Zoroquiain, P | 1 |
| González, S | 1 |
| Molgó, M | 1 |
| Valbuena, JR | 1 |
| Uner, A | 1 |
| Gualco, G | 1 |
| Bacchi, CE | 1 |
| Pregno, P | 2 |
| Bellò, M | 1 |
| Giunta, F | 1 |
| Limerutti, G | 1 |
| Menga, M | 1 |
| Nicolosi, M | 1 |
| Priolo, G | 1 |
| Vaggelli, L | 1 |
| Bisi, G | 1 |
| Suzuki, Y | 1 |
| Togano, T | 1 |
| Miyamoto, S | 1 |
| Iwabuchi, K | 1 |
| Nakayama, M | 1 |
| Horie, R | 1 |
| Talbott, MS | 1 |
| Greer, JP | 2 |
| Morgan, DS | 1 |
| Yang, QX | 1 |
| Pei, XJ | 1 |
| Tian, XY | 1 |
| Wagner, T | 1 |
| Brechemier, D | 1 |
| Dugert, E | 1 |
| Le Guellec, S | 1 |
| Hitzel, A | 1 |
| Beyne-Rauzy, O | 1 |
| Tazi, I | 2 |
| Nafil, H | 2 |
| Mahmal, L | 3 |
| Ezer, A | 1 |
| Parlakgümüş, A | 1 |
| Kocer, NE | 1 |
| Colakoğlu, T | 1 |
| Nursal, GN | 1 |
| Yildirim, S | 1 |
| Heutte, N | 1 |
| Robu, D | 1 |
| Safar, V | 1 |
| García, M | 2 |
| Müller, C | 1 |
| Wiesen, MH | 1 |
| Nickenig, C | 1 |
| Peter, N | 2 |
| Lengfelder, E | 1 |
| Metzner, B | 1 |
| Reiser, M | 3 |
| Spaziani, E | 1 |
| Di Filippo, A | 1 |
| Picchio, M | 1 |
| De Angelis, F | 1 |
| Corazza, S | 1 |
| Narilli, F | 1 |
| Cimino, G | 1 |
| Duehrsen, U | 1 |
| Bacon, P | 1 |
| Peter, NM | 1 |
| Khooshabeh, R | 1 |
| Lai, S | 1 |
| Leslie, W | 1 |
| Gregory, S | 1 |
| Dörken, B | 1 |
| Wei, WX | 3 |
| Dorth, JA | 1 |
| Coleman, RE | 1 |
| Wang, XL | 1 |
| Mu, YM | 1 |
| Dou, JT | 1 |
| Lu, JM | 1 |
| Zhong, WW | 1 |
| Pan, CY | 1 |
| Wen, W | 1 |
| d'Amore, ES | 3 |
| O'Neill, S | 2 |
| Dunphy, CH | 2 |
| Zhao, XF | 3 |
| Etzell, J | 1 |
| El-Sharkawi, D | 1 |
| Basu, S | 1 |
| Ocampo, C | 1 |
| D'Sa, S | 1 |
| Hoskin, PJ | 2 |
| Walter, E | 1 |
| Schmitt, T | 1 |
| Ho, A | 1 |
| Lota, HK | 1 |
| Dusmet, M | 1 |
| Steele, K | 1 |
| Wells, AU | 1 |
| Nicholson, AG | 1 |
| Hansell, DM | 1 |
| Renzoni, EA | 1 |
| Khodabakhshi, AH | 1 |
| Whiteside, MD | 1 |
| Zare, H | 1 |
| Lo, K | 1 |
| Gottardo, R | 1 |
| Brinkman, FS | 1 |
| Zivković, R | 1 |
| Hajder, J | 1 |
| Stanisavljevic, N | 1 |
| Olivieri, A | 3 |
| Bocci, C | 1 |
| Montanari, M | 1 |
| Trappolini, S | 1 |
| Olivieri, J | 1 |
| Brunori, M | 2 |
| Giuliodori, L | 1 |
| Marcellini, M | 1 |
| Poloni, A | 1 |
| Leoni, P | 2 |
| Lefrère, F | 1 |
| Bastit-Barrau, D | 1 |
| Hequet, O | 1 |
| Bourin, P | 1 |
| Mathieu-Nafissi, S | 1 |
| Bohbot, A | 1 |
| Lapierre, V | 1 |
| Micléa, JM | 1 |
| Isebaert, L | 1 |
| Rozman, S | 1 |
| Sonc, M | 1 |
| Novakovic, BJ | 1 |
| Crisel, RK | 1 |
| Knight, BP | 1 |
| Wang, E | 1 |
| Papavassiliou, P | 1 |
| Sebastian, S | 1 |
| Nakashima, T | 1 |
| Kiba, T | 1 |
| Kimura, A | 1 |
| Kido, M | 1 |
| Okikawa, Y | 1 |
| Ito, T | 1 |
| Hosokawa, A | 1 |
| Shintani, H | 1 |
| Okada, Y | 1 |
| Taniyama, K | 1 |
| Kozawa, K | 1 |
| Niimi, H | 1 |
| Ogawa, K | 1 |
| Miserocchi, E | 1 |
| Modorati, G | 1 |
| De Benedetto, U | 1 |
| Colucci, A | 1 |
| Bandello, F | 1 |
| Vivekanandarajah, A | 1 |
| Bhatt, VR | 1 |
| Krishnarasa, B | 1 |
| Murukutla, S | 1 |
| Brenner, A | 1 |
| Gupta, S | 2 |
| Katusiime, C | 1 |
| Kambugu, A | 1 |
| Halasz, LM | 1 |
| Jacene, HA | 1 |
| Catalano, PJ | 1 |
| Van den Abbeele, AD | 1 |
| Fratino, L | 1 |
| Magagnoli, M | 2 |
| Talamini, R | 1 |
| Giacalone, A | 1 |
| Ravaioli, E | 1 |
| Chimienti, E | 1 |
| Berretta, M | 1 |
| Lleshi, A | 1 |
| Santoro, A | 1 |
| Tirelli, U | 1 |
| Levidou, G | 1 |
| Economopoulou, P | 1 |
| Efthimiou, A | 1 |
| Constantinou, N | 1 |
| Katsigiannis, A | 1 |
| Economopoulou, C | 1 |
| Georgiou, G | 1 |
| Beris, P | 1 |
| Dervenoulas, J | 2 |
| Li, B | 2 |
| Zou, SM | 1 |
| Li, YX | 3 |
| Song, YW | 2 |
| Zheng, S | 1 |
| Zhang, CG | 2 |
| Feng, FY | 2 |
| Shinagare, AB | 1 |
| Shinagare, SA | 1 |
| Dewar, R | 1 |
| Weckstein, D | 1 |
| Mauch, P | 1 |
| Ramaiya, NH | 1 |
| Freedman, AS | 1 |
| Nielsen, O | 1 |
| Lee, L | 1 |
| Khor, S | 1 |
| Hoch, JS | 1 |
| Luo, J | 1 |
| Bremner, K | 1 |
| Krahn, M | 2 |
| Ziesmer, SC | 1 |
| Zurawska, U | 1 |
| Hicks, LK | 1 |
| Woo, G | 1 |
| Bell, CM | 1 |
| Chan, KK | 1 |
| Feld, JJ | 1 |
| Cesaretti, M | 1 |
| Barbui, A | 1 |
| Miranda, EC | 1 |
| Guida, A | 1 |
| Tatsukawa, T | 1 |
| Yamaguchi, T | 2 |
| Egawa, T | 1 |
| Hidaka, N | 1 |
| Ido, K | 1 |
| Suemaru, K | 1 |
| Araki, H | 1 |
| Shen, D | 1 |
| Ni, X | 1 |
| Lu, SC | 1 |
| Moon, SH | 1 |
| Park, LC | 2 |
| Hwang, DW | 1 |
| Maeng, CH | 1 |
| Shen, B | 1 |
| Stopeck, AT | 1 |
| Farnsworth, B | 1 |
| Iannone, M | 1 |
| Glenn, MJ | 1 |
| Jung, HA | 1 |
| Cho, JH | 1 |
| Cardesa-Salzmann, TM | 1 |
| Tubbs, R | 2 |
| Kim, SM | 1 |
| Pircher, A | 1 |
| Gassner, EM | 1 |
| Steurer, M | 1 |
| Wolf, D | 1 |
| Yin, QS | 1 |
| Yang, WP | 1 |
| Xu, HY | 1 |
| Cheng, ZX | 1 |
| Zou, SH | 1 |
| Chen, FY | 1 |
| Cheng, YF | 1 |
| Ma, XB | 1 |
| Eberle, FC | 1 |
| Yoshita, H | 1 |
| Sugiyama, T | 1 |
| Shih, SJ | 1 |
| Fass, J | 1 |
| Buffalo, V | 1 |
| Lin, D | 1 |
| Singh, SP | 1 |
| Diaz, MO | 1 |
| Vaughan, AT | 1 |
| Mahrous, M | 1 |
| Berinstein, N | 1 |
| Imrie, KR | 1 |
| Valentino, C | 2 |
| Brunhoeber, P | 2 |
| Jang, SJ | 1 |
| Lü, Z | 1 |
| Hyunyoon, D | 1 |
| Jang, JS | 1 |
| Eom, H | 1 |
| Baek, SK | 1 |
| Hay, AE | 1 |
| Meyer, RM | 1 |
| Fu, Z | 1 |
| Abe, A | 1 |
| Terazawa, T | 1 |
| Yanada, M | 1 |
| Kanie, T | 1 |
| Tsuzuki, M | 1 |
| Akatsuka, Y | 1 |
| Emi, N | 1 |
| His, ED | 1 |
| Boelens, J | 1 |
| Vanhoecke, B | 1 |
| Beck, I | 1 |
| Van Melckebeke, H | 1 |
| Philippé, J | 1 |
| Bracke, M | 1 |
| Lust, S | 1 |
| Carbone, M | 1 |
| Buccisano, F | 1 |
| Lenci, I | 1 |
| Baiocchi, L | 1 |
| Abruzzo, LV | 1 |
| Xia, XY | 1 |
| Jenabi, A | 1 |
| Mooraki, A | 1 |
| Jabbari, M | 1 |
| Shayanfar, N | 1 |
| Ghods, AJ | 1 |
| Ziari, MB | 1 |
| Bastani, B | 1 |
| Pajares, V | 1 |
| Torrego, A | 1 |
| Granell, M | 1 |
| Szafranska, J | 1 |
| Puzo, C | 1 |
| Wu, RY | 1 |
| Wang, WH | 1 |
| Wang, SL | 1 |
| Fang, H | 1 |
| Liu, QF | 1 |
| Qi, SN | 1 |
| Lu, NN | 1 |
| Liu, XF | 1 |
| Yu, ZH | 1 |
| Yoon, YH | 1 |
| Cho, KS | 1 |
| Gupta, M | 1 |
| Wellik, LE | 1 |
| Law, ME | 1 |
| Han, JJ | 1 |
| Lugtenburg, P | 1 |
| Noens, L | 1 |
| Krall, W | 1 |
| Simon, Z | 2 |
| Miltényi, Z | 1 |
| Forsterova, K | 1 |
| Votavova, H | 1 |
| Stritesky, J | 1 |
| Velenska, Z | 1 |
| Prochazka, B | 1 |
| Graziadio, M | 1 |
| Medina, N | 1 |
| Amato, M | 1 |
| Ardaiz, Mdel C | 1 |
| Ilutovich, S | 1 |
| Torino, M | 1 |
| Batty, N | 1 |
| Ghonimi, E | 1 |
| Manabe, M | 1 |
| Yoshii, Y | 1 |
| Mukai, S | 1 |
| Hayama, T | 1 |
| Fukushima, H | 1 |
| Teshima, H | 1 |
| Matsuda, Y | 1 |
| Takai, M | 1 |
| Tasaki, T | 1 |
| Tai, K | 1 |
| Hosono, N | 1 |
| Ikegaya, S | 1 |
| Kishi, S | 1 |
| Yoshida, A | 2 |
| Urasaki, Y | 1 |
| Li, XX | 1 |
| Sang, W | 1 |
| Shi, XL | 1 |
| Gulinaer, A | 1 |
| Yang, WT | 1 |
| Gray, R | 1 |
| Lemma, S | 1 |
| Kassam, S | 1 |
| de Vos, J | 1 |
| Nelson, M | 1 |
| Marcus, R | 1 |
| Edwards, SG | 1 |
| Seeram, V | 1 |
| Shujaat, A | 1 |
| Jones, L | 1 |
| Bajwa, A | 1 |
| Lee, EM | 1 |
| Ye, BJ | 1 |
| Luo, R | 1 |
| Beam, E | 1 |
| Mansfield, AS | 1 |
| García-Suárez, J | 2 |
| Flores, E | 1 |
| Callejas, M | 1 |
| Arribas, I | 2 |
| Gil-Fernández, JJ | 1 |
| Curto, N | 1 |
| Guillén, H | 1 |
| Casco, CR | 1 |
| Martín, Y | 1 |
| Burgaleta, C | 2 |
| Amini, RM | 2 |
| Thunberg, U | 1 |
| Connerotte, T | 1 |
| Min, JJ | 1 |
| Kweon, SS | 1 |
| Kim, HW | 1 |
| Bom, HS | 1 |
| Wu, YX | 1 |
| Li, JH | 1 |
| Chen, SQ | 1 |
| Jyrkkiö, S | 1 |
| Erlanson, M | 1 |
| Kolstad, A | 1 |
| Fosså, A | 1 |
| Ostenstad, B | 1 |
| Löfvenberg, E | 1 |
| Nordström, M | 1 |
| Janes, R | 1 |
| Anderson, H | 2 |
| Bai, H | 1 |
| Wei, J | 1 |
| Xu, R | 1 |
| Palickova, M | 1 |
| Vernerova, Z | 1 |
| Kozak, T | 1 |
| Foroughinia, F | 1 |
| Baniasadi, S | 1 |
| Seifi, S | 1 |
| Fahimi, F | 1 |
| Liu, CL | 1 |
| Wang, XY | 1 |
| Xue, XM | 1 |
| Gao, ZF | 1 |
| Yao, WK | 1 |
| Peng, F | 1 |
| Zou, YB | 1 |
| Gao, JN | 1 |
| Liu, XL | 2 |
| Delfau-Larue, MH | 1 |
| Becher, C | 1 |
| Schmelter, C | 1 |
| Sinclair, N | 1 |
| Nurmi, H | 1 |
| Treaba, DO | 1 |
| Stachurski, D | 1 |
| Kendrick, S | 1 |
| Weisenburger, D | 1 |
| Jaffe, E | 1 |
| Grogan, T | 1 |
| Sikkema, T | 1 |
| Schuiling, WJ | 1 |
| Oh, MY | 1 |
| Wilder, RB | 1 |
| Tucker, SL | 2 |
| Hess, MA | 1 |
| Cox, JD | 1 |
| Yata, K | 1 |
| Mikami, M | 1 |
| Tsujioka, T | 1 |
| Suemori, S | 1 |
| Suetsugu, Y | 1 |
| Nakanishi, H | 1 |
| Otsuki, T | 1 |
| Yamada, O | 1 |
| Yawata, Y | 1 |
| Morioka, M | 2 |
| Sadahira, Y | 1 |
| Sugihara, T | 1 |
| Porcar Ramells, C | 1 |
| Clemente González, C | 1 |
| García Parés, D | 1 |
| Guardia Sánchez, R | 1 |
| Pérez Ayuso, MJ | 1 |
| García-Bragado Dalmau, F | 1 |
| Ergul, SM | 1 |
| Lal, A | 1 |
| Afri, L | 1 |
| Frei-Lahr, D | 1 |
| Dargent, JL | 1 |
| Meiers, I | 1 |
| Lespagnard, L | 1 |
| Dehou, MF | 1 |
| Verhest, A | 1 |
| Chang, CC | 1 |
| Bunyi-Teopengco, E | 1 |
| Eshoa, C | 1 |
| Chitambar, CR | 1 |
| Kampalath, B | 1 |
| Matsuzaki, J | 1 |
| Kitami, K | 1 |
| Hirokawa, M | 1 |
| Aloulou, S | 1 |
| Vanel, D | 2 |
| Hock, LM | 1 |
| Lynch, JC | 1 |
| Watts, RG | 1 |
| Hilliard, LM | 1 |
| Berkow, RL | 1 |
| Pérez-Simón, JA | 1 |
| Iriondo, A | 1 |
| Lahuerta, JJ | 2 |
| Marín, J | 1 |
| Gandarillas, M | 2 |
| Zuazu, J | 1 |
| Rubio, V | 1 |
| Carreras, E | 1 |
| García-Conde, J | 2 |
| García-Laraña, J | 1 |
| Rifón, J | 1 |
| Pérez-Equiza, C | 1 |
| Varela, R | 1 |
| García Ruíz, JC | 1 |
| Albó, C | 2 |
| Cabrera, R | 1 |
| San Miguel, JF | 2 |
| Carpaneto, A | 1 |
| Alterini, R | 2 |
| Carrai, V | 2 |
| Bernardi, F | 2 |
| Bellesi, G | 1 |
| Longo, G | 2 |
| Rossi Ferrini, P | 1 |
| Zecca, M | 1 |
| Marchi, A | 1 |
| de Stefano, P | 1 |
| Sammarchi, L | 1 |
| Locatelli, F | 2 |
| Kavlick, MF | 1 |
| Mitsuya, H | 1 |
| Franchini, G | 1 |
| Gutierrez, M | 4 |
| Raffeld, M | 4 |
| Shearer, G | 1 |
| Calva, A | 2 |
| Mak, YK | 1 |
| Chan, CH | 1 |
| Li, CK | 1 |
| Lee, MP | 1 |
| Tsang, YW | 1 |
| Szánthó, A | 1 |
| Bálega J, Já | 1 |
| Csapó, Z | 1 |
| Sréter L, Lí | 1 |
| Papp, Z | 1 |
| Jabri, A | 1 |
| Jabri, L | 1 |
| Harif, M | 1 |
| Quessari, A | 1 |
| Benchakroun, Y | 1 |
| Iraqi, A | 1 |
| Benchekroun, S | 1 |
| Wunderlich, A | 1 |
| Kloess, M | 1 |
| Rudolph, C | 1 |
| Bittner, S | 1 |
| Schmalenberg, H | 1 |
| Schmits, R | 2 |
| Ferrucci, PF | 1 |
| Mingrone, W | 3 |
| Cocorocchio, E | 1 |
| De Luzio, K | 1 |
| Santoro, P | 1 |
| Mazzetta, C | 1 |
| Kahlifa, M | 1 |
| Perez-Ordoñez, B | 1 |
| Smyth, EF | 1 |
| Bartlett, RJ | 1 |
| Shields, ML | 1 |
| White, TJ | 1 |
| Wengraf, C | 1 |
| MONTORSI, W | 1 |
| COSTE, F | 1 |
| CAYLA, J | 1 |
| DUBOIS-FERRIERE, H | 1 |
| GORSUCH, GE | 1 |
| SCHOYER, NH | 1 |
| HARTAI, F | 1 |
| BOOTSMA, BK | 1 |
| KARNOFSKY, DA | 1 |
| DEBLASIIS, M | 1 |
| LIBERTI, R | 1 |
| EAKINS, D | 1 |
| FULTON, T | 1 |
| HADDEN, DR | 1 |
| Afridi, NA | 1 |
| Holmvang, G | 1 |
| Zukerberg, LR | 1 |
| Fukutani, K | 1 |
| Koyama, Y | 1 |
| Fujimori, M | 1 |
| Ishida, T | 2 |
| Isobe, K | 1 |
| Kawakami, H | 1 |
| Yasuda, S | 1 |
| Aruga, T | 1 |
| Kawata, T | 1 |
| Shigematsu, N | 1 |
| Hatano, K | 1 |
| Mikata, A | 1 |
| Mohren, M | 1 |
| Essbach, U | 1 |
| Franke, A | 1 |
| Klink, A | 1 |
| Maas, C | 1 |
| Markmann, I | 1 |
| Pelz, AF | 1 |
| Jentsch-Ullrich, K | 1 |
| Katano, H | 1 |
| Niino, H | 1 |
| Yasuoka, A | 1 |
| Vianelli, N | 1 |
| Koehler, F | 1 |
| Borges, AC | 1 |
| Fotuhi, PC | 1 |
| Motegi, S | 1 |
| Nishizaki, Y | 1 |
| Muramatsu, C | 1 |
| Kobayashi, F | 1 |
| Shiozawa, H | 1 |
| Kamochi, J | 1 |
| Itakura, M | 1 |
| Shibuya, M | 1 |
| Matsuzaki, S | 1 |
| Lee, MW | 1 |
| Sung, KJ | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Yun, T | 1 |
| Kim, TY | 1 |
| Bang, YJ | 2 |
| Kim, BK | 1 |
| Kim, NK | 1 |
| Virion, JM | 1 |
| Lederlin, P | 3 |
| Aki, H | 1 |
| Tuzuner, N | 1 |
| Sahinler, I | 1 |
| Ulku, B | 1 |
| Aktuglu, G | 1 |
| Rosenquist, R | 1 |
| Menestrina, F | 2 |
| Lestani, M | 2 |
| Küppers, R | 1 |
| Bräuninger, A | 1 |
| Mohammad, RM | 3 |
| Al-Katib, A | 3 |
| Doerge, DR | 1 |
| Sarkar, F | 1 |
| Kucuk, O | 1 |
| Todeschini, G | 1 |
| Secchi, S | 1 |
| Morra, E | 3 |
| Orlandi, E | 2 |
| Pasini, F | 1 |
| Gallo, E | 5 |
| Tecchio, C | 1 |
| Gabbas, A | 1 |
| Gallamini, A | 1 |
| Gargantini, L | 3 |
| Pizzuti, M | 2 |
| Fioritoni, G | 1 |
| Gottin, L | 1 |
| Lazzarino, M | 3 |
| Paulli, M | 1 |
| Palestro, M | 1 |
| Di Vito, F | 2 |
| Pizzolo, G | 2 |
| Boulaich, M | 1 |
| Oujilal, A | 1 |
| Nazih, N | 1 |
| Filali, A | 1 |
| Lazrak, A | 1 |
| Kzadri, M | 1 |
| Jermann, M | 1 |
| Jost, LM | 3 |
| Taverna, Ch | 1 |
| Jacky, E | 2 |
| Honegger, HP | 1 |
| Betticher, DC | 1 |
| Egli, F | 1 |
| Kroner, T | 2 |
| Stahel, RA | 3 |
| Dictor, M | 1 |
| Kvaløy, S | 1 |
| Akerman, M | 2 |
| Cavallin-Ståhl, E | 3 |
| Castañeda, C | 4 |
| Talavera, A | 6 |
| Murillo, E | 2 |
| Koike, H | 1 |
| Tamura, Y | 1 |
| Wöhrer, S | 1 |
| Püspök, A | 1 |
| Drach, J | 2 |
| Hejna, M | 2 |
| Raderer, M | 2 |
| Janik, JE | 2 |
| Morris, JC | 1 |
| McDonald, K | 1 |
| Waldmann, TA | 1 |
| Hoshino, A | 1 |
| Kawada, E | 1 |
| Ukita, T | 1 |
| Mantani, N | 1 |
| Kogure, T | 1 |
| Tamura, J | 1 |
| Cohen, Y | 3 |
| Amir, G | 1 |
| Schibi, G | 1 |
| Amariglio, N | 1 |
| Harandi, A | 1 |
| Ghesani, M | 1 |
| Polosajian, L | 1 |
| Tupper, T | 1 |
| Sara, G | 1 |
| Gu, DZ | 1 |
| Wang, QL | 2 |
| Santoe, MF | 1 |
| Van Houten, AA | 1 |
| Muller, AF | 1 |
| Berghout, A | 1 |
| Liu, JK | 1 |
| Kan, P | 1 |
| Schmidt, MH | 1 |
| Fernándezb, R | 1 |
| Pérez, F | 1 |
| Zeidman, A | 1 |
| Horowitz, A | 1 |
| Fradin, Z | 1 |
| Cohen, A | 1 |
| Wolfson, L | 1 |
| Elimelech, O | 1 |
| Girard, T | 1 |
| Nochy, D | 1 |
| Montravers, F | 1 |
| Der Sahakian, G | 1 |
| Fior, R | 1 |
| Galanaud, P | 1 |
| Sharma, R | 1 |
| Abdou, S | 1 |
| Plymyer, MR | 1 |
| Rohatgi, C | 1 |
| Deshmukh, C | 1 |
| Bakshi, A | 1 |
| Parikh, P | 1 |
| Pai, V | 1 |
| Shaikh, A | 1 |
| Muckaden, M | 1 |
| Naresh, K | 1 |
| Saikia, T | 1 |
| Camilleri-Broët, S | 1 |
| Cassard, L | 1 |
| Sautès-Fridman, C | 1 |
| Zhang, CQ | 1 |
| Wang, ZH | 2 |
| Wang, ZQ | 1 |
| Nakamura, Y | 4 |
| Nagao, J | 1 |
| Saida, Y | 1 |
| Asai, K | 1 |
| Kusachi, S | 1 |
| Sumiyama, Y | 1 |
| Katahira, T | 1 |
| Takayama, T | 1 |
| Miyanishi, K | 1 |
| Hayashi, T | 1 |
| Takahashi, Y | 1 |
| Niitsu, Y | 2 |
| Miles, SA | 1 |
| McGratten, M | 1 |
| Perna, AG | 1 |
| Jones, DM | 1 |
| Duvic, M | 1 |
| Huang, DZ | 1 |
| Wu, YH | 1 |
| Laver, JH | 3 |
| Kraveka, JM | 1 |
| Hutchison, RE | 3 |
| Chang, M | 1 |
| Kepner, J | 1 |
| Schwenn, M | 3 |
| Tarbell, N | 1 |
| Weinstein, HJ | 4 |
| Murphy, SB | 3 |
| Hornberger, JC | 1 |
| Best, JH | 1 |
| Milling, DL | 1 |
| Lazarchick, J | 1 |
| Chaudhary, UB | 1 |
| Dem, A | 1 |
| Traore, B | 1 |
| Diallo, BK | 1 |
| Mbodj, M | 1 |
| Dieng, MM | 1 |
| Kasse, AA | 1 |
| Dangou, JM | 1 |
| Diouf, R | 1 |
| Toure, P | 1 |
| Hansen, T | 1 |
| Burg, JE | 1 |
| Koutsimpelas, D | 1 |
| Mann, WJ | 1 |
| Kirkpatrick, CJ | 1 |
| Wang, JC | 1 |
| Lu, CL | 1 |
| Lu, WP | 1 |
| Escalón, MP | 1 |
| Liu, NS | 1 |
| Hess, M | 2 |
| Walker, PL | 1 |
| Smith, TL | 1 |
| Dang, NH | 1 |
| Jetsrisuparb, A | 1 |
| Wiangnon, S | 1 |
| Komvilaisak, P | 1 |
| Kularbkaew, C | 1 |
| Yutanawiboonchai, W | 1 |
| Mairieng, E | 1 |
| Uesato, M | 1 |
| Miyazawa, Y | 1 |
| Gunji, Y | 1 |
| Ochiai, T | 1 |
| Lepage, E | 4 |
| Karim, R | 1 |
| Nathwani, BN | 3 |
| Espina, B | 1 |
| Levine, AM | 1 |
| Kloke, O | 1 |
| Fridlander, T | 1 |
| Ilan, Y | 1 |
| Shibolet, O | 1 |
| Rucińska, M | 1 |
| Maramorosz-Kurianowicz, M | 1 |
| Mruk, A | 1 |
| Piróg, K | 1 |
| Utych, G | 1 |
| Bodzioch, P | 1 |
| Srebro-Stariczyk, M | 1 |
| Włodarska, I | 1 |
| Stachura, J | 1 |
| Lloveras, N | 1 |
| Mate, JL | 1 |
| Yang, BY | 1 |
| Yong, WB | 1 |
| Zhang, YT | 1 |
| Meng, SN | 1 |
| Angelucci, E | 1 |
| Boccomini, C | 2 |
| Calvi, R | 2 |
| Genua, A | 1 |
| Deliliers, GL | 1 |
| Levis, A | 3 |
| Parvis, G | 2 |
| Pavone, E | 2 |
| Sborgia, M | 1 |
| Fitzgerald, C | 2 |
| Gill, K | 2 |
| MacPherson, N | 2 |
| O'Reilly, S | 2 |
| Sutherland, J | 3 |
| Wilson, KS | 2 |
| Ishikura, S | 2 |
| Ohtsu, A | 2 |
| Oda, I | 2 |
| Mera, K | 2 |
| Tamaki, Y | 1 |
| Yamamoto, S | 1 |
| Halaas, JL | 1 |
| Portlock, C | 2 |
| Köksal, Y | 1 |
| Kiratli, H | 1 |
| Varan, A | 1 |
| Akçören, Z | 1 |
| Büyükpamukçu, M | 1 |
| Agada, FO | 1 |
| Mistry, D | 1 |
| Grace, AR | 1 |
| Coatesworth, AP | 1 |
| Moiseeva, TN | 1 |
| Zybunova, EE | 1 |
| Lorie, IuIu | 1 |
| Margolin, OV | 1 |
| Chernova, NG | 1 |
| Ryzhko, VV | 1 |
| Pavlisa, G | 2 |
| Planinc-Peraica, A | 2 |
| Anic, P | 1 |
| Copson, E | 2 |
| Plemons, JM | 1 |
| Benton, E | 1 |
| Rankin, KV | 1 |
| Santini, G | 2 |
| Chisesi, T | 2 |
| De Souza, C | 2 |
| Rubagotti, A | 2 |
| Aversa, S | 1 |
| Porcellini, A | 2 |
| Candela, M | 1 |
| Centurioni, R | 2 |
| Congiu, AM | 2 |
| Nati, S | 2 |
| Spriano, M | 2 |
| Vimercati, R | 2 |
| Marino, G | 1 |
| Contu, A | 2 |
| Tedeschi, L | 2 |
| Majolino, I | 2 |
| Crugnola, M | 1 |
| Sertoli, MR | 2 |
| Dawson, MA | 1 |
| Mariani, J | 1 |
| Taylor, A | 1 |
| Koulouris, G | 1 |
| Avery, S | 1 |
| Enschede, SH | 1 |
| Dzhumabaeva, BT | 1 |
| Shavlokhov, VS | 1 |
| Vishnevskaia, ES | 1 |
| Frank, GA | 1 |
| Rosolen, A | 1 |
| Garaventa, A | 1 |
| Burnelli, R | 1 |
| Giuliano, M | 1 |
| Comis, M | 1 |
| Cesaro, S | 1 |
| Tettoni, K | 1 |
| Moleti, ML | 1 |
| Tamaro, P | 1 |
| Visintin, G | 1 |
| Zanesco, L | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 2 |
| Shahar, KH | 1 |
| Carpenter, LS | 1 |
| Jorgensen, J | 1 |
| Truong, L | 1 |
| Baker, K | 1 |
| Teh, BS | 1 |
| Al-Rajhi, N | 1 |
| Voss, N | 1 |
| Paltiel, C | 1 |
| Oprea, C | 1 |
| Cainap, C | 1 |
| Azoulay, R | 1 |
| Assaf, E | 1 |
| Jabbour, E | 1 |
| Vaseemuddin, M | 1 |
| Sam, R | 1 |
| Wu, HJ | 1 |
| Zhang, QY | 1 |
| Chen, DF | 1 |
| Guan, XJ | 1 |
| Zhang, BL | 1 |
| Ryu, MH | 1 |
| Oh, SJ | 1 |
| Suh, CW | 1 |
| Ryoo, BY | 2 |
| Kang, YK | 1 |
| Martini, V | 1 |
| Ando, M | 1 |
| Isobe, Y | 1 |
| Ando, J | 1 |
| Oshimi, K | 1 |
| Ochiai, A | 1 |
| Yokoi, T | 1 |
| Kitadai, Y | 1 |
| Broglia, C | 1 |
| Valentino, F | 1 |
| Lombardo, M | 1 |
| Polimeno, G | 2 |
| Riezzo, A | 1 |
| Lambelet, P | 1 |
| Rovati, A | 1 |
| Corazza, GR | 1 |
| Kurtin, PJ | 1 |
| Johnston, KL | 1 |
| Manske, BR | 1 |
| Luppi, M | 1 |
| Lazzerini, A | 1 |
| Potenza, L | 1 |
| Cavallini, GM | 1 |
| Torelli, G | 1 |
| Montalbetti, L | 1 |
| Fava, S | 1 |
| Pagnucco, G | 1 |
| Pascutto, C | 1 |
| Kodama, F | 1 |
| Harano, H | 1 |
| Kanamori, H | 2 |
| Jung, HD | 1 |
| Hyun, MS | 1 |
| Yi, JQ | 1 |
| He, YJ | 4 |
| Xia, YF | 2 |
| Xu, RH | 2 |
| Yu, YX | 1 |
| Bu, Q | 2 |
| Lin, XB | 2 |
| Wang, FH | 1 |
| Li, YH | 1 |
| Peng, YL | 1 |
| Pan, ZH | 2 |
| Wang, SS | 2 |
| Kober, T | 1 |
| Hülsewede, H | 1 |
| Bohlius, J | 1 |
| Canal, F | 1 |
| Parolini, C | 1 |
| Andreoli, A | 1 |
| Kubo, Y | 1 |
| Kihara, K | 1 |
| Bai, CM | 1 |
| Yang, T | 1 |
| Zhu, YL | 1 |
| Chen, SC | 1 |
| Cassileth, PA | 1 |
| Cohn, JB | 1 |
| Dakhil, SR | 1 |
| Kolonić, SO | 1 |
| Dzebro, S | 1 |
| Dominis, M | 1 |
| Coso, D | 1 |
| Boulat, O | 1 |
| Biron, P | 1 |
| Rey, J | 1 |
| Aurran, T | 1 |
| Chabannon, C | 1 |
| Xerri, L | 1 |
| Chetaille, B | 1 |
| Esterni, B | 1 |
| Ivanov, V | 1 |
| Stoppa, AM | 1 |
| Schiano de Collela, JM | 1 |
| Gastaut, JA | 1 |
| Maraninchi, D | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Kotani, T | 1 |
| Ueda, M | 1 |
| Yamato, H | 1 |
| Ehira, N | 1 |
| Shimoyama, N | 1 |
| Tanaka, J | 1 |
| Imamura, M | 2 |
| Asaka, M | 2 |
| Hasegawa, T | 1 |
| Masauzi, N | 2 |
| Vara Castrodeza, A | 1 |
| Torres Nieto, A | 1 |
| Mendo González, M | 1 |
| Rodríguez Toves, A | 1 |
| Peñarrubia Ponce, MJ | 1 |
| de la Fuente Bobillo, MA | 1 |
| Shivakumar, L | 1 |
| Ogawa, S | 1 |
| Ueno, S | 1 |
| Kimura, M | 1 |
| Nishikawa, H | 1 |
| Shiku, H | 1 |
| Espinosa, I | 1 |
| Bordes, R | 1 |
| Brunet, S | 1 |
| Martino, R | 1 |
| Prat, J | 1 |
| Ganjoo, KN | 1 |
| An, CS | 1 |
| Robertson, MJ | 1 |
| Sen, JA | 1 |
| Weisenbach, J | 1 |
| Schwartz, LK | 1 |
| Lichtiger, S | 1 |
| Scherl, E | 1 |
| Burcheri, S | 1 |
| Xiang, XJ | 1 |
| Lui, DG | 1 |
| Lin, JY | 1 |
| Piccaluga, PP | 1 |
| Vigna, E | 1 |
| Placci, A | 1 |
| Laterza, C | 1 |
| Papayannidis, C | 1 |
| Leone, O | 1 |
| Ataergin, S | 1 |
| Arpaci, F | 1 |
| Beyzadeoglu, M | 1 |
| Safali, M | 1 |
| Hallack Neto, AE | 1 |
| Beitler, B | 1 |
| Chamone, DA | 1 |
| Llacer, PD | 1 |
| Dulley, FL | 1 |
| Macedo, MC | 1 |
| Chaoubah, A | 1 |
| Shirao, S | 1 |
| Kida, M | 1 |
| Watanabe, H | 2 |
| Konuma, Y | 1 |
| Hirayama, Y | 1 |
| Kohda, K | 1 |
| Ramadan, KM | 1 |
| Schubert, J | 1 |
| Lin, PC | 1 |
| Poh, SB | 1 |
| Goldsmith, SJ | 1 |
| Christos, P | 1 |
| Atasever, T | 1 |
| Chandramouly, A | 1 |
| Verma, S | 1 |
| Kothari, P | 1 |
| Madeb, R | 1 |
| Rub, R | 1 |
| Erlich, N | 1 |
| Hegarty, PK | 1 |
| Yachia, D | 1 |
| Geyer, S | 1 |
| White, WL | 1 |
| Gerrard, M | 1 |
| Michon, J | 1 |
| Pinkerton, R | 1 |
| Sposto, R | 1 |
| Weston, C | 1 |
| Raphael, M | 1 |
| McCarthy, K | 1 |
| Cairo, MS | 1 |
| Kröber, SM | 1 |
| Zou, GR | 1 |
| Zhang, YJ | 1 |
| Xie, FY | 1 |
| Li, HX | 1 |
| Isoda, A | 1 |
| Hatsumi, N | 1 |
| Guerra, J | 1 |
| Echevarria-Escudero, M | 1 |
| Barrio, N | 1 |
| Velez-Rosario, R | 1 |
| Landgren, O | 1 |
| Sugimoto, T | 2 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Cao, YB | 1 |
| Xu, GC | 1 |
| Goli, AK | 1 |
| Koduri, M | 1 |
| Goli, SA | 1 |
| Byrd, RP | 1 |
| Roy, TM | 1 |
| Iwagami, Y | 1 |
| Sumitani, M | 1 |
| Imahashi, Y | 1 |
| Kiyota, H | 1 |
| Kawano, Y | 1 |
| Takifuji, N | 1 |
| Takeda, K | 2 |
| Kashii, T | 1 |
| Bañas, H | 1 |
| De Miguel, D | 1 |
| Pascual, T | 1 |
| Okamoto, K | 1 |
| Chonabayashi, K | 1 |
| Lee, DA | 1 |
| Tatevian, N | 1 |
| Herring, RA | 1 |
| McClain, KL | 1 |
| Adde, M | 1 |
| Taskinen, M | 1 |
| Blomqvist, C | 1 |
| Tadokoro, J | 1 |
| Arai, Y | 1 |
| Tokita, K | 1 |
| Iso, H | 1 |
| Maki, K | 1 |
| Walsh, KJ | 1 |
| Al-Quran, SZ | 1 |
| Braylan, RC | 1 |
| Lynch, JW | 1 |
| Siegel, AB | 1 |
| Bertini, M | 4 |
| Mozzana, R | 1 |
| Cabras, G | 1 |
| Naglieri, E | 1 |
| Yamagata, M | 1 |
| Murohisa, T | 1 |
| Tsuchida, K | 1 |
| Okamoto, Y | 1 |
| Kusano, K | 1 |
| Majima, Y | 1 |
| Kuniyoshi, T | 1 |
| Iijima, M | 1 |
| Sugaya, H | 1 |
| Hiraishi, H | 1 |
| Villela, LM | 1 |
| Blanco-Salazar, A | 1 |
| Caballero, R | 1 |
| Borbolla-Escoboza, R | 1 |
| Collins-Burow, B | 1 |
| Santos, ES | 1 |
| Usui, N | 2 |
| Kamezaki, K | 2 |
| Takase, K | 1 |
| Henzan, H | 1 |
| Nonami, A | 2 |
| Arima, F | 1 |
| Takenaka, K | 2 |
| Hayashi, S | 1 |
| Ohno, Y | 1 |
| Shi, JY | 1 |
| Goustin, AS | 1 |
| Banerjee, S | 1 |
| Nikolovska-Coleska, Z | 1 |
| Verona, C | 1 |
| Patriarca, C | 1 |
| Prievara, FT | 1 |
| Viski, A | 1 |
| Bajzik, G | 1 |
| Torday, L | 1 |
| Wang, ZC | 1 |
| Chen, XD | 1 |
| Vachani, C | 1 |
| Gemmati, D | 1 |
| Ongaro, A | 1 |
| Tognazzo, S | 1 |
| Catozzi, L | 1 |
| Federici, F | 1 |
| Mauro, E | 1 |
| Della Porta, M | 1 |
| Campioni, D | 1 |
| Bardi, A | 1 |
| Gilli, G | 1 |
| Pellati, A | 1 |
| Caruso, A | 1 |
| Scapoli, GL | 1 |
| De Mattei, M | 1 |
| Omer, HA | 1 |
| Hussein, MR | 1 |
| Medina-Franco, H | 1 |
| Germes, SS | 1 |
| Maldonado, CL | 1 |
| Zeng, XY | 1 |
| Fitzgerald, CA | 1 |
| Gill, KK | 1 |
| Wagner, SA | 1 |
| Mehta, AC | 1 |
| Laber, DA | 1 |
| Sertiç, J | 1 |
| Hansen, M | 2 |
| Kurup, SK | 1 |
| Levy-Clarke, G | 1 |
| Calvo, KR | 1 |
| Nussenblatt, RB | 1 |
| Chan, CC | 1 |
| Nagajothi, N | 1 |
| Dham, SK | 1 |
| Gelfand, Y | 1 |
| Sanmugarajah, J | 1 |
| Contreras, M | 1 |
| Ichikawa, N | 1 |
| Shimizu, I | 1 |
| Yotsumoto, M | 1 |
| Ueno, M | 1 |
| Su, ZY | 1 |
| Zhang, DS | 1 |
| Zhu, MQ | 1 |
| Tarr, T | 1 |
| Ress, Z | 1 |
| Kiss, E | 1 |
| Meyer, GS | 1 |
| Hales, CA | 1 |
| Amrein, PC | 1 |
| Kradin, RL | 1 |
| Nascimento, AF | 1 |
| Winters, GL | 1 |
| Pinkus, GS | 2 |
| Mi, C | 1 |
| Wang, YL | 1 |
| Li, YY | 1 |
| Xiang, MH | 1 |
| Sabin, P | 1 |
| Rifá, J | 1 |
| Gómez-Codina, J | 1 |
| Lobo, F | 1 |
| García, R | 1 |
| Herrero, J | 1 |
| Jara, C | 1 |
| Wang, BF | 1 |
| Yuh, YJ | 1 |
| Palmowski, M | 1 |
| Zechmann, C | 1 |
| Satzl, S | 1 |
| Bartling, S | 1 |
| Hallscheidt, P | 1 |
| Yang, HB | 1 |
| De Bock, R | 1 |
| Berneman, Z | 1 |
| Ferrant, A | 1 |
| Kaufman, L | 1 |
| Dauwe, M | 1 |
| Koffi, G | 1 |
| Kouakou, B | 1 |
| Ndiaye, FS | 1 |
| Ndathz, E | 1 |
| Sanogo, I | 1 |
| Sangare, A | 1 |
| Peng, LP | 1 |
| Ye, L | 1 |
| Feldmann, G | 1 |
| Nattermann, J | 1 |
| Gerhardt, T | 1 |
| Nähle, CP | 1 |
| Spengler, U | 1 |
| Woitas, R | 1 |
| Bestetti, RB | 1 |
| Miguel, CE | 1 |
| Marchi, E | 2 |
| Yoshimura, J | 1 |
| Kato, S | 1 |
| Tamaki, K | 1 |
| Kohno, K | 1 |
| Kaneyuki, U | 1 |
| Saikusa-Itoh, Y | 1 |
| Hayashida, A | 1 |
| Suefuji, H | 1 |
| Okuda, S | 1 |
| Huang, MQ | 1 |
| Qiao, H | 1 |
| Smolej, L | 1 |
| Hrudková, M | 1 |
| Stepánkovd, P | 1 |
| Slykorová, A | 1 |
| Zák, P | 1 |
| Bukac, J | 1 |
| Mato, AR | 1 |
| Morgans, AK | 1 |
| Roullet, MR | 1 |
| Bagg, A | 1 |
| Glatstein, E | 2 |
| Litt, HI | 1 |
| Downs, LH | 1 |
| Olson, ER | 1 |
| Andreadis, C | 1 |
| Ravasio, R | 1 |
| Rosado, M | 1 |
| Wongchaowart, N | 1 |
| Schiby, G | 1 |
| Byrne, GE | 3 |
| Mateos, MV | 1 |
| Fernández-Rañada, JM | 1 |
| Alonso, N | 1 |
| García Vela, JA | 1 |
| Garzón, S | 1 |
| Erre, GL | 1 |
| Pardini, S | 1 |
| Faedda, R | 1 |
| Passiu, G | 1 |
| Hermine, O | 2 |
| Theate, I | 1 |
| Thirot-Bidault, A | 1 |
| Ben Mansour, J | 1 |
| Bou-Farah, R | 1 |
| Pallier, C | 1 |
| Buffet, C | 1 |
| Solomonov, A | 1 |
| Zuckerman, T | 1 |
| Goralnik, L | 1 |
| Hunt, KE | 1 |
| Reichard, KK | 1 |
| Chen, CQ | 1 |
| Peng, CH | 1 |
| Ye, M | 1 |
| Chen, GM | 1 |
| Zhou, HJ | 1 |
| Li, HW | 1 |
| Fan, YZ | 1 |
| Mori, A | 1 |
| Ibata, M | 1 |
| Mashiko, S | 1 |
| Hashino, S | 1 |
| Sasaki, S | 1 |
| Shikama, N | 1 |
| Koiwai, K | 1 |
| Kadoya, M | 1 |
| Castellucci, P | 1 |
| Farsad, M | 1 |
| de Vivo, A | 1 |
| van Galen, JC | 1 |
| Muris, JJ | 1 |
| Giroth, CP | 1 |
| Vos, W | 1 |
| Ossenkoppele, GJ | 1 |
| Meijer, CJ | 2 |
| Oudejans, JJ | 1 |
| Jambusaria, A | 1 |
| Shafer, D | 1 |
| Wu, H | 1 |
| Al-Saleem, T | 1 |
| Perlis, C | 1 |
| Wuntakal, R | 1 |
| Janga, D | 1 |
| Satyanarayana, D | 1 |
| Reynolds, K | 1 |
| Hollingworth, A | 1 |
| Hegde, U | 1 |
| Vujasinovic-Stupar, N | 1 |
| Pejnovic, N | 1 |
| Babic, G | 1 |
| Belch, A | 1 |
| Corrado, C | 1 |
| Scheliga, A | 1 |
| Michelis, FV | 1 |
| Petrogiannopoulos, CL | 1 |
| Papamichael, KX | 1 |
| Kostakos, ND | 1 |
| Kiagia, EZ | 1 |
| Deliousis, A | 1 |
| Zacharof, AK | 1 |
| Narimatsu, H | 1 |
| Ito, M | 2 |
| Naoe, T | 1 |
| Stasi, R | 1 |
| Evangelista, ML | 1 |
| Brunetti, M | 1 |
| Bussa, S | 1 |
| Maritati, R | 1 |
| Turrini, L | 1 |
| Taccogna, S | 1 |
| Crescenzi, A | 1 |
| Angelini, F | 1 |
| Hazarika, N | 1 |
| Dhabhar, B | 1 |
| Saikia, TK | 1 |
| Minato, M | 1 |
| Tsukuda, H | 1 |
| Yoshimoto, M | 2 |
| Tsujisaki, M | 2 |
| Vetsch, G | 1 |
| Baumann, CK | 1 |
| Kläy, M | 1 |
| Leupin, N | 1 |
| Rentsch, C | 1 |
| Mueller-Garamvölgyi, E | 1 |
| Bürgi, U | 1 |
| Schiemann, U | 1 |
| Rodriguez-Justo, M | 1 |
| Ye, H | 1 |
| Chuang, SS | 1 |
| Munson, P | 1 |
| Prada-Puentes, C | 1 |
| Ballonoff, A | 1 |
| Rusthoven, KE | 1 |
| Schwer, A | 1 |
| McCammon, R | 1 |
| Kavanagh, B | 1 |
| Bassetti, M | 1 |
| Newman, F | 1 |
| Rabinovitch, R | 1 |
| Barnett, CR | 1 |
| Husain, S | 1 |
| Grossman, ME | 1 |
| Goslen, JB | 1 |
| Graham, W | 1 |
| Lazarus, GS | 1 |
| Bogusławska-Jaworska, J | 1 |
| Grześkowiak-Melanowska, J | 1 |
| Kaczmarek, M | 1 |
| Kościelniak, E | 1 |
| Legutko, L | 1 |
| Sońta-Jakimczyk, D | 1 |
| Sroczyńska, M | 1 |
| Wojcik, Z | 1 |
| Rassiga, AL | 1 |
| Newcomer, LN | 1 |
| Cadman, EC | 1 |
| Nerenberg, MI | 1 |
| Bertino, JR | 2 |
| Farber, LR | 2 |
| Laurence, J | 1 |
| Allen, SL | 1 |
| Silver, RT | 3 |
| Pasmantier, M | 1 |
| Burgess, MA | 1 |
| Bodey, GP | 2 |
| Freireich, EJ | 3 |
| Sampi, K | 1 |
| Honda, T | 1 |
| Hattori, M | 1 |
| Takayama, S | 1 |
| Johnson, GJ | 2 |
| Costello, WG | 2 |
| Oken, MM | 2 |
| Sponzo, RW | 1 |
| Barnes, JM | 1 |
| Ezdinli, EZ | 4 |
| Bennett, JM | 4 |
| Silverstein, MN | 2 |
| Glick, JH | 1 |
| Berard, CW | 5 |
| Monfardini, S | 4 |
| Rilke, F | 1 |
| Valagussa, P | 3 |
| Bajetta, E | 1 |
| Canetta, R | 1 |
| Buzzoni, R | 1 |
| Giardini, R | 2 |
| Viviani, S | 1 |
| Lieber, IH | 1 |
| Stoneburner, SD | 1 |
| Floyd, M | 1 |
| McGuffin, WL | 1 |
| Haller, DG | 1 |
| Todd, M | 1 |
| Cadman, E | 1 |
| Spiro, P | 1 |
| Bertino, J | 2 |
| Farber, L | 1 |
| Waldron, J | 1 |
| Fischer, D | 1 |
| James, WD | 1 |
| Odom, RB | 1 |
| Antunez, A | 1 |
| Kraus, TA | 1 |
| Fabian, CJ | 1 |
| Dixon, D | 1 |
| Potter, JF | 1 |
| Lack, EE | 1 |
| Cassady, JR | 1 |
| Fyfe, MA | 1 |
| Lewis, J | 1 |
| Dick, FR | 2 |
| Corder, MP | 2 |
| Garneau, SC | 1 |
| Platz, CE | 2 |
| Slymen, DJ | 1 |
| Dixon, DO | 2 |
| Jones, SE | 5 |
| Hartsock, RJ | 2 |
| Rebuck, JW | 1 |
| Sheehan, WW | 1 |
| Coltman, CA | 4 |
| Rappaport, H | 2 |
| Sweet, DL | 2 |
| Golomb, HM | 2 |
| DeVita, VT | 10 |
| Bostick, F | 1 |
| Vanhaelen, C | 1 |
| Howser, DM | 1 |
| Hubbard, SM | 1 |
| Young, RC | 9 |
| Berard, C | 4 |
| Sokal, JE | 1 |
| Matzner, Y | 1 |
| Prococimer, M | 1 |
| Rubinger, D | 1 |
| Popovtzer, MM | 1 |
| Deonarine, L | 1 |
| Weinerman, BH | 2 |
| MacDougall, BK | 1 |
| Kemel, S | 1 |
| Lishner, M | 1 |
| Slingerland, J | 1 |
| Theresa, C | 1 |
| Sutcliffe, SB | 1 |
| Costa, MA | 1 |
| Rabinowits, M | 1 |
| Froimtchuk, MJ | 1 |
| Olivatto, LO | 1 |
| Allan, SE | 1 |
| Gil, RA | 1 |
| Andrade, CA | 1 |
| Martino, JL | 1 |
| Dobbin, JA | 1 |
| Carriço, MK | 1 |
| Delgado, S | 1 |
| Alatriste, S | 1 |
| Díaz-Maqueo, JC | 3 |
| Earle, JD | 1 |
| Fuller, LM | 4 |
| Krasin, MJ | 1 |
| Velasquez, WS | 2 |
| Swan, F | 2 |
| Palmer, JL | 1 |
| García, EL | 1 |
| Brugger, W | 1 |
| Engelhardt, R | 1 |
| Kanz, L | 1 |
| Reale, MA | 1 |
| Yen, Y | 1 |
| Strair, RK | 1 |
| Flynn, SD | 1 |
| Sawada, U | 1 |
| Tsuboi, I | 1 |
| Yamazaki, T | 1 |
| Satou, Y | 1 |
| Horie, T | 1 |
| Peacock, JE | 1 |
| Greven, CM | 1 |
| Cruz, JM | 1 |
| Hurd, DD | 1 |
| Fields, LL | 1 |
| White, CR | 1 |
| O'Reilly, SE | 6 |
| Ohnoshi, T | 3 |
| Hayashi, K | 4 |
| Tagawa, S | 3 |
| Saito, S | 3 |
| Matsutomo, S | 3 |
| Kimura, I | 2 |
| Okubo, Y | 1 |
| Nakazawa, K | 1 |
| Topilow, AA | 1 |
| Guerra, OR | 1 |
| Tarantolo, SR | 1 |
| Lerner, WA | 1 |
| Snyder, GC | 1 |
| Waits, TM | 1 |
| Greco, FA | 1 |
| Tada, A | 1 |
| Mizuta, J | 1 |
| Schaberg, SJ | 1 |
| Daniels, CA | 1 |
| Loomer, L | 1 |
| Addante, RR | 1 |
| Umeda, M | 1 |
| Shirai, T | 1 |
| Schoeppner, HL | 1 |
| Wong, DK | 1 |
| Bresalier, RS | 1 |
| Touroutoglou, N | 1 |
| Pugh, W | 1 |
| Cox, J | 1 |
| Brice, P | 2 |
| Pautier, P | 1 |
| Sandlund, JT | 1 |
| Pui, CH | 1 |
| Roberts, WM | 1 |
| Santana, VM | 1 |
| Morris, SW | 1 |
| Ribeiro, RC | 1 |
| Mahmoud, H | 3 |
| Crist, WM | 1 |
| Finlay, JL | 1 |
| Anderson, JR | 2 |
| Cecalupo, AJ | 1 |
| Hutchinson, RJ | 1 |
| Kadin, ME | 2 |
| Kjeldsberg, CR | 1 |
| Provisor, AJ | 1 |
| Woods, WG | 1 |
| Meadows, AT | 1 |
| Nishiuchi, R | 1 |
| Maluf, PT | 1 |
| Odone Filho, V | 1 |
| Cristofani, LM | 1 |
| Britto, JL | 1 |
| Almeida, MT | 1 |
| Pontes, E | 1 |
| Maksoud, JG | 1 |
| Manissadjian, A | 1 |
| Dahlberg, S | 1 |
| Pavlidis, NA | 1 |
| Elisaf, M | 1 |
| Bai, M | 1 |
| Tolis, C | 1 |
| Papadimitriou, C | 1 |
| Howdle, S | 1 |
| Klimo, P | 6 |
| Stuart, DS | 1 |
| Gryn, J | 1 |
| Gordon, R | 1 |
| Bapat, A | 1 |
| Goldman, N | 1 |
| Goldberg, J | 2 |
| Plowman, PN | 1 |
| Montefiore, DS | 1 |
| Lightman, S | 1 |
| Sebastián, JJ | 1 |
| Fuentes, J | 1 |
| García, S | 1 |
| Uribarrena, R | 1 |
| Yus, C | 1 |
| Boldova, I | 1 |
| Janicek, M | 1 |
| Canellos, GP | 11 |
| Shulman, LN | 1 |
| d'Agay, MF | 1 |
| Lavignac, C | 1 |
| Fillet, G | 1 |
| Diebold, J | 1 |
| Reyas, F | 1 |
| Mizusawa, H | 1 |
| Okaneya, T | 1 |
| Yoneyama, T | 1 |
| Taguchi, I | 1 |
| Keung, YK | 1 |
| Cobos, E | 1 |
| Meyerrose, GE | 1 |
| Roberson, GH | 1 |
| Fidias, P | 1 |
| Wright, C | 1 |
| Harris, NL | 1 |
| Urba, W | 1 |
| Grossbard, ML | 2 |
| Soslow, RA | 1 |
| Warnke, RA | 3 |
| Cleary, ML | 1 |
| Kamel, OW | 1 |
| Giudici, MC | 1 |
| Sadler, RL | 1 |
| Robken, JA | 1 |
| Ahearn, MA | 1 |
| Sekharan, R | 1 |
| Kovach, G | 1 |
| Vaughan Hudson, B | 3 |
| Hancock, BW | 1 |
| Cunningham, DC | 2 |
| Newland, AC | 1 |
| Milligan, DW | 1 |
| Stevenson, PA | 1 |
| Wood, JK | 1 |
| MacLennan, KA | 2 |
| Anderson, L | 3 |
| Gregory, WM | 1 |
| Vaughan Hudson, G | 3 |
| Hill, ME | 1 |
| Burke, M | 1 |
| Clarke, P | 1 |
| Di Stefano, F | 1 |
| Mason, D | 1 |
| Selby, P | 1 |
| Dent, S | 1 |
| Eapen, L | 1 |
| Girard, A | 1 |
| Hugenholtz, H | 1 |
| DaSilva, V | 1 |
| Stewart, DJ | 1 |
| Patarca, R | 1 |
| Freidlander, A | 1 |
| Harrington, WJ | 1 |
| Cabral, L | 1 |
| Byrnes, JJ | 1 |
| Fletcher, MA | 1 |
| Ang, PT | 1 |
| Amigo, ML | 1 |
| Revilla, R | 1 |
| Sánchez, C | 1 |
| del Cañizo, C | 1 |
| Pomeranz, HD | 1 |
| McEvoy, LT | 1 |
| Lueder, GT | 1 |
| Andersen, J | 2 |
| Neiman, RS | 1 |
| Bauer, KD | 1 |
| Lackner, RP | 1 |
| Galbraith, TA | 1 |
| Cortellazzo, S | 1 |
| Freilone, R | 2 |
| Falda, M | 1 |
| Cinieri, S | 1 |
| Lovisone, E | 1 |
| Marmont, F | 1 |
| Viero, P | 2 |
| Barbui, T | 2 |
| Grignani, F | 1 |
| Resegotti, L | 1 |
| Engelhard, M | 1 |
| Brittinger, G | 1 |
| Huhn, D | 1 |
| Gerhartz, HH | 1 |
| Meusers, P | 1 |
| Siegert, W | 1 |
| Thiel, E | 1 |
| Wilmanns, W | 1 |
| Aydemir, U | 1 |
| Bierwolf, S | 1 |
| Griesser, H | 1 |
| Tiemann, M | 1 |
| Lennert, K | 1 |
| Lee, AY | 1 |
| Vásquez, E | 1 |
| Takano, H | 1 |
| Sato, N | 1 |
| Natoya, A | 1 |
| Tarumi, T | 1 |
| Hirayama, S | 1 |
| Koizumi, K | 1 |
| Takahashi, TA | 1 |
| Sekiguchi, S | 1 |
| Koike, T | 1 |
| Fonseca, R | 1 |
| Tefferi, A | 1 |
| Strickler, JG | 1 |
| Maymind, M | 1 |
| Mergelas, JE | 1 |
| Seibert, DG | 1 |
| Hostetter, RB | 1 |
| Chang, WW | 1 |
| Meguerian-Bedoyan, Z | 1 |
| Hopfner, C | 1 |
| Chittal, S | 1 |
| Carolin, KA | 1 |
| Prakash, SH | 1 |
| Silva, YJ | 1 |
| Bellavita, P | 1 |
| Marchioli, R | 1 |
| Marfisi, RM | 1 |
| Hoskins, PJ | 2 |
| Le, N | 1 |
| Geetha, N | 1 |
| Ittyavirah, K | 1 |
| Ajitkumar, TV | 1 |
| Sreedeviamma, N | 1 |
| Nair, MK | 1 |
| Sakai, C | 1 |
| Kumagai, K | 1 |
| Kuwahara, K | 1 |
| Fukata, J | 1 |
| Kamio, M | 1 |
| Mochizuki, T | 1 |
| Tsuchiya, A | 1 |
| Cazals, D | 1 |
| Verola, O | 1 |
| Neidhart-Berard, AM | 1 |
| Remenieras, L | 1 |
| Doyen, C | 1 |
| Hamelsand, J | 1 |
| Moulonguet, I | 1 |
| Bendandi, M | 2 |
| Buzzi, M | 1 |
| Sabattini, E | 2 |
| Gherlinzoni, F | 2 |
| Albertini, P | 1 |
| Tura, S | 2 |
| Stuschke, M | 1 |
| Nowrousian, MR | 1 |
| Yamaguchi, Y | 1 |
| Takasaki, N | 1 |
| Kato, A | 1 |
| Saito, T | 2 |
| Tajima, N | 1 |
| Kuraishi, Y | 1 |
| Alvarez-Carmona, AM | 1 |
| Maldonado, J | 1 |
| Alcalá, A | 1 |
| Zubizarreta, A | 1 |
| Sancho-Tello, R | 1 |
| Carbonell, F | 1 |
| Contreras, E | 1 |
| Besses, C | 1 |
| Hernando, A | 1 |
| Fontanillas, M | 1 |
| Fajardo Montañana, C | 1 |
| Merino Torres, JF | 1 |
| Campos Alborg, V | 1 |
| Garcerá Juan, S | 1 |
| Piñón Sellés, F | 1 |
| Salvagno, L | 1 |
| Vespignani, M | 1 |
| Soracco, M | 1 |
| Guarnaccia, C | 1 |
| Pescosta, N | 1 |
| Rossi, E | 1 |
| Zambaldi, G | 1 |
| Mangoni, L | 1 |
| Rizzoli, V | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Bernasconi, C | 1 |
| Lobo, FD | 1 |
| Bansal, R | 1 |
| Naik, R | 1 |
| Pai, MR | 1 |
| Dinesh, D | 1 |
| Perales, M | 1 |
| Cervantes, F | 1 |
| Cobo, F | 1 |
| Kaplan, SS | 1 |
| Rybka, WB | 1 |
| Blom, J | 2 |
| Shekhter-Levin, S | 1 |
| Miyata, A | 1 |
| Fujiwara, T | 1 |
| Kikuchi, T | 1 |
| Osada, T | 1 |
| Ben-Yehuda, D | 1 |
| Dommann-Scherrer, C | 1 |
| Maurer, R | 1 |
| Glanzmann, C | 1 |
| Pichert, G | 1 |
| Pestalozzi, B | 1 |
| Marincek, B | 1 |
| Sauter, C | 1 |
| Honegger, H | 1 |
| Chim, CS | 2 |
| Lie, AK | 1 |
| Lee, CK | 1 |
| Liang, R | 2 |
| Shinohara, K | 1 |
| Kameda, N | 1 |
| Katsuki, K | 1 |
| Ariyoshi, K | 1 |
| Kamei, T | 1 |
| Fraternali-Orcioni, G | 1 |
| Falini, B | 2 |
| Quaini, F | 1 |
| Piccioli, M | 1 |
| Gamberi, B | 1 |
| Pasquinelli, G | 1 |
| Poggi, S | 1 |
| Sanz García, RM | 1 |
| Guerra Vales, JM | 1 |
| de Prada, I | 1 |
| Martínez, MA | 1 |
| Guillén Camargo, V | 1 |
| Mwangi, JW | 1 |
| Nakahara, T | 1 |
| Muroi, A | 1 |
| Sugiura, Y | 1 |
| Sugiyama, Y | 1 |
| Yamamoto, T | 1 |
| De la Maya, MD | 1 |
| Escalante, R | 1 |
| Torre, A | 1 |
| Urdambidelus, C | 1 |
| Canales Albendea, MA | 1 |
| Alvarez Román, MT | 1 |
| del Pozo Pozo, I | 1 |
| Hernández Navarro, F | 1 |
| Yoshitomi, A | 1 |
| Chida, K | 1 |
| Suda, T | 1 |
| Kuwata, H | 1 |
| Todate, A | 1 |
| Bekkenk, MW | 1 |
| Vermeer, MH | 1 |
| Geerts, ML | 1 |
| Noordijk, EM | 1 |
| Heule, F | 1 |
| van Voorst Vader, PC | 1 |
| van Vloten, WA | 1 |
| Tondini, C | 1 |
| Siracusano, L | 1 |
| Rampinelli, I | 1 |
| Bonadonna, G | 4 |
| Schuetze, SM | 1 |
| Weiden, PL | 1 |
| Bieri, S | 1 |
| Roggero, E | 2 |
| Pianca, S | 1 |
| Sanna, P | 1 |
| Pedrinis, E | 2 |
| Bernier, J | 1 |
| Khaled, HM | 1 |
| Zekri, ZK | 1 |
| Ali, NM | 1 |
| Darwish, T | 1 |
| Elattar, I | 1 |
| Gaafar, R | 1 |
| Moawad, MS | 1 |
| Loudon, JA | 1 |
| Marsh, WL | 1 |
| Allen, CM | 1 |
| Brugières, L | 1 |
| Quartier, P | 1 |
| Le Deley, MC | 1 |
| Pacquement, H | 1 |
| Perel, Y | 1 |
| Bergeron, C | 1 |
| Schmitt, C | 1 |
| Landmann, J | 1 |
| Terrier-Lacombe, MJ | 1 |
| Hartmann, O | 1 |
| Koniaris, LG | 1 |
| Lillemoe, KD | 1 |
| Yeo, CJ | 1 |
| Abrams, RA | 1 |
| Colemann, J | 1 |
| Nakeeb, A | 1 |
| Pitt, H | 1 |
| Cameron, JL | 1 |
| Baumann, TP | 1 |
| Hurwitz, N | 1 |
| Karamitopolou-Diamantis, E | 1 |
| Probst, A | 1 |
| Herrmann, R | 1 |
| Steck, AJ | 1 |
| Van Der Klooster, JM | 1 |
| Van Der Wiel, HE | 1 |
| Van Saase, JL | 1 |
| Grootendorst, AF | 1 |
| Carey, MJ | 1 |
| Smith, AG | 1 |
| Townsend, JJ | 1 |
| Valencak, J | 1 |
| Osterreicher, C | 1 |
| Kornek, G | 1 |
| Scheithauer, W | 1 |
| Brodowicz, T | 1 |
| Dragosics, B | 1 |
| Jillella, AP | 1 |
| Day, DS | 1 |
| Severson, K | 1 |
| Kallab, AM | 1 |
| Burgess, R | 1 |
| Alexandrakis, MG | 1 |
| Chatzivasili, A | 1 |
| Stefanaki, K | 1 |
| Eliopoulos, GD | 1 |
| Chen, CL | 1 |
| Chiang, IP | 1 |
| Chen, LT | 1 |
| Higgins, JP | 1 |
| Chevlen, EM | 1 |
| Lyons, JA | 1 |
| Myles, J | 1 |
| Macklis, RM | 1 |
| Crowe, J | 1 |
| Crownover, RL | 1 |
| Bernasconi, A | 1 |
| Donnelly, GB | 1 |
| Glassman, J | 1 |
| Long, C | 1 |
| Torres, P | 1 |
| Straus, DJ | 1 |
| O'Brien, JP | 1 |
| Filipits, M | 1 |
| Simonitsch, I | 1 |
| Chizzali-Bonfadin, C | 1 |
| Heinzl, H | 1 |
| Pirker, R | 1 |
| Gaynor, ER | 1 |
| White, LA | 1 |
| Mills, GM | 1 |
| Balcerzak, SP | 1 |
| Varterasian, M | 1 |
| Ruiz Hernández, G | 1 |
| Pallardó-Calatayud, J | 1 |
| Ferrer Albiach, C | 1 |
| Balaguer-Martínez, JV | 1 |
| Romero-de-Avila, C | 1 |
| Castillo-Pallarés, FJ | 1 |
| Bocchia, M | 1 |
| Gobbi, M | 1 |
| Brage, A | 1 |
| Castroagudín, J | 1 |
| Bustamante, M | 1 |
| Pérez-Encinas, M | 1 |
| Petroni, GR | 1 |
| Parker, BA | 1 |
| Wagner, ND | 1 |
| Gockerman, JP | 1 |
| Omura, GA | 1 |
| Robert, M | 1 |
| Johnson, JL | 1 |
| Adachi, H | 1 |
| Tsuboi, M | 1 |
| Chan, AC | 1 |
| Hervás Benito, I | 1 |
| Vera Espallardo, F | 1 |
| Saura Quiles, A | 1 |
| González Cabezas, P | 1 |
| Bello Arques, P | 1 |
| Rivas Sánchez, A | 1 |
| Alonso Monfort, J | 1 |
| Pérez Velasco, R | 1 |
| Mateo Navarro, A | 1 |
| Edwards, MJ | 1 |
| Walker, R | 1 |
| Vinnicombe, S | 1 |
| Barlow, C | 1 |
| MacCallum, P | 1 |
| Pick, TE | 2 |
| Hutchinson, RE | 1 |
| Ochoa, S | 2 |
| Shuster, JJ | 2 |
| Bertè, R | 1 |
| Civardi, G | 1 |
| Moroni, CF | 1 |
| Lazzaro, A | 1 |
| Cavanna, L | 1 |
| Rontogianni, D | 1 |
| Papageorgiou, E | 1 |
| Bollas, G | 1 |
| Mantzios, G | 1 |
| Kalantzis, D | 1 |
| Koumarianou, A | 1 |
| Raptis, S | 1 |
| Aman, P | 1 |
| Torlakovic, E | 1 |
| Mitelman, F | 1 |
| Fioretos, T | 1 |
| Ross, KN | 1 |
| Kutok, JL | 1 |
| Aguiar, RC | 1 |
| Gaasenbeek, M | 1 |
| Angelo, M | 1 |
| Reich, M | 1 |
| Ray, TS | 1 |
| Koval, MA | 1 |
| Last, KW | 1 |
| Norton, A | 1 |
| Mesirov, J | 1 |
| Neuberg, DS | 1 |
| Lander, ES | 1 |
| Golub, TR | 1 |
| Mayer, A | 1 |
| Dumontet, C | 1 |
| Barbier, Y | 1 |
| Felman, P | 1 |
| Ducottet, X | 1 |
| Martin, C | 1 |
| Orgiazzi, J | 1 |
| Murohashi, I | 1 |
| Kashimura, T | 1 |
| Tominaga, K | 2 |
| Wakao, D | 1 |
| Akiba, M | 1 |
| Yagasaki, F | 1 |
| Itoh, Y | 1 |
| Sakata, T | 1 |
| Kawai, N | 1 |
| Matsuda, A | 1 |
| Hirashima, K | 2 |
| Bessho, M | 1 |
| Kpemissi, E | 1 |
| Tatagan, A | 1 |
| Akakpo, O | 1 |
| Napo-Koura, G | 1 |
| Khoury, J | 1 |
| Jerushalmi, J | 1 |
| Cohen, HI | 1 |
| Nasrallah, S | 1 |
| Osorio, S | 1 |
| Bernis, C | 1 |
| de La Cámara, R | 1 |
| Vivenza, D | 1 |
| Zagonel, V | 1 |
| Ariatti, C | 1 |
| Milan, I | 1 |
| Palestro, G | 1 |
| Saglio, G | 1 |
| Rieux, C | 1 |
| Beaujean, F | 1 |
| Simon, D | 1 |
| Gaulard, PH | 1 |
| Gisselbrecht, CH | 1 |
| Song, DK | 1 |
| Boulis, NM | 1 |
| McKeever, PE | 1 |
| Quint, DJ | 1 |
| el Omari-Alaoui, H | 1 |
| Kebdani, T | 1 |
| Benjaafar, N | 1 |
| el Ghazi, E | 1 |
| Erriahni, H | 1 |
| el Gueddari, BK | 1 |
| Kornacker, M | 1 |
| Kraemer, A | 1 |
| Leo, E | 1 |
| Van den Bruel, A | 1 |
| Drijkoningen, M | 1 |
| Oyen, R | 1 |
| Vanfleteren, E | 1 |
| Bouillon, R | 1 |
| Sbaï, A | 1 |
| Wechsler, B | 1 |
| Godeau, P | 1 |
| Piette, JC | 1 |
| Cole, D | 1 |
| Pearson, D | 1 |
| Drbohlav, N | 1 |
| Janik, J | 1 |
| Longo, DL | 1 |
| Harris, N | 1 |
| Wittes, R | 1 |
| Balis, F | 1 |
| Cairoli, R | 1 |
| Grillo, G | 1 |
| Tedeschi, A | 1 |
| Marenco, P | 1 |
| Tresoldi, E | 1 |
| Barbarano, L | 1 |
| Nosari, AM | 1 |
| Singhal, D | 1 |
| Witham, TF | 1 |
| Germanwala, A | 1 |
| Flickinger, JC | 1 |
| Schiff, D | 1 |
| Kondziolka, D | 1 |
| Akhtar, S | 1 |
| Kazama, Y | 1 |
| Shimizu, H | 1 |
| Imai, K | 1 |
| Porcaro, AB | 1 |
| D'Amico, A | 1 |
| Novella, G | 1 |
| Curti, P | 1 |
| Ficarra, V | 1 |
| Antoniolli, SZ | 1 |
| Martignoni, G | 1 |
| Matteo, B | 1 |
| Malossini, G | 1 |
| Chabner, B | 1 |
| Schein, P | 1 |
| Hubbard, SP | 1 |
| O'Neill, TJ | 1 |
| Kardinal, CG | 1 |
| Tierney, LM | 1 |
| De Lena, M | 1 |
| Lattuada, A | 1 |
| Milani, F | 1 |
| Beretta, G | 1 |
| Pouillart, P | 2 |
| Hayat, M | 2 |
| Schwarzenberg, L | 2 |
| Amiel, JL | 2 |
| Mathé, G | 2 |
| Tubiana, M | 1 |
| Bakemeier, RF | 1 |
| Carbone, PP | 6 |
| Ezdinli, E | 2 |
| Lenhard, RE | 4 |
| Adler, S | 1 |
| Shimaoka, K | 1 |
| Han, T | 1 |
| Tsukada, Y | 1 |
| Schein, PS | 4 |
| Hubbard, S | 1 |
| Tancini, G | 1 |
| DeLena, M | 1 |
| Donner, L | 2 |
| Schmidt, CG | 1 |
| Johnson, BL | 1 |
| Simon, R | 1 |
| Anderson, T | 1 |
| Bender, RA | 1 |
| Norton, L | 2 |
| Luce, JK | 2 |
| McKelvey, EM | 2 |
| Moon, TE | 2 |
| Pocock, SJ | 1 |
| Nissen, NI | 4 |
| Pajak, T | 1 |
| Glidewell, O | 3 |
| Blom, H | 1 |
| Flaherty, M | 1 |
| Hayes, D | 1 |
| McIntyre, R | 1 |
| Holland, JF | 5 |
| Gamble, JF | 3 |
| Butler, JJ | 1 |
| Sinkovics, JG | 1 |
| Wallace, S | 1 |
| Martin, RG | 1 |
| Gehan, EA | 2 |
| Shullenberger, CC | 1 |
| Rossof, AH | 1 |
| Kerr, RO | 1 |
| Braine, HG | 1 |
| Rodriguez, V | 2 |
| Parris, TM | 1 |
| Knight, JG | 1 |
| Hess, CE | 2 |
| Constable, WC | 1 |
| Gorin, NC | 2 |
| David, R | 2 |
| Stachowiak, J | 2 |
| Najman, A | 2 |
| Duhamel, G | 2 |
| Levitt, M | 1 |
| Babick, T | 1 |
| Davey, FR | 1 |
| Gottlieb, AJ | 2 |
| Lopes Cardozo, E | 1 |
| Durant, JR | 2 |
| Gams, RA | 1 |
| Bartolucci, AA | 1 |
| Dorfman, RF | 3 |
| Johnson, RE | 1 |
| Brereton, HD | 1 |
| Laurens, A | 1 |
| Thevenot, J | 1 |
| Charron, D | 1 |
| Jorry, F | 1 |
| Dumonchel, P | 1 |
| Martola, R | 1 |
| Rubio-Félix, D | 1 |
| Maicas, M | 1 |
| Rubio-Vitaller, A | 1 |
| Gil, JL | 1 |
| Giralt, M | 1 |
| Raichs, A | 1 |
| Brecher, ML | 1 |
| Sinks, LF | 1 |
| Thomas, RR | 1 |
| Freeman, AI | 1 |
| Ultmann, JE | 2 |
| Costello, W | 1 |
| Horton, J | 1 |
| Amorisi, EL | 1 |
| Stolbach, L | 2 |
| Wolter, J | 1 |
| Harrison, DT | 1 |
| Neiman, PE | 1 |
| Sullivan, K | 1 |
| Hafermann, M | 1 |
| Rudolph, RH | 1 |
| Einstein, AB | 1 |
| Elias, L | 1 |
| Rosenberg, SA | 3 |
| Gomez, GA | 1 |
| Stutzman, L | 2 |
| Forcier, RJ | 2 |
| McIntyre, OR | 1 |
| Pajak, TF | 2 |
| Posner, JB | 1 |
| Howieson, J | 1 |
| Cvitkovic, E | 1 |
| Moran, EM | 2 |
| Hayes, DM | 2 |
| Rege, V | 1 |
| Falkson, G | 1 |
| Spurr, CL | 2 |
| Harley, JB | 1 |
| Cuttner, J | 2 |
| Leimert, JT | 1 |
| Misset, JL | 1 |
| de Vassal, F | 1 |
| Musset, M | 1 |
| Belpomme, D | 1 |
| Jasmin, C | 1 |
| Albahary, C | 1 |
| Depierre, R | 1 |
| Kaplan, HS | 2 |
| Young, CW | 1 |
| Prentice, RL | 1 |
| Owens, AH | 1 |
| Bakemeier, R | 1 |
| Horton, JH | 1 |
| Shnider, BI | 1 |
| Klein, HO | 1 |
| Gottlieb, JA | 1 |
| Wilson, HE | 3 |
| Haut, A | 1 |
| Talley, RW | 1 |
| Lane, M | 1 |
| Grozea, PN | 2 |
| Gutterman, J | 1 |
| Coltman, C | 1 |
| Fried, J | 1 |
| Arlin, Z | 1 |
| Alikpala, A | 1 |
| Tan, CT | 1 |
| Clarkson, B | 1 |
| Slome, R | 1 |
| Timme, A | 1 |
| Warikoo, S | 1 |
| Gonick, P | 1 |
| Morgenfeld, MC | 2 |
| Pavlovsky, A | 1 |
| Suarez, A | 1 |
| Somoza, N | 1 |
| Pavlovsky, S | 1 |
| Palau, M | 1 |
| Barros, CA | 1 |
| Young, RD | 1 |
| Bergsagel, DE | 1 |
| Brown, TC | 1 |
| Loeb, V | 1 |
| Dorfman, R | 1 |
| Chan, YK | 1 |
| Hunt, FA | 1 |
| Lander, CM | 1 |
| Uwabe, Y | 1 |
| Yoshida, H | 1 |
| Onishi, M | 1 |
| Kudo, K | 1 |
| Motoyoshi, K | 1 |
| Aida, S | 1 |
| Berkman, N | 1 |
| Lafair, J | 1 |
| Okon, E | 2 |
| Terashima, T | 1 |
| Tuji, M | 1 |
| Takeuchi, H | 1 |
| Bashir, RM | 1 |
| Bierman, P | 1 |
| McComb, R | 1 |
| Morita, K | 1 |
| Maehara, T | 1 |
| Mitsuhashi, M | 1 |
| Omine, M | 1 |
| Naruse, T | 1 |
| Yatabe, H | 1 |
| Cavallero, GB | 1 |
| Comotti, B | 1 |
| Ghio, R | 1 |
| Luxi, G | 1 |
| Meneghini, V | 1 |
| Itoh, T | 1 |
| Sakata, Y | 1 |
| Sugimoto, N | 1 |
| Sohma, N | 1 |
| Kishibe, T | 1 |
| Higuchi, S | 1 |
| Seino, Y | 1 |
| Matsui, T | 1 |
| Nakao, Y | 1 |
| Fujita, T | 1 |
| Breda, E | 1 |
| Temperilli, L | 1 |
| Marosi, C | 1 |
| Heinz, R | 1 |
| Steger, G | 1 |
| Fortelny, A | 1 |
| Hanak, H | 1 |
| Radaszkiewicz, T | 1 |
| Baur, M | 1 |
| Kreiner, G | 1 |
| Schwarzinger, I | 1 |
| Nakano, M | 1 |
| Kawanishi, Y | 1 |
| Kuge, S | 1 |
| Kuriyama, Y | 1 |
| Kuwabara, S | 1 |
| Yaguchi, M | 1 |
| Koza, I | 1 |
| Mardiak, J | 1 |
| Bohunický, L | 1 |
| Svancárová, L | 1 |
| Fuchsberger, P | 1 |
| Gyárfás, J | 1 |
| Horák, I | 1 |
| Spánik, S | 1 |
| Sufliarsky, J | 1 |
| Thalmeinerová, Z | 1 |
| Harrington, D | 1 |
| Colgan, J | 1 |
| Glick, J | 1 |
| Neiman, R | 1 |
| Mann, R | 1 |
| Resnick, GD | 1 |
| Barcos, M | 2 |
| Gottlieb, A | 1 |
| Sumimura, J | 1 |
| Miyata, M | 1 |
| Nakao, K | 1 |
| Kamiike, W | 1 |
| Matsuda, H | 1 |
| Guglielmi, C | 4 |
| Papa, G | 2 |
| Mandelli, F | 4 |
| Kawano, E | 1 |
| Hirasawa, A | 1 |
| Morio, S | 1 |
| Aotuka, N | 1 |
| Oh, H | 1 |
| Asai, T | 1 |
| Tsukada, T | 2 |
| Ohno, T | 2 |
| Tsuji, K | 1 |
| Kita, K | 2 |
| Deguchi, K | 1 |
| Shirakawa, S | 1 |
| Kihira, H | 1 |
| Taniguchi, M | 1 |
| Arima, S | 1 |
| Yamada, H | 1 |
| Akasaka, Y | 1 |
| Yokoi, H | 1 |
| Stroup, RM | 1 |
| Sheibani, K | 1 |
| Moncada, A | 1 |
| Purdy, LJ | 1 |
| Battifora, H | 1 |
| Ginsberg, SJ | 1 |
| Bloomfield, CD | 1 |
| Nissen, N | 1 |
| Henderson, ES | 1 |
| Ng, V | 1 |
| Jagannath, S | 1 |
| North, LB | 1 |
| Redman, JR | 1 |
| Wilson, M | 1 |
| Doggett, R | 1 |
| Nathrath, W | 1 |
| Permanetter, W | 1 |
| Gokel, JM | 1 |
| Fox, K | 1 |
| Silfen, D | 1 |
| Alavi, A | 1 |
| Rodríguez García, JL | 1 |
| Marcos Robles, J | 1 |
| Serrano, M | 1 |
| Arechaga, S | 1 |
| Perales, J | 1 |
| Bellas, C | 1 |
| Huerta, J | 1 |
| Zepeda, G | 1 |
| Guzmán, R | 1 |
| Díaz-Maqueo, J | 1 |
| Axelsen, RA | 1 |
| Laird, PP | 1 |
| Horn, M | 1 |
| Winter, SS | 1 |
| Duncan, MH | 1 |
| Foucar, E | 1 |
| McConnell, TS | 1 |
| Cartwright, KC | 1 |
| Asano, Y | 1 |
| Yoshizawa, S | 1 |
| Shiraishi, G | 1 |
| Coluzzi, S | 1 |
| Nand, S | 1 |
| Mullen, GM | 1 |
| Lonchyna, VA | 1 |
| Moncada, R | 1 |
| Nishikawa, K | 1 |
| Sekiyama, S | 1 |
| Matsukawa, W | 1 |
| Tamai, H | 1 |
| Yoshida, F | 1 |
| Fukatsu, A | 1 |
| Matsuo, S | 1 |
| Shigematsu, H | 1 |
| Dragoni, F | 1 |
| Debranin, CO | 1 |
| Spagliardi, E | 1 |
| Longo, A | 1 |
| Blanco, GF | 1 |
| Ruggeri, C | 1 |
| Buscaglia, M | 1 |
| Torelli, P | 1 |
| Sandvei, R | 1 |
| Lote, K | 1 |
| Svendsen, E | 1 |
| Thunold, S | 1 |
| Epelbaum, R | 2 |
| Faraggi, D | 1 |
| Ben-Arie, Y | 1 |
| Ben-Shahar, M | 2 |
| Haim, N | 2 |
| Ron, Y | 2 |
| Robinson, E | 1 |
| Sivkovich, SA | 1 |
| Kindzel'skiĭ, LP | 1 |
| Galakhin, KA | 1 |
| Yoshimoto, T | 1 |
| Araki, Y | 1 |
| Kawano, K | 1 |
| Kamata, T | 1 |
| Okamoto, S | 1 |
| Todd, MB | 1 |
| Holford, TR | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Schaafsma, MR | 1 |
| Peters, WG | 1 |
| Tham, RT | 1 |
| Alleman, MJ | 1 |
| Chadha, M | 1 |
| Shank, B | 1 |
| Fuks, Z | 1 |
| Clarkson, BD | 1 |
| Bonfiglio, P | 1 |
| Gnecco, C | 1 |
| Gulati, S | 1 |
| Czerniak, A | 1 |
| Soreide, O | 1 |
| Halnan, K | 1 |
| Krausz, T | 1 |
| Edwards, WH | 1 |
| Blumgart, LH | 1 |
| Neilan, B | 1 |
| Lipschitz, DA | 1 |
| Freter, CE | 1 |
| Lee, TC | 1 |
| Billingham, ME | 1 |
| Chak, L | 1 |
| Bristow, MR | 1 |
| Gottlieb, D | 1 |
| Commens, C | 1 |
| Stewart, FM | 1 |
| Williamson, BR | 1 |
| Innes, DJ | 1 |
| Knobler, H | 1 |
| Rubinstein, N | 1 |
| Sherman, Y | 1 |
| Chajek-Shaul, T | 1 |
| Vandenberg, TA | 1 |
| Maroun, JA | 1 |
| Qiu, W | 1 |
| Schneck, SA | 1 |
| Penn, I | 2 |
| Pierce, JC | 1 |
| Madge, GE | 1 |
| Lee, HM | 1 |
| Hume, DM | 1 |
| Silverman, EM | 1 |
| Reed, RE | 1 |
| Mann, M | 1 |
| Rüttner, JR | 1 |
| Maier, C | 1 |
| Kiely, JM | 1 |
| Hoerni, B | 1 |
| Brunet, R | 1 |
| Hoerni-Simon, G | 1 |
| Helft, F | 1 |
| Bomchil, G | 1 |
| Luthardt, T | 1 |
| Todt, R | 1 |
| Gregl, A | 1 |
| Prindul, F | 1 |
| Weigel, F | 1 |
| Krack, U | 1 |
| Van Thiel, DH | 1 |
| Sherins, RJ | 2 |
| Myers, GH | 1 |
| De Vita, VT | 2 |
| Hamlin, JA | 1 |
| Kagan, AR | 1 |
| Friedman, NB | 1 |
| Stammberger, K | 1 |
| Wachtel, D | 1 |
| Walbom-Jorgensen, S | 1 |
| Fortuny, IE | 1 |
| Theologides, A | 1 |
| Kennedy, BJ | 1 |
| Rubin, P | 1 |
| Novis, BH | 1 |
| Kahn, LB | 1 |
| Bank, S | 1 |
| Schein, PJ | 1 |
| Bagley, CM | 1 |
| Host, H | 1 |
| Abrahamsen, AF | 1 |
| Aungst, CW | 2 |
| Myers, BD | 1 |
| Kessler, E | 1 |
| Levi, J | 1 |
| Pick, A | 1 |
| Rosenfeld, JB | 1 |
| Tikvah, P | 1 |
| Stein, RS | 1 |
| Desser, RK | 1 |
| Miller, JB | 1 |
| Guisan, Y | 1 |
| Enderlin, F | 1 |
| Harder, F | 1 |
| Brunner, F | 1 |
| Thiel, G | 1 |
| Bernhardt, JP | 1 |
| Schädeli, J | 1 |
| Mihatsch, M | 1 |
| Wenz, B | 1 |
| Friedman, G | 1 |
| Ellison, RR | 1 |
| Weil, M | 1 |
| Jacquillat, C | 1 |
| Boiron, M | 1 |
| Bernard, J | 1 |
| Sawitsky, A | 1 |
| Rosner, F | 1 |
| Gussoff, B | 1 |
| Karanas, A | 1 |
| Leone, LA | 1 |
| Haurani, F | 1 |
| Kyle, R | 1 |
| Hutchison, JL | 1 |
| Muehlbauer, MA | 1 |
| Rabhan, NB | 1 |
| Taylor, JJ | 1 |
| Goudemand, M | 1 |
| Sautière-Habay, D | 1 |
| Bauters, F | 1 |
| Lerche-Habart, B | 1 |
| Firat, D | 1 |
| Eridani, S | 1 |
| Esposito, R | 1 |
| Ponti, GB | 1 |
| Giangrande, A | 1 |
| Monto, RW | 1 |
| Isaacs, BL | 1 |
| Palmer, RL | 1 |
| Hewlett, JS | 1 |
| Deodhar, SD | 1 |
| Konomi, K | 1 |
| Kuruvila, KC | 1 |
| Plenderleith, IH | 1 |
| Mukherji, B | 1 |
| Oettgen, HF | 1 |
| Yagoda, A | 1 |
| Krakoff, IH | 1 |
| Hammond, W | 1 |
| Brettschneider, L | 1 |
| Starzl, TE | 1 |
| Olweny, CL | 1 |
| Ziegler, JL | 1 |
| Cajozzo, A | 1 |
| Citarrella, P | 1 |
| Carreca, I | 1 |
| D'Eredità, F | 1 |
| Leroy, EC | 1 |
| Sjoerdsma, A | 1 |
| Hall, TC | 1 |
| Choi, OS | 1 |
| Abadi, A | 1 |
| Krant, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL[NCT01516567] | Phase 2 | 47 participants (Actual) | Interventional | 2012-04-01 | Active, not recruiting | ||
| A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly [NCT01855750] | Phase 3 | 838 participants (Actual) | Interventional | 2013-09-03 | Completed | ||
| Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's Syndrome[NCT03054896] | Phase 2 | 67 participants (Anticipated) | Interventional | 2017-03-08 | Recruiting | ||
| A Phase Ib/II, Open-Label Study Evaluating the Safety, Efficacy and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell[NCT02055820] | Phase 1/Phase 2 | 267 participants (Actual) | Interventional | 2013-11-17 | Completed | ||
| A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Di[NCT03274492] | Phase 3 | 1,000 participants (Actual) | Interventional | 2017-11-16 | Active, not recruiting | ||
| Interim PET/CT Guided Cycle Numbers of R-CHOP in Patients With Diffuse Large B-cell Lymphoma: a Exploratory Phase II Study Study[NCT01804127] | Phase 2 | 196 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma[NCT02529852] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2015-11-04 | Completed | ||
| Intravenous Methotrexate 1g/m2 as Central Nervous System Prophylaxis for High Risk Diffuse Large B Cell Lymphoma: a Prospective, Phase III, Randomized, Controlled Study[NCT05054426] | Phase 3 | 488 participants (Anticipated) | Interventional | 2021-10-08 | Recruiting | ||
| Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line[NCT01122472] | Phase 3 | 650 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma[NCT00049036] | Phase 2 | 106 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP[NCT02889523] | Phase 1/Phase 2 | 214 participants (Actual) | Interventional | 2016-10-31 | Active, not recruiting | ||
| Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas[NCT00118209] | Phase 3 | 524 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™[NCT03263026] | Phase 3 | 256 participants (Actual) | Interventional | 2018-03-20 | Completed | ||
| [NCT02787239] | Phase 3 | 407 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas[NCT01994850] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)[NCT00974792] | Phase 2 | 150 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | ||
| A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL[NCT01287741] | Phase 3 | 1,418 participants (Actual) | Interventional | 2011-07-26 | Terminated (stopped due to The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.) | ||
| Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised Stage I or II CD20+ Diffuse Large B-cell Lymphoma[NCT01279902] | Phase 2 | 32 participants (Actual) | Interventional | 2010-08-31 | Active, not recruiting | ||
| A Prospective, Single Arm, Open-label, Phase II Study of Chidamide in Combination With R-CHOP in the Treatment of de Novo, Elderly, High-risk Diffuse Large B-cell Lymphoma[NCT02753647] | Phase 2 | 49 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Di[NCT03899337] | Phase 2 | 105 participants (Anticipated) | Interventional | 2019-07-23 | Recruiting | ||
| Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Prognos[NCT01659099] | Phase 3 | 671 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to experimental treatment not Superior to standard - no need to continue the follow-up) | ||
| Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.[NCT03647072] | Phase 3 | 60 participants (Anticipated) | Interventional | 2018-08-01 | Recruiting | ||
| Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.[NCT02012088] | Phase 2 | 91 participants (Actual) | Interventional | 2013-10-11 | Active, not recruiting | ||
| Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated[NCT02285062] | Phase 3 | 570 participants (Actual) | Interventional | 2015-02-17 | Completed | ||
| A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma[NCT02142049] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Phase 1, Open-label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With High Risk (IPI 3 or More) Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3B Follicular Lymphoma.[NCT02343536] | Phase 1 | 59 participants (Actual) | Interventional | 2015-04-29 | Completed | ||
| Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.[NCT00144755] | Phase 3 | 600 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Year[NCT00052936] | Phase 3 | 1,506 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Transformed Waldenström Macroglobulinaemia: Clinical Presentation and Outcome. A Multi-institutional Retrospective Study of 77 Cases From the French Innovative Leukemia Organization (FILO)[NCT03611959] | 77 participants (Actual) | Observational | 1995-01-31 | Completed | |||
| Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma[NCT00841945] | Phase 3 | 334 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to other drugs other studies) | ||
| A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With [NCT00790036] | Phase 3 | 742 participants (Actual) | Interventional | 2009-07-24 | Completed | ||
| Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma[NCT01622439] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors[NCT05349227] | 660 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy[NCT01414855] | Phase 2 | 100 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma[NCT01092182] | Phase 2 | 194 participants (Actual) | Interventional | 2010-03-25 | Completed | ||
| A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement[NCT04432714] | Phase 1/Phase 2 | 81 participants (Anticipated) | Interventional | 2020-06-09 | Recruiting | ||
| Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma[NCT03681535] | 241 participants (Actual) | Interventional | 2019-02-13 | Active, not recruiting | |||
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [NCT01958996] | Phase 1/Phase 2 | 27 participants (Anticipated) | Interventional | 2009-01-31 | Completed | ||
| Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.[NCT00889798] | 3,795 participants (Actual) | Observational [Patient Registry] | 2009-04-30 | Completed | |||
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma[NCT00001337] | Phase 2 | 348 participants (Actual) | Interventional | 1993-05-08 | Active, not recruiting | ||
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)[NCT00907348] | Phase 2 | 49 participants (Anticipated) | Interventional | 2007-10-31 | Active, not recruiting | ||
| National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparati[NCT00268853] | Phase 2 | 124 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Early Detection of Cardiac Toxicity in Childhood Cancer Survivors[NCT03038997] | 42 participants (Actual) | Observational | 2014-11-30 | Terminated (stopped due to IRB approval expired) | |||
| A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma[NCT00944567] | 125 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-p[NCT00486759] | Phase 3 | 787 participants (Actual) | Interventional | 2007-07-26 | Terminated (stopped due to Due to an unfavorable benefit/risk ratio.) | ||
| A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS[NCT04181489] | Phase 2 | 55 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| A Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With CD20-Positive B-Cell Non Hodgkin Lymphoma (NHL)[NCT01569750] | Phase 1 | 33 participants (Actual) | Interventional | 2012-06-14 | Completed | ||
| Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma[NCT00670358] | Phase 1/Phase 2 | 138 participants (Actual) | Interventional | 2008-08-25 | Active, not recruiting | ||
| Retrospective Multicenter International Study on Prognostic Factors, Management And Outcome Of Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Patients With Central Nervous System (CNS) Involvement[NCT06024694] | 45 participants (Anticipated) | Observational | 2022-06-10 | Recruiting | |||
| Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.[NCT00140595] | Phase 3 | 380 participants (Anticipated) | Interventional | 2003-12-31 | Completed | ||
| Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma[NCT03018626] | Phase 3 | 402 participants (Anticipated) | Interventional | 2017-07-27 | Recruiting | ||
| An Open, Randomized Controlled Clinical Trial to Compare the Prophylactic Use or Preemptive Use of an Anti-viral Drug Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers[NCT02777814] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-05-01 | Recruiting | ||
| An Open, Randomized Controlled Clinical Trial to Compare the Prophylactic Use or Preemptive Use of an Anti-viral Drug Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers[NCT02777801] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A Prospective , Multicenter, Randomized Phase III Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients[NCT01793844] | 732 participants (Anticipated) | Observational | 2008-01-31 | Recruiting | |||
| Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome[NCT01171378] | Phase 2 | 43 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study[NCT00544219] | 156 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| A Randomized, Open-Label, Multicenter Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germi[NCT01040871] | Phase 2 | 164 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma[NCT00135499] | Phase 3 | 138 participants (Actual) | Interventional | 2001-10-16 | Terminated (stopped due to Recruitment too low) | ||
| Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)[NCT00144807] | Phase 2 | 128 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0)[NCT00140660] | Phase 3 | 223 participants (Actual) | Interventional | 2003-12-31 | Terminated (stopped due to Low acrual) | ||
| Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-adjusted Ipi >or= 2)[NCT00169143] | Phase 2 | 60 participants | Interventional | 2004-05-31 | Completed | ||
| Phase II Study of Mini-CHOP Plus Rituximab in Non Previously Treated Patients Aged Over 80 Years With CD 20+ Diffuse Large B-Cell Lymphoma[NCT01087424] | Phase 2 | 150 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-line CHOP[NCT01868035] | Phase 2 | 15 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study[NCT03795571] | Phase 1 | 12 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000] | Phase 3 | 226 participants (Anticipated) | Interventional | 2017-07-26 | Recruiting | ||
| A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin[NCT00332202] | Phase 3 | 758 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)[NCT01334502] | Phase 1 | 26 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin's Lymphoma[NCT00005089] | Phase 2 | 71 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| Total-body 18F-FDG PET / CT in the Evaluation of Treatment and Prognosis of Patients With Lymphoma[NCT04931875] | 100 participants (Anticipated) | Observational | 2021-10-11 | Enrolling by invitation | |||
| Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma[NCT00003150] | Phase 3 | 630 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| The Roles of Education and Patient Engagement to Improve Symptom Management and the Quality of Life for Patients With Chronic Lymphocytic Leukemia[NCT03231579] | 85 participants (Actual) | Observational | 2017-07-21 | Completed | |||
| Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning[NCT00274924] | Phase 2 | 100 participants (Actual) | Interventional | 2006-09-26 | Completed | ||
| Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Random[NCT02428751] | Phase 3 | 216 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma[NCT00001563] | Phase 2 | 39 participants (Actual) | Interventional | 1997-01-08 | Completed | ||
| Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497] | Phase 1 | 10 participants (Actual) | Interventional | 2017-09-05 | Active, not recruiting | ||
| First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP: a Randomized, Open, Multicenter Clinical Study[NCT05280626] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-03-25 | Not yet recruiting | ||
| Multicenter Cross Sectional Study of Primary Intestine Lymphoma: Treatment Outcome and Quality of Life[NCT01043302] | 545 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma[NCT02767674] | Phase 3 | 258 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Randomized Phase II Study of Two Associations of Rituximab and Chemotherapy, With a PET -Driven Strategy, in Patients From 18 to 59 With DLBCL CD20+ Lymphoma and 2 or 3 Adverse Prognostic Factors of the Age-adjusted IPI[NCT00498043] | Phase 2 | 222 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma in Patients Treated With R-CHOP; Consortium for Improving Survival of Lymphoma (CISL) Study[NCT01266668] | 100 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| Multi-center Phase II Study of the Combination of R-CHOP (RItuximab Plus Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) and Prophylactic Intrathecal Chemotherapy With Methotrexate in Patients With CD20+ Primary Breast Diffuse Large B-cell Ly[NCT01448096] | Phase 2 | 33 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)[NCT01148446] | Phase 3 | 226 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT][NCT00400907] | 667 participants (Anticipated) | Observational | 2006-01-31 | Active, not recruiting | |||
| A Retrospective and Prospective Observational Study Reviewing Supportive Care Management of NHL Patients Treated With CHOP-14 or 21 Chemotherapy(With or Without Rituximab) (CHOP = Cyclophosphamide, Hydroxyrubicin (Adriamycin), Oncovin (Vincristine), Predn[NCT00903812] | 1,837 participants (Actual) | Observational | 2007-02-28 | Completed | |||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Phase II Study Of Dose-Adjusted Epoch-Rituximab (EPOCH-R) Chemotherapy For Patients With Previously Untreated Aggressive CD20+ B-Cell Non-Hodgkin's Lymphoma (NHL)[NCT00032019] | Phase 2 | 78 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxor[NCT00726700] | Phase 2 | 109 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL[NCT00121199] | Phase 2 | 73 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Development of a Predictive Model for Treatment Outcome and Treatment-related Morbidity in a Prospective Cohort Study of Patients With Lymphoma[NCT00822731] | 953 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Treatment With Infusional Dose-adjusted Etoposide/Vincristine/Doxorubicin/Bolus Cyclophosphamide/Dexamethasone and Rituximab (DA-EDOCH14-R) in Patients With Poor-prognosis Diffuse Large B-cell Lymphoma[NCT01066429] | Phase 2 | 30 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma[NCT03293173] | Phase 2 | 120 participants (Anticipated) | Interventional | 2017-08-04 | Recruiting | ||
| CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study[NCT01502982] | Phase 2 | 160 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin[NCT00002618] | Phase 3 | 242 participants (Anticipated) | Interventional | 1994-12-31 | Completed | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258] | Phase 4 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell[NCT02916316] | 127 participants (Actual) | Observational | 2014-02-12 | Active, not recruiting | |||
| Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.[NCT00429065] | 30 participants | Observational | 2007-01-31 | Recruiting | |||
| Analysis of E4494 Tissues to Determine the Prognostic Significance of Biomarkers in Diffuse Large B Cell Lymphoma (DLBCL) Treated With Standard Chemotherapy (CHOP) Plus Rituximab ®)1[NCT00898157] | 1,600 participants (Actual) | Observational | 2007-09-24 | Completed | |||
| A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma[NCT00301821] | Phase 2 | 107 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study[NCT00002757] | Phase 3 | 1,148 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| [NCT00850512] | Phase 2 | 55 participants (Actual) | Interventional | Completed | |||
| A Prospective, Single-arm, Open-label, Phase 2 Study to Evaluate Efficacy and Safety of DA-EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis[NCT01818908] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab[NCT00064116] | Phase 3 | 824 participants (Actual) | Interventional | 2001-05-08 | Completed | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation[NCT00169195] | Phase 2 | 49 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Phase II Study of the Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma[NCT00169468] | Phase 2 | 48 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis[NCT00261118] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma[NCT01415765] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2011-07-15 | Withdrawn | ||
| Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma[NCT05996185] | Phase 2 | 36 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
EFS: duration from randomization date to PD date, relapse from CR assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either PET-positive/ biopsy-proven residual disease upon completion of >=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to approximately 4.5 years
| Intervention | Months (Median) |
|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP | 48.56 |
| Treatment Arm A: Placebo+R-CHOP | 48.16 |
EFS: duration from randomization date to disease progression(PD) date, relapse from complete response(CR) assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either positron emission tomography(PET)-positive/ biopsy-proven residual disease upon completion of >=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in sum of product of diameters(SPD) of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to 5.5 years
| Intervention | Months (Median) |
|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP | 49.64 |
| Treatment Arm A: Placebo+R-CHOP | 54.77 |
Overall survival was defined as the duration from the date of randomization to the date of the participant's death. Median Overall Survival was estimated by using the Kaplan-Meier method. (NCT01855750)
Timeframe: Up to 5.5 years
| Intervention | Months (Median) |
|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP | NA |
| Treatment Arm A: Placebo+R-CHOP | NA |
Percentage of participants with measurable disease who achieved CR were reported. CR: disappearance of all evidence of disease. CR Criteria: Complete disappearance of all disease-related symptoms; all lymph nodes and nodal masses regressed to normal size (less than or equal to [<=]1.5 cm in greatest transverse diameter [GTD] for nodes greater than [>]1.5 cm before therapy). Previous nodes of 1.1 to 1.5 cm in long axis and greater than (>)1.0 cm in short axis before treatment decreased to <=1.0 cm in short axis after treatment. Disappearance of all splenic and hepatic nodules and other extranodal disease; a negative positron emission tomography (PET) scan. A posttreatment residual mass of any size but PET-negative; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to approximately 4.5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP | 67.3 |
| Treatment Arm A: Placebo+R-CHOP | 68.0 |
PFS was defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. Progressive Disease (PD): any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 centimeter (cm) in any axis, 50% increase in SPD of >1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. (NCT01855750)
Timeframe: Up to approximately 4.5 years
| Intervention | Months (Median) |
|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP | 48.56 |
| Treatment Arm A: Placebo+R-CHOP | NA |
Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life. (NCT01855750)
Timeframe: Up to approximately 4.5 years
| Intervention | Months (Median) |
|---|---|
| Treatment Arm B: Ibrutinib+R-CHOP | 11.7 |
| Treatment Arm A: Placebo+R-CHOP | 35.0 |
Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 32.1 |
Cmax was determined using the post-dose Doxorubicin plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 1260 |
Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 326 |
Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: >/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions. (NCT02055820)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 85.71 |
| Venetoclax 400 mg + R-CHOP | 100.00 |
| Venetoclax 600 mg + R-CHOP | 87.50 |
| Venetoclax 800mg + R-CHOP | 66.67 |
| Venetoclax + R-CHOP 800 mg Phase II | 88.99 |
| Venetoclax 200mg + G-CHOP | 100.00 |
| Venetoclax 400mg + G-CHOP | 75.00 |
| Venetoclax 600mg + G-CHOP | 100.00 |
| Venetoclax 800 mg + G-CHOP A | 100.00 |
| Venetoclax 800 mg + G-CHOP B | 100.00 |
CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to NCT02055820)
Timeframe: Baseline up to end of treatment (approx. 6 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 37.4 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 66.7 |
"Objective Response defined as PR (partial response) or CR (complete response) at end of treatment.~CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.~PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR" (NCT02055820)
Timeframe: Baseline to end of treatment (up to approximately 6 months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 81.5 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake NCT02055820)
Timeframe: Baseline up to end of treatment (up to approximately 6 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Venetoclax + R-CHOP 800 mg Phase II | 68.2 |
Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 173 |
Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2. (NCT02055820)
Timeframe: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax 800 mg | 26.1 |
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade >/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs. (NCT02055820)
Timeframe: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)
| Intervention | Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 1 |
| Venetoclax 400 mg + R-CHOP | 0 |
| Venetoclax 600 mg + R-CHOP | 1 |
| Venetoclax 800mg + R-CHOP | 0 |
| Venetoclax 200mg + G-CHOP | 2 |
| Venetoclax 400mg + G-CHOP | 1 |
| Venetoclax 600mg + G-CHOP | 1 |
| Venetoclax 800 mg + G-CHOP A | 0 |
| Venetoclax 800 mg + G-CHOP B | 0 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02055820)
Timeframe: Baseline up to approximately 36 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Venetoclax 200 mg + R-CHOP | 100.00 |
| Venetoclax 400 mg + R-CHOP | 100.00 |
| Venetoclax 600 mg + R-CHOP | 100.00 |
| Venetoclax 800mg + R-CHOP | 100.00 |
| Venetoclax + R-CHOP 800 mg Phase II | 99.0 |
| Venetoclax 200mg + G-CHOP | 100.00 |
| Venetoclax 400mg + G-CHOP | 100.00 |
| Venetoclax 600mg + G-CHOP | 100.00 |
| Venetoclax 800 mg + G-CHOP A | 100.00 |
| Venetoclax 800 mg + G-CHOP B | 100.00 |
"AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as hour*micrograms per milliliter (hr*mcg/mL)" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | hr*mcg/mL (Mean) |
|---|---|
| Venetoclax 800mg + R-CHOP | .66 |
| Venetoclax 200 mg + R-CHOP | 2.51 |
| Venetoclax 400 mg + R-CHOP | 3.87 |
| Venetoclax 600 mg + R-CHOP | 3.70 |
| Venetoclax + R-CHOP 800 mg | 4.51 |
| Venetoclax 200mg + G-CHOP | 2.55 |
| Venetoclax 400mg + G-CHOP | 4.33 |
| Venetoclax 600mg + G-CHOP | 5.13 |
| Venetoclax + G-CHOP 800mg | 6.20 |
"Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.~Data are reported as micrograms per milliliter" (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | Ug/ML (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | .09 |
| Venetoclax 200 mg + R-CHOP | .58 |
| Venetoclax 400 mg + R-CHOP | .92 |
| Venetoclax 600 mg + R-CHOP | .85 |
| Venetoclax 800mg + R-CHOP | 1.15 |
| Venetoclax 200mg + G-CHOP | .52 |
| Venetoclax 400mg + G-CHOP | 1.26 |
| Venetoclax 600mg + G-CHOP | 1.00 |
| Venetoclax + G-CHOP 800 mg | 1.54 |
Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | 0.0714 |
| Venetoclax 200 mg + R-CHOP | 0.522 |
| Venetoclax 400 mg + R-CHOP | 0.253 |
| Venetoclax 600 mg + R-CHOP | 0.387 |
| Venetoclax 800mg + R-CHOP | 0.640 |
| Venetoclax 200mg + G-CHOP | 0.134 |
| Venetoclax 400mg + G-CHOP | 0.395 |
| Venetoclax 600mg + G-CHOP | 0.612 |
| Venetoclax + G-CHOP 800 mg | 0.628 |
Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. (NCT02055820)
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
| Intervention | Hour (Mean) |
|---|---|
| Venetoclax + R-CHOP 100 mg | 4.0 |
| Venetoclax 200 mg + R-CHOP | 4.59 |
| Venetoclax 400 mg + R-CHOP | 6.50 |
| Venetoclax 600 mg + R-CHOP | 5.52 |
| Venetoclax 800mg + R-CHOP | 5.53 |
| Venetoclax 200mg + G-CHOP | 5.72 |
| Venetoclax 400mg + G-CHOP | 6.56 |
| Venetoclax 600mg + G-CHOP | 5.30 |
| Venetoclax + G-CHOP 800 mg | 5.79 |
Cmax was determined using the post-dose Vincristine plasma concentrations. (NCT02055820)
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
| Intervention | mcg/mL (Mean) |
|---|---|
| Venetoclax PK Popluation | 54.0 |
AUC was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | hr*mcg/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 195 | 184 |
Cmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | Ng/ML (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 49.9 | 43.2 |
Tmax was determined based on measurement of Predisone concentrations in plasma over time. (NCT02055820)
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
| Intervention | Hour (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 2, Day 1 | |
| Venetoclax PK Popluation | 2.19 | 3.80 |
Dose intensity was categorized as < 80%, 80% to < 85%, 85% to < 90%, or >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)
| Intervention | Percentage of Partcipants (Number) | |||
|---|---|---|---|---|
| <80% | 80-<85% | 85-<90% | >=90% | |
| Venetoclax + G-CHOP 800 mg | 83.3 | 0.00 | 16.7 | 0.00 |
| Venetoclax + G-CHOP 800mg B | 100.0 | 0.00 | 0.00 | 0.00 |
| Venetoclax + R-CHOP 800 mg Phase II | 26.0 | 3.4 | 2.9 | 67.6 |
| Venetoclax 200 mg + R-CHOP | 71.4 | 0.00 | 0.00 | 28.6 |
| Venetoclax 200mg + G-CHOP | 100.00 | 0.00 | 0.00 | 0.00 |
| Venetoclax 400 mg + R-CHOP | 0.00 | 0.00 | 0.00 | 100.00 |
| Venetoclax 400mg + G-CHOP | 14.3 | 14.3 | 0.00 | 71.4 |
| Venetoclax 600 mg + R-CHOP | 12.5 | 12.5 | 12.5 | 62.5 |
| Venetoclax 600mg + G-CHOP | 50.0 | 16.7 | 0.00 | 33.3 |
| Venetoclax 800mg + R-CHOP | 0.00 | 0.00 | 0.00 | 100.00 |
Maintenance of relative dose intensity was defined as a dose intensity of >/= 90%. (NCT02055820)
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Cyclophosphamide | Doxorubicin | Vincristine | Prednisone | |
| Venetoclax + R-CHOP Arm | 89.5 | 88.6 | 86.6 | 87.4 |
| Venetoclax 600mg + G-CHOP | 77.4 | 77.4 | 78.1 | 81.3 |
Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days
| Intervention | proportion (Number) |
|---|---|
| EPOCH + Concurrent Rituximab | 0.69 |
| EPOCH Followed by Rituximab | 0.53 |
The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response) (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm B - DA-EPOCH-R | 86.7 |
| Arm A - R-CHOP | 88.0 |
Overall survival is defined as the time from randomization to death due to any cause. The overall survival (OS) rate (percentage of participants who are still alive) at 2 and 5 years Kaplan Meier estimates and 95% confidence intervals are reported below. (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-year OS rate | 5-year OS rate | |
| Arm A - R-CHOP | 85.7 | 78.5 |
| Arm B - DA-EPOCH-R | 86.5 | 77.5 |
"Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse>~≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.>~Appearance of any new lesion during or after completion of therapy.>~PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.>~The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below." (NCT00118209)
Timeframe: Up to 5 years post-registration
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-year PFS | 5-year PFS | |
| Arm A - R-CHOP | 75.5 | 66.0 |
| Arm B - DA-EPOCH-R | 78.9 | 68.0 |
Dose-limiting toxicity (DLT) is any grade 3 or 4 new non-hematologic toxicity occurring during Cycle 1 requiring a dose delay of >14 days from the planned Day 1 of Cycle 2 (21 days from Day 1 of Cycle 1). The initial planned dose of brentuximab vedotin for the Phase I cohort of 6 patients is 1.8 mg/kg. This cohort will be evaluated for DLT in the first cycle of treatment. Dose de-escalation to 1.2 mg/kg will occur if ≥ 2 of 6 patients at the 1.8 mg/kg dose level experience a DLT. (NCT01994850)
Timeframe: 21 days (Cycle 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I/II | 0 |
DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression >/= 50%. Progression/relapse: at least 50% increase in nodal lesions or >/=50% increase in any node > 1 cm or >/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%. (NCT01287741)
Timeframe: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
| Intervention | months (Median) |
|---|---|
| Rituximab+Chemotherapy | 71.9 |
| Obinutuzumab+Chemotherapy | NA |
Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. (NCT01287741)
Timeframe: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
| Intervention | months (Median) |
|---|---|
| Rituximab+Chemotherapy | NA |
| Obinutuzumab+Chemotherapy | 65.4 |
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by CT/MRI. (NCT01287741)
Timeframe: Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)
| Intervention | months (Mean) |
|---|---|
| Rituximab+Chemotherapy | 74.5 |
| Obinutuzumab+Chemotherapy | 68.3 |
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)
| Intervention | months (Median) |
|---|---|
| Rituximab+Chemotherapy | NA |
| Obinutuzumab+Chemotherapy | NA |
Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease [PD]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 cm or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with diameter 1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants. (NCT01287741)
Timeframe: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
| Intervention | months (Median) |
|---|---|
| Rituximab+Chemotherapy | NA |
| Obinutuzumab+Chemotherapy | NA |
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter 1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI). (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)
| Intervention | months (Median) |
|---|---|
| Rituximab+Chemotherapy | 74.5 |
| Obinutuzumab+Chemotherapy | 68.3 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)
| Intervention | percentage of participants (Number) |
|---|---|
| Rituximab+Chemotherapy | 95.3 |
| Obinutuzumab+Chemotherapy | 98.1 |
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. (NCT01287741)
Timeframe: Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, approximately 6.5 years (31 January 2018)
| Intervention | months (Median) |
|---|---|
| Rituximab+Chemotherapy | NA |
| Obinutuzumab+Chemotherapy | NA |
The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Change Baseline, Cycle 3 Day 1 | Change Baseline, Study Completion | Change Baseline, Follow-Up Month 12 | Change Baseline, Follow-Up Month 24 | Change Baseline, Follow-Up Month 36 | Change Baseline, Follow-Up Month 48 | Change Baseline, Follow-Up Completion | |
| Rituximab+Chemotherapy | 59.81 | 6.37 | 9.84 | 12.67 | 14.74 | 15.01 | 16.62 | 8.74 |
The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change Baseline, Cycle 3 Day 1 | Change Baseline, Study Completion | Change Baseline, Follow-Up Month 12 | Change Baseline, Follow-Up Month 24 | Change Baseline, Follow-Up Month 30 | Change Baseline, Follow-Up Month 36 | Change Baseline, Follow-Up Month 48 | Change Baseline, Follow-Up Completion | |
| Obinutuzumab+Chemotherapy | 58.55 | 7.51 | 10.22 | 13.84 | 15.81 | 58.33 | 17.99 | 17.53 | 8.46 |
The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Score Change, Cycle 3 Day 1 | Score Change, Study Compl./Discont. | Score Change, Follow-Up Month 12 | Score Change, Follow-Up Month 24 | Score Change, Follow-Up Month 36 | Score Change, Follow-Up Month 48 | Score Change, Follow-Up Term./Compl. | |
| Rituximab+Chemotherapy | 45.34 | 3.83 | 5.03 | 6.37 | 7.07 | 7.57 | 8.22 | 5.51 |
The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement. (NCT01287741)
Timeframe: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Score Change, Cycle 3 Day 1 | Score Change, Study Compl./Discont. | Score Change, Follow-Up Month 12 | Score Change, Follow-Up Month 24 | Score Change, Follow-Up Month 30 | Score Change, Follow-Up Month 36 | Score Change, Follow-Up Month 48 | Score Change, Follow-Up Term./Compl. | |
| Obinutuzumab+Chemotherapy | 45.18 | 3.70 | 4.35 | 6.18 | 6.66 | 25.00 | 7.31 | 7.37 | 5.55 |
Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Without PET | With PET | |
| Obinutuzumab+Chemotherapy | 35.4 | 56.5 |
| Rituximab+Chemotherapy | 33.9 | 59.1 |
Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants. (NCT01287741)
Timeframe: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Without PET | With PET | |
| Obinutuzumab+Chemotherapy | 39.1 | 66.7 |
| Rituximab+Chemotherapy | 34.4 | 65.3 |
Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. (NCT01287741)
Timeframe: Baseline up to approximately 6.5 years (up to 31 January 2018)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Without PET | With PET | |
| Obinutuzumab+Chemotherapy | 81.4 | 77.1 |
| Rituximab+Chemotherapy | 80.1 | 77.6 |
Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants. (NCT01287741)
Timeframe: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Without PET | With PET | |
| Obinutuzumab+Chemotherapy | 82.3 | 82.1 |
| Rituximab+Chemotherapy | 80.2 | 81.1 |
The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants. (NCT01287741)
Timeframe: Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Screening | Cycle 4 Day 1 | Study Completion / Early Discontinuation | Follow-Up Month 6 | Follow-Up Month 12 | Follow-Up Month 18 | Follow-Up Month 24 | Follow-Up Month 30 | Follow-Up Completion/ Early Discontinuation | Unscheduled | |
| Obinutuzumab+Chemotherapy | 2.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab. (NCT01287741)
Timeframe: C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 8 pre-infusion | Cycle 1, Day 15 pre-infusion | Cycle 2, Day 1 pre-infusion | Cycle 4, Day 1 pre-infusion | Cycle 6, Day 1 pre-infusion | Cycle 8, Day 1 pre-infusion | Cycle 1, Day 1 post-infusion | Cycle 1, Day 1 20-28 hours after end of infusion | Cycle 1, Day 1 66-80 hours after end of infusion | Cycle 1, Day 8 post-infusion | Cycle 1, Day 15 post-infusion | Cycle 2, Day 1 post-infusion | Cycle 4, Day 1 post-infusion | Cycle 6, Day 1 post-infusion | Cycle 8, Day 1 post-infusion | |
| Obinutuzumab+Chemotherapy | 174 | 320 | 431 | 352 | 378 | 478 | 435 | 259 | 219 | 578 | 718 | 938 | 817 | 813 | 881 |
Duration of complete response was calculated for complete responders only and was defined as the time from documented initial complete response prior to initiation of subsequent systemic antilymphoma therapy until documented disease progression or death, whichever occurred earlier. Participants who had not progressed or died at the time of the analysis were censored at the date of last response assessment demonstrating no disease progression. Participants who changed treatment without evidence of disease progression were censored at the last assessment showing no progression prior to treatment change. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months.
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | NA |
| Placebo Plus R-CHOP | NA |
Overall survival was assessed by the Independent Response Adjudication Committee (IRAC) and defined as time from randomization until death due to any cause. Participants who withdrew consent were censored at the time of withdrawal. Participants who were still alive before the clinical data cutoff date and participants who were lost to follow-up were censored at date last known alive. (NCT02285062)
Timeframe: From randomization until death due to any cause (up to approximately 86 months)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | NA |
| Placebo Plus R-CHOP | NA |
Time to next lymphoma therapy was defined as the time from randomization to the time of treatment change for the next lymphoma treatment. Participants without treatment change were censored at date last known alive. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as treatment change for the next lymphoma therapy if the decision to treat and the location to be treated were determined prior to randomization. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | NA |
| Placebo Plus R-CHOP | NA |
EFS was defined as the time (months) from randomization until occurrence of one of the following events, whichever occurred first: • Disease progression • Initiation of subsequent systemic anti-lymphoma therapy • Death due to any cause The assessment of EFS was conducted by the IRAC using the International Working Group (IWG) criteria for NHL. Pre-specified optional therapies such as the extra 2 doses of single agent rituximab after Cycle 6 or consolidation radiotherapy did not count as an EFS event (initiation of subsequent systemic anti-lymphoma therapy) if the decision to treat and the location to be treated was determined prior to randomization. Participants who did not experience any of the events defined in the categories above before the clinical data cutoff date were censored at date last known alive. (NCT02285062)
Timeframe: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | NA |
| Placebo Plus R-CHOP | NA |
Progression free survival was defined as the time (months) from the date of randomization to the date of disease progression or death (any cause), whichever occurred earlier and was assessed by the Independent Response Adjudication Committee (IRAC). Relapse from complete response (CR) was considered as disease progression throughout the study. Disease progression was determined based on the Revised Response Criteria for Malignant Lymphoma. The PFS analysis was based on the censoring rules using the Food and Drug Administration (FDA) Guidance. Participants who did not experience disease progression and who did not die before the clinical data cutoff date were censored at the date of last adequate response assessment. (NCT02285062)
Timeframe: From the date of randomization up to the data cut off date of 15 March 2019; median follow-up of 24.5 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | NA |
| Placebo Plus R-CHOP | NA |
The percentage of participants who achieved a CR after initiation of the study treatment and prior to initiation of subsequent systemic antilymphoma therapy as assessed by the IRAC. A CR = complete metabolic response; target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow per International Working Group (IWG) 2014 for Non-Hodgkin's Lymphoma (NHL). Participants who did not have any adequate response assessments during this period were not considered as responders. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median follow-up was 24.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | 69.1 |
| Placebo Plus R-CHOP | 64.9 |
An objective response = percentage of participants who achieved a complete response or partial response after initiation of the treatment and prior to initiation of subsequent systemic anti-lymphoma therapy. A CR = complete metabolic response; Target nodes/nodal masses regressed on computed tomography to (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy. Regressed to normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, no evidence of fluorodeoxyglucose avid disease in marrow. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter; no new lesions. Participants who did not have any adequate response assessments during this period were not considered as responders. (NCT02285062)
Timeframe: From randomization date up to the data cut off date of 15 March 2019; median total treatment duration was 18.10 weeks for both treatment arms; range = 1.6 to 29.0 weeks for R2-CHOP arm and 0.3 to 22.9 weeks for placebo-R-CHOP arm
| Intervention | Percentage of Participants (Number) |
|---|---|
| Lenalidomide Plus R-CHOP (R2-CHOP) | 90.9 |
| Placebo Plus R-CHOP | 90.9 |
"The EQ-5D-3L questionnaire includes a visual analogue scale which records the respondent's self-rated health on a vertical, 0-100 scale where 100 = Best imaginable health state and 0 = Worst imaginable health state. Higher scores again indicate better HRQoL and positive change scores indicate that post screening values were higher than those observed at screening. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to no problems, some problems and extreme problems." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Units on a Scale (Mean) | |||
|---|---|---|---|---|
| Midcycle | C6 D1 | EoT = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | 4.0 | 6.0 | 8.0 | 12.0 |
| Placebo Plus R-CHOP | 3.0 | 9.0 | 6.0 | 9 |
"The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to no problems, some problems and extreme problems. The instrument is scored as a single summary index using one of the available EQ-5D-3L value sets; in this study the UK scoring weights 9 were used. The UK index ranges from -0.594 to 1, where 0 equates to death and 1 equates to full health (-0.594 is considered 'worse than death')." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Units on a Scale (Mean) | |||
|---|---|---|---|---|
| Midcycle | C6 D1 | EoT = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | 0.08 | 0.10 | 0.10 | 0.15 |
| Placebo Plus R-CHOP | 0.08 | 0.14 | 0.06 | 0.09 |
"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms such as pain, itching, night sweats,trouble sleeping, fatigue and trouble concentrating and concerns regarding lumps and swelling, fevers, infections, weight, appetite, emotional stability and treatment. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The Additional Concerns subscale ranges from 0 to 60, where higher scores reflect better HRQoL." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Units on a Scale (Mean) | |||
|---|---|---|---|---|
| Midcycle | C6 D1 | EoT = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | 3.8 | 5.8 | 6.6 | 8.3 |
| Placebo Plus R-CHOP | 4.1 | 5.2 | 4.5 | 6.5 |
"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The functional well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Units on a Scale (Mean) | |||
|---|---|---|---|---|
| Midcycle | C6 D1 | EoT = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | -0.5 | 0.0 | 1.0 | 2.3 |
| Placebo Plus R-CHOP | 0.5 | 1.4 | 0.7 | 3.1 |
"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The physical well-being subscale ranges from 0 to 28, where higher scores reflect better HRQoL." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Units on a Scale (Mean) | |||
|---|---|---|---|---|
| Midcycle | C6 D1 | EoT = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | -0.7 | -0.0 | 1.5 | 2.8 |
| Placebo Plus R-CHOP | 0.2 | 0.9 | 0.7 | 2.6 |
"The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on HRQL and contains 42 questions covering HRQL and common lymphoma symptoms and treatment side-effects. It begins with the Functional Assessment of Cancer Therapy - General (FACT-G), which contains 27 questions covering four core subscales: Physical Wellbeing (7 items), Social/Family Wellbeing (7), Emotional Wellbeing (6), and Functional Wellbeing (7). The FACT-Lym also includes an Additional Concerns subscale (15 questions) used to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from not at all (0) to very much (4). The FACT-Lym TOI is calculated by summing the Physical Well-being, Functional Well-being and Additional Concerns scores and has a range of 0 to 116. Higher scores reflect better HRQoL or fewer symptoms." (NCT02285062)
Timeframe: Baseline and Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Units on a Scale (Mean) | |||
|---|---|---|---|---|
| Midcycle | C6 D1 | EoT = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | 2.6 | 5.9 | 9.1 | 13.5 |
| Placebo Plus R-CHOP | 4.6 | 7.5 | 5.8 | 12.2 |
"The completion rate for EQ-5D assessments was judged by looking at the number of completed assessments at each time point. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The EQ-5D-3L is a generic, self-reported preference-based measure of health across five dimensions: mobility, self-care, pain, usual activities, and anxiety/depression. Each dimension has three levels of 'severity' corresponding to no problems, some problems and extreme problems. The instrument is scored using the United Kingdom (UK) index ranges from -0.594 - 1, where 0 equates to death and 1 equates to full health -0.594 is considered 'worse than death'." (NCT02285062)
Timeframe: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Screening | Midcycle | End of Treatment (EoT) | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | 98.9 | 87.0 | 76.5 | 68.1 |
| Placebo Plus R-CHOP | 97.9 | 86.3 | 79.6 | 69.1 |
The completion rate for FACT-Lym assessments was judged by looking at the number of completed FACT-Lym assessments at each time point. The FACT-Lym was considered completed if at least 1 calculable score was present. Completion rates were calculated as the number and percentage of participants out of the total number of patients in the ITT population and summarized by visit/cycle and treatment group. The FACT-Lym is a health related quality of life (HRQoL) questionnaire targeted to the management of chronic illness, predominantly within oncology and is considered an extension of the FACT-General questionnaire. (NCT02285062)
Timeframe: Screening, Midcycle = after Cycle 3 but before Cycle 4, Cycle 6 Day 1 (C6D1), End of Treatment (C6,D21), and Follow-Up Period up to Week 34
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Screening | Midcycle = After Cycle 3, but before Cycle 4 | End of Treatment (EoT) = 3-4 weeks after C6 | Follow-Up Period: Week 34 | |
| Lenalidomide Plus R-CHOP (R2-CHOP) | 98.6 | 87.0 | 76.1 | 67.7 |
| Placebo Plus R-CHOP | 98.2 | 86.3 | 79.6 | 69.5 |
Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented. (NCT02142049)
Timeframe: From initial response date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose.
| Intervention | Months (Median) |
|---|---|
| All Subjects Treated at RP2D Who Achieved Overall Response | 3.94 |
| ABC Subjects Treated at RP2D Who Achieved Overall Response | 4.09 |
Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator. (NCT02142049)
Timeframe: 1 year after last subjects received the first dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1: Dose Level 1 | 1 |
| Part 1: Dose Level 2 | 2 |
| Part 1: Dose Level 3 | 0 |
| Part 1: Dose Level 4 | 3 |
| Part 1: All Treated | 6 |
Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a Complete Response or a Partial Response according to the international Working Group Response Criteria for NHL as assessed by investigator. (NCT02142049)
Timeframe: 1 year after last subjects received the first dose
| Intervention | Participants (Count of Participants) |
|---|---|
| All Subjects Treated at RP2D | 16 |
| ABC Subjects Treated at RP2D | 9 |
Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R (NCT02142049)
Timeframe: 1 year after last subjects received the first dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1: Dose Level 1 | 0 |
| Part 1: Dose Level 2 | 0 |
| Part 1: Dose Level 3 | 0 |
| Part 1: Dose Level 4 | 1 |
| Part 1: All Treated | 1 |
Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported. (NCT02142049)
Timeframe: 1 year after last subjects received the first dose
| Intervention | Participants (Count of Participants) |
|---|---|
| All Subjects Treated at RP2D | 26 |
| ABC Subjects Treated at RP2D | 14 |
Part 2: PFS will be measured as time from first study drug administration to disease progression or death from any cause. OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology. (NCT02142049)
Timeframe: From initial dose date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose, up to 36 months at the most.
| Intervention | Months (Median) | |
|---|---|---|
| Progression Free Survival (PFS) | Overall Survival (OS) | |
| ABC Subjects Treated at RP2D | 4.86 | 15.84 |
| All Subjects Treated at RP2D | 4.86 | 15.84 |
DFS was defined as the time from date of randomization to the date of event defined as the first documented relapse of the disease or death due to any cause. Relapse was based on investigator assessment and was assigned only if: It was documented according to Cheson guidelines by an objective radiological assessment method; It was documented by a biopsy proven lymphoma including new or recurrent bone marrow involvement; A new anticancer therapy for lymphoma started with subsequent confirmation of the relapse within 4 weeks of the start of this anticancer therapy (NCT00790036)
Timeframe: From date of randomization to the date of event defined as the first documented recurrence of the disease, or death due to any cause and up to 6 years
| Intervention | Percentage of participants (Number) |
|---|---|
| RAD001 (Everolimus)1 | 77.8 |
| Placebo | 77.0 |
LSS was defined as time from randomization to death as a result of lymphoma. (NCT00790036)
Timeframe: From randomization to death documented as a result of lymphoma up to 7 years
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 2 years | 3 years | 4 years | 5 years | 6 years | |
| Placebo | 90.5 | 88.8 | 86.9 | 85.4 | 85.4 |
| RAD001 (Everolimus)1 | 94.9 | 93.1 | 91.6 | 89.4 | 89.4 |
OS was defined as the time from date of randomization to date of death due to any cause. If the patient was not known to have died, survival was censored at the date of the last contact. (NCT00790036)
Timeframe: From date of randomization to date of death due to any cause up to around 7 years
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 2 years | 3 years | 4 years | 5 years | 6 years | |
| Placebo | 88.3 | 83.7 | 80.7 | 77.4 | 77.4 |
| RAD001 (Everolimus)1 | 90.7 | 88.0 | 85.4 | 83.4 | 80.3 |
Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Obinutuzumab + CHOP | 58.0 |
Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). CR is the disappearance of all evidence of disease. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Obinutuzumab + CHOP | 55.0 |
DOR is defined as first occurrence of documented response (CR or PR) until the first occurrence of relapse or progression or death of any cause. CR: disappearance of all evidence of disease. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. (NCT01414855)
Timeframe: From the response assessment to relapse, progression, or death (up to 64 months)
| Intervention | months (Median) |
|---|---|
| Obinutuzumab + CHOP | 45.6 |
Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, FDG-PET and computed tomography (CT). CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Obinutuzumab + CHOP | 82.0 |
Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Obinutuzumab + CHOP | 75.0 |
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug or other protocol-imposed intervention. Preexisting conditions that worsened during the study were reported as adverse events. (NCT01414855)
Timeframe: From the first dose of study treatment to end of study (up to 5 years 4 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Obinutuzumab + CHOP | 100.0 |
PFS was defined as the time from the date of the first dose of study treatment until the date of disease progression, relapse, or death from any cause. (NCT01414855)
Timeframe: From the first dose of study treatment to PFS assessment (up to 64 months)
| Intervention | months (Median) |
|---|---|
| Obinutuzumab + CHOP | 48.3 |
SDI 120 is a shorter duration infusion of 120 minutes and SDI 90 is shorter duration infusion of 90 minutes. Grade 3 IRR AE: Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4 IRR AE: Life-threatening consequences; urgent intervention indicated. (NCT01414855)
Timeframe: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
| Intervention | participants (Number) | |
|---|---|---|
| SDI 120 (n=5) | SDI 90 (n=70) | |
| Obinutuzumab + CHOP | 0 | 0 |
Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
| Intervention | μg/mL (Mean) | |
|---|---|---|
| Cycle 1 | Cycle 8 (n = 85) | |
| Obinutuzumab + CHOP | 297 | 574 |
Blood was collected for PK parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in in day times micrograms per milliliter (day*μg/mL). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
| Intervention | day*μg/mL (Mean) | |
|---|---|---|
| Cycle 1 (n = 59) | Cycle 8 (n = 74) | |
| Obinutuzumab + CHOP | 1320 | 3300 |
Cl is the volume of serum cleared of the drug per unit of time. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters/day (mL/day). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
| Intervention | mL/day (Mean) | |
|---|---|---|
| Cycle 1 (n = 54) | Cycle 8 (n = 37) | |
| Obinutuzumab + CHOP | 456 | 143 |
T1/2 is the time required for the concentration of the drug to reach half of its original value. Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in days (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
| Intervention | days (Mean) | |
|---|---|---|
| Cycle 1 (n = 37) | Cycle 8 (n = 21) | |
| Obinutuzumab + CHOP | 6.04 | 23 |
V is the apparent volume in which a drug is distributed in the body. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters (mL). (NCT01414855)
Timeframe: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
| Intervention | mL (Mean) | |
|---|---|---|
| Cycle 1 (n = 54) | Cycle 8 (n = 37) | |
| Obinutuzumab + CHOP | 4580 | 9210 |
The predictive value of early FDG-PET/CT scans on PFS was assessed after cycle 2. PFS is the time interval from start of treatment to documented evidence of disease progression, assessed by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: After 2 cycles of therapy and prior to cycle 3
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 90.0 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 78.7 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01092182)
Timeframe: Date treatment consent signed to date off study, approximately 102 months and 25 days for Group A, 125 months and 28 days for Group B and 117 months and 29 days for group C.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 13 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 87 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 72 |
OS was calculated from the enrolment date until date of death or last follow-up using the Kaplan Meier. Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: At 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 84.9 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 76.7 |
EFS was determined from the date of enrolment in the study until the date of progression, last documentation of disease at or after the last treatment cycle, death, or last follow-up (whichever occurred first). Disease progression was measured by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: At 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 82.1 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 71.0 |
PFS is the time interval from start of treatment to documented evidence of disease progression. Disease progression was measured by the International Workshop Criteria (IWC). Progression is a positive positron emission tomography (PET) finding corresponding to the computed tomography (CT) abnormality (new lesion, increasing size of previous lesion), or a negative PET and a CT abnormality (new lesion, increasing size of previous lesion) of < 1.5 cm (< 1.0 cm in the lungs). Kaplan-Meier curves were constructed with an 95% confidence interval. (NCT01092182)
Timeframe: Time of progression or death at 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Group A - Low-risk Burkitt Lymphoma (BL) | 100 |
| Group B - High-Risk Burkitt Lymphoma (BL) | 82.1 |
| Group C - High-Risk Diffuse Large B Cell Lymphoma (DLBCL) | 71.0 |
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
OR = a complete response (CR), an unconfirmed CR, or a partial response (PR). CR = Complete disappearance of disease and disease-related symptoms. All lymph nodes and nodal masses regressed on computed tomography (CT) to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and > 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on physical examination, normal size by imaging, and disappearance of nodules related to lymphoma. If bone marrow was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. No new sites of disease. (NCT00486759)
Timeframe: At the end of treatment (Cycle 8, up to 12 months)
| Intervention | Percentage of patients (Number) |
|---|---|
| Bevacizumab + Rituximab + CHOP | 63.1 |
| Placebo + Rituximab + CHOP | 70.5 |
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. (NCT00486759)
Timeframe: Baseline to end of the study (up to 4 years, 4 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Rituximab + CHOP | NA |
| Placebo + Rituximab + CHOP | NA |
PFS was defined as the time from the date of randomization to the date of disease progression (PD)/relapse, as determined by the investigator, or death from any cause, whichever occurred earlier. A patient with PD/relapse must meet at least 1 of the following criteria: (1) Appearance of any new lesion > 1.0 cm in the short axis during or at the end of therapy. (2) ≥ 50 % increase from nadir in the sum of the products of diameters (SPD, maximum diameter of a tumor x largest diameter perpendicular to the maximum diameter) of any previously involved nodes, in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis < 1.0 cm must increase by ≥ 50% to a size of 1.5 x 1.5 cm or > 1.5 cm in the long axis. (3) ≥ 50 % increase in the greatest diameter of any previously identified node > 1.0 cm in its short axis or in the SPD of more than 1 node. (NCT00486759)
Timeframe: Baseline to end of the study (up to 4 years, 4 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Rituximab + CHOP | 40.2 |
| Placebo + Rituximab + CHOP | 42.9 |
Other Phase II Cohorts were not evaluable for event-free survival analysis. (NCT00670358)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Ph II, DLBCL/Mixed | 44 |
"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions~Other Phase II Cohorts were not evaluable for progression-free survival analysis." (NCT00670358)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ph II, Transformed/Composite | 27 |
(NCT00670358)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | Grade 3+ Hem Adverse Event | Grade 4+ Hem Adverse Event | Grade 3+ Non-Hem Adverse Event | |
| Ph 1, DL 1 | 3 | 2 | 3 | 2 | 1 |
| Ph1, DL 2 | 3 | 1 | 3 | 1 | 1 |
| Ph1, DL 3 | 5 | 4 | 5 | 4 | 2 |
"Complete response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.~Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.~PET scan was negative.~The spleen and/or liver, if enlarged before therapy on the basis of physical examination or CT scan, was not palpable on physical examination and was considered normal size by imaging studies; all splenic and hepatic nodules related to lymphomas disappeared.~If bone marrow was involved before treatment, the infiltrate cleared on repeated bone marrow biopsy.~No new sites of disease were detected." (NCT01040871)
Timeframe: 6 cycles
| Intervention | percentage of participants (Number) |
|---|---|
| VR-CAP | 64.5 |
| R-CHOP | 63.5 |
"Overall response = Complete Response (CR) + Partial Response (PR) Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, and end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma.~Complete Response: see primary endpoint Partial Response: At least a 50% decrease in the sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses." (NCT01040871)
Timeframe: 6 cycles
| Intervention | percentage of participants (Number) |
|---|---|
| VR-CAP | 93.4 |
| R-CHOP | 98.6 |
Kaplan-meier estimate of overall survival at 1-year measured from date of randomization. (NCT01040871)
Timeframe: 1 year
| Intervention | percentage of partipants (Number) |
|---|---|
| VR-CAP | 94.1 |
| R-CHOP | 84.2 |
Kaplan-meier estimate of progression-free survival at 1-year. Progression-free survival was defined as the interval between the date of randomization and the date of first documented evidence of disease progression or death. (NCT01040871)
Timeframe: 1 year
| Intervention | percentage of partipants (Number) |
|---|---|
| VR-CAP | 78.9 |
| R-CHOP | 83.9 |
Proportion of subjects who achieved a CR with duration of at least 6 months (NCT01040871)
Timeframe: Median follow up approx 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| VR-CAP | 44.7 |
| R-CHOP | 47.3 |
Proportion of subjects who achieved a CR or PR with duration of at least 6 months. Duration of response (CR or PR) was calculated from the date of initial documentation of a response to the date of first documented evidence of disease progression or death due to disease progression. Response was evaluated by an Independent Radiology Review Committee using available computed tomography (CT) and positron emission tomography (PET) scans collected at Baseline, end of cycle 3, end of cycle 6 (or end of treatment) based on the Revised Response Criteria for Malignant Lymphoma. (NCT01040871)
Timeframe: Median follow up approx. 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| VR-CAP | 53.9 |
| R-CHOP | 67.6 |
Kaplan-meier estimate of subsequent anti-lymphoma therapy at 1-year. Time to subsequent anti-lymphoma therapy was measured from the date of randomization to the start date of new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti-lymphoma treatment was censored at the date of death or the last date known to be alive. (NCT01040871)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| VR-CAP | 71.1 |
| R-CHOP | 80.2 |
Overall survival (time to death) is defined from the start of treatment to the date of death from any cause. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | months (Median) |
|---|---|
| TST/Iodine I-131 TST | NA |
PFS is defined as the time from the start of treatment to the first documented progression or death. Duration measures were calculated using Kaplan-Meier techniques. Disease progression was based on radiographic or photographic evidence, and assessments were made by the investigator. PD is defined as a >=50% increase from nadir in SPPD of splenic and hepatic nodules or the appearance of any new lesion during or at the end of therapy that was >1.5 centimeters (cm) by radiographic evaluation or >1.0 cm by physical examination. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | months (Median) |
|---|---|
| TST/Iodine I-131 TST | 63.0 |
TTF is defined as the time from the start of treatment to the first occurrence of treatment withdrawal, decision to seek additional therapy, study removal, disease progression, or death. Duration measures were calculated using Kaplan-Meier techniques. Disease progression was based on radiographic or photographic evidence, and assessments were made by the investigator. PD is defined as a >=50% increase from nadir in SPPD of splenic and hepatic nodules or the appearance of any new lesion during or at the end of therapy that was >1.5 centimeters (cm) by radiographic evaluation or >1.0 cm by physical examination. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | months (Median) |
|---|---|
| TST/Iodine I-131 TST | 63.0 |
TBRT is the time at which the activity of infusion is 37% of that at time zero. Whole body images from anterior and posterior gamma camera scans were collected to assess dosimetry. The assessment of organ dosimetry required gamma camera scans from at least 4 time points. Nuclear medicine reviewers conducted a visual examination of the gamma camera scans and calculated the TBRTs. Residence time is calculated from the rate of total body clearance of iodine I-131 radioactivity during the dosimetric dose. Residence time is a measure of how long the drug resides in the body. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | hours (Mean) |
|---|---|
| TST/Iodine I-131 TST | 105.5 |
Duration of response for all participants with confirmed PR, confirmed CRu, or confirmed CR is defined as the time from the first documented response to the first documented progression. CR is defined as the complete disappearance of all detectable clinical/radiographic evidence of disease, the disappearance of all disease-related symptoms if present before therapy, and the normalization of biochemical abnormalities definitely assignable to NHL. PR is defined as a >=50% decrease in the sum of the perpendicular diameters (SPPD) of splenic and hepatic nodules determined at Baseline. PD is defined as a >=50% increase from nadir in SPPD of splenic and hepatic nodules or the appearance of any new lesion during or at the end of therapy that was >1.5 centimeters (cm) by radiographic evaluation or >1.0 cm by physical examination. Confirmed response requires that the same or better response be confirmed by two consecutive post-therapy response evaluations at least 4 weeks apart. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | months (Median) | |
|---|---|---|
| All confirmed responders, n=14 | Confirmed complete responders, n=12 | |
| TST/Iodine I-131 TST | 58.4 | 58.4 |
Hematology toxicities included ANC (calculated), hemoglobin, platelet count, WBC count. Nadir is defined as lowest counts that the cells reach after chemotherapy. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | 10^3 cells/millimeters cubed (mm^3) (Mean) | |||
|---|---|---|---|---|
| Nadir, Baseline, ANC | Nadir, Baseline, Hemoglobin | Nadir, Baseline, platelet count | Nadir, Baseline, WBC count | |
| TST/Iodine I-131 TST | 1.1 | 10.5 | 89.9 | 2.2 |
CR is defined as the complete disappearance of all detectable clinical/radiographic evidence of disease, the disappearance of all disease-related symptoms if present before therapy, and normalization of biochemical abnormalities definitely assignable to non Hodgkin's lymphoma (NHL). PR is defined as a >=50% decrease in the sum of perpendicular diameters (SPPD) of splenic and hepatic nodules determined at Baseline. SD is defined as less than a PR, but not PD, which is defined as a >=50% increase from nadir in SPPD of splenic and hepatic nodules or the appearance of any new lesion during or at the end of therapy that was >1.5 centimeters (cm) by radiographic evaluation or >1.0 cm by physical examination. RD is defined as the appearance of any new lesion or an increase of >= 50% in the size of nodules. Confirmed response requires that the same or better response be confirmed by two consecutive post-therapy response evaluations at least 4 weeks apart. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| CR | CRu | CR + CRu | PR | SD | PD | |
| TST/Iodine I-131 TST | 12 | 0 | 13 | 1 | 0 | 0 |
The number of participants who developed human anti-murine (mouse) anibodies (HAMA) after treatment was measured. (NCT01868035)
Timeframe: Baseline; any follow-up visit (up to 72 months)
| Intervention | participants (Number) | |
|---|---|---|
| Positive | Negative | |
| TST/Iodine I-131 TST | 1 | 14 |
During the administration of unlabeled Anti-B1 antibody and Iodine-131 Anti-B1 antibody, emergency support for anaphylaxis, including epinephrine, diphenhydramine, hydrocortisone, a laryngoscope, and an endotracheal tube, was readily available. The use of steroids were discouraged unless other measures were ineffective. (NCT01868035)
Timeframe: Week 7 and Week 13
| Intervention | participants (Number) | |
|---|---|---|
| Week 7, any supportive care | Week 13, any supportive care | |
| TST/Iodine I-131 TST | 3 | 3 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and does not necessarily have to have a casual relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or significant worsening of a pre-existing sign or symptom, or disease temporally associated with the use of a medicinal product. An SAE is defined as any experience occurring at any dose that results in the following outcomes: death, a life-threatening adverse experience, in-patient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. See the SAE/AE module for a complete list of SAEs/AEs. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | participants (Number) | |
|---|---|---|
| Any AE | Any SAE | |
| TST/Iodine I-131 TST | 14 | 3 |
Hematology parameter grades were summarized according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 2.0. Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling; Grade 5, death. Data are presented for those participants who experienced Grade 4 toxicities. Grade 4 hematological toxicities included absolute neutrophil count (ANC) (calculated) <1000 cells/millimeters cubed (mm^3), white blood cells (WBC) <2000 cells/mm^3, platelets <50000 cells/mm^3, and hemoglobin < 8.0 grams/deciliter. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ANC (calculated) | WBC count | Platelet count | Hemoglobin | |
| TST/Iodine I-131 TST | 1 | 1 | 1 | 1 |
Hematology toxicities included ANC (calculated), WBC count, platelet count, and hemoglobin. Nadir is defined as the lowest counts (for ANC, WBC, and platelet counts)/concentration (for hemoglobin) that the cells reach after chemotherapy. Time to nadir is defined as the time from Baseline to the lowest value recorded up to 120 days following the therapeutic dose. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | days (Mean) | |||
|---|---|---|---|---|
| Time to nadir, ANC | Time to nadir, Hemoglobin | Time to nadir, Platelet count | Time to nadir, WBC count | |
| TST/Iodine I-131 TST | 55.0 | 49.5 | 35.5 | 52.7 |
Hematology toxicities included ANC (calculated), WBC count, platelet count, and hemoglobin. Time to recovery to Baseline grade for participants with Grade 0 toxicity at Baseline was defined as the time from the date of the last administration of study drug to the first post-nadir date with Grade 0 toxicity, with no other Grade 1-4 toxicities recorded during the next week. For participants with a Grade 1-4 toxicity at Baseline, time to recovery was defined as the time from the last administration of study drug to the first post-nadir date with a Baseline grade or better, with no other higher grade toxicities recorded during the next week. For participants with a nadir grade less than or equal to the Baseline grade, the time to recovery to the Baseline grade equaled the time to nadir. (NCT01868035)
Timeframe: From Baseline until Week 25 and follow-up (up to 130 months)
| Intervention | days (Median) | |||
|---|---|---|---|---|
| ANC (calculated) | Hemoglobin | Platelet count | WBC count | |
| TST/Iodine I-131 TST | 78.5 | 69.0 | 51.0 | 77.0 |
Disease-free survival at 2 years (DFS2) is defined as the rate of DFS at 2 years from the date of study enrollment and is determined using the distribution of overall DFS times. Disease-free survival rates at 2 years will be estimated using the Kaplan-Meier method. (NCT00332202)
Timeframe: Baseline to 2 Years
| Intervention | proportion of participants (Number) |
|---|---|
| Enzastaurin: Arm A - Experimental | 0.785 |
| Placebo: Arm B - Control | 0.748 |
Event-Free Survival at 2 years (EFS2) is defined as the rate of EFS at 2 years from the date of study enrollment and is determined using the distribution of overall EFS times. Event-free survival rates at 2 years will be estimated using the Kaplan-Meier method. (NCT00332202)
Timeframe: Baseline to 2 Years
| Intervention | Proportion of participants (Number) |
|---|---|
| Enzastaurin: Arm A - Experimental | 0.781 |
| Placebo: Arm B - Control | 0.734 |
Number of participants with treatment-emergent adverse events. (NCT00332202)
Timeframe: First dose through 30 days post-study treatment discontinuation (up to 81.30 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Enzastaurin: Arm A - Experimental | 459 |
| Placebo: Arm B - Control | 230 |
Overall Disease-Free Survival (DFS) time is defined as the time from the date of study enrollment to the first date of objectively determined disease recurrence (progressive disease) or death from any cause. DFS was assessed according to International Working Group recommendations. Progressive disease (PD) is defined as a ≥ 50% increase from the lowest point in the sum of the product of the diameters (SPD) of any previously identified abnormal node for partial or nonresponders, or the appearance of any new lesion during or at the end of therapy. (NCT00332202)
Timeframe: Baseline to Measured Progressive Disease or Death from Any Cause (up to 80.30 months)
| Intervention | Month (Median) |
|---|---|
| Enzastaurin: Arm A - Experimental | 42.8 |
| Placebo: Arm B - Control | 43.1 |
(NCT00332202)
Timeframe: Month 2, Month 4: Predose
| Intervention | nanomole/liter (nmol/L) (Geometric Mean) |
|---|---|
| Total Enzastaurin Population | 2370 |
Reported are the DFS based on PKC-β2 protein expression. Immunohistochemistry (IHC) staining was performed to assess protein expression of PKC-β2 in cytoplasm scored for percent of tumor cells stained, and using 50% positive staining as the cutoff for high/low expression (high expression: >=50% staining, low expression: <50% staining). (NCT00332202)
Timeframe: Baseline to 94.5 months
| Intervention | percentage of participants (Number) |
|---|---|
| Enzastaurin: Arm A With PKC-β2 Cytoplasm (High Expression) | 64.86 |
| Enzastaurin: Arm A With PKC-β2 Cytoplasm (Low Expression) | 81.16 |
| Placebo: Arm B With PKC-β2 Cytoplasm (High Expression) | 61.54 |
| Placebo: Arm B With PKC-β2 Cytoplasm (Low Expression) | 70.58 |
Reported are the DFS for GCB and non-GCB status. DLBCL molecular subtypes of GCB/non-GCB using Hans' algorithm were determined by protein expression by immunohistochemistry (IHC) staining was used to assess molecular subtype characterization of GCB and non-GCB. (NCT00332202)
Timeframe: Baseline to 24 months (2 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Enzastaurin: Arm A - Experimental With Germinal-center B-cells | 76.31 |
| Enzastaurin: Arm A - Experimental Non-germinal-center B-cells | 75.97 |
| Placebo: Arm B - Control With Germinal-center B-cells | 66.21 |
| Placebo Arm B- Control With Non-germinal-center B-cells | 68.20 |
The EQ-5D instrument is a participant-rated questionnaire used to evaluate health status. The EQ-5D assesses five dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression) that participants rate using three levels (no problem, some problem, or extreme problem), as well as overall health status. The five dimensions can be combined using country-specific weights to create an estimate of overall health status score. The possible values for score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state. This analysis utilized mixed-effect model repeated measure (MMRM) analysis of change from baseline in the EQ-5D for the United Kingdom population-based index score adjusting for baseline covariates. (NCT00332202)
Timeframe: Baseline, Month 6; Baseline, Month 24; Baseline, Month 33
| Intervention | Units on a Scale (Mean) | ||
|---|---|---|---|
| Month 6 | Month 24 | Month 33 | |
| Enzastaurin: Arm A - Experimental | 0.02 | 0.02 | 0.03 |
| Placebo: Arm B - Control | 0.00 | 0.03 | 0.03 |
Overall Event-Free Survival (EFS) time is defined as the time from the date of study enrollment to the first date of objectively determined disease recurrence (progressive disease), institution of a new anti-cancer treatment, or death from any cause. Progressive disease (PD) is defined as a ≥ 50% increase from the lowest point in the sum of the product of the diameters (SPD) of any previously identified abnormal node for partial or nonresponders, or the appearance of any new lesion during or at the end of therapy. (NCT00332202)
Timeframe: Baseline to Objective PD, Start of New Therapy or Death From Any Cause (up to 76.81 months)
| Intervention | Month (Number) | |
|---|---|---|
| Minimum EFS Survival | Maximum EFS Survival | |
| Enzastaurin: Arm A - Experimental | 0.03 | 76.81 |
| Placebo: Arm B - Control | 0.03 | 71.56 |
Overall survival (OS) time is defined as the time from the date of study enrollment to the date of death from any cause. (NCT00332202)
Timeframe: Baseline to Date of Death from Any Cause (up to 80.30 months)
| Intervention | Month (Number) | |
|---|---|---|
| Minimum OS Survival | Maximum OS Survival | |
| Enzastaurin: Arm A - Experimental | 0.03 | 76.81 |
| Placebo: Arm B - Control | 0.03 | 80.30 |
The FACT-Lym assesses health-related quality of life (HRQoL) in participants with non-Hodgkin lymphoma. It includes the 27-item cancer-specific FACT-G (General), which assesses physical, social/family, emotional and functional well-being, plus a 15-item subscale that assesses concerns specific to lymphoma. Each item is scored on a scale from 0 (not at all) to 4 (very much), yielding a possible score of 0-168, with higher scores representing better HRQoL. This analysis utilized mixed-effect model repeated measure (MMRM) analysis of change from baseline adjusting for baseline covariates. (NCT00332202)
Timeframe: Baseline, Month 2; Baseline, Month 4; Baseline, Month 6; Baseline, Month 12; Baseline, Month 18; Baseline, Month 24; Baseline, Month 36
| Intervention | Units on a Scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Month 2 | Month 4 | Month 6 | Month 12 | Month 18 | Month 24 | Month 36 | |
| Enzastaurin: Arm A - Experimental | 2.45 | 2.56 | 2.04 | 3.85 | 2.87 | 2.72 | 2.54 |
| Placebo: Arm B - Control | 1.86 | 2.51 | 2.82 | 2.11 | 1.73 | 3.96 | 4.22 |
2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS. (NCT00274924)
Timeframe: Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.
| Intervention | probability (Number) |
|---|---|
| Group I (PET Negative) | 0.76 |
| Group II (PET Positive) | 0.42 |
5-year overall survival is defined as the probability of patients who remain alive at 5 years from study entry. The method of Kaplan and Meier (1958) was used to estimate overall survival. (NCT00274924)
Timeframe: Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry.
| Intervention | probability (Number) |
|---|---|
| Group I (PET Negative) | 0.77 |
| Group II (PET Positive) | 0.69 |
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00121199)
Timeframe: 0-1 year
| Intervention | percentage of participants (Number) |
|---|---|
| CHOP + Rituximab + Bevacizumab | 77 |
Measured from time of registration to date of of first observation of progression/relapse, or death due to any cause, or last contact date (NCT00121199)
Timeframe: 0-2 years
| Intervention | percentage of participants (Number) |
|---|---|
| CHOP + Rituximab + Bevacizumab | 69 |
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. (NCT00121199)
Timeframe: Patients were assessed for adverse events after every cycle (1 cycle = 21 days) of protocol treatment
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | Allergic reaction/hypersensitivity | Anorexia | Cardiac General-Other (Specify) | Cardiac troponin I (cTnI) | Cardiopulmonary arrest, cause unknown (non-fatal) | Constipation | Dehydration | Distention/bloating, abdominal | Dry mouth/salivary gland (xerostomia) | Dyspnea (shortness of breath) | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Fever in absence of neutropenia, ANC lt1.0x10e9/L | Glucose, serum-high (hyperglycemia) | Hemoglobin | Hemolysis | Hemorrhage, GI - Colon | Hemorrhage, pulmonary/upper respiratory - Nose | Hypertension | Hypotension | Hypoxia | Inf (clin/microbio) w/Gr 3-4 neuts - Lung | Inf (clin/microbio) w/Gr 3-4 neuts - Skin | Inf (clin/microbio) w/Gr 3-4 neuts - UTI | Inf w/normal ANC or Gr 1-2 neutrophils - Ab NOS | Inf w/normal ANC or Gr 1-2 neutrophils - Blood | Inf w/normal ANC or Gr 1-2 neutrophils - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Skin | Inf w/normal ANC or Gr 1-2 neutrophils - UTI | Insomnia | Left ventricular diastolic dysfunction | Left ventricular systolic dysfunction | Leukocytes (total WBC) | Lymphopenia | Mucositis/stomatitis (clinical exam) - Oral cavity | Muscle weakness, not d/t neuropathy - body/general | Nausea | Neuropathy: motor | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Obstruction, GI - Jejunum | Pain - Abdomen NOS | Pain - Bone | Pain - Throat/pharynx/larynx | Perforation, GI - Jejunum | Perforation, GI - Small bowel NOS | Perforation, GI - Stomach | Platelets | Pneumonitis/pulmonary infiltrates | Pneumothorax | Potassium, serum-low (hypokalemia) | Pruritus/itching | Pulmonary/Upper Respiratory-Other (Specify) | Renal failure | Sodium, serum-low (hyponatremia) | Somnolence/depressed level of consciousness | Sudden death | Thrombosis/thrombus/embolism | Voice changes/dysarthria | Vomiting | Weight loss | |
| CHOP + Rituximab + Bevacizumab | 1 | 1 | 5 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 8 | 11 | 1 | 2 | 8 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 28 | 10 | 2 | 2 | 2 | 3 | 1 | 33 | 1 | 4 | 1 | 1 | 2 | 1 | 1 | 12 | 1 | 1 | 2 | 1 | 2 | 1 | 3 | 1 | 2 | 4 | 1 | 1 | 1 |
Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the SPD for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes. (NCT00121199)
Timeframe: After Cycle 4 (Day 64) but prior to Cycle 5 (Day 85) and after Cycle 8 (Day 181). After completion of protocol treatment, every 6 months for 2 years, then annually for a maximum of five years.
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Unconfirmed Complete Response (UCR) | Unconfirmed Partial Response (UPR) | No Response | |
| CHOP + Rituximab + Bevacizumab | 22 | 20 | 6 | 1 | 15 |
The primary endpoint of the trial was the percentage of the eligible patients who were alive and event-free 12 months after enrollment to the study (EFS12). (NCT00301821)
Timeframe: From Baseline to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Epratuzumab + Rituximab + CHOP | 78 |
Overall response rate will be estimated by the number of patients with objective status of partial response (PR), unconfirmed complete response (CRu), or complete response (CR) during the first 6 cycles of treatment divided by number of evaluable patients (met eligibility criteria, signed consent form, and started treatment). Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: Baseline to first 6 cycles of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Epratuzumab + Rituximab + CHOP | 95 |
Percentage of participants alive at different time points (NCT00301821)
Timeframe: time from study entry to 36 months
| Intervention | percentage of Participants (Number) | ||
|---|---|---|---|
| Overall Survival at 12 months | Overall Survival at 24 months | Overall Survival at 36 months | |
| Epratuzumab + Rituximab + CHOP | 89 | 81 | 80 |
Percentage of participants Progression-free at different time points. Response was assessed using International Workshop Response Criteria.38 Response is based on CT alone. Relapse or progression is defined as Enlarging liver/spleen, new sites, New or increased lymph nodes, New or Increased lymph node masses, bone marrow reappearance. (NCT00301821)
Timeframe: the time from study entry to 36 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Progression Free Survival at 12 months | Progression Free Survival at 24 months | Progression Free Survival at 36 months | |
| Epratuzumab + Rituximab + CHOP | 85 | 77 | 76 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
237 reviews available for prednisone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2021 |
Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 2021 |
DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2021 |
Double-hit lymphoma: optimizing therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Management; Doxorubicin; H | 2021 |
Limited-stage diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Management; Doxor | 2022 |
Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, | 2022 |
The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Cyclophosphamide; Doxorubicin; Huma | 2023 |
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2022 |
Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Fol | 2022 |
Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: a single-center KwaZulu-Natal, South African hospital 12-year retrospective review.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2022 |
DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2022 |
[Current status and future prospects of diffuse large B-cell lymphoma treatment].
Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2022 |
Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2022 |
Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Cyclophosphamide; Doxorubicin; H | 2023 |
Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubici | 2023 |
Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2023 |
Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus In | 2023 |
Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Child; Cyclophosphamide; Cytarabine | 2019 |
Diagnosis and Management of Cutaneous B-Cell Lymphomas.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; An | 2019 |
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nerv | 2020 |
[Diffuse large B-cell lymphoma: standard treatment and research questions].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2019 |
Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomar | 2020 |
Diffuse large B-cell lymphoma involving the left sternoclavicular joint mimicking rheumatoid arthritis flare: a case-based review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Diagn | 2020 |
Perspectives on chemotherapy for the management of double-hit lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoie | 2020 |
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclophosphamide; Doxorubicin; Etoposide; | 2020 |
Diffuse large B cell lymphoma in a preceding IgG4-related disease with kidney restricted lambda light chain expression: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Fluorodeoxygl | 2020 |
Primary diffuse large B cell lymphoma of Uterine Cervix: Treatment outcomes of a rare entity with literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cervix Uteri; Chemoradiotherapy; Cyclophospha | 2020 |
Composite lymphoma of cervical lymph nodes with classical Hodgkin lymphoma and diffuse large B cell lymphoma: a case report and literature review.
Topics: Composite Lymphoma; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Hodgkin Disease; Humans; Ly | 2020 |
Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2021 |
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 2020 |
Immunotherapy with cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic | 2020 |
R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2020 |
Primary diffuse large B cell lymphoma of the lactating left breast. A case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2020 |
Limited-stage diffuse large B-cell lymphoma: current management and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials as Topic; Cycloph | 2021 |
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Cell Lineage; Combined Modalit | 2021 |
Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment - A systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphami | 2021 |
The use of frailty assessments in treating older adults with aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2021 |
R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2021 |
Primary adrenal diffuse large B cell lymphoma arising within an adrenal myelolipoma: A case report and review of the literature.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2021 |
Long-term endoscopic remission in Crohn's disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma: case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Cyclophosphamide; Doxorubicin; | 2021 |
When Too Many Hits Break the Heart: A Case of Radiation Induced Takotsubo Cardiomyopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; | 2021 |
Lenalidomide in DLBCL: are we past the cell of origin?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineop | 2021 |
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2021 |
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Genome-Wide Associati | 2022 |
Current progress and future perspectives of research on intravascular large B-cell lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell | 2021 |
Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2021 |
An update for Richter syndrome - new directions and developments.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2017 |
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2017 |
Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Biopsy; Chemotherapy, Adjuvant; Cholangi | 2017 |
[Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Double-Hit Large B Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Ge | 2017 |
Intestinal perforation secondary to intestinal diffuse large b-cell lymphoma in a patient with coeliac disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Colectomy; Combined Modality | 2018 |
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Topics: Aftercare; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; C | 2018 |
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2017 |
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose Fractionation, Radiation; Dox | 2018 |
Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Cyclophosphamide; | 2018 |
Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2018 |
Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2018 |
Topics: Adenine; Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineopla | 2018 |
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; | 2018 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2018 |
[New case of intradural extramedullary capillary haemangioma].
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arter | 2018 |
Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Topics: Adenine; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineopla | 2018 |
Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2018 |
Optimizing initial therapy in DLBCL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2018 |
The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2019 |
DLBCL Cell of Origin: What Role Should It Play in Care Today?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2018 |
Curing diffuse large B-cell lymphomas in elderly patients.
Topics: Activities of Daily Living; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Ch | 2018 |
Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Germinal Center; Hematop | 2018 |
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Clinical Trials as Topic; Comb | 2019 |
[MYC-associated B-cell lymphomas: pathophysiology and treatment].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2019 |
Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neop | 2019 |
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Decis | 2019 |
Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bi | 2019 |
Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 2019 |
Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Fe | 2019 |
Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2013 |
Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
[Interest of an intensive chemotherapy for intravascular large B cell lymphoma].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
[The primary mediastinal lymphoma: state of the art and therapeutical perspectives].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2013 |
Ovarian ALK+ diffuse large B-cell lymphoma: a case report and a review of the literature.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2013 |
The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antir | 2013 |
Gastric diffuse large B cell lymphoma presenting as paraneoplastic cerebellar degeneration: case report and review of literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2013 |
CD56 positive diffuse large B-cell lymphoma: a case report and literature review.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Bio | 2013 |
[Significance and application of c-myc in diffuse large B-cell lymphoma].
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyc | 2013 |
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Asymptomatic gastrosplenic fistula in a patient with marginal zonal lymphoma transformed to diffuse large B cell lymphoma--a case report and review of literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic | 2014 |
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Tandem triplication of the BCL2 gene in CD5-positive intravascular large B cell lymphoma with bone marrow involvement.
Topics: Aged, 80 and over; Aneuploidy; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2014 |
Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2014 |
FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.
Topics: Amino Acid Substitution; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophospha | 2014 |
[Treatment strategy of gray zone lymphomas].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Proto | 2014 |
Vincristine-induced blindness: a case report and review of literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blindn | 2014 |
Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biopsy; Bone Marrow; Bone Marrow Exam | 2016 |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte | 2015 |
Management of diffuse large B-cell lymphoma (DLBCL).
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2015 |
Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2015 |
Richter syndrome: an aggressive transformation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Cyclophosphami | 2015 |
[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Central Nervous System; C | 2016 |
Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2015 |
CD 30-positive transformed follicular lymphoma: two case reports and literature review.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell T | 2015 |
Primary renal diffuse large B-cell lymphoma with central nervous system involvement: a rare case report and literature review.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2015 |
The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemoradioth | 2015 |
Consolidative Radiation in DLBCL: Evidence-Based Recommendations.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2015 |
[Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2015 |
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2015 |
[RS3PE syndrome associated with senile Epstein-Barr virus-positive diffuse large B cell lymphoma of a patient with colon cancer].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2015 |
[Current therapeutic strategies for diffuse large B‑cell lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2016 |
Diffuse large B-cell lymphoma recurring with zosteriform cutaneous lesions.
Topics: Acyclovir; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2017 |
[Recent advances in the understanding and treatment of diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F1 | 2016 |
Cutaneous Richter Syndrome mimicking a lower limb cellulitis infection - a case report and review of the literature.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2016 |
Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte | 2016 |
Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2016 |
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Treatment of Diffuse Large B-Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2016 |
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomedical R | 2016 |
Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2017 |
Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; | 2017 |
How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2008 |
[Treatment of diffuse large B-cell lymphoma].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
[Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2008 |
Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2008 |
Successful treatment of primary vaginal diffuse large B-cell lymphoma using chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin | 2008 |
Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
[A rare case of primitive prostatic large B-cell lymphoma and review of literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dia | 2009 |
A rare case of non-Hodgkin lymphoma in a pacemaker pocket.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Device Remo | 2009 |
Second-line treatment paradigms for diffuse large B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2009 |
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Early detection of patients with poor risk diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Ea | 2009 |
Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2009 |
Primary pituitary lymphoma: idiopathic anasarca with relapse in bone marrow only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyc | 2010 |
Unresolved issues in diffuse large B-cell lymphomas.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2010 |
Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
Front-line management of diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2010 |
[Standard or up-to-date treatment for high risk, relapsed and refractory DLBCL].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2010 |
[Peritoneal disseminated recurrence after total gastrectomy for perforated gastric malignant lymphoma--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gastrectomy; Hu | 2010 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
CD5-positive follicular lymphoma: a case report and literature review.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CD5 Antigens | 2011 |
Prostate involvement by intravascular large B-cell lymphoma: a case report with literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cycloph | 2011 |
Composite lymphoma in the anterior mediastinum: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Composite Lymphoma | 2011 |
Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2012 |
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2012 |
HIV-associated lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2012 |
Treatment of the elderly patient with diffuse large B cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
New developments in the management of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2012 |
Maintenance therapy in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2012 |
Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease | 2012 |
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
[Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2012 |
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytara | 2002 |
Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etopo | 2003 |
Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
[Radiation therapy of localized diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2003 |
[THERAPY OF HEMOLYMPHOPATHIES WITH PREDNISONE AT HIGH DOSES].
Topics: Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Liver; Lymphoma; Lymphoma, Large B-Cell, Diffu | 1964 |
[Primary malignant lymphoma of the prostate: report of a case achieving complete response to combination chemotherapy and review of 22 Japanese cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administra | 2003 |
T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 2004 |
[A case report of unresectable mesenteric malignant lymphoma with long survival].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2004 |
Primary non-Hodgkin's lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cy | 2005 |
ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclo | 2005 |
Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Do | 2005 |
The best treatment for diffuse large B-cell lymphoma: a German perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free | 2005 |
Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
HIV-related lymphoma treated with maintenance thalidomide.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2005 |
[Primary central nervous system lymphoma--a report of 32 cases with literature review].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chi | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gene Expression Regul | 2006 |
De novo CD5-positive diffuse large B-cell lymphoma of the temporal bone presenting with an external auditory canal tumor.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2006 |
Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Standard treatment of advanced-stage diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Treatment of diffuse large B-cell lymphoma: a risk-based approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
[Primary breast lymphoma--a report of 27 cases with literature review].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast N | 2007 |
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Specificity; Antig | 2007 |
[Hematological malignancies].
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2007 |
Diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
Rituximab-induced interstitial lung disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biopsy; Cyclophosph | 2007 |
Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature.
Topics: Antibodies, Antiphospholipid; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antico | 2008 |
[Fatal liver failure after hepatitis B reactivation following chemotherapy for lymphoma in a patient with only anti-HBc antibody and review of the literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; | 2007 |
Non-Hodgkin's lymphoma presenting as an endobronchial tumor: report of eight cases and literature review.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Ge | 2008 |
[High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Forecasting; Hu | 2008 |
Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
Strategies for improving outcomes with 14-day anthracycline-based regimens in patients with aggressive lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Advances in adult non-Hodgkin's lymphoma. Current concepts of classification, diagnosis, and management.
Topics: Adult; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; L | 1980 |
Non-Hodgkin's lymphomas.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1984 |
Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis?
Topics: Animals; Antibodies, Protozoan; Antineoplastic Combined Chemotherapy Protocols; Antiprotozoal Agents | 1995 |
[Occurrence of follicular small cleaved cell lymphoma following chemotherapy for diffuse large cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Fol | 1994 |
Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 1993 |
Primary lymphoma of the pericardium: report on a "cured" case and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Heart Neoplasms; Humans; Lymphoma, | 1994 |
Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Cyclophosphamide; | 1996 |
Primary tracheal non-Hodgkin's lymphoma. A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asthma; Bronchoscopy; Combined Modality Therapy; Cyc | 1996 |
Primary cerebral lymphoma--a case report and review of the management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cyclophosphamide; Doxorubicin; | 1995 |
Malignant lymphomas in the elderly.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 1997 |
Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topi | 1997 |
Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dendritic Cells; Dia | 1997 |
Primary non-Hodgkin's lymphoma of the common bile duct.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 1997 |
Anaplastic large cell lymphoma of maternal origin involving the placenta: case report and literature survey.
Topics: Adult; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Prot | 1997 |
Gastrosplenic fistulas: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fistula; Gastric Fist | 1997 |
Non-Hodgkin's lymphoma associated with Gaucher's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Susceptibility; Doxorubici | 1998 |
Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
[Thyroid scintigraphy and body scanning with 67 Ga in a case of primary thyroid lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Therapy; Cyclophos | 2001 |
Rituximab in the treatment of diffuse large B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2002 |
The role of mitoxantrone in non-Hodgkin's lymphoma.
Topics: Age Factors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2002 |
Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
Primary lymphoma of the kidney. Report of a case and update of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Combined Modality Therapy | 2002 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.
Topics: Adult; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1977 |
Chemotherapy of non-Hodgkin lymphoma: the diffuse types.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Drug Therapy, | 1978 |
Obstructive solitary bronchial non-Hodgkin's lymphoma--a rare presentation of primary extranodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Combined Modality Therapy | 1992 |
Primary esophageal non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 1992 |
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Huma | 1990 |
The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Huma | 1990 |
[Rare primary hepatic neoplasms. Our experience in 2 cases: a primary lymphoma and a leiomyosarcoma of the liver].
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cycloph | 1990 |
[Primary hepatic lymphoma in a patient with autoimmune hemolytic anemia and SLE].
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 1990 |
Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Follow-Up Studies; Humans; Lymphoma; Lymp | 1972 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
349 trials available for prednisone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2021 |
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Response R | 2021 |
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclo | 2022 |
Safety and efficacy of durvalumab with R-CHOP or R
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dise | 2022 |
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosph | 2022 |
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2022 |
Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F1 | 2022 |
No Evident Prognostic Benefit of Statin Use in Diffuse Large B-Cell Lymphoma Patients with Unfavorable Disease Features Treated with R-DA-EPOCH.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Hy | 2022 |
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2023 |
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2023 |
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; | 2023 |
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2023 |
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2023 |
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2023 |
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up | 2023 |
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2023 |
Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2023 |
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2023 |
In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo | 2020 |
Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autograf | 2020 |
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2020 |
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biosimilar Pharmaceuticals; | 2019 |
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cy | 2020 |
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H | 2020 |
Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP - the PLRG report.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2020 |
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Etopos | 2021 |
A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Biphenyl Compou | 2020 |
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2021 |
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2020 |
Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2020 |
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Et | 2020 |
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Fe | 2020 |
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pha | 2020 |
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the fina
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Contro | 2020 |
Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Gene | 2020 |
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; | 2021 |
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2021 |
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophos | 2020 |
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2020 |
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2020 |
Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2020 |
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2020 |
Primary breast lymphoma: A single-centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2019 |
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2020 |
R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2020 |
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2020 |
Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Case-Control Studies; | 2020 |
Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Diseas | 2020 |
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2021 |
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; | 2020 |
Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cyclophosphamide; Doxorubicin; Fam | 2021 |
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2021 |
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2021 |
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2021 |
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: A real-life study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxor | 2021 |
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; H | 2021 |
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Dox | 2021 |
Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2021 |
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2022 |
BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2017 |
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2017 |
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
TP53 mutation and survival in aggressive B cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2017 |
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymp | 2018 |
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclona | 2017 |
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2017 |
The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C | 2017 |
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2018 |
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy | 2018 |
Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2018 |
Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Denmark; Doxorubicin; Drug Adminis | 2018 |
Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow | 2018 |
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2018 |
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Histone | 2018 |
R-mini CHP in ≥80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 2018 |
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2018 |
The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2018 |
Transient adrenal insufficiency in diffuse large B cell lymphoma patients after chemotherapy with short-course, high-dose corticosteroids.
Topics: Adrenocorticotropic Hormone; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2018 |
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2018 |
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2019 |
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Surviva | 2019 |
Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2019 |
Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.
Topics: Adult; Aged; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2019 |
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2018 |
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2018 |
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2018 |
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2018 |
Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma.
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cyclop | 2018 |
Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood | 2018 |
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2019 |
Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemot | 2019 |
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 2019 |
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2019 |
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2019 |
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamid | 2019 |
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; | 2019 |
Rituximab-PECC induction followed by
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aut | 2019 |
Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2019 |
Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2019 |
Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantatio
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Disease-Free Su | 2019 |
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2013 |
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Tissue microarray in a subset of South African patients with DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes | 2013 |
Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2014 |
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2014 |
Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2014 |
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleom | 2014 |
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2014 |
Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
Topics: Acyclovir; Aged; Aged, 80 and over; Aging; Anti-Infective Agents; Antibodies, Monoclonal, Murine-Der | 2014 |
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derive | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplast | 2014 |
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2015 |
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho
Topics: Adult; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2015 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2015 |
Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2015 |
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
[Late cardiotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cardiotoxicity; Daunorubi | 2015 |
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; | 2016 |
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2016 |
Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Et | 2016 |
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2016 |
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
[Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
[Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2016 |
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Everolimus; Fea | 2016 |
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2016 |
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2016 |
Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body M | 2017 |
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2017 |
Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autogr | 2017 |
Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD5 Antigens; Cyclop | 2017 |
Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemoth | 2017 |
Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2017 |
Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Cycl | 2017 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2017 |
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2016 |
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Do six or eight cycles work better with CHOP-14 and rituximab?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
[Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
[Efficacy of conservative treatment of gastric lymphosarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymph | 2008 |
Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, N | 2009 |
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2009 |
Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2009 |
Rituximab and dose-dense chemotherapy in primary testicular lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
[Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2009 |
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2010 |
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2010 |
Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2010 |
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2010 |
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2010 |
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combi | 2010 |
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cyta | 2010 |
Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Anal | 2011 |
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplast | 2011 |
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2010 |
Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2011 |
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Topics: Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2011 |
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Topics: Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2011 |
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Topics: Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2011 |
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Topics: Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2011 |
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2011 |
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2011 |
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2011 |
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2011 |
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2011 |
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lym
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2011 |
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2012 |
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Topics: Adolescent; Adult; Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2012 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2012 |
Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body W | 2012 |
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body W | 2012 |
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body W | 2012 |
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body W | 2012 |
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; | 2012 |
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Concurrent administration of rituximab and CHOP chemotherapeutic agents for outpatients with CD20-positive lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemoth | 2012 |
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-De | 2012 |
Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Muri | 2012 |
[Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2012 |
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2012 |
Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2013 |
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2013 |
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2013 |
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2013 |
CHOP and rituximab in elderly patients.
Topics: Aged; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2002 |
Radiotherapy versus combined therapy in early stages with bulky disease aggressive malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality The | 2003 |
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2003 |
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2004 |
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transp | 2004 |
Maintenance therapy with interferon-alpha 2b, cyclophosphamide, and prednisone in aggressive diffuse large cell lymphoma.
Topics: Adult; Aged; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up S | 2004 |
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2004 |
Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2004 |
Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chi | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosp | 2005 |
Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2005 |
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 2005 |
Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2005 |
Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2006 |
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2006 |
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplasti | 2006 |
Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2006 |
Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2006 |
Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2006 |
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2006 |
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2007 |
Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2007 |
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Sur | 2008 |
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyc | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2008 |
Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as | 1982 |
Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as | 1983 |
A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials | 1984 |
Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclop | 1984 |
Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1994 |
Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1995 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Dise | 1994 |
Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1994 |
In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1993 |
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cyclophosphamid | 1996 |
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etop | 1996 |
PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 1996 |
Peripheral blood T cell subsets as prognostic indicators of chemotherapy outcome in AIDS patients with large cell lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Cell Div | 1996 |
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Com | 1997 |
Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1997 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Erythroid Precursor C | 1997 |
Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1998 |
Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cyta | 1998 |
[Value of radiotherapy in disseminated highly malignant non-Hodgkin's lymphoma. Comment on the article by U. Kaiser, R. Pfab, K. Havemann, Strahlenther Onkol 1997, 173, 136-40 (No. 3)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1998 |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hem
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Data Interpretation, S | 1998 |
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1998 |
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubici | 1998 |
A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 1999 |
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2001 |
Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho | 2001 |
Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2001 |
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2001 |
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; D | 2001 |
Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blotting, Southe | 2002 |
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Cyclophosphamide; Doxorubic | 2002 |
Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamid | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2002 |
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease-Free Su | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2002 |
Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fem | 2002 |
Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata.
Topics: Antineoplastic Agents; Bleomycin; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1975 |
Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.
Topics: Bleomycin; Carmustine; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug T | 1976 |
Multiple agent chemotherapy for advanced histiocytic lymphoma.
Topics: Adult; Aged; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1976 |
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group.
Topics: Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration | 1977 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.
Topics: Adult; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1977 |
Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Team approach to management of non-Hodgkin's lymphomas: past and present.
Topics: BCG Vaccine; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1977 |
Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Bleomycin; Cyclophosphamide; D | 1979 |
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin | 1977 |
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Topics: Adult; Aged; Blood Platelets; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Drug Evaluation; Drug | 1978 |
Combination chemotherapy of non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female | 1978 |
Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Dru | 1979 |
Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial.
Topics: Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Prospe | 1976 |
Combination chemotherapy of the malignant lymphomas: a controlled clinical trial.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Evaluation Studies as Topic; F | 1976 |
MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1992 |
MACOP-B treatment in patients with Ki-1-positive large-cell anaplastic lymphoma.
Topics: Adult; Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bleom | 1992 |
Intensive combination chemotherapy (TTL-I protocol) of large cell and immunoblastic lymphomas--long-term observation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1992 |
Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethas | 1992 |
F-MACHOP in advanced aggressive lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Do | 1992 |
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Rel | 1990 |
Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 1991 |
The role of maintenance therapy in the treatment of large-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubi | 1991 |
The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophospham | 1991 |
CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Huma | 1990 |
The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Huma | 1990 |
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Tria | 1986 |
Combination chemotherapy of lymphomas other than Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination | 1974 |
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Examination; Child; Child, Preschool; Cyclophospha | 1971 |
Clinical experience with antilymphocyte globulin (ALG) in renal transplantation.
Topics: Anaphylaxis; Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Drug Synergism; Graft Rej | 1971 |
Treatment of histiocytic lymphoma in Uganda adults.
Topics: Adult; Cyclophosphamide; Drug Combinations; Evaluation Studies as Topic; Female; Humans; Hydrazines; | 1971 |
1764 other studies available for prednisone and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2019 |
Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2021 |
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Etoposide; Hum | 2021 |
Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2022 |
Safety, Feasibility, and Effects of Short-Term Calorie Reduction during Induction Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Pilot Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caloric Restriction; Combined Modality Therapy | 2021 |
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cyclophosp | 2022 |
Primary diffuse large B-cell lymphoma of the uterus: A SEER database analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2021 |
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cyclophospha | 2022 |
A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center; Huma | 2022 |
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density; Cyclophosphamide; Doxorubicin; Humans; | 2022 |
Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fe | 2022 |
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female | 2021 |
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Feasibility Studies; | 2022 |
Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2021 |
Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Electronics; Fr | 2022 |
Primary breast lymphoma - a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 2021 |
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; D | 2022 |
Lymphoma presented as dysphagia: a diagnosis hard to swallow.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deglutition Disorders; | 2021 |
Clinical benefit of R-CHOP without splenectomy in stage I primary splenic diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2022 |
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutrop | 2022 |
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophospha | 2022 |
Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease-Free Su | 2022 |
Prognostic significance of clinical characteristics and
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fl | 2022 |
Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Card | 2021 |
TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 2022 |
Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2021 |
Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Delivery of Health Ca | 2022 |
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2022 |
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; L | 2022 |
[Clinical Characteristics and Long-term Prognosis Analysis of Patients with Primary Bone Lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2022 |
[Systemic chemotherapy combined with thrombopoietin receptor agonist for the treatment of diffuse large B-cell lymphoma complicated with aplastic anemia].
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hum | 2022 |
[Low psoas muscle index as independent poor prognostic factor for diffuse large B-cell lymphoma in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2022 |
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail E | 2022 |
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Et | 2022 |
Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Cyclophosphamide; Doxo | 2022 |
Successful multidisciplinary management of an asymptomatic gastrosplenic fistula in a diffuse large B cell lymphoma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fistula; H | 2022 |
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunot | 2022 |
Dose-adjusted EPOCH-R is a safe and well tolerated outpatient treatment regimen in double-hit lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Primary myocardial diffuse large B cell lymphoma. Report of one case.
Topics: Aged; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Rituximab; Vincri | 2021 |
Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2022 |
Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Etoposi | 2022 |
[Rupture of hepatic lesion of diffuse large B-cell lymphoma following immunochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Liver | 2022 |
Management of elderly patients with malignant lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2022 |
Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cohort Studies; Cyclo | 2022 |
Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Filgrastim; Humans; L | 2022 |
Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit | 2022 |
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; L | 2022 |
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hexokinase; Humans; L | 2022 |
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2022 |
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biosimilar P | 2022 |
[A comparison of R-CHOP and R-DA-EPOCH as a first-line regimen treatment of diffuse large B cell lymphoma with non-GCB subtypes: a retrospective study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2022 |
[Rituximab-Based Regimens for Treatment of Primary Gastric Diffuse Large B-Cell Lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2022 |
[Correlation between Serum miR-34a Level and Thrombocytopenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Interleukin-1 | 2022 |
Use of benzodiazepines is the risk factor for infection in patients aged 80 years or older with diffuse large B-cell lymphoma: A single-institution retrospective study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzod | 2022 |
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide | 2022 |
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Hypogonadism; | 2022 |
Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
"Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Developing Countries; Doxoru | 2022 |
Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Down-Regulati | 2022 |
[Therapeutic developments and advances in B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hem | 2022 |
Primary diffuse large B-cell lymphoma of the Larynx.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fe | 2023 |
The Endothelial Activation and Stress Index (EASIX) score is an independent prognostic factor in patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Creatinine; | 2022 |
Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Doxorubicin; Human | 2023 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, | 2022 |
Infectious complications and long-term outcomes in patients with diffuse large B-Cell lymphoma and diabetes mellitus.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Dog Diseas | 2023 |
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Human | 2022 |
Severe Pancytopenia After COVID-19 Revealing a Case of Primary Bone Marrow Diffuse Large B Cell Lymphoma.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 2022 |
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
The multilobated morphology is still a better prognosis factor of diffuse large B-cell lymphoma in the R-CHOP era.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2022 |
About time: why central nervous system prophylaxis timing in diffuse large B-cell lymphoma matters and does the protocol need updating?
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2022 |
Evaluation of the Effects of R-CHOP Chemotherapy on Brain Glucose Metabolism in Patients with Diffuse Large B Cell Lymphoma: A Baseline, Interim, and End-of-Treatment PET/CT Study.
Topics: Antibodies, Monoclonal, Murine-Derived; Brain; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F18 | 2022 |
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Dif
Topics: Canada; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Cost-Effectiveness Analysis; Cyclo | 2023 |
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Et | 2023 |
An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 2023 |
High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Huma | 2023 |
Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Basic Helix- | 2023 |
Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chile; C | 2022 |
Primary esophageal diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diabetes Mellitus, Type 2; D | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
How I treat older patients with DLBCL in the frontline setting.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pro | 2022 |
[New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma].
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab | 2022 |
[New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma].
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab | 2022 |
[New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma].
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab | 2022 |
[New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma].
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab | 2022 |
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2023 |
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2023 |
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2023 |
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2023 |
Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2023 |
Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2023 |
Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2023 |
Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2023 |
[Multiple Intestinal Perforations Caused by Diffuse Large B-Cell Lymphoma-A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Intestinal Perforation; I | 2022 |
Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lympho | 2023 |
A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large-B cell lymphoma during treatment with immunochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hemorrhage; Humans; L | 2023 |
The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fluorescence | 2023 |
Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Humans; Immediate-Early Proteins; Lympho | 2023 |
Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy-treated diffuse large B-cell lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bio | 2023 |
Successful Treatment of Large B-Cell Lymphoma in a Child with Compound Heterozygous Mutation in the
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia; Ataxia Telangiectasia Mutated | 2023 |
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cel | 2023 |
A Prospective Study of Preemptive Tenofovir Disoproxil Fumarate Therapy in HBsAg-Positive Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Alanine Transaminase; Antiviral Agents; Cyclophosphamide; DNA, Viral; Doxorubicin; Hepatitis B Surfa | 2023 |
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Doxorubici | 2023 |
Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Long-term excess mortality and net survival among elderly diffuse large B-cell lymphoma patients after front-line R-CHOP treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunot | 2023 |
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Tapering; Humans | 2023 |
A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2023 |
The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2023 |
Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; | 2023 |
The lymphoma microenvironment comes of age in the R-CHOP era?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Lym | 2023 |
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Croatia; Cyclophosphamide; | 2023 |
Diffuse Large B-Cell Lymphoma and Related Entities.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2023 |
Non-operative Management of Spontaneous Gastropleural Fistula Caused by Primary Gastric Diffuse Large B-cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fistula; Humans | 2023 |
Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; HIV Infection | 2023 |
Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2023 |
Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2023 |
Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Huma | 2023 |
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Frailty; Humans | 2023 |
Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkısh oncology group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2023 |
Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cyclo | 2023 |
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Topics: Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lactate Dehydrogenases; Lymphoma, Large B-Cell, Di | 2023 |
Resistance to vincristine in DLBCL by disruption of p53-induced cell cycle arrest and apoptosis mediated by KIF18B and USP28.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cyclophosphamide; | 2023 |
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Doxorubicin; Hep | 2023 |
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neop | 2023 |
A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2023 |
Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2023 |
Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clustered Regularly Interspaced Short Palindromic Re | 2023 |
Transcriptomic analysis of neutrophil apoptosis induced by diffuse large B-cell lymphoma unveils a potential role in neutropenia.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apo | 2023 |
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Doxorubicin; | 2023 |
The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2023 |
[Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Doxorubicin; Humans; | 2023 |
[Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2023 |
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Topics: Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Ce | 2023 |
Rare case of primary bone lymphoma of the femur.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Femur; Humans; Lympho | 2023 |
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
Prognostic Value of Differential Expression of Polymerase Eta Gene in Nonresponding Patients With Diffuse Large B-cell Lymphoma.
Topics: Disease-Free Survival; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Predniso | 2024 |
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Hum | 2023 |
Diffuse Large B-Cell Lymphoma with Cutaneous Manifestations in a Young Patient Using Clozapine for Schizophrenia: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clozapine; Cyclophosphamide; Doxorubicin; Fem | 2023 |
EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Biomarkers; Cyclophosphamide; Doxorubicin; Humans; Lym | 2023 |
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?
Topics: Adenine; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Pipe | 2019 |
Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2019 |
Pulmonary intravascular large B-cell lymphoma accompanying synchronous primary pulmonary adenocarcinoma and benign interstitial lesions.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 2019 |
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD47 Antigen; Cell Line, Tumor; Cyclophosphamide; Do | 2019 |
Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007-2015.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Comorbidity | 2020 |
Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Head and Neck | 2020 |
Breastfeeding during R-CHOP chemotherapy: please abstain!
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Breast Feeding; Chromatography, | 2019 |
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyc | 2019 |
Diffuse large B-cell lymphoma in a patient with dermatomyositis-associated interstitial lung disease: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Dermatomyositis; Doxorubic | 2019 |
Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gene Expression Regul | 2019 |
Reply to T.M. Weis et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2019 |
Dosing Vincristine in Dose-Adjusted EPOCH-R: To Cap or Not to Cap?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2019 |
Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiother | 2020 |
The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2020 |
Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus In | 2019 |
[Relationship between p53 rs1625895 polymorphism and prognosis in diffuse large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2019 |
Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cyclophosphamide; Doxorubicin; | 2019 |
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2020 |
[Diffuse large B-cell lymphoma relapsing with intravascular large B-cell lymphoma-like perivascular and intravascular lesions].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2019 |
CD5
Topics: Aged; CD5 Antigens; Disease-Free Survival; Doxorubicin; Female; Gene Expression Regulation, Neoplast | 2020 |
Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Cyclophosphamide; D | 2020 |
Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnostic Errors; Doxorubicin; Hu | 2019 |
Composite lymphoma of concurrent T zone lymphoma and large cell B cell lymphoma in a dog.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Dog Disea | 2019 |
Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl | 2020 |
Application of contrast-enhanced ultrasonography in the diagnosis of post-kidney transplant lymphoproliferative disorder in native kidney- a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Cyclophosphamide; Doxorubicin; | 2019 |
Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Cytokines; Doxorubici | 2020 |
Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-M | 2020 |
Primary cardiac lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dyspnea; Echocardiogr | 2019 |
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like | 2019 |
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2020 |
A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cough; Cyclop | 2019 |
[Clinicopathological features of primary cardiac CD5-positive and bcl-2 and C-MYC double expression diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2019 |
Natural course of diffuse large B cell lymphoma-a manifestation in buccal mucosa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxoru | 2019 |
Epstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified, carrying a t(19;22)(q13;q11) translocation.
Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Chromosomes | 2020 |
A case report of primary prostate intravascular large B cell lymphoma presenting as prostatic hyperplasia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnostic Errors; Doxorubic | 2019 |
Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; In | 2020 |
Association between Comorbidity and Relative Dose Intensity in Patients with Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2019 |
Impact of SNPs/Haplotypes of
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamid | 2019 |
Diffuse large B-cell lymphoma of the vagina in pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dysuria; Femal | 2020 |
Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2020 |
Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, | 2020 |
Intravenous methotrexate at a dose of 1 g/m
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cerebrospinal Fluid; C | 2020 |
Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2020 |
A Diffuse Medullary Hypercaptation With No Bone Lesion.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Fatal Outcome; Humans; Immunosupp | 2020 |
MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2020 |
Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diff | 2020 |
Primary spinal epidural lymphoma: a rare entity with an ambiguous management.
Topics: Aged; Cyclophosphamide; Decompression, Surgical; Epidural Space; Humans; Laminectomy; Lymphoma, Larg | 2020 |
Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autograf | 2020 |
Shape of the Heart: A 68-Year-Old Man With a Primary Cardiac Non-Hodgkin Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Heart Neoplasms | 2020 |
Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2020 |
Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2020 |
Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Databases | 2020 |
Prognostic significance of the modified Barthel index in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Lymphoma, Large B-Cell, D | 2020 |
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2020 |
A case report of sinusoidal diffuse large B-cell lymphoma in a STK4 deficient patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2020 |
Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central | 2020 |
[Feasibility of PEG-rhG-CSF in the first-line treatment of diffuse large B-cell lymphoma receiving dose-adjusted EPOCH plus rituximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Feasibilit | 2020 |
[A Case of Diffuse Large B-Cell Lymphoma of the Ascending Colon].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Ascending; Colonic Neoplasms; Cyclophos | 2019 |
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2020 |
Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2020 |
Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Composite Lymphoma; Cyclophospham | 2020 |
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosph | 2020 |
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2020 |
Presentation and management of primary mediastinal large B-cell lymphoma: a retrospective cohort analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2020 |
Prognostic significance of infectious episodes occurring during first-line therapy for diffuse large B-cell lymphoma - A nationwide cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2020 |
Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gene Rearrangement; G | 2020 |
Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cell Line, Tumor; Cyclophos | 2020 |
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hepatitis B Surface A | 2020 |
The clinical outcomes of rituximab biosimilar CT-P10 (Truxima
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biosimilar P | 2020 |
Diffuse large B-cell lymphoma of the rectum in a patient with Crohn's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Combined Modality Therapy; Crohn | 2020 |
A Rare Case of Ileocecal Valve Stricture.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Constriction, Pathologic; Cycloph | 2020 |
[Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
Topics: Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Primary Lymphoma of Liver-a Rare Space-Occupying Lesion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cyclophosphamide; Doxoru | 2020 |
Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Prot | 2020 |
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Cyclophosphamide; Doxorubi | 2020 |
A case of bilateral methotrexate-associated diffuse large B-cell lymphomas of the breasts with unique clinical presentation and outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Arthritis, Rheumatoid; Biopsy; | 2020 |
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabi | 2020 |
Progressive dyspnea and diffuse ground-glass opacities after treatment for lymphoma with rituximab-containing chemotherapy: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Dyspnea; Etoposide; H | 2020 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Activ | 2020 |
Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gene E | 2020 |
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2020 |
Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Bioavailable 25(OH)D level is associated with clinical outcomes of patients with diffuse large B-cell lymphoma: An exploratory study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclophosphamide; Doxorubic | 2021 |
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2020 |
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2020 |
Prognostic impact of B-vitamins involved in one-carbon metabolism in patients with diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carbon; Cyclophosphamide; Doxorub | 2020 |
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cycl | 2020 |
A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Examination; Cyclophospha | 2021 |
Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cycloph | 2020 |
TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; CREB-Binding Protein; Cyclophosphamide; | 2020 |
Unilateral multiple serous retinal detachments secondary to non-Hodgkin's lymphoma responsive to systemic steroids.
Topics: Adult; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Lo | 2021 |
Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gene Re | 2020 |
Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Res | 2020 |
Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosph | 2020 |
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2020 |
Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Incid | 2020 |
Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Eto | 2020 |
Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections | 2020 |
Secondary cutaneous involvement by direct extension in high-grade B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Cyclophos | 2021 |
Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Topics: Adenine; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marr | 2020 |
Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prognosis; Retro | 2020 |
The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ch | 2020 |
Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
A case of intravascular large B-cell lymphoma with renal involvement presenting with elevated serum ANCA titers.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2021 |
R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; C | 2020 |
Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined | 2020 |
MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Fe | 2020 |
Non-Hodgkin's lymphoma in an elderly patient with renal dysfunction: a case report.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2020 |
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Da | 2020 |
[Analysis of Factors Influencing Clinical Efficacy of Rituximab on Patients with Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Herpesvirus 4, Human; | 2020 |
Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2020 |
Outcomes of treatment with CHOP and EPOCH in patients with HIV associated NHL in a low resource setting.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug A | 2020 |
Therapeutic vaccines for aggressive B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2020 |
Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Pancreatitis; Bile Ducts; Female; H | 2021 |
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone and | 2021 |
ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; | 2021 |
Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2020 |
Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2021 |
Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2020 |
Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cluster Analysis; Cyclophosphamide; Doxorubicin; Hum | 2021 |
B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Res | 2021 |
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2020 |
Ulcerated cutaneous Richter syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophospham | 2020 |
Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Doxorubici | 2021 |
Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2021 |
Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C | 2021 |
Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.
Topics: Animals; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; | 2021 |
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2021 |
A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2021 |
The Outcome of Diffuse Large B Cell Lymphoma Patients in Adolescent and Young Adult Age Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease-Free Su | 2021 |
Peripheral blood cell ratios as prognostic factors in canine diffuse large B-cell lymphoma treated with CHOP protocol.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Cyclophosphamide; Dog Diseases | 2021 |
Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Doxorubicin; HIV; HIV Infec | 2020 |
[Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2020 |
The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Antineoplas | 2020 |
Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2021 |
Primary pulmonary diffuse large B-cell lymphoma with multiple ground-glass nodules as the primary manifestation: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cough; Cyclophosphamide; Diagnosis, Differenti | 2020 |
Primary diffuse large B cell lymphoma (DLBCL) of the prostate presenting with lower urinary tract symptoms (LUTS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Biopsy, Large-Core Needle; Cyclophosphamide; | 2020 |
Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Computat | 2021 |
Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2021 |
Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Cur | 2021 |
Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagic Cell De | 2021 |
Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colitis, Ulcerative; Cyclophospham | 2021 |
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Ma | 2021 |
Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cycl | 2021 |
A prognostic gene signature for predicting survival outcome in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Datasets as Topic; Doxorubicin; Hu | 2021 |
Masquerading of COVID-19 Infection as Primary Mediastinal Large B-Cell Lymphoma
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Cyclophosp | 2021 |
High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cyclophosphamide; Disease- | 2021 |
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2021 |
Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; China; Cyclophosphamide; Do | 2021 |
Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Carcinoma Camouflage.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 2021 |
Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Cycl | 2021 |
5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.
Topics: 5-Methylcytosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacol | 2021 |
Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents, Immunological; Antineop | 2021 |
The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2021 |
Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report.
Topics: Aftercare; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamid | 2021 |
Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2021 |
Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2021 |
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematop | 2021 |
Unclassifiable lymphoma in pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Cyclophosphamide; Doxorubic | 2021 |
Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80-results from a single-center survey.
Topics: Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols | 2021 |
Haemorrhagic shock from solid tumours of the adrenal gland: a case of bleeding primary adrenal lymphoma.
Topics: Abdominal Pain; Adrenal Gland Diseases; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherap | 2021 |
Eruptive lichen planus-like keratoses induced during R-CHOP 21 chemotherapy for diffuse large B-cell (gastric) lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Keratos | 2021 |
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2021 |
Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febril | 2021 |
Prognostic significance of bone marrow 2-[
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cyclophosphamide; Doxorub | 2021 |
Interim and end-of-treatment PET-CT suffers from high false-positive rates in DLBCL: Biopsy is needed prior to treatment decisions.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Clinical Decision-Making; Confidence I | 2021 |
Posterior reversible encephalopathy syndrome in a patient with Richter's syndrome on combination DA-R-EPOCH chemotherapy regimen: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Huma | 2021 |
Central Nervous System International Prognostic Index Impacts Overall Survival in Diffuse Large B-cell Lymphoma Treated with R-Chop in a third Level Cancer Center from Mexico: A Survey of 642 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous | 2021 |
Novel model predicts prognosis for patients with diffuse large B-cell lymphoma in first relapse after initial R-CHOP therapy: a single-institution study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Doxorubicin; Humans; Lympho | 2021 |
Composite lymphoma of T-cell rich, histiocyte-rich diffuse large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Composite Lymphoma; Doxorubicin; Histiocytes; | 2021 |
Individualized Treatment and Palliative Care for A 90-Year-Old Patient with Primary Gastric Diffuse Large-B Cell Lymphoma: 4 Year Follow-up and Inspiration.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2021 |
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lympho | 2021 |
Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
Topics: Aminoisobutyric Acids; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzimidazo | 2021 |
[Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance].
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Calcium Channe | 2021 |
A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 2021 |
IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Datasets as Top | 2021 |
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2022 |
Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2021 |
Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2021 |
Primary Mediastinal Large B-cell Lymphoma : Impact of Chemotherapy Choice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2021 |
Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Di | 2021 |
Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 2021 |
Intravascular lymphoma presenting with hypoxaemia, platypnoea and lactic acidosis.
Topics: Acidosis, Lactic; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubici | 2021 |
Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2022 |
[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Japan; Lympho | 2021 |
[Current achievements and future perspectives in the research on intravascular large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; | 2021 |
Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2021 |
Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2021 |
Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2021 |
Synchronous gastric cancer and primary lymphoma of right adrenal gland: a case report.
Topics: Adrenal Glands; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2021 |
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2022 |
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Topics: Activities of Daily Living; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 2022 |
Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin | 2021 |
Very delayed sinus arrest during complete remission of diffuse large B-cell lymphoma invading right atrium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bradycardia; Cyclophosphamide; Doxorubicin; Electroc | 2021 |
Primary cardiac B cell lymphoma in an immunocompetent patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2021 |
MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Division; Cyclophosph | 2021 |
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Doxorubicin; | 2021 |
[Doxorubicin Hydrochloride Liposome-Based CHOP Regimen in the Initial Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2021 |
c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2021 |
Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Herpesviru | 2022 |
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorub | 2022 |
Unusual presentation of extranodal diffuse large B-cell lymphoma in a solid-organ recipient during long-term immunosuppressive treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease Managem | 2021 |
Tiny transformed diffuse large B cell lymphoma localized to the left conjunctiva.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Conjunctiva; Conjunctival Neoplasms; Cycloph | 2021 |
Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Stu | 2021 |
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cyclopho | 2021 |
Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2017 |
Bilateral sciatic nerve neurolymphomatosis: PET/CT findings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Craniospinal Irradiation; Cyclophospham | 2017 |
A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Diffuse large B-cell lymphoma with a bulky mass in the cranial vault.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2017 |
The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2017 |
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Anti | 2017 |
Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients.
Topics: Amino Acid Substitution; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Primary diffuse large B cell lymphoma of the uterine cervix successfully treated by combined chemotherapy alone: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cervix Uteri; Cyclophosphamid | 2017 |
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bio | 2017 |
Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Topics: Aged, 80 and over; Aging; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2017 |
Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2017 |
Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
Topics: Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Dif | 2017 |
Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cardi | 2017 |
[Recent development of hypertension and acute renal failure in a 59-year-old woman].
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr | 2017 |
Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2018 |
Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Comorb | 2017 |
High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Treatment outcome of diffuse large B-cell lymphoma involving the head and neck: Two-institutional study for the significance of radiotherapy after R-CHOP chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemoradioth | 2017 |
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Gene Rearr | 2018 |
[Clinical Efficacy of EPOCH±R Followed by DICE±R Regimen for Primary Breast Diffuse Large B-Cell Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Eto | 2017 |
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Doxorubicin | 2017 |
Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell P | 2018 |
Primary CD30-positive Diffuse Large B-cell Lymphoma in the Superior Vena Cava.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2017 |
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2017 |
Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Gene E | 2017 |
The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency.
Topics: Adrenal Insufficiency; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Low signal intensity lesions on brain susceptibility-weighted MRI in a patient with intravascular large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cerebr | 2017 |
The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2018 |
Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2017 |
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with car
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts; | 2017 |
Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials.
Topics: Adult; Antibodies, Monoclonal, Humanized; Child; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, La | 2017 |
Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2017 |
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit | 2018 |
DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cycloph | 2017 |
Relapse in stage I(E) diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2018 |
Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2017 |
Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Case-Control | 2017 |
TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2017 |
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2019 |
Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Do | 2018 |
Prognostic significance of Ki67 and its correlation with mitotic index in dogs with diffuse large B-cell lymphoma treated with 19-week CHOP-based protocol.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Brazil; Cyclophosphamide; Dog D | 2018 |
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph | 2018 |
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; He | 2018 |
Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cy | 2018 |
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Cyclophosphamide; Dietary Sup | 2018 |
An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Cyclophospham | 2018 |
Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2017 |
Antenatal chemotherapy in a case of diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cyclophosphamide; Diarrhea; Dox | 2018 |
Synchronous diffuse large B-cell lymphoma of the stomach and small cell lung carcinoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Small Cell; Cyclophosphamide; Dox | 2017 |
Intravascular Large B-Cell Lymphoma of the Gallbladder.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Vessel | 2018 |
[A Case Report of Inguinal Malignant Lymphoma after Surgery for Hepatocellular Carcinoma].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2017 |
[ALC/AMC Value and Prognosis in Patients with Primary Follicular Lymphoma Treated with R-CHOP Chemotherapy].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
[Change of Neutrophils/ Lymphocyte Ratio in Patients with DLBCL before and after CHOP or R-CHOP Chemotherapy and Its Effect on Survival of Patients].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
Anti-H antibody of unusually high titer showing variable reactivities against group A red cells and broad thermal amplitude in a patient with lymphoma.
Topics: ABO Blood-Group System; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2018 |
Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2018 |
Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD8-Posi | 2018 |
Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
[Rectal diffuse large B cell lymphoma appearing after immunosuppression for ulcerative colitis. Report of one case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Biopsy; Colitis, Ulcerative; Cyclophos | 2017 |
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumo | 2018 |
A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors.
Topics: Acute Disease; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2018 |
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphami | 2018 |
Usefulness of chemotherapy for the treatment of very elderly dogs with multicentric lymphoma.
Topics: Aging; Animals; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Do | 2018 |
Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Chemical and Drug | 2018 |
Intravascular Large B-Cell Lymphoma Within a Thyroid Nodule: A Diagnostic Pitfall.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2018 |
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2018 |
[A case of neurolymphomatosis presented as cauda equine syndrome accompanied with M-proteinemia].
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyc | 2018 |
The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.
Topics: Alleles; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Ary | 2018 |
A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2018 |
[Analysis of the Clinicopathological Characteristics, Treatment and Prognosis of Unclassifiable B-Cell Lymphoma Intermediated between DLCBL and BL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2018 |
High 18F-fluorodeoxyglucose uptake in primary bilateral adrenal diffuse large B-cell lymphomas with nongerminal center B-cell phenotype: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F1 | 2018 |
Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2018 |
[Intravascular Large B-cell Lymphoma: a Clinical Analysis of 17 Cases].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Primary diffuse large B-cell lymphoma in the maxilla: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2018 |
[Primary renal lymphoma: a clinical analysis of 5 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2018 |
Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2018 |
Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Surviva | 2018 |
A Very Rare Case of Sarcoid-Lymphoma Syndrome Imposing an Intriguing Diagnostic Challenge.
Topics: Acute Kidney Injury; Adult; Biopsy; Child; Glucocorticoids; Humans; Hypercalcemia; Lymphoma, Large B | 2018 |
[Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2018 |
Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma: A STROBE-compliant article.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Case-Control | 2018 |
Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2019 |
Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2019 |
Extreme exigency in the extremity: an illustrative case of diffuse large B-cell lymphoma occurring in the arm.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2018 |
Relapsed lymphoma mimicking venous ulcer: A case report.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2018 |
Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamid | 2019 |
Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2018 |
Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
Intravascular large B-cell lymphoma presenting as multiple stroke: A case report.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2019 |
[The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fema | 2019 |
Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; | 2019 |
Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2018 |
Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2018 |
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2018 |
Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast | 2018 |
Towards the better diagnosis of lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating Tumor DNA; Clinical Decision-Making; Cyc | 2018 |
How dogs are teaching researchers new tricks for treating cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials, Veterinar | 2018 |
Diffuse large B cell lymphoma and schistosomiasis: a rare simultaneous occurrence.
Topics: Abdomen, Acute; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxoru | 2019 |
Primary diffuse large B-cell lymphoma as a chest-wall mass: A case report.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antineoplastic Combined Chemothera | 2018 |
Epitrochlear lymphadenopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymph Nodes; | 2019 |
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2019 |
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2019 |
Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marro | 2019 |
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cy | 2019 |
Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2018 |
New high-risk molecular subtypes of DLBCL identified.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2019 |
Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2019 |
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2019 |
Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma - a nationwide population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbid | 2019 |
Anthracycline induced inconsistent left ventricular segmental systolic function variation in patients with lymphoma detected by three-dimensional speckle tracking imaging.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2019 |
A rare diagnosis of primary native kidney non-hodgkin's lymphoma after kidney transplantation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2019 |
A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; C | 2019 |
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CD47 Antigen | 2019 |
PET-derived tumor metrics predict DLBCL response and progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclopho | 2019 |
Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2019 |
Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Doxorubic | 2019 |
Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center.
Topics: Age Factors; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2019 |
Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2019 |
Diagnosis and treatment complications of primary cardiac lymphoma in an immunocompetent 28-year old man: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arrhy | 2019 |
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2019 |
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care - Authors' reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2019 |
GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2019 |
Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Disease P | 2019 |
Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2019 |
Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA Methylat | 2019 |
Diffuse Large B-Cell Lymphoma Arising within Ileal Neobladder: An Expanding Spectrum of Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Ep | 2019 |
Promising new combination therapy for non-GCB DLBCL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclop | 2019 |
Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2019 |
De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.
Topics: Adenine; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Pipe | 2019 |
Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2019 |
MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line; Cyclophosphamide; Do | 2019 |
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2019 |
Hidden superpower.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Art; | 2019 |
Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder.
Topics: Adult; Aged; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 2019 |
Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2019 |
Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cyclophosph | 2019 |
[Cauda equina syndrome as the first presentation of intravascular large B-cell lymphoma: a lung biopsy case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2019 |
[Triple expressor lymphoma in a kidney transplant patient].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubic | 2019 |
[A case of secondary central nervous system lymphoma presenting marked hypoglycorrhachia].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2019 |
Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2019 |
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; DNA Mutatio | 2019 |
Nephrotic syndrome without kidney injury revealing intravascular large B cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic | 2019 |
Neuroinvasive West Nile Virus Disease in an Elderly Patient with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Case Report
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C | 2019 |
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2019 |
Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2019 |
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2020 |
A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies | 2019 |
Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Do | 2019 |
High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Doxorubicin; Ery | 2019 |
A Rapidly Enlarging Neck Mass: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Cyclophosphamide; Doxorub | 2019 |
A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Agents, Immunological; Cyclophosphamide; Doxorubicin; Humans; L-Lactate Dehydro | 2019 |
Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclopho | 2019 |
Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn's disease treated with infliximab and azathioprine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Azathioprine; Colorectal Neopl | 2020 |
CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2019 |
Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2020 |
A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal, Murine-De | 2013 |
Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2013 |
R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2013 |
CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Gene expression-based risk score in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2012 |
Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistanc | 2013 |
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Antibodies, Monoclonal, Murine-Derived; Antineopla | 2013 |
Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2014 |
Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2013 |
CD30, another useful predictor of survival in DLBCL?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 2013 |
Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2004 |
c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplast | 2012 |
Successful treatment of non-Hodgkin lymphoma associated immune thrombocytopenia with involved field radiotherapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 2013 |
Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Micro | 2013 |
Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy | 2013 |
Vanishing right ventricular outflow obstruction: an unusual presentation of mediastinal lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2013 |
[Development of syndrome of inappropriate secretion of ADH and reversible posterior leukoencephalopathy during initial rituximab-CHOP therapy in a patient with diffuse large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; Cyclo | 2013 |
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2013 |
Lymphomatoid granulomatosis: a case report with unique clinical and histopathologic features.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothe | 2013 |
[EBV-positive diffuse large B-cell lymphoma in young individual: report of a case].
Topics: Adult; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Cyclophosphamide | 2013 |
Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2013 |
[Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2013 |
Histologic transformation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; | 2013 |
TP53 and outcome in DLBCL: not only the coding region.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2013 |
Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clini | 2013 |
A rare case of anaplastic variant of diffuse large B-cell lymphoma presenting as a lung primary.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lung Ne | 2014 |
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2013 |
Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
IgA monoclonal gammopathy accompanying extranodal B cell lymphomas.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2014 |
Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; | 2013 |
[Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2014 |
Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Doxorub | 2013 |
The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine | 2014 |
Primary ovarian lymphoma--a rare entity.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2013 |
Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic | 2013 |
Cirrhosis and intestinal B-cell lymphoma: two entities that are rarely associated with celiac disease.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Celiac Disea | 2013 |
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
[Diagnosis and treatment of primary colorectal non-Hodgkin's lymphoma: analysis of 52 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2013 |
Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2014 |
Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
[Picture in clinical hematology].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphom | 2013 |
Intravascular large B cell lymphoma: widespread but not everywhere.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Primary extranodal B-cell non-Hodgkin lymphoma mimicking an endodontic lesion: report of 2 cases.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2013 |
Intravascular large B-cell lymphoma--a diagnostic dilemma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 2013 |
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau | 2013 |
Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2013 |
[Case of primary malignant lymphoma of the bladder].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2013 |
Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibo | 2013 |
[Treatment outcome in primary testicular non-Hodgkin lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Primary hepatic lymphoma mimicking acute hepatitis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female | 2013 |
Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S | 2014 |
[Expression and clinical significance of Ki-67 in diffuse large B cell lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
R-CHOP: does one size fit all in diffuse large B cell lymphoma?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2015 |
Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineopl | 2013 |
Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined | 2013 |
Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
[B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 2013 |
[Diffuse large B-cell lymphoma of testis: a clinicopathologic and immunophenotypic study of 58 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2013 |
Orbital signet-ring cell lymphoma of diffuse, large, B-cell type.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclop | 2013 |
[Clinicopathological and survival features of primary hepatic lymphoma: an analysis of 35 cases].
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antigens, CD20; Antineoplastic Combined Chemotherapy Pr | 2013 |
[Primary diffuse large B-cell lymphoma of the uterine cervix successfully treated with rituximabplus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy-a case report].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
First case of T-cell/histiocyte-rich-large B-cell lymphoma presenting with duodenal obstruction.
Topics: Abdominal Pain; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2013 |
[Comparison between CHOP-like and R-CHOP in diffuse large B cell and follicular lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospectiv
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi | 2013 |
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ant | 2014 |
Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthropometry; Antibodies, Monoclonal, Murine-Derived; A | 2014 |
Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Survival of patients with transformed lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
[Primary cutaneous follicle centre lymphoma: report of a case].
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; CD79 Antigens; Cyc | 2013 |
HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; China; Cyclo | 2014 |
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2014 |
[Expression and clinical significance of CD40 in diffuse large B-cell lymphoma].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2013 |
[CD5-positive cardiac intravascular diffuse large-B cell lymphoma: report of a case].
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Pegfilgrastim-induced pain in patients with lymphoma.
Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Murine-Derived; Antineo | 2014 |
Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; | 2014 |
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2014 |
Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2014 |
Impact of inadequate doses of rituximab in the treatment of diffuse large B cell lymphoma in Malaysian patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Murine-Derived; Cyclin D1; Cyclopho | 2014 |
[Ictus cerebellopontine as first manifestation of an intravascular diffuse large B cell lymphoma involving at the kidney].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2015 |
High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2014 |
Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antibodies, Monoclonal, Murine-De | 2014 |
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ant | 2015 |
Diffuse large B-cell lymphoma of stomach presenting with paraneoplastic cerebellar degeneration syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2014 |
MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.
Topics: Age Factors; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2014 |
The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
[Combined modality therapy for a patient with primary adrenal lymphoma].
Topics: Adrenal Gland Neoplasms; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2014 |
HBV reactivation in immunosuppressed patients: prevention or containment?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
[Long-term follow-up for 39 newly diagnosed diffused large B-cell lymphoma patients treated by (R)-EPOCH].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2014 |
A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
An unresectable Klatskin's tumor?
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined C | 2014 |
Epstein-Barr virus-associated diffuse large B-cell lymphoma arising in atrial myxoma: a proposal for a modified therapeutic approach.
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epstein-Barr Virus | 2015 |
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, Neopla | 2014 |
Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resi | 2014 |
[Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
The utility of online haemodiafiltration in methotrexate poisoning.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antine | 2014 |
Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-L | 2014 |
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central | 2015 |
Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort S | 2015 |
R-CHOP versus R-COMP: are they really equally effective?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cyclophosphamide; Dis | 2014 |
Primary thyroid lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Ther | 2014 |
[Clinical outcome of 489 patients with diffuse large B-cell lymphoma and associated factors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; China; Cyclo | 2014 |
Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined | 2014 |
Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Comb | 2014 |
Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2014 |
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2014 |
The management of an orbital diffuse large B-cell lymphoma.
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2014 |
The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2014 |
[Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Comb | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2014 |
Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lympho
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2015 |
Dramatic regression of recalcitrant human papillomavirus type 1-related palmar verrucae and squamous cell carcinoma in situ following R-CHOP chemotherapy and transition to sirolimus in a renal transplant patient with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2015 |
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Body M | 2014 |
A treatment for activated B-cell-like DLBCL?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherap | 2014 |
A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibo | 2014 |
Education and Imaging. Gastroenterology: mesenteric lymphoma with chylous ascites.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chylou | 2014 |
Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; China; | 2015 |
MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Double-hit primary unilateral adrenal lymphoma with good outcome.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2014 |
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy | 2015 |
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2014 |
Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: 3' Untranslated Regions; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2014 |
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2014 |
Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Primary diffuse large B-cell lymphoma associated with chronic osteomyelitis of the knee.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2014 |
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2014 |
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2014 |
Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi | 2014 |
A case of primary dural lymphoma: diffuse large B-cell type.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2014 |
Diffuse large B-cell lymphoma resembling a metastatic liver tumour.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2015 |
Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Topics: Annexin A5; Antineoplastic Agents; Cell Line, Tumor; Cyclophosphamide; Doxorubicin; Drug Resistance, | 2014 |
Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2015 |
The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2015 |
Immunohistochemical expression of CD-10, BCL-6 and MUM-1 antibodies and immediate clinical response in patients of diffuse large B-cell lymphomas after six cycles of chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; DN | 2014 |
ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemot | 2014 |
Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Lineage; Cyclophosphamide | 2015 |
Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2015 |
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2015 |
An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
[Lingua villosa nigra after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2014 |
Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Secondary orbital lymphoma].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Exophthalmos; F | 2015 |
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2015 |
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2015 |
What is your diagnosis? Cutaneous B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2014 |
The impact of age on survival of diffuse large B-cell lymphoma - a population-based study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2015 |
The first case report of composite bone marrow involvement by simultaneously developed peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 2015 |
Validation of an enhanced International Prognostic Index (NCCN-IPI) in an Asian cohort of patients with diffuse large B cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2015 |
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; | 2015 |
A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Huma | 2015 |
[Efficacy and safety of rituximab combined with CHOP or combined with dose fractionated CHOP in the treatment of primary gastric diffuse large B cell lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2015 |
R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2015 |
Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Line, T | 2015 |
Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Topics: Adult; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Stud | 2015 |
Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; | 2015 |
Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cluster Anal | 2015 |
Pediatric B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma and Burkitt lymphoma: a report of two cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child, Preschool; Cycl | 2015 |
HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.
Topics: Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antibodies, Monoclonal, Murine-Derived; Anti | 2015 |
[Salvage gastrectomy and radiotherapy for R-CHOP-refractory gastric malignant lymphoma].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemor | 2014 |
[A case of fixing an anastomotic site to the abdominal wall out of the abdominal cavity for a small intestinal perforation during chemotherapy].
Topics: Abdominal Cavity; Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2014 |
The efficacy of ibrutinib in the treatment of Richter syndrome.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antibodies, Monoclonal, Murine-Derived; Antineop | 2015 |
Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Aged; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Proto | 2015 |
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Topics: Aged; Aged, 80 and over; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 2014 |
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2015 |
Diffuse large B-cell lymphoma (DLBCL) in the bypassed stomach after obesity surgery.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Impact of rituximab and IPI on survival in diffuse large B cell lymphoma patients treated at a tertiary level cancer centre in Pakistan: a single-centre experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2015 |
Incidentally discovered diffuse large B-cell lymphoma limited to the endocervical mucosa in a young female patient.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2015 |
Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
Increased levels of tumor necrosis factor-α involved in rituximab-related acute pulmonary fibrosis in diffuse large B-cell lymphoma.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2015 |
Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2015 |
A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Topics: Aneuploidy; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineoplastic Combined Chem | 2015 |
Primary mediastinal (thymic) B-cell lymphoma presenting as cutaneous vasculitis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2015 |
[Clinical and Pathological Analysis of 9 Patients with Primary Breast Diffuse Large B-cell Lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2015 |
Diffuse large B-cell lymphoma causing acute liver failure: a rare case of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2015 |
PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2016 |
The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lympho | 2015 |
Rare cause of a common symptom: primary cardiac lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2015 |
[A case of primary testicular diffuse large B-cell lymphoma with a p53 gene point mutation].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Topics: Adolescent; Adult; Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Case Study: Diffuse Large B-Cell Lymphoma Arising in Ovarian Mature Cystic Teratoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Append | 2015 |
Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
[A case of neurolymphomatosis presenting extended involvement of spinal nerve roots].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cerebrospina | 2015 |
Case 3: Hepatosplenomegaly in a 2-year-old Boy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Child, Presc | 2015 |
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2016 |
Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2016 |
Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2015 |
Diffuse systemic large B-cell lymphoma with secondary skin involvement.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; | 2015 |
Intravascular Large B-Cell Lymphoma Complicated by Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that was Successfully Treated with Rituximab-Containing Chemotherapy.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2015 |
Case Report Diffuse large B-cell lymphoma in the primary bone marrow.
Topics: Bone Marrow; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Ag | 2015 |
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 2015 |
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Diffuse large B cell lymphoma of the cranial vault: two case reports.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2015 |
A Demyelinating Disease; What Lies Beneath?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Child, Pres | 2016 |
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; Doxoru | 2015 |
Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2016 |
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 2015 |
Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome A | 2016 |
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2016 |
Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2015 |
The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 2015 |
Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2016 |
Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
[A Case of Neurally Mediated Syncope Caused by Cervical Malignant Lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Head an | 2015 |
Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine | 2015 |
Tenofovir-induced severe hepatitis in occult hepatitis B reactivation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Ag | 2015 |
Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combi | 2015 |
Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma--De Novo Occurrence or Transformation.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Biop | 2015 |
Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Bilateral psoas muscle lymphoma: an unusual presentation of EBV-positive diffuse large B-cell lymphoma of the elderly.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2015 |
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2016 |
Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2015 |
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2015 |
LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2017 |
[The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, Differentiation, B | 2016 |
Genetics and diffuse large B-Cell lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; Gene Expression Regulati | 2015 |
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Gene Re | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2016 |
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Ant | 2016 |
High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Diagnosis of Giant Cell Arteritis in an Asymptomatic Patient.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Asymptomatic Diseases; Cyclo | 2016 |
[Gastric cytomegalovirus infection in a patient with non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytomegalovirus | 2015 |
Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Primary Cardiac Lymphoma in an Immunocompetent 71-Year-Old Man.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2015 |
HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2016 |
Complete resolution of autoimmune thyroiditis after R-CHOP in a patient with thyroid lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2015 |
[Expression of CD68, cyclin D1 and rearrangement of bcl-6 gene are adverse prognostic factors in diffuse large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ant | 2015 |
Primary Pancreatic Malignant Lymphoma Diagnosed from Endoscopic Ultrasound-guided Fine-needle Aspiration Findings.
Topics: Abdominal Pain; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Primary Cardiac Lymphoma: Diagnosis and the Impact of Chemotherapy on Cardiac Structure and Function.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, | 2016 |
The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2016 |
[A Case of MALT Lymphoma of the Rectum Treated with Intersphincteric Resection (ISR)].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2015 |
miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Do | 2015 |
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2016 |
Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2016 |
High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymp | 2016 |
Unilateral uveitis masquerade syndrome caused by diffuse large B-cell lymphoma diagnosed using multiparametric flow cytometry of the aqueous humor.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Aqueous Humor; B-Lymphocytes; Biomarke | 2017 |
Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2016 |
Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2016 |
Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabin | 2016 |
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studi | 2016 |
Histological improvement in salivary gland along with effector memory Th17-1 cell reduction in a primary Sjogren's syndrome patient with dermatomyositis and diffuse large B-cell lymphoma by R-CHOP therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Prolife | 2016 |
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2016 |
Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Radiation Therapy for Diffuse Large B-Cell Lymphoma: Indications, Outcomes, and Controversies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubici | 2016 |
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, | 2016 |
Polymyositis following autologous haematopoietic stem cell transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
A Surgical Case of Primary Splenic Malignant Lymphoma Complicating Chronic Hepatitis C.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2016 |
Primary Uterine Cervical Lymphoma Manifesting as Menolipsis Staged and Followed Up by FDG PET/CT.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2016 |
Disseminated Lymphoma Evolving into Neurolymphomatosis during Mid-cycle of Chemotherapy Detected by (18)F-FDG PET/CT.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2015 |
[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Primary Mediastinal Large B-Cell Lymphoma As an Incidental Finding: Report of a Case.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2018 |
Presentation of Diffuse Large B-Cell Lymphoma Relapse as a Penile Mass.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.
Topics: Alleles; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; bcl | 2017 |
Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2016 |
Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Primary thyroid lymphoma presenting as dermatomyositis: a first case and review of the literature.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Early change in left atrial function in patients treated with anthracyclines assessed by real-time three-dimensional echocardiography.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com | 2016 |
Thrombocytopenia and fever: not just another infection….
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2016 |
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2016 |
Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; An | 2016 |
A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; | 2016 |
Guidelines for the management of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; China; Coho | 2016 |
Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2016 |
CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antigens, CD | 2016 |
Clinical case report: a rare cause of acute kidney failure - tissue is the issue.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Murine-Derived | 2017 |
Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.
Topics: Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Positron Emission Tomography Computed Tom | 2016 |
Development tuberculous meningitis during chemotherapy for CD5-positive diffuse large B-cell lymphoma.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2016 |
Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2017 |
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
[Rituximab plus Autologous Hemotopoietic Stem Cell Transplantation for The Treatment of CD5 Positive Diffuse Large B Cell Lymphoma with Autoimmune Hemolytic Anemia].
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2016 |
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hospitalization | 2016 |
Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; | 2016 |
Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2016 |
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
Topics: Abdominal Fat; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr | 2016 |
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Glycogen S | 2016 |
Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cent | 2017 |
Endobronchial High-Grade Non-Hodgkin's Lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bronch | 2016 |
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydr | 2016 |
R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cyclopho | 2016 |
BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dog Di | 2017 |
Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
[REACTIVATION OF TUBERCULOSIS PRESENTING WITH EMPYEMA DUE TO ANTICANCER CHEMOTHERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antitu | 2016 |
[Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2016 |
25 Years Old Women With Inflammatory Low Back Pain.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2016 |
Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2016 |
Primary cranial vault lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2018 |
Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2016 |
Detection of the value of consecutive serum total light chain (sTLC) in patients diagnosed with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central | 2016 |
Intravascular large B-cell lymphoma associated with silicone breast implant, HLA-DRB1*11:01, and HLA-DQB1*03:01 manifesting as macrophage activation syndrome and with severe neurological symptoms: a case report.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Impla | 2016 |
Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2016 |
Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2017 |
[Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
CD4
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemother | 2016 |
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2016 |
[Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Ce | 2017 |
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2017 |
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2016 |
Treatment-responsive Diffuse Pancreatic Swelling: Seems Similar, Yet Is It?
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2016 |
CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Combined Modali | 2017 |
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
[Analysis of Clinical Feature and Treatment Outcome of Patients with Renal Diffuse Large B Cell Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2016 |
Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2017 |
Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
[A Giant Malignant Lymphoma of the Ileocecum Treated with Laparoscopic Surgery].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2016 |
Non-Hodgkin's lymphoma involving a femur bone and bilateral adrenal glands alone with adrenal insufficiency.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Topics: Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide | 2017 |
Genetic polymorphism at
Topics: Alleles; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyc | 2017 |
Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
A case report of a renal diffuse B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2017 |
Sequential development of peripheral t-cell lymphoma post immunochemotherapy of diffuse large B cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Cytarabine; Epstein-Barr Vi | 2017 |
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2017 |
Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2017 |
Primary B cell lymphoma of the tongue base: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Humans; Lymphoma | 2016 |
Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murin | 2008 |
Inappropriate antidiuretic hormone production in diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2008 |
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2008 |
Successful autologous peripheral blood stem cell transplantation for a patient with primary adrenal lymphoma with hemophagocytic syndrome.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Diffuse large B-cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2008 |
My turn.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Cyclophosphamide; Doxor | 2008 |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Muri | 2008 |
Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Topics: Adult; Anaplastic Lymphoma Kinase; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2009 |
[Prognosis of primary non-Hodgkin's lymphoma of the breast].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bre | 2008 |
[Treatment of diffuse large B-cell lymphosarcoma with involvement of bone marrow in an old female patient].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cyclophospha | 2008 |
[Intensive chemotherapy of diffuse large B-cell lymphosarcoma in a female patient with chronic renal failure and afunctional left kidney].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Daunorubicin; Diagnosis, Differential; | 2008 |
Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2008 |
[Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2008 |
A male with primary breast lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2009 |
[Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2008 |
Neutropenic fever following chemotherapy in a patient with lymphoma.
Topics: Aged; Antibiotic Prophylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antine | 2008 |
Primary non-Hodgkin's lymphoma of the gallbladder diagnosed by laparoscopic cholecystectomy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Thyroid diffuse large B cell lymphoma (DLBCL) following thyroid medullary cancer: long-term complete remission with R-CHOP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Cyclophosphamide; Doxorubicin; | 2009 |
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antigens, CD20 | 2009 |
ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Stromal gene signatures in large-B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Microenvironmental protection in diffuse large-B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Renal vein lymphoma embolism in non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2009 |
Therapeutic vignette: old and new drugs in mixed connective tissue disease.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Comorbidity; Disease Progression; Drug Therapy, Combin | 2008 |
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Successful combined treatment of primary cardiac malignant lymphoma with urgent cardiac operation and chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
[Cutaneous presentation of plasmablastic lymphoma in a patient with HIV Infection].
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophospha | 2008 |
[The value of radiotherapy in the treatment of aggressive and localised gastric lymphomas].
Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosph | 2009 |
Hepatic rosai-dorfman disease with coincidental lymphoma: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Histioc | 2010 |
Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic C | 2009 |
Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
[Primary hepatic lymphoma - favorable outcome with chemotherapy plus rituximab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2008 |
Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.
Topics: Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; | 2009 |
Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Hematology: germinal center or nongerminal center DLBCL?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center; Huma | 2009 |
Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cervix Uteri; Cyclophospham | 2009 |
Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug The | 2009 |
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
B-cell lymphoma of the female breast: comparison of mammography, ultrasound and dynamic MRI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast; Breast Neoplasms; Cycl | 2010 |
CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Primary non-Hodgkin's lymphoma of rectum presenting with rectal prolapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Colonic Polyps; Combi | 2009 |
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Antineopl | 2009 |
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antineoplas | 2009 |
Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comparative Genomic Hybridization; Cycl | 2009 |
A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
Molecular outcome prediction in diffuse large-B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gene Expression; Huma | 2009 |
Primary cutaneous diffuse large B-cell lymphoma, leg type, with features simulating POEMS syndrome.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2010 |
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy | 2009 |
A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2010 |
Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antigens, CD20; Antineoplast | 2009 |
Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Murin | 2010 |
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2010 |
Primary diffuse large B-cell lymphoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 2009 |
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2009 |
Intrathecal MTX for DLBCL: from an inappropriate prophylactic tradition to a medical error?
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Disea | 2009 |
Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Diffuse involvement of the heart and great vessels in primary cardiac lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2010 |
Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma: effect of prior corticosteroid therapy.
Topics: Aged; Female; Histiocytes; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; S | 2009 |
Improved survival for patients with large B-cell lymphoma after introduction of rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Therapy of diffuse large B-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2009 |
[Intravascular large B-cell lymphoma: report of a case].
Topics: Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2009 |
Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2010 |
[Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2009 |
Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Monotherapy with anti-CD20 monoclonal antibody in a heart transplant recipient with sick sinus syndrome and posttransplantation lymphoproliferative disorder: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2009 |
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2010 |
[Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Cyclophosphamide; | 2010 |
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2009 |
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2010 |
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly | 2009 |
Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclo | 2010 |
Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T | 2010 |
Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclo | 2010 |
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2010 |
[Management of lymphoma with respect to pathologic classification: updates and controversies].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineopl | 2009 |
Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.
Topics: Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; A | 2010 |
Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Dox | 2010 |
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chi-Square Distribution; Cyclophosphamid | 2010 |
Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2010 |
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Retroperitoneal diffuse large B-cell lymphoma presenting as pseudoachalasia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Central nervous system involvement in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Monotypic epithelioid angiomyolipoma of the liver with TFE3 expression.
Topics: Adult; Angiomyolipoma; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucin | 2010 |
High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
[Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2010 |
Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2010 |
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Hodgkin's lymphoma variant of Richter's syndrome.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2010 |
[A rare thyroid tumor].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2010 |
Periorbital non-Hodgkin's lymphoma after blunt trauma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Bilateral primary adrenal lymphoma.
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2010 |
Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
[Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine- | 2010 |
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2010 |
Management of stage one and two-E gastric large B-cell lymphoma: chemotherapy alone or surgery followed by chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2010 |
[A case of primary hepato-biliary malignant lymphoma effectively treated with R-CHOP chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2010 |
[Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases].
Topics: Adult; Aged; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 2010 |
Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2010 |
How I treat elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Comb | 2010 |
Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothe | 2010 |
PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2010 |
Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2010 |
Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2010 |
CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Ki-1 An | 2010 |
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2010 |
Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2010 |
Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Antibodies, Monoclonal, Murine-Derived; Antineoplast | 2010 |
[Epstein-Barr virus-positive diffuse large B-cell lymphoma following peripheral T-cell lymphoma, not otherwise specified: report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Vi | 2010 |
[Richter syndrome: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2010 |
[Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2010 |
Conjunctival lymphoma in a child.
Topics: Adolescent; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Conju | 2011 |
Relevance of the International Prognostic Index in the rituximab era.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2011 |
[Clinical analysis of primary gastric diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Murine-Derived; Antine | 2010 |
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Artificial Int | 2011 |
Testicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2010 |
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ant | 2011 |
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Primary bone marrow diffuse large B cell lymphoma: a case series and review.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2011 |
Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CASP8 and | 2011 |
CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Richter's transformation of chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2011 |
Patient with high-grade fever, night sweats, and hepatosplenomegaly.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2011 |
Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphami | 2011 |
Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2010 |
Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com | 2011 |
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Treatment of a patient with adnexal lymphoma with Rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2011 |
Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
Topics: 14-3-3 Proteins; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug | 2011 |
Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomedical R | 2011 |
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Topics: Alkyl and Aryl Transferases; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineop | 2011 |
The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2012 |
[A case of synchronous double primary cancer of gastric adenocarcinoma and diffuse large B cell lymphoma].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2011 |
[Primary hepatic lymphoma: an infrequent cause of focal hepatic lesion].
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cyclophosphamide; Fatal Outcome; Female; | 2010 |
Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Integrated profiling of diffuse large B-cell lymphoma with 7q gain.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromo | 2011 |
[Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antineoplastic Combined Chemotherapy Pro | 2011 |
NMR metabolic and physiological markers of therapeutic response.
Topics: Aged; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Hope for very elderly patients with diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Comparative | 2011 |
High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2011 |
MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cluster | 2011 |
Primary colonic lymphoma: an analysis of 74 cases with localized large-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Pretreatment serum level of 15-kDa granulysin might have a prognostic value in patients with diffuse large B cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agen | 2011 |
Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antine | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Mono | 2011 |
Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Pro | 2011 |
[Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antineoplastic | 2011 |
[Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2011 |
Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Pe | 2011 |
Diffuse large B-cell lymphoma complicated with autoimmune thrombocytopenia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphamide; Doxorubicin; Female; | 2011 |
Primary bilateral adrenal lymphoma revealed by hemophagocytic syndrome.
Topics: Adrenal Gland Neoplasms; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2011 |
Splenic gas as a result of a non-Hodgkin's lymphoma in a patient with common variable immunodeficiency.
Topics: Abdominal Abscess; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemothera | 2011 |
Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
The unexpected evolution of a case of diffuse large B-cell non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Fatal Outcome | 2011 |
FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2011 |
Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
[Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2011 |
Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous Syste | 2011 |
EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2011 |
The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2011 |
Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined | 2011 |
Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclo | 2012 |
Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
[Definitive diagnosis of intravascular large B-cell lymphoma by random skin biopsy].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2011 |
[A case of gastric stenosis due to primary gastric malignant lymphoma during administration of R-CHOP].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2011 |
Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2012 |
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Bilateral primary adrenal lymphoma accompanying hypertension.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2012 |
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplast | 2011 |
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2011 |
[Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2011 |
Rituximab in DLBCL: 6 years on.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2011 |
Intravascular large B-cell lymphoma of the kidney: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2011 |
Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosph | 2012 |
Diagnosis of a primary cardiac B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2012 |
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2012 |
Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2012 |
Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy P | 2011 |
Intravascular B-cell lymphoma with hypercalcemia as the initial presentation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Hyperca | 2011 |
Clinical pathological conference: a non-Hodgkin's lymphoma patient with persistent anaemia after chemotherapy.
Topics: Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubici | 2011 |
Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Su | 2011 |
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Comorb | 2012 |
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Intensified chemotherapy for diffuse large B-cell lymphomas.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2011 |
Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2011 |
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Primary thyroid lymphoma: a rare thyroid malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cyclophosphamide; Doxorubicin; | 2011 |
[ALK-positive large B-cell lymphoma: report of a case].
Topics: Adult; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
Topics: Aged; Aged, 80 and over; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; CD79 Antige | 2011 |
The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Intravascular large B-cell lymphoma diagnosed by FDG-PET/CT and endometrial biopsy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; | 2011 |
Leukocytoclastic vasculitis as early manifestation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2012 |
Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Comb | 2012 |
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2012 |
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Fatal renal failure due to self administration of Aristolochia Longa after treatment with chemotherapy.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Aristolochia; Cyclophosphamide; | 2012 |
Primary adrenal non-Hodgkin's lymphoma: report of two cases.
Topics: Adrenal Gland Neoplasms; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2011 |
My treatment approach to patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cen | 2012 |
Elevated soluble CD 27 levels (TNF-receptor) may predict survival in diffuse large B-cell lymphoma--revisiting "the super- family " saga.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
[The age factor in bilateral hydrocele diagnosis secondary to a primitive testis lymphoma: case report, diagnosis and therapy].
Topics: Age of Onset; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Che | 2012 |
Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
[Vocal cord paralysis secondary to vincristine].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2012 |
Low-grade systemic lymphoma with aggressive transformation in the lacrimal sac.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Transfo | 2012 |
Chemo-immunotherapy dosing in older patients with diffuse large B-cell lymphoma: is this how we should treat our parents?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Relapsed diffuse large B-cell lymphoma--10 years later.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Cyclophosphamide; | 2011 |
High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Diffuse large cell non-Hodgkin lymphoma with pituitary and bilateral adrenal involvement.
Topics: Adrenal Glands; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethason | 2012 |
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortiu
Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplast | 2012 |
A rapidly growing lung mass with air crescent formation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2012 |
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined C | 2013 |
Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Reversible, complete atrioventricular block caused by primary cardiac lymphoma in a nonimmunocompromised patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Cyclophosphamide; Diagnosis, | 2012 |
A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstei
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Epst | 2012 |
[A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Birdshot retinochoroidopathy masquerading as intraocular lymphoma.
Topics: Adult; Antigens, CD19; Antigens, CD20; Birdshot Chorioretinopathy; Central Nervous System Neoplasms; | 2012 |
Right upper quadrant pain and mass in a 41-year-old previously healthy man: a presenting feature of HIV-associated extranodal diffuse large B cell lymphoma with cardiac involvement.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2012 |
A rare entity of primary extranodal diffuse large B cell lymphoma of the lower limb calf in an HIV-infected young adult on highly active antiretroviral therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2012 |
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2012 |
Primary bone lymphoma involving bilateral tibia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; | 2012 |
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2012 |
Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-B | 2012 |
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Pe | 2012 |
Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2012 |
The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2012 |
Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplast | 2012 |
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
Topics: Academic Medical Centers; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplas | 2012 |
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 2012 |
[Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2012 |
[Clinical characterization of 61 cases of diffuse large B-cell lymphoma with different prognosis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; | 2012 |
[Clinicopathological and molecular genetic characteristics of childhood diffuse large B cell lymphoma].
Topics: Adolescent; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; | 2012 |
[CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma].
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
[Gastric malignant lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2012 |
Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy.
Topics: Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cyclophosphamide | 2012 |
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Topics: 12E7 Antigen; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; | 2012 |
[Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
Topics: Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2012 |
Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2012 |
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit | 2012 |
Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2012 |
Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Antineoplastic Combine | 2012 |
Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2012 |
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cycl | 2013 |
Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Double-hit diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2012 |
An unusual endoscopic finding in a patient with melena: multiple gastric ulcers of regular shape.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2013 |
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Topics: Adult; Aged; Alleles; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2012 |
Three prognostic factors influence clinical outcomes of primary testicular lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Multifocal cranial plasmablastic lymphoma as a rare manifestation of posttransplant lymphoproliferative disorder.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Facial | 2012 |
Recurrent endobronchial diffuse large B-cell lymphoma. Diagnosed by cryoprobe.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2013 |
Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2014 |
Synchronous, primary, diffuse, large B-cell lymphomas involving the ethmoid sinus and epiglottis: a rare clinical entity.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2013 |
Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; | 2012 |
The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
[Primary bone lymphoma with multicentric involvement].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2012 |
[Initial treatment of diffuse large B-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2012 |
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
TP53 mutations and rituximab-CHOP.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2012 |
Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combin | 2012 |
Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
[Clinicopathologic study of 20 cases of anaplastic large-cell lymphoma].
Topics: Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cycl | 2013 |
Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2013 |
A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
An 82-year-old woman with left upper lobe atelectasis. Diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2012 |
Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
68-year-old man with neutropenic fever and upper extremity hematoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherap | 2012 |
High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Prognostic factors of primary gastric diffuse large B cell lymphoma: a retrospective study of 75 cases in China.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2013 |
MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Doxorubicin; Dru | 2013 |
BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleom | 2013 |
Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2012 |
[Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protoco | 2012 |
[Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorimetry; Cyclophosphamide; DNA, Neoplasm; Doxoru | 2013 |
Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2013 |
Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2013 |
Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2002 |
[Seven patients with stage I and II primary testicular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2002 |
Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cecal Neoplasms; Chemotherapy, Adjuvant; | 2002 |
Primary mediastinal large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2002 |
Diffuse large B-cell lymphoma with fibrillary matrix.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin; | 2002 |
CD5+ T-cell/histiocyte-rich large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD5 Antigens; Clone Cells; Cyclophosphamide; Disease | 2002 |
[A case of primary malignant lymphoma of the pararectal space].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospham | 2002 |
Unusual sites of involvement in non-Hodgkin's lymphoma: Case 2. Isolated meningeal anaplastic large-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2002 |
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2003 |
Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Chemotherap | 2002 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmusti | 2003 |
Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2003 |
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2003 |
Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac | 2003 |
Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
Primary non-Hodgkin's lymphoma of the uterine cervix successfully treated by neoadjuvant chemotherapy: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Hyste | 2003 |
[Primary non-Hodgkin lymphoma of the mandible: apropos of three cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Humans; | 2003 |
ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2003 |
Sarcomatoid variant of B-cell lymphoma of the uterine cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Female | 2003 |
Richter's syndrome: a novel presentation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 2003 |
[A further possible indication for use of prednisone: several mesenchymal neoplasms].
Topics: Child; Humans; Infant; Leukemia; Leukemia, Myeloid; Liver; Liver Neoplasms; Lymphoma, Large B-Cell, | 1955 |
[Reticulosarcoma of the scapula; treatment with delta cortisone].
Topics: Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Prednisone; Sarcoma; Scap | 1957 |
[Massive dosage of prednisone in lymphogranuloma, lymphosarcoma and reticulum cell sarcoma].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | 1957 |
Cutaneous lymphoblastoma: a case of reticulum cell sarcoma with prominent skin manifestations and a brief but dramatic remission with prednisone therapy.
Topics: Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Medical Records; Neoplasms; Predniso | 1958 |
[A case of reticulosarcoma treated with large doses of prednisone].
Topics: Cell- and Tissue-Based Therapy; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neop | 1959 |
[The use of Degranol pills in hemoblastosis and other neoplastic diseases].
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphogranuloma Venereum; Lymphoma; Lymphoma, Large B-Cell, Di | 1963 |
[EXPERIENCES IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. (I)].
Topics: Antineoplastic Agents; Cortisone; Hodgkin Disease; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Lar | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
[THE RETICULO-ENDOTHELIAL SYSTEM AND LYMPHOSARCOMAS].
Topics: Adolescent; Adrenal Cortex Hormones; Geriatrics; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follic | 1964 |
RETICULUM CELL SARCOMA OF THE SMALL BOWEL AND STEATORRHOEA.
Topics: Ascorbic Acid; Blood Transfusion; Body Weight; Bone Marrow Examination; Celiac Disease; Diet; Diet T | 1964 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2003. A 44-year-old man with HIV infection and a right atrial mass.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2003 |
Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2003 |
Acute myelofibrosis in a patient with diffuse large cell non Hodgkin's lymphoma and renal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Chromosome Aberr | 2003 |
Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2003 |
Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; | 2003 |
Large B cell lymphoma with cardiac infiltration.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Echocardiograp | 2003 |
Hemophagocytic syndrome in ileum-origin B-cell lymphoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Extensive xanthelasma associated with anaplastic large cell lymphoma and hyperimmunoglobulin E syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Cyclophosphamide; Diagnosis, Dif | 2003 |
Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2003 |
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2004 |
Indications for peripheral light-chain revision and somatic hypermutation without a functional B-cell receptor in precursors of a composite diffuse large B-cell and Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Clone Cells; Cyclophosphamide; | 2004 |
Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cyclophosphami | 2003 |
[Non-Hodgkin lymphoma of the infratemporalis fossa: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cranial Fossa, Middle; | 2003 |
[Primary malignant lymphoma of the urinary bladder: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2004 |
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Do | 2004 |
Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biopsy; Bone Marrow; Bone Marrow Cell | 2004 |
Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis.
Topics: Adult; Biopsy; Complementarity Determining Regions; Cyclophosphamide; Diagnosis, Differential; Disea | 2004 |
Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 1. Demonstration of CNS lymphoma by positron emission tomography scan affects management.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2004 |
[Primary central nervous system lymphoma: a report of 28 patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2004 |
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2004 |
[A pregnant woman with autoimmune thyroiditis and recurrent goiter].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Combined Modality Therapy; Cy | 2004 |
Diffuse large B-cell lymphoma presenting as a sacral tumor. Report of two cases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
Fulminant intravascular lymphoma presenting as fever of unknown origin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Cyclophosphamide; Doxorubicin; Fever of U | 2004 |
Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2004 |
Disseminated plasmablastic lymphoma.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Acti | 2004 |
Primary non-Hodgkin's lymphoma of the bone: a single institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 2004 |
FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
[Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2004 |
Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2004 |
Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
Topics: Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2005 |
Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamid | 2004 |
[Clinicopathologic features of primary thyroid lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2005 |
Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Caspase 3; Caspas | 2005 |
Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2005 |
Primary mediastinal large B-cell lymphoma in an HIV-infected patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; | 2005 |
[Primary lymphoma of the thyroid: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Hum | 2004 |
Cervical adult rhabdomyoma presenting as a rapidly growing mass in a patient with diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Diagnosis | 2005 |
[Spindle cell variants of diffuse large B cell lymphoma: report of 2 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cyclophosphamide; Diagnosi | 2005 |
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alky | 2005 |
Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy | 2005 |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Diagnos | 2005 |
Large solitary splenic diffuse large B cell lymphoma in a hepatitis C virus-infected patient.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Biopsy; Cyclophosphamide; Doxor | 2005 |
The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2005 |
[Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2005 |
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Primary lacrimal sac non-Hodgkin's lymphoma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Doxorubicin; Et | 2005 |
Large B-cell non-Hodgkin's lymphoma presenting as a laryngeal cyst.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
[A CHOP-21 course efficacy in therapy of diffuse large B-cell lymphosarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; D | 2005 |
Pneumomediastinum as a complication to treatment of mediastinal (thymic) large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; | 2005 |
Non-Hodgkin's lymphoma and acquired immune deficiency syndrome (AIDS). A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Facial Neoplasms; Fat | 2005 |
The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2006 |
[Efficacy of different chemotherapy programs, indications for surgery and radiotherapy in primary mediastinal B-cell lymphosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 2005 |
An aggressive extranodal NK-cell lymphoma arising from indolent NK-cell lymphoproliferative disorder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorub | 2005 |
Role of radiation therapy in a patient with primary pancreatic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2005 |
Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; British C | 2006 |
Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2005 |
Large B-cell non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2005 |
[Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; A | 2005 |
Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2006 |
[Diffuse large B-cell lymphoma expressing surface immunoglobulin heavy chain (Ig alpha) and lacking light chains].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Immun | 2005 |
Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cyclophosphamide; Disease Prog | 2006 |
Abnormal positron emission tomography (PET) scan secondary to the use of hematopoietic growth factors.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2005 |
Ocular involvement as first sign of isolated CNS relapse in diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Doxorubicin; Eye | 2006 |
Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Doxorubi | 2006 |
[Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 2006 |
[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineo | 2006 |
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2006 |
Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
[Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow | 2006 |
Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA-Binding Pr | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxor | 2006 |
A case of non-Hodgkin's lymphoma and invasive thymoma treated with R-CHOP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C | 2006 |
Diagnosis of a primary testicular lymphoma by echography and magnetic resonance imaging.
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, | 2006 |
Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease.
Topics: Adult; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Colitis, Ulcerative; C | 2006 |
A paraumbilical lymphomatous mass.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxoru | 2006 |
[Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cyclophosphamide | 2006 |
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Results of CHOP chemotherapy for diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dise | 2006 |
[De novo CD5-positive diffuse large B-cell lymphoma associated with autoimmune hemolytic anemia presenting as erythroid hypoplasia].
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antin | 2006 |
A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 2007 |
Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2007 |
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2006 |
Long standing priapism as presentation of lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C | 2007 |
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2007 |
[Intravascular lymphoma causing acute abdomen].
Topics: Abdomen, Acute; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyc | 2007 |
[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2006 |
Rapid bone marrow dissemination after surgery in localized gastric diffuse large B-cell lymphoma: a case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2006 |
Primary endobronchial anaplastic large cell lymphoma in a pediatric patient.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antin | 2006 |
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
Epitrochlear lymph node: an unusual physical finding in lymphoma with important clinical significance.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 2006 |
[A case of intravascular lymphomatosis with no abnormal findings on chest computed tomography and with diffuse pulmonary uptake of 67Ga on scintigraphy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carbon Monoxide; Cyclophosphamide; Doxorubic | 2006 |
Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
Primary large B-cell lymphoma of the bone marrow.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic | 2007 |
Therapy for older patients with diffuse large cell lymphoma: targeting the treatment to the patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Surv | 2007 |
Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
Aggressive lymphoma involving intracranial epidural region.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2007 |
Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamide | 2007 |
Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; A | 2007 |
Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
[A case report of composite lymphoma].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 2007 |
Tumor lysis syndrome.
Topics: Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dehydration; Do | 2007 |
Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antimetabolites, Antineoplastic | 2007 |
[The standard treatments for patients with hematological malignancies in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Primary renal lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Urea Nitrogen; Creatine; Cyc | 2007 |
Prognostic factors in primary gastric lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2007 |
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2007 |
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2007 |
Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cycl | 2007 |
Primary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids.
Topics: Administration, Oral; Fluorescein Angiography; Glucocorticoids; Humans; Lymphoma, B-Cell; Lymphoma, | 2007 |
Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2007 |
[Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2007 |
[Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 2007 |
Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Case records of the Massachusetts General Hospital. Case 26-2007 - a 61-year-old man with recurrent fevers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2007 |
Primary cardiac lymphoma: clinical, histologic, immunophenotypic, and genotypic features of 5 cases of a rare disorder.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnos | 2007 |
Echocardiographic findings of intracardiac mass.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
[Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases].
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2007 |
R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined M | 2007 |
Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Topics: Abdominal Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2008 |
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 2008 |
[Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cote d'Ivoire; C | 2007 |
[Prognostic factors of invasive non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2007 |
Can stem blood cell transplantation be an adjuvant treatment for primary cardiac lymphoma?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Mesangiolytic glomerulopathy after radiotherapy and chemotherapy of gastric lymphoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 2007 |
In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2007 |
Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma--a single-center, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Primary cardiac lymphoma: utility of multimodality imaging in diagnosis and management.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Ant | 2007 |
Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Topics: Adolescent; Adult; Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monocl | 2008 |
[Primary diffuse large B-cell non-Hodgkin's lymphoma of the small intestine: clinicopathologic features, management, and prognosis in 24 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2007 |
Long-term administration of a low-molecular-weight heparin contributed to successful treatment in a patient with primary mediastinal large B-cell lymphoma and venous thromboembolism.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
Relationship between the response to treatment and the prognosis of patients with aggressive lymphomas treated with chemotherapy followed by involved-field radiotherapy: radiographic assessment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2008 |
Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lympho | 2008 |
Cutaneous plasmablastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposid | 2008 |
An unusual cause of postmenopausal bleeding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Diagnosis, Differential; D | 2008 |
Influence of rituximab-CHOP therapy on clinical course and autoimmune parameters in rheumatoid arthritis associated with diffuse large B cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Lymphomatous pericardial effusion positive for Mycobacterium tuberculosis by PCR analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Cyclophosphamide; Doxorubicin | 2008 |
Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineo | 2008 |
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Adverse prognosis of bulky disease in good-risk DLBCL.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimet | 2009 |
Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass--a diagnostic dilemma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2008 |
Successful treatment of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy and FDG-PET scan.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2008 |
[Malignant lymphoma of the prostate--diagnosis on the second biopsy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Humans; Lymph | 2008 |
Cyclin D1-positive diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2008 |
Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2008 |
Intravascular B-cell lymphoma: the role of skin biopsy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic C | 2008 |
Cutaneous polyarteritis nodosa. Report of a case associated with Crohn's disease.
Topics: Antigen-Antibody Complex; Complement C3; Crohn Disease; Cyclophosphamide; Humans; Lymphoma, Large B- | 1983 |
[Preliminary therapeutic results of treatment of non-Hodgkin lymphoma in children according to the BACOP program].
Topics: Adolescent; Bleomycin; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Dru | 1980 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclo | 1982 |
Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclo | 1983 |
[Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1983 |
A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1984 |
Potassium-wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome.
Topics: Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Bartter Syndrome; Bleomycin; Cyclophosp | 1984 |
Chemotherapy-induced transverse white lines in the fingernails.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Human | 1983 |
The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1983 |
APO therapy for malignant lymphoma of large cell "histiocytic" type of childhood: analysis of treatment results for 29 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubi | 1984 |
Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1984 |
Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1982 |
The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group.
Topics: Adolescent; Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Large B-Cel | 1982 |
The treatment of histiocytic lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Humans; Leucovorin; Leukopenia; Ly | 1980 |
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Erythrocytes; Hodgkin Disease; Humans | 1980 |
Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1980 |
Hypophosphatemia in a patient with lymphoma in leukemic phase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Drug Therapy, Combination; Extracellular Sp | 1981 |
Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Histiocytes; | 1982 |
The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosp | 1994 |
Long-term results with MACOP-B in the treatment of aggressive non-Hodgkin's lymphomas. The experience in Brazil.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1994 |
Impact of radiation dose and tumor size on large cell lymphoma patients in complete response after integrated CHOP-Bleo-radiation treatment protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1995 |
Reply to editorial by Dr. Earle.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Combined Modality Ther | 1995 |
The management of primary mediastinal B-cell lymphoma with sclerosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 1994 |
Pseudoleukemia after granulocyte colony-stimulating factor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposid | 1995 |
[Long term remission following relapsed CNS lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Cyclophosphamide; Doxoru | 1995 |
Rapid development of disseminated superficial porokeratosis after transplant induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 1995 |
Is there a role for MACOP-B in the treatment of diffuse large cell lymphoma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
Successful treatment of non-Hodgkin's lymphoma in a patient with common variable immunodeficiency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Common Variable Immunodeficiency; | 1993 |
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality The | 1993 |
[Recombinant G-CSF and the interstitial pneumonia during MACOP-B therapy in two cases of non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Granulocyt | 1993 |
COP-BLAM multidrug infusion chemotherapies for lymphoma: results in a community hospital setting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1993 |
Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
Bilateral hard palate masses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Diagnosis, | 1993 |
[COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1993 |
Primary small bowel lymphoma manifested as obstructive jaundice in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cholangio | 1995 |
Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; | 1995 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyt | 1994 |
Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chil | 1994 |
Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Cyclophos | 1994 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cis | 1993 |
Multiagent chemotherapy in the salvage cure of ocular lymphoma relapsing after radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Eye Neopl | 1993 |
[Primary gastric lymphoma in an HIV positive patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gastroscopy; H | 1995 |
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relatio | 1995 |
[Primary malignant lymphoma of the adrenal gland: a case report].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Combin | 1995 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati | 1996 |
Complete atrioventricular block due to large cell lymphoma: resolution with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Node; Combined Modality Therapy; Cy | 1996 |
Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosome | 1996 |
[Spinal cord compression as the presenting form of non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1995 |
Orbital tumor in a child with posttransplantation lymphoproliferative disorder.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Doxoru | 1996 |
Tracheoesophageal fistula developing during chemotherapy for non-Hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Large B-C | 1996 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 1997 |
CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 1997 |
Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cyclophosphamid | 1997 |
Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Movement; Colony | 1996 |
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cyta | 1997 |
Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1997 |
"Primary lymphoma of the liver".
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Diagno | 1998 |
[Interstitial pneumonia in patients treated with VACOP-B therapy for malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1998 |
Angiotropic large cell lymphoma which infiltrated to the adrenal glands presenting as reversible adrenal insufficiency.
Topics: Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Antineoplastic Combined Chemotherapy Protocols | 1998 |
[Primary cardiac non-Hodgkin's lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Heart Neoplasms; Humans; Lym | 1998 |
[Thyroid lymphoma: a not so unusual disease].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1998 |
Primary testicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow Cells; Chemotherapy, Adj | 1998 |
Tetraploidy in acute myeloid leukemia secondary to large cell lymphoma.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Chromosome Aberra | 1998 |
[Sick sinus syndrome after chemotherapy for malignant lymphoma with right atrial tumor at initial presentation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gallium Radioisotopes | 1998 |
Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Cyclophosphamide; Doxo | 1999 |
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Fr | 1999 |
Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclopho | 1999 |
Beta-HCG aberrant expression in primary mediastinal large B-cell lymphoma.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Nucleus; Chorio | 1999 |
[Localized Castleman's disease associated with high-grade lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Castleman Disease; Cyclophosphamide; D | 1999 |
HIV-associated lymphoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclophosphamide; Doxorubicin; | 1999 |
Intravascular lymphomatosis presenting as an ascending cauda equina: conus medullaris syndrome: remission after biweekly CHOP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cauda Equina; Cyclophosphamide; Doxorubicin; Humans; | 1999 |
[Primary hepatic non-Hodgkin's lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 1999 |
[Lymphoma of the mandible: presentation of 2 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fema | 1999 |
[Pyothorax associated lymphoma treated by chemotherapy after thoracostomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1999 |
Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Bacterial Agents; Antineoplastic Combined Chemother | 1999 |
Diffuse large-cell lymphoma of the testis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 1999 |
Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy | 1999 |
Destructive midline palatal lesion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2000 |
Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow Tra | 2000 |
Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma?
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2000 |
Diagnosis and treatment of intravascular lymphomatosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Diagnosis, | 2000 |
Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female | 2000 |
Pathologic quiz case: progressive diffuse weakness after chemotherapy for large cell lymphoma in a middle-aged woman. Lymphomatous meningitis with neurolymphomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Brain; Cyclophosphamide; Diagnosis, Differe | 2000 |
Chemotherapy for the treatment of patients with primary high grade gastric B-cell lymphoma of modified Ann Arbor Stages IE and IIE.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2000 |
Non-Hodgkin's lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Cyclophosphamide; Cy | 2000 |
Co-existence of cutaneous true histiocytic lymphoma with refractory anaemia: report of a case.
Topics: Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2000 |
Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2000 |
Large B-cell lymphoma of thyroid. Two cases with a marginal zone distribution of the neoplastic cells.
Topics: Adenocarcinoma; Aged; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2000 |
Don't treat a relative? I'm glad I did.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2000 |
Treatment of prognosis of primary breast lymphoma: a review of 13 cases.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormona | 2000 |
Prognostic models for diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Coho | 2000 |
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy.
Topics: Actuarial Analysis; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2000 |
Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transport | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi | 2001 |
[Primary liver lymphoma. Diagnostic and therapeutic implications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin; Femal | 2001 |
[Intravascular lymphomatosis: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Doxorubicin; Huma | 2001 |
Sclerosing malignant lymphoma mimicking idiopathic retroperitoneal fibrosis: importance of clonality study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 2001 |
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2001 |
Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Doxorubicin; Femal | 2001 |
Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2001 |
T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2001 |
Primary thyroid lymphoma is a heterogeneous disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Goiter, Nodul | 2002 |
[Malignant non-Hodgkin's lymphoma of the lip: a case report].
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Chil | 2001 |
Ga-67 imaging in the diagnosis and management of primary non-Hodgkin's lymphoma of the larynx.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow- | 2002 |
CHOP plus rituximab--balancing facts and opinion.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2002 |
Lactic Acidosis in Non-Hodgkin's Lymphoma and response to Chemotherapy.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; C | 2002 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2002 |
Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2001 |
Angiotropic large cell lymphoma with imaging characteristics of CNS vasculitis.
Topics: Anti-Inflammatory Agents; Central Nervous System; Diagnosis, Differential; Diagnostic Errors; Fatal | 2002 |
[Non-Hodgkin's lymphoma of the uterus: apropos of 4 cases and review of the literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cervix Uteri; Cyclophosphamide; Diagno | 2002 |
Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclona | 2002 |
Diagnostic fine-needle aspiration cytology and immunocytochemistry analysis of a primary thyroid lymphoma presenting as an anatomic emergency.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Combined Modality Therapy; Cyc | 2002 |
[Multinodular hepatopathy].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 2002 |
Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2002 |
Rituximab plus CHOP for diffuse large-B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2002 |
De novo CD5-positive diffuse large B cell lymphoma solely presenting as multiple subcutaneous nodules.
Topics: Adipose Tissue; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arthritis, | 2002 |
Advanced diffuse histiocytic lymphoma, a potentially curable disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biopsy; Cyclophosphamide; Drug Therapy, Co | 1975 |
Reversible interstitial pneumonitis associated with low dose bleomycin.
Topics: Abdominal Neoplasms; Bleomycin; Doxorubicin; Female; Humans; Lymphatic Metastasis; Lymphoma, Large B | 1975 |
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV.
Topics: Adult; Antineoplastic Agents; Azirines; Bleomycin; Cyclophosphamide; Daunorubicin; Etoposide; Female | 1975 |
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Topics: Adult; Aged; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Admini | 1976 |
Cyclophosphamide, vincristine, and prednisone (CVP) versus adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Child; Cyclophosphamide; Doxorubicin; Dru | 1977 |
Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
Topics: Adult; Bleomycin; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Resistance; Drug Therapy, Com | 1977 |
[Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Chlorambucil; Cyclophosphamide; Doxorubicin; Dru | 1977 |
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow Diseases; Cyclophosphamide; Doxorubicin; | 1977 |
A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients.
Topics: Adolescent; Adult; Aged; Bleomycin; Doxorubicin; Drug Administration Schedule; Female; Hodgkin Disea | 1978 |
Severe radiation pneumonitis precipitated by withdrawal of corticosteroids: a diagnostic and therapeutic dilemma.
Topics: Adolescent; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Pneumonia; Prednis | 1979 |
Combination of cyclophosphamide, vincristine, and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma, Large B-Cell | 1977 |
Diffuse histiocytic lymphoma. The need for aggressive restaging.
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma, Large B-Cell, Di | 1977 |
Histiocytic lymphoma of B cell origin.
Topics: B-Lymphocytes; Cell Membrane; Humans; Immunoglobulins; Lymphoma, Large B-Cell, Diffuse; Lymphoma, No | 1977 |
[Epidural localization of malignant lymphomas with pressure on the spinal cord].
Topics: Aged; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Midd | 1977 |
[Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1977 |
[Therapy of non-Hodgkin lymphomas with COP and COPP regimens (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1977 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combinat | 1978 |
Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Doxorubicin; Drug The | 1978 |
Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Doxorubicin; Drug The | 1978 |
Cell cycle agents and cyclophosphamide in the treatment of diffuse histiocytic lymphoma.
Topics: Adult; Aged; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leucovorin; Ly | 1978 |
Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lym | 1978 |
"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dexamethasone; Dysgerminoma; Epidural Space; Humans; | 1977 |
Evolution of immunoblastic lymphoma in angioimmunoblastic lymphadenopathy.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lym | 1978 |
Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma, L | 1979 |
[Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
Topics: Adolescent; Adult; Aged; Child; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Toler | 1975 |
Non-Hodgkin's lymphomas-present status of chemotherapy.
Topics: Adult; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B | 1975 |
[Combination chemotherapy and synchronization therapy in lymphogranulomatosis and non-Hodgkin's lymphomas].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphom | 1976 |
[Cyclophosphamide-vincristine-prednisone combination in the treatment of lympho- and reticulosarcomas in adults (60 cases)].
Topics: Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lymphoma, Large B-Cell | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Kinetic response of human leukemic and lymphoma cells in vivo to combination chemotherapy using flow microfluorometry.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Doxorubicin; Drug Therapy, Combination; Female; Flu | 1976 |
Diffuse arteritis, long-term immunosuppression and malignancy.
Topics: Aortic Aneurysm; Arteritis; Autopsy; Humans; Long-Term Care; Lymphoma, Large B-Cell, Diffuse; Male; | 1976 |
Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy.
Topics: Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymph Nodes | 1975 |
Testicular lymphoma.
Topics: Aged; Cyclophosphamide; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prog | 1975 |
Trichlortriethylamine (TS-160 Spofa) in combination chemotherapy of malignant lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Lymp | 1975 |
Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Femal | 1975 |
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1975 |
The influence of chemotherapy on the management of non-Hodgkin's lymphomata at the Princess Margaret Hospital. A comparison of the results from 1962-64 with 1967-69.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgki | 1975 |
1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
Topics: Carmustine; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Lar | 1975 |
Successful use of combination chemotherapy in pure red cell aplasia associated with malignant lymphoma, histiocytic type.
Topics: Aged; Anemia, Aplastic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma, Large | 1975 |
Primary mediastinal diffuse large cell lymphoma initially presented with pericardial infiltration.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiac Tamponade; Cyclophosphamid | 1992 |
[Splenic lymphoma of Ki-1 positive B-cell type treated with CHOP].
Topics: Aged; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 1992 |
Inflammatory peripheral neuropathy following high dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 1992 |
Ki-1-positive large-cell anaplastic lymphoma with protean manifestations including central nervous system involvement.
Topics: Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone and Bo | 1992 |
[A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophospham | 1992 |
Effect of combination chemotherapy with cefoperazone on non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cefoperazone; Cyclophosphamide; Cytarabin | 1992 |
[Intestinal lymphoma. A report of 2 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colectomy; Colonic Neoplasms; Combined Mo | 1992 |
Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Doxorubici | 1992 |
Primary malignant lymphoma of the spleen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1992 |
[Multiple myeloma in a patient in remission from malignant lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunog | 1992 |
Primary epidural non-Hodgkin's lymphoma in clinical stage IEA presenting with paraplegia and showing complete recovery after combination therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 1992 |
Salvage therapy for diffuse large-cell lymphoma.
Topics: Bleomycin; Cyclophosphamide; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Procarb | 1990 |
Angiotropic (intravascular) large cell lymphoma. A clinicopathologic study of seven cases with unique clinical presentations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etop | 1990 |
Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1991 |
MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1991 |
Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclopho | 1991 |
[Lennert's lymphoma and glomerulonephritis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diagnosis, Differential | 1991 |
Applications of gallium-67 scintigraphy in the management of patients with malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Citrates; Citric Acid; Cyclophosph | 1991 |
[The treatment of large-cell non-Hodgkin's lymphomas with the MACOP-B protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1991 |
Intravascular large cell lymphoma: diagnosis on renal biopsy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Female; Fluor | 1991 |
Childhood Ki-1 lymphoma: presentation as a buttock mass.
Topics: Aneuploidy; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomar | 1991 |
Modified CHOP in an aged patient with non-Hodgkin's lymphoma and probable extensive pulmonary involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; | 1991 |
The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fluoroura | 1991 |
Clinical and pathological restaging in aggressive non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Fe | 1991 |
Primary lymphoma of the heart. Prolonged survival with early systemic therapy in a patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Heart Neoplas | 1991 |
A case of angiotropic large cell lymphoma manifesting nephrotic syndrome and treated successfully with combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph | 1991 |
ECAPP chemotherapy for lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fema | 1990 |
Successful pregnancy following treatment of primary malignant lymphoma of the uterine cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1990 |
Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1990 |
[The diagnosis and treatment of giant-cell histiocytic non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Cyclophosp | 1990 |
Prognostic indicators in diffuse large-cell (histiocytic) lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Cytarabine | 1986 |
Acute leukemia in a patient cured of diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Deletion; Chromosomes, Human, | 1986 |
Gall bladder perforation in response to chemotherapy in a patient with a histiocytic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bile; Bleomycin; Chylous Ascites; Cy | 1988 |
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Arachn | 1985 |
[Treatment of large cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Israe | 1989 |
Improved survival of poor prognosis diffuse histiocytic (large cell) lymphoma managed with sequential induction chemotherapy, "boost" radiation therapy, and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1988 |
Primary non-Hodgkin's lymphoma of the liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1987 |
Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Endocardium; | 1986 |
Recurrent "flare" of dermatitis herpetiformis after cytotoxic therapy for malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dermatitis Herpetiformis; Doxorubi | 1986 |
Residual tumor masses following treatment for advanced histiocytic lymphoma. Diagnostic and therapeutic implications.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 1985 |
Cutaneous nodules as the first manifestation of gastrointestinal lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Digesti | 1985 |
Granulomatous hepatitis in a patient with previously treated histiocytic lymphoma.
Topics: Biopsy, Needle; Granuloma; Hepatitis; Humans; Immunosuppression Therapy; Intestinal Neoplasms; Lymph | 1985 |
[Experience treating 30 cases of oromaxillofacial non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1985 |
De-novo brain tumours in renal-transplant recipients.
Topics: Adolescent; Adult; Azathioprine; Brain; Brain Neoplasms; Cadaver; Follow-Up Studies; Humans; Immunos | 1971 |
Lymphoma, a complication of renal allotransplantation in man.
Topics: Adolescent; Adult; Azathioprine; Dactinomycin; Histocompatibility Testing; Humans; Kidney Transplant | 1972 |
The nitroblue tetrazolium test in lymphoma.
Topics: Adult; Diagnosis, Differential; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, | 1973 |
[Reticulosarcomatosis with immunological phenomena following several years lasting thrombopenia].
Topics: Adult; Blood Cell Count; Blood Platelets; Coombs Test; Female; Humans; Leukopenia; Lymphoma, Large B | 1967 |
Symptomatic control of fever in lymphoma and leukemia.
Topics: Adolescent; Adult; Aged; Aminopyrine; Analgesics; Aspirin; Female; Fever; Hodgkin Disease; Humans; I | 1969 |
[Richter's syndrome. 4 cases and an attempt at analysis].
Topics: Aged; Carcinoma, Squamous Cell; Chlorambucil; Cyclophosphamide; Deglutition Disorders; Drug Therapy, | 1973 |
[Different response of the superficial and deep lymph nodes to therapy in malignant lymphoreticulopathies].
Topics: Adult; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphoid; Lymphatic Metastasis; Lym | 1968 |
[Efficiency and value of modern diagnostic methods for cytomegalic inclusion disease].
Topics: Blood Group Incompatibility; Brain Diseases; Calcinosis; Child, Preschool; Chorioretinitis; Compleme | 1970 |
[Therapy and course of malignant diseases of the lymphoreticular system in infancy and early childhood].
Topics: Age Factors; Antineoplastic Agents; Child, Preschool; Hodgkin Disease; Humans; Infant; Infant, Newbo | 1973 |
Evidence for a specific seminiferous tubular factor affecting follicle-stimulating hormone secretion in man.
Topics: Adult; Biopsy; Cell Count; Clomiphene; Cyclophosphamide; Follicle Stimulating Hormone; Hodgkin Disea | 1972 |
Lymphomas of the testicle.
Topics: Adult; Aged; Cyclophosphamide; Hodgkin Disease; Humans; Lymph Nodes; Lymphoma; Lymphoma, Large B-Cel | 1972 |
[Stability of the toxoplasmin tests in patients treated with immunosuppressive agents].
Topics: Adult; Antigens; Antineoplastic Agents; Complement Fixation Tests; False Negative Reactions; Hodgkin | 1972 |
[Hodgkin's disease and other malignant lymphomas].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednison | 1972 |
Non-Hodgkin's lymphomas. II. Single agent chemotherapy.
Topics: Alkylating Agents; Chlorambucil; Cyclophosphamide; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse | 1972 |
Single, combined and sequential use of uracil mustard and prednisone in the treatment of lymphoreticular tumors.
Topics: Drug Synergism; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Prednisone; Urac | 1972 |
Management of patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Lymphography; Ly | 1973 |
Updated Hodgkin's disease. C. Advanced disease and special problems. Comment: the non-Hodgkin's lymphomas.
Topics: Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Large B-C | 1973 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-1973.
Topics: Abdominal Neoplasms; Aged; Aspergillosis; Bronchopneumonia; Cyclophosphamide; Humans; Immunosuppress | 1973 |
Hypercalcemia and an elevated alkaline phosphatase level.
Topics: Alkaline Phosphatase; Alkylating Agents; Anemia, Hemolytic; Diagnosis, Differential; Fatigue; Fever; | 1973 |
Alpha-chain disease in subSaharan Africa.
Topics: Adolescent; Adult; Cobalt Isotopes; Female; Heavy Chain Disease; Humans; Immunoelectrophoresis; Immu | 1973 |
Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Biopsy; Burkitt Lymphoma; Cyclophosphamide; Germ Cells; Ho | 1973 |
Combination chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone in the treatment of malignant lymphomas.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Injectio | 1973 |
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1974 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
Kaposi sarcoma in kidney transplant recipients.
Topics: Adult; Antilymphocyte Serum; Autopsy; Azathioprine; Brain Neoplasms; Cadaver; Female; Graft Rejectio | 1974 |
[Malignant tumors following transplantation. Case reports and review of the literature].
Topics: Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Graft Rejection; Humans; Kidney | 1973 |
Acquired factor VIII inhibitor in a patient with malignant lymphoma.
Topics: Blood Cell Count; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Proteins; Blood Urea N | 1974 |
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examinati | 1968 |
Reticulocellsarcoma of the retroperitoneum, gastric perforation and steroids.
Topics: Abscess; Cyclophosphamide; Female; Humans; Lymph Nodes; Lymphography; Lymphoma, Large B-Cell, Diffus | 1968 |
Pituitary-adrenal suppression and Cushing's syndrome after intermittent dexamethasone therapy.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Creatinine; Cushing Syndrome; Depression, Chemica | 1968 |
Pseudoagglutination in albumin.
Topics: Agglutination; Antibodies; Blood Protein Electrophoresis; Blood Transfusion; Chemical Precipitation; | 1969 |
[Association of nitrogen mustard, vincristine, methylhydrazine and prednisone in treatment of diffuse forms of Hodgkin's disease and ganglionic sarcomas].
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Synergism; Female; Hodgkin Disease; Humans; Hydrazi | 1968 |
Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia.
Topics: Cortisone; Glucocorticoids; Hodgkin Disease; Hydrocortisone; Leukemia, Lymphoid; Lymphoma, Large B-C | 1969 |
[The role of vinblastine in the treatment of malignant lymphomas].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Larg | 1968 |
Hairy cell leukemia.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Cyclophosphamide; Hepatomegaly; H | 1970 |
Cyclic chemotherapy in lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzoates; Cyclophosphamide; Evaluation Studies as Topic; Female | 1971 |
Malignant lymphomas in transplantation patients.
Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppre | 1969 |
[Effectiveness of polychemotherapeutic treatments of lymphoproliferative diseases].
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Hodgkin Disease; Humans; Leukemia; L | 1970 |
Elevated plasma levels of a hydroxyproline-containing protein in Hodgkin's disease and their relation to disease activity.
Topics: Adolescent; Adult; Blood Proteins; Cyclophosphamide; Female; Hodgkin Disease; Humans; Hydroxyproline | 1966 |
High-dose corticoid therapy in Hodgkin's disease and other lymphomas.
Topics: Adolescent; Adult; Aged; Cortisone; Diabetes Mellitus; Female; Gastrointestinal Diseases; Hodgkin Di | 1967 |